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Abstract
Aim
The purpose of this investigation was to evaluate the clinical decision support capacity of 
commercial  computer  software  designed  to  assist  pharmacists  performing  medication 
reviews.
The  primary  hypothesis  was:  If  medication  review  software  is  related  to  pharmacist 
knowledge, then the detection of therapeutic problems will result in a similar frequency and 
scope of identified problems as those identified by pharmacists.
Method
Home medication review data collected during 2008 for a previous study were used for this 
investigation.  The  data  contained  original  pharmacist  findings  of  drug-related  problems 
(DRPs),  patient  demographics,  medications,  laboratory  results  and  diagnoses.  Two 
commercial  software applications  advertising decision support were assessed,  Monitor-Rx 
(MRX) utilising  simple  rules  triggered  by the  presence  of  medication  and Medication™ 
Review Mentor  (MRM) utilising an advanced artificial  intelligence rules-based approach. 
The  previously  collected  data  were  entered  into  each  of  the  applications  and  the  DRPs 
identified  by  each  tool  were  recorded.  Additionally, published  prescribing  criteria,  Beers 
(2003 and 2012 versions), Screening Tool of Older Person’s Prescriptions and Screening Tool 
to Alert doctors to Right Treatment (STOPP/START) and Prescribing Indicators in Elderly 
Australians (PIEA) were also adapted so as to be applied computationally over the same set 
of patient data.
DRPs were  assigned broad DOCUMENT classifications  and examined by frequency and 
type. A common vocabulary of descriptive  classifications capturing essential DRP concepts 
was developed to allow detailed comparison between the various DRP sources. The ability of 
software to identify the same classifications in the same patients as pharmacists was assessed 
as a crude measure of clinical relevance. A panel of pharmacology experts assessed the DRPs 
identified by pharmacists, MRM, MRX and the STOPP/START prescribing criteria for their 
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opinions  concerning  clinical  relevance,  excessive  DRP  findings,  missed  DRPs  and  the 
appropriateness of recommendations.
A qualitative survey of pharmacists  who used MRM was also undertaken to obtain their 
opinions of the decision support capability of MRM.
Results
In total,  across  570 patients,  pharmacists identified 2020 DRPs, MRM 3209, PIEA 1492, 
STOPP 1032, Beers03 404 and Beers12 399. Ten percent of the volume of DRPs identified 
by MRM were found to be duplicated DRPs, where the same essential problem was identified 
more than once for a patients, typically via different rules. Using a smaller sub-sample of 100 
patients, MRX identified 1265 DRPs. Pharmacist DRPs encompassed the widest range of 
DOCUMENT classifications,  followed by MRM, then the sets  of prescribing criteria and 
finally MRX.
A list  of 141 descriptive  classifications was developed which described the various DRP 
concepts in depth. Pharmacist-only descriptive classifications involving compliance and not-
classifiable DRPs were excluded from assessment, since it was impossible to detect these 
DRPs without access to additional patient data that was not included in pharmacists written 
reports.  Pharmacist  DRPs  were  associated  with  113  different  descriptive  classifications, 
MRM 100 and MRX 17. MRM was able to identify 90 differing classification types that were 
also identifiable by pharmacists. MRM was able to identify the same problems in the same 
patients as the reviewing pharmacists identified in 389 instances, whereas MRX identified the 
same problems in the same patients in  only 11 instances.
Assessment  of  expert  opinions  found that  experts  generally  agreed  that  MRM presented 
clinically relevant DRPs  (80%) and appropriate recommendations for DRP resolution. This 
finding contrasted strongly for MRX, with experts of the opinion that MRX presented few 
clinically relevant DRPs (13%). Similarly, relatively few experts agreed that MRM presented 
too many DRP findings (19%) whereas the vast majority of experts agreed MRX presented 
an excessive number of findings (93% of opinions).
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Pharmacists  who  used  MRM  agreed  with  the  expert  panel  regarding  MRM.  These 
pharmacists also found MRM to be easy to use (mean 76 on scale of 0 to 100) and useful  
(mean 5.6 on a  scale  of  1  to  7).  The pharmacists  agreed that  MRM identified  clinically 
relevant  DRPs (73%) and also agreed that  MRM identified clinically relevant  DRPs that 
would otherwise have been overlooked by pharmacists (73%).
Discussion
Both  MRM and MRX identified  a  greater  number  of  DRPs  than  pharmacists.  However, 
MRM was considered,  by both the expert  panel  members  and pharmacist  subscribers,  to 
identify an acceptable number of mostly clinically relevant DRPs and to present appropriate 
recommendations to resolve DRPs. In contrast, the expert panel thought MRX identified an 
excessive number of mostly irrelevant DRPs.  The contrast between the relevance of MRM 
and lack of relevance of MRX highlighted the different approaches used by each product. 
MRX utilised a simple approach through the identification only of medications of interest, 
whereas  MRX  incorporated  a  range  of  variables  such  as  examining  all  medications, 
medication doses, medical history, laboratory results. The integration of a range of variables 
allowed MRM to provide far greater context to the DRPs found for each patient. Application 
of the DOCUMENT classifications and the descriptive classifications found that MRX was 
capable of identifying a very limited range of DRP types, whereas MRM was capable of 
identifying a wide range of DRP types, approaching the range of problem types identifiable 
by pharmacists. 
The  descriptive  classification  comparison  of  MRM  and  MRX  findings  with  the  sets  of 
prescribing criteria  found that  MRX was more closely aligned with  the Beers12 criteria, 
whereas MRM was more closely aligned with the STOPP/START criteria. Interestingly the 
STOPP/START criteria  were  also  considered,  by  the  expert  panel,  to  provide  clinically 
relevant  findings.  This  may  be  due  to  patient  contextualisation  via  the  incorporation  of 
medication-medication interactions and medication-diagnosis interactions within many of the 
STOPP/START criteria.  However,  compared  to  MRX,  MRM  and  pharmacists'  original 
findings,  STOPP/START found  the  smallest  number  of  problems.  These  findings  were 
naturally  limited  to  the  set  of  74  criteria  which  implemented  in  this  investigation.  An 
additional finding was the STOPP/START criteria were found to be the closest of all the sets 
vii
of prescribing criteria to the pharmacists' findings, both in terms of scope of problem types as 
well as by frequency.
Greater contextualisation of DRPs certainly provided greater clinical relevance,  as shown 
with  the  STOPP/START  prescribing  criteria  and  exemplified  by  MRM.  However, 
STOPP/START was limited to a set of specific consensus-based rules, limiting opportunities 
to expand on the identification of clinically relevant DRPs. MRM did not have this limitation, 
allowing an expert in the the knowledge domain of medication reviews to add and refine 
numerous rules incorporating patient-specific data  to  maximise the detection of clinically 
relevant  DRPs.  A  strong  rationale   for  the  use  of  MRM,  or  similarly  implemented 
technologies, was not only MRM's clinical relevance but also MRM's practical usefulness in 
the  detection  of  missed  opportunities  – pharmacist  subscribers  confirmed that  MRM did 
identify clinically relevant DRPs that the pharmacists themselves had missed.
Conclusion
The implementation of overly simple rules, such as the mere presence of a medication as was 
used by MRX, was insufficient to provide good decision support as it resulted in an excessive 
abundance of a narrow range of mostly clinically irrelevant DRPs.
Automated versions of the prescribing criteria STOPP/START, PIEA, and Beers proved to be 
a  slightly  better  tool  for  identifying  DRPs  as  took  into  account  a  broader  spectrum  of 
information  about  the patient’s condition  (typically  diagnoses),  allowing them to identify 
more targeted and relevant problems. 
However, the  use of  artificial  intelligence  technology by MRM allowed for  both  greater 
contextualisation and variety of clinically relevant DRPs. MRM identified a higher frequency 
of DRPs than did pharmacists. In part, the greater frequency of DRPs identified by MRM 
may represent  clinically  relevant  DRPs that  were  missed by reviewing pharmacists.  This 
capacity  to  supplement  clinically  relevant  DRPs  complements  the  consistency  and 
thoroughness of the pharmacists medication reviews.
In light of the performance of MRM seen in this research, it  is reasonable to expect that  
future clinical decision support system (CDSS) applications using the multiple-classification 
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ripple-down rules  (MCRDR)  approach  could  provide  significant  benefits  over  the  much 
simpler technologies that are typically utilised, with very limited success, worldwide. These 
benefits include the identification of clinically relevant problems both more frequently, and 
more consistently, yet with very few clinically irrelevant problems identified. Furthermore, 
this consistently high performance level leads to better uptake and acceptance rates by users, 
ensuring  that  the  problems  are  not  only  identified,  but  are  actually  acted  upon  when 
appropriate to do so. Such CDSS implementations might be successfully incorporated into a 
wide  variety  of  healthcare  settings,  such as  hospital,  general  and specialist  practice,  and 
community pharmacy. Given the results of this thesis, that the technology now exists, and 
that quality patient electronic health record (EHR) data is gradually becoming more available, 
it seems that the time has come for this technology to be applied more widely.
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Introduction
 1 Introduction
Analogous with many developed nations in the early part of the 21st century, the Australian 
population is undergoing a shift towards an increased proportion of older citizens.1,2 Older 
people  are  associated  with  greater  frequency  of  chronic  conditions,  co-morbidity  and 
medication use.3 Expenditure on medications in Australia grew from $13.9 billion in 2007-08 
to $18.4 billion in 2010-11, perhaps not surprising considering the shift toward an ageing 
population.4,5
Unfortunately, although mostly life  enhancing,  medications  do contribute to  patient  harm 
including  hospitalisations  and  death.  Australian  studies  have  identified  that  up  to  5.6% 
hospital  admissions  were  related  to  adverse  drug  events  (ADEs),  with  a  third  of  these 
associated with older people.6,7 Activities, or interventions, to  minimise such events may 
involve patient education, as well as prescriber education, such as the implementation of best 
practice  guidelines.  Interventions  targeting  improvements  in  the  use  of  medications, 
particularly in older patients, may be expected to benefit society through better health and 
reduced healthcare utilisation.8–10 
A range of medication safety intervention strategies were reviewed by Semple and Roughead 
which  concluded  that  clinical  pharmacist  services  showed  benefit.10 Pharmacists  are 
extensively trained in pharmacotherapy and may reasonably be expected to possess a wider 
scope of  pharmaceutical  knowledge than  other  health  professionals.11 Such knowledge is 
suited to the task of patient medicines review for identification of drug-related problems and 
recommendations for improved therapy.9,12
Around the  world  medication  review  programs  have  been  developed  to  capitalise  on 
pharmacist  drug  knowledge.  The  United  Kingdom  National  Health  Service  implements 
pharmacist  initiated medicines reviews through several  hospital  and community programs 
(medicines use review, dispensing review of use of medicines, chronic medication service, 
comprehensive  medication  review,  clinical  medication  review).13 Finland  has  performed 
pharmacist-conducted medicines reviews since 2005 with aspects drawn from the Australian 
and  USA programs,  although  this  program has  not  been  nationally  funded.14 Medication 
therapy review an element of medication therapy management is  performed in pharmacy 
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practice in the USA and funded through Medicare Part D,  to improve medicines use through 
patient targeted programs and healthcare collaboration.15 
The  Australian  Government  Department  of  Health  and  Ageing  funds  pharmacists  who 
undertake additional training to become accredited to perform medicines review services. 
Such services are directed at aged care residents as well as patients who reside in their own 
homes and meet  selection criteria which are designed to identify patients in need of this 
service. An example may be a patient who regularly consumes five or more medications on a 
daily basis.16,17
The medicines review task requires the pharmacist to obtain a range of information about the 
patient's  current  medication therapy and incorporate  many factors  which may actually  or 
potentially impact on the best possible therapy. A critical step in the review process is the 
analysis  of  information  to  identify  suboptimal  treatment  and  provide  relevant 
recommendations for consideration by the patient's GP. Such analysis requires the reviewing 
pharmacist to have proficient knowledge, not only of medications, but of medical conditions 
associated with the elderly, laboratory test results and familiarity with current evidence-based 
disease management and medicine guidelines.
There  is  some evidence  that  pharmacist  medicines  review can reduce  polypharmacy and 
improve patient outcomes.18–20 However, a 2008 Australian report of pharmacist medication 
reviews identified some reservations from GPs such as “... sometimes supply irrelevant or 
unhelpful information ...”.21 Also pharmacists had reservations including a lack of confidence 
in making clinical recommendations and concerns about time constraints.21 
In Australia and overseas, software has been developed to aid pharmacist medicines review 
activities and some of this software has incorporated an additional clinical decision support 
functionality, see section 3.8. Clinical decision support systems (CDSS) may have a role to 
play, by assisting pharmacists  with  both the  identification of  suboptimal  therapy and the 
provision  of  recommendations  for  their  resolution.  Such  computerised  clinical  decision 
support may address some of the reservations by aiding pharmacist confidence and improving 
the clinical information that is provided to GPs in medicines review reports.
2
Introduction
There have been numerous studies investigating the effects of CDSS on prescriber practice 
and  patient  outcomes.22–24 However,  little  investigation  has  been  undertaken  on  the 
capabilities of CDSS developed for medicines review in general or for pharmacist medicines 
review in  particular, see  section  3.7. Information  technology is  widespread in  the  health 
sector and electronic health records and system interoperability is improving. However, there 
has  been  limited  investigation  into  the  validation  of  commercial  systems.  This  thesis 
evaluates two commercial products and investigates the applicability of CDSS for medicines 
review.  It is important that commercial products of this nature are evaluated as they need to 
show  they  can  support  a  fundamental  activity  such  as  healthcare.  Both  healthcare 
professionals and healthcare consumers need to be reassured that the products in use will 
benefit them, and if not, that such products are clearly identified and avoided. 
3
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This chapter covers some of the issues of  the inappropriate use of medicines, or drug-related 
problems (DRPs), in older people. The factors associated with DRPs are discussed as well as 
their frequency. Two approaches which are synergistic and closely associated with the central 
work of pharmacists are discussed: the use of prescribing criteria  - measures of good and bad 
prescribing, and medicines review also known as medication therapy management. The home 
medicines review (HMR) is talked about specifically as the data on which this thesis is based 
is drawn from HMR reports.16,25
Appropriate medication use is termed quality use of medicines (QUM); defined as “Selecting 
management  options  wisely;  choosing  suitable  medicines  if  a  medicine  is  considered 
necessary; and using medicines safely and effectively”26 This is an ideal goal, however, there 
is a gap between knowing what best practice is, and actually implementing best practice. The 
difference between accepted current research identifying evidence of best medication therapy 
and the actual practice is known as the evidence-practice gap (EPG). Australian studies have 
identified EPGs for a range of medications.27–30
It is important to identify DRPs and do what can be done to improve QUM through resolving 
or  minimising  the  potential  for  harm.  Addressing  DRPs  in  older  people  is  important  as 
adverse drug reactions (ADRs) lead to greater rates of hospitalisation in older people than in 
the general population, are costly to society and are detrimental to the individual's quality of 
life.6,31
 2.1 Drug-related problems
A central component of pharmacist medicines review is the identification of DRPs.25,32 DRPs 
are defined by the Pharmaceutical Care Network Europe as “... an event or circumstance 
involving drug therapy that actually or potentially interferes with desired health outcomes”33 
This definition is broad in that it covers actual problems that have occurred, that is ADEs, of 
which adverse drug reactions (ADRs) are a subset, as well as potential problems that may 
occur. The relationships between the components contributing to DRPs are shown in Figure 1 
as a Venn diagram adapted from Nebeker et al.34
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An example of a potential DRP is the prescribing of dextropropoxyphene, an opioid analgesic 
prescribed  for  pain  management.  Studies  have  shown  both  dextropropoxyphene  and  the 
metabolite  nordextropropoxyphene accumulate  in  the  elderly  due  to  reduced hepatic  and 
renal clearance35, and cardiac toxicity.36 Additionally, dextropropoxyphene is considered to be 
no more effective than paracetamol or aspirin and was considered to be relatively toxic even 
as  far  back  as  the  1970s.37 As  such  dextropropoxyphene  has  been  included  in  several 
iterations  of  the  Beers  criteria  as  a  potentially  inappropriate  medication  (PIM)  in  older 
people, and prescribing dextropropoxyphene in this cohort  would be considered a potential 
DRP.38,39 
Another  type  of  DRP is  lack  of  treatment  for  existing  disease  or  symptoms,  or  lack  of 
treatment  to  prevent  a  disease  occurring.  Examples  include  preventative  therapy  with 
antiosteoporotics, calcium and vitamin D to reduce incidence of osteoporotic fractures40, or 
improved survival in patients with heart failure with the addition of  angiotensin-converting 
5
Figure 1: Relationship between medication errors, ADEs and ADRs  
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enzyme inhibitors (ACEIs) or beta-blocking drugs.41 Several studies have identified problems 
relating to drug treatment omissions in hospitalised and community-based elderly ranging 
from 16% to 42% of patients.42–45 
 2.1.1  Factors associated with DRPs in older people
Studies have identified a variety of factors which have been associated with DRPs, not only 
drug specific factors but also factors involving organisational systems and patient-specific 
factors of compliance, cost of medications, health literacy, culture and language barriers.6 
An Australian study published in 2004 by Roughead  et al.  identified a variety of factors 
associated  with  DRPs  in  older  adults.46 The  majority  of  these  DRPs  were  related  to  the 
prescriber  and  involved  inappropriate  medicines,  inappropriate  dosages  or  therapeutic  or 
monitoring omissions. Proportions of DRP factors are illustrated in a National Prescribing 
Service (NPS) Medicinewise News publication,47 see Figure 2.
6
Figure 2: DRPs in older Australians. Figure reproduced from NPS Medicinewise News 
September 2013.47 Data from Roughead et al.46
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The following factors have been found to be associated with DRPs in older people. Such 
factors may not present in isolation and their additive or synergistic effects may enhance the 
opportunity for undesirable outcomes in older people. 
  Pharmacodynamics and pharmacokinetics
Older people have differing biological processes compared to younger people. Renal function 
declines  reducing  elimination  of  renally  excreted  medication.3 Hepatic  function  declines 
which  may  have  various  consequences  such  as  reduced  first  pass  metabolism,  reduced 
prodrug activation, and reduced or altered metabolism of active drugs and metabolites,3 such 
as dextropropoxyphene mentioned earlier. The ability to maintain homeostasis (autonomic 
functioning,  blood pressure,  blood chemistry)  is  reduced.  Pharmacodynamic  responses  to 
medications  may  be  accentuated  or  diminished,  examples  are:  a  reduced  response  to  β-
agonist inhalers, or excessive sedation with the use of benzodiazepines.3,48
  Medical conditions and co-morbidity
Chronic medical conditions occur more often in older people and co-morbidities occur with 
greater  frequency  with  increased  age.49,50 Americans  aged  65  and  over  had  the  highest 
proportion of one (87%) or more (67%) chronic medical conditions of any age group.50 Co-
morbidities have been identified as factors associated with DRPs.51 Co-morbidity was also 
associated with conflicting treatment leading to DRPs.52–54
Co-morbidity  of  chronic  medical  conditions  of  diabetes  mellitus,  coronary  artery  disease 
(CAD), congestive heart failure (CHF), and geriatric syndromes of  falls and incontinence 
were  found  to  co-exist  in  substantial  proportions  of  American  patients.49 Similarly,  co-
morbidity  was  not  uncommon  in  Australian  patients  with  one  or  more  of  arthritis, 
hypertension, cardiovascular disease, diabetes, asthma and mental health conditions found to 
co-exist.55 Co-morbid hypertension and diabetes was found to exacerbate cognitive decline in 
older people.56
  Polypharmacy
Polypharmacy is a common theme associated with ADEs in older people. As people age there 
is  greater  incidence  of  chronic  disease  and  consequently  the  use  of  medications  to  treat 
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disease.3 Polypharmacy is often defined as the use of 5 or more medications at  the same 
time.57 Polypharmacy has been identified as a factor in elderly hospital admissions.51,58 Even 
after hospital discharge, polypharmacy in older people remained associated with ADEs.59 An 
increase in the number of medications has been shown to have a linear relationship with 
increased DRP frequency, based on medicines review of hospital admissions in Norway.57 A 
very  similar  result  was  found  from a  review  of  Australian  general  practice  patient  case 
notes.60 Graphs  of  each  of  these  study  results  are  shown  in  Figure  3 and  Figure  4. 
Polypharmacy has also been associated with inappropriate prescribing.61
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Figure 3: Linear increase of DRPs with greater 
polypharmacy, reproduced from Viktil et al.57
Figure 4: Increased medication problems with increased medication use, figure 
reproduced from Runciman et al.75 based on data from Gilbert et al.60
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  Drug classes
Various classes of medications have been associated with ADEs in older people. Easton et al.6 
presented a table of drugs and drug classes involved in ADEs in older people, developed from 
a review of studies. Several drug classes were commonly associated with ADEs and included: 
antibiotics,  cardiovascular  drugs,  anticoagulants,  non-steroidal  anti-inflammatory  drugs 
(NSAIDs),  hypoglycaemics,  antidepressants  and  anticholinergics.  Studies  published  since 
this review support these drug classes as key ADE contributors.62–64
  Adherence
Adherence is a term commonly used to describe patient behaviour concerning medication-
use. Adherence is defined as “the extent to which the person's behaviour – taking medication 
…  corresponds  with  the  agreed  recommendations  from  a  health  care  provider”65 Non-
adherence typically consists of never beginning treatment, not persisting with treatment or 
not conforming with the recommended treatment regimen.66 These steps are illustrated in 
Figure 5 from Iron Health Alliance67. Several patient factors are implicated in non-adherence 
including:  misunderstanding  instructions,  forgetfulness,  fears  and  beliefs  related  to  side-
effects and regimen complexity.66
9
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A study  in  the  Netherlands  found impaired  cognition  and treatment  non-adherence  were 
associated with hospital admissions.51 Lack of patient knowledge and related non-adherence 
have  been  associated  with  DRPs  in  several  studies.60,68,69 In  Australia  26%  of  hospital 
admissions were related to not conforming or not persisting with therapy.58 Higher mortality 
has  been  linked  with  poorer  health  literacy  in  a  study  of  patient's  ability  to  read  and 
understand  medication  directions.70 Financial  limitations  may  also  affect  the  purchase  of 
medications resulting in non-adherence.71
  Physical factors
Physical  limitations  may  affect  older  peoples'  ability  to  access  or  utilise  medication, 
subsequently reducing adherence to therapy. Poor physical strength or dexterity may cause 
difficulty  with  opening  medication  containers,  splitting  tablets  or  actuating  medication 
inhalers.71,72 Reduced vision may affect interpretation of written labels and the consumption 
of  the  presumed  correct  medications.71 Swallowing  difficulties  can  affect  medication 
adherence  and  may  be  compounded  by  drugs  affecting  saliva  production  or  muscle 
10
Figure 5: Adherence and patient actions. script = prescription, meds = medication. Figure 
reproduced from Iron Health Alliance67
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movement,  tablet  or  pill  size,  or  disease  states  resulting  in  reduced saliva  or  pharyngeal 
muscle movement.73,74 
  Health system factors
Health system factors encompass prescribing, dispensing and administration errors including 
communication  failures,  particularly  informing  health  care  professionals  after  hospital 
discharge.7 Prescribing errors were not  infrequent in hospital  practice.  A 2003 systematic 
review found administration  errors  occurred  at  rates  ranging  from 5% to  20%,  typically 
involving dose timing being too early or late or dose omission.75 Prescribing errors occurred 
in 2.4% of prescriptions, typically involving wrong, unclear or missing dosing.75 Hospital 
dispensing errors also occurred with low frequency, 0.08% to 0.8% of prescriptions.75 
A 2008 USA survey of pharmacy directors  from over  1300 hospitals  showed a range of 
measures were implemented to reduce the incidence of dispensing and administration errors, 
including robots and automated dispensing, smart infusion pumps, two-pharmacist checks for 
high risk medication,  pharmacist review of emergency department medication orders and 
administration  checks  –  verbally  confirming  the  right  patient  or  using  bar-code 
confirmation.76 A study in a English teaching hospital compared changes after  automated 
dispensing, patient bar-code identification and electronic medication administration records 
were introduced. The study found significant reductions in prescribing errors (3.8% to 2.0%) 
and  medication  administration  errors  (7.0%%  to  4.3%)  and  improved  patient  identity 
checking (17.4% to 81.1%).77
An observational  study of  administration  errors  in  12 assisted  living  centres  found,  after 
excluding wrong timing of medication administration,  an error rate of 8.2% consisting of 
wrong, excessive or omitted doses and incorrect or unauthorised medication.78 The assisted 
living centres primarily employed non-medically trained staff.78 
 2.1.2  Frequency of adverse drug events
ADEs have been defined as “Medication incidents that cause harm to the patient”6 A subset of 
ADEs, ADRs have been defined as “A response to a drug that is noxious and unintended, and 
which occurs at doses normally used in humans for the prophylaxis, diagnosis or therapy of 
disease, or for the modification of physiological function”.79
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In  Australia  a  study  conducted  in  1994  found  hospitalisations  associated  with  ADEs 
accounted for 5.7% of hospital admissions.80 Additionally, a Canadian study conducted in 
2006 found emergency department admissions from ADEs were associated with an almost 
doubled of cost of care compared to admissions due to other reasons.81 ADEs were also a 
common event among ambulatory patients with 10% of Australian general practice patients 
having experienced an ADE within 6 months prior to  GP consultation.82  Overseas studies 
have shown roughly similar rates of ADEs, shown in Table 1.
Table 1: Hospital admissions associated with ADEs
Study Country ADE-related hospitalisation 
rate
Hohl et al. 201181 Canada 12%
Wu et al. 201064 England 1.1%
Pirmohamed et al. 200483 England 6.5%
Leendertse et al. 200851 Netherlands 5.6%
Brvar et al. 200984 Slovenia 5.8%
Kongkaew et al. 200885 Various 0.16% - 15.7%
A study of Australian general practice patients aged 45 years old and older, from 2007 and 
2010 data found an ADE rate of 11.6% made up primarily of known drug side effects from 
commonly used drug groups (opioids, lipid-modifiers, cardiovascular drugs, and anti-diabetic 
drugs).86 Rates of ADEs among older people have been shown to be even higher, with up to a 
third  of  hospital  admissions  and  discharges  involving  ADEs  and  higher  rates  among 
ambulatory older people.58,59,82 
 2.2 Prescribing criteria for older people
Attempts to reduce the incidence of DRPs have led to the development of various QUM 
guidelines designed to be applicable to older patients. Older patients are the typical cohort for 
medication reviews. Published prescribing criteria include: Beers 2003 version (Beers03)38, 
the recently updated Beers 2012 version (Beers12)87, Improved Prescribing in the Elderly 
Tool88, Screening Tool of Older Persons Prescriptions and  Screening Tool to Alert doctors to 
Right  Treatment  (STOPP/START)89,  McLeod  criteria90,  Drug  Burden  Index  (DBI)91, 
Medication  Appropriateness  Index  (MAI)92 and  an  Australian  specific  tool  Prescribing 
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Indicators in Elderly Australians (PIEA) developed in 2008, and further validated and refined 
in 2012.93,94
Prescribing criteria are intended to be broadly applicable to select patient populations yet 
require professional interpretation for each individual patient. Criteria cannot truly prescribe 
individual  patient  solutions  as  patient-specific  context  is  lacking,  although  each  set  of 
prescribing criteria attempt to incorporate some patient-relevant factors to contextualise the 
relevance of any recommendations made.38,89,90,93 True patient context is a conglomeration of 
unique  factors  including  demographic  information,  co-morbidities,  pathology,  treatment 
goals,  patient  physical  capabilities,  patient  understanding,  and  history  of  successful  and 
unsuccessful treatments and treatment regimens.95 Despite this caveat, prescribing criteria are 
intended to point the healthcare professional in the right direction by providing evidence-
based rules of what are or are not suitable therapeutic options.
Many  sets  of  prescribing  criteria have  been  developed  by  expert  consensus.38,89,90,96–99 
Prescribing  criteria often cite  evidence  supporting  their  recommendations.87,89,93,100 Several 
sets of prescribing  criteria for use in older people have been compared and critiqued,101–104 
likely spurring the development of newer guidelines. Concerns have included: the lack of a 
holistic approach through the exclusion of patient's life expectancy, quality of life, social and 
financial  factors101,102;  Another  concern  is  the  time  cost  to  apply  prescribing  criteria, 
particularly the MAI, taking about 10 minutes per drug assessed.101,102 
Evidence behind prescribing criteria have also been critiqued and considered deficient.105–108 
The plethora of prescribing criteria and criteria fatigue has also been noted, perhaps limiting 
their application and effectiveness.108,109 Prescribing criteria have been developed and trialled 
in older people, typically those aged 65 years old and older. However, their application in 
much older patients, such as those over 75 years old, may require greater caution.102 To quote 
geriatrician Virginia Aylett:
'We care for the patient who would never be included in a randomised controlled trial:  
the cognitively impaired, the patient with multiple comorbidities, the patient with not  
long to live,  the patient  where the researcher stands at  the end of the bed and says,  
“Perhaps not.”' 106
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Another  pertinent  issue  is  the  applicability  of  prescribing  criteria developed  in  other 
countries.  Prescribing  criteria for  older  people  have  been  developed  specifically  for  use 
within many countries: Australia93, Japan110, Italy96, France98, Canada90, Thailand97, Norway99, 
Germany111 and USA.38 The reason for such diversity appears to be the need to have criteria 
designed for medications available within each country. Despite these concerns, several trials 
have shown prescribing  criteria do support  the identification of  clinically  relevant  DRPs, 
discussed in the following sub-sections.
 2.2.1  Beers03
The Beers0338 criteria were developed to bring up to date an earlier version published in the 
199739 in the USA. It was acknowledge that the earlier Beers criteria required updating due to 
discontinuation of older drugs, new drugs becoming available and changed use of existing 
drugs. This version of the Beers criteria was developed using a modified Delphi technique 
which involved iterative feedback from a group of 12 medical experts to reach consensus or 
otherwise on the proposed criteria.
The Beers03 criteria was designed to be applicable to “... the general population of patients 
65 years and older”38.  Criteria were assembled into two tables: a table for PIMs, drugs to 
avoid or avoid at higher doses, totalling 49 criteria and; a table of 19 disease context PIM 
criteria. The criteria are detailed in  Appendix 1. Each criterion was assigned a high or low 
severity rating to assist interpretation. Several studies have supported the use of the Beers03 
criteria.112–115 A  recent  study  found  Beers03  could  be  used  as  a  measure  to  identify 
inappropriate prescribing more generally, beyond the medications listed in the criteria.115 MAI 
scores  for  non-Beers03  listed  medications  were  higher  (indicating  inappropriateness)  in 
patients  who  were  also  prescribed  Beers03  PIMs  compared  to  patients  who  were  not 
prescribed Beers03 PIMs.115 An Australian study of nursing home residents (1993 to 2005) 
found  the  use  of  Beers03  criteria  listed  medications  were  not  generally  associated  with 
increased hospitalisations.116 However, high-care residents had a greater likelihood of hospital 
admissions that were attributable to Beers03 PIMs.116
Criticisms include: criteria recommending against the use of amiodarone or fluoxetine, these 
medications  are  considered  useful  if  appropriately  monitored;  few  drug-drug  interaction 
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criteria; lack of drug-disease interactions such as NSAIDs in heart failure.103 An investigation 
into emergency hospitalisations  due to ADEs in older patients were not representative of 
Beers03  criteria  and  were  mainly  associated  with  four  classes  of  medications:  warfarin, 
insulins,  oral  antiplatelets and oral hypoglycaemics.63 Steinman  et al. study examined the 
drugs to avoid in older people according to the Beers03 criteria.117 Through expert review 
they found the majority of drugs to avoid were not actually causing problems  and concluded 
“...they are insufficiently accurate to use as stand-alone measures of prescribing quality”117
 2.2.2  Beers12
Subsequent to criticisms and the publication of studies showing the comparative advantage of 
the newer STOPP criteria, an updated version of the Beers criteria (Beers12) was released in 
2012.87,103,118,119 Details  of  the  Beers12  criteria  are  tabled  in  Appendix  1.  It  was  again 
acknowledged that the earlier Beers criteria required updating due to new drugs becoming 
available and the use of existing drugs in line with best practice. The 2012 version of the 
Beers criteria was developed using a modified Delphi  technique which involved iterative 
feedback from a group of medical experts to reach consensus or otherwise on the proposed 
criteria.  Rarely  used  medications  and  medications  no  longer  marketed  in  the  USA were 
removed and newer  medications  or  medication  classes  were  added,  details  are  shown in 
Appendix 2. 
Recent studies have investigated the use of the Beers12 criteria. One study of patients in 
Lanzarote, Spain120 found the Beers12 criteria had minimal overlap with the STOPP/START 
criteria and suggested the two tools were complementary, a finding similar to that published 
out of this thesis.121 In an Italian study Pasina  et al.122 compared Beers12 with Beers03 in 
patients 3 months post-hospitalisation and concluded patient using criteria-listed medications 
were not more likely to be at higher risk of ADEs, re-hospitalisation or mortality. 
We have since written an article utilising the Beers12 criteria which compared the frequency 
and  type  of  DRPs  identified  alongside  the  STOPP/START and  PIEA criteria  as  well  as 
original reviewing pharmacist findings.121 Of the three sets of criteria examined, the Beers12 
criteria was found to be the least representative of the original pharmacist findings.121
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 2.2.3  STOPP/START
The  STOPP and START (STOPP/START) criteria  were published in  2008 and contained 
explicit  criteria  which  had  been  validated  by  expert  consensus.89 STOPP/START  was 
developed out of limited information of benefit pertaining to existing criteria such as the 
Beers and Zahn criteria. Additionally, the applicability of such criteria in everyday practice 
was considered to be limited.89 The STOPP/START criteria were prepared from published 
details  of  inappropriate  prescribing  in  older  people.  These  sources  included  text  on 
pharmacology in older people and the British National Formulary.123–126 As with the Beers03 
and  Beers12  criteria,  the  draft  STOPP/START criteria  were  validated  through  a  Delphi 
process by a panel of experts in geriatric pharmacology.89
The 65 STOPP criteria identified instances of PIMs and the 22 START criteria identified 
instances of potential therapeutic omission. Details of the STOPP and START criteria are 
shown in Appendix 1.
An Irish study of acute hospital admissions related to ADEs found STOPP, unlike Beers03, 
was  more  strongly  associated  with  detection  of  avoidable  ADEs  contributing  to 
hospitalisations.118 Study summary is shown in Figure 6.
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A  review  of  medication  appropriateness  tools  recommended  the  use  of  STOPP  over 
Beers03.103 The START component was applied to elderly patients admitted to hospital and 
found to be simple to apply and effective in identifying prescribing omissions which were 
subsequently corrected in most patients.127
 2.2.4  PIEA
The PIEA93 was published in 2008 based on frequently prescribed Australian medications for 
common medical conditions rather than the expert panel consensus approach used with Beers 
and STOPP/START. The PIEA was developed from an investigation  of  frequent  medical 
conditions of older people encountered by GPs in Australia as well as common reasons for 
hospitalisation in older people. These conditions were narrowed to those conditions for which 
treatment  by  medication  was  available.  Medications  commonly  prescribed  for  these 
conditions  were  identified  through  the  Australian  Government  funded  Pharmaceutical 
Benefits Scheme. Australian drug information sources were used to create preferred treatment 
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Figure 6: Avoidable ADEs associated with STOPP and Beers03. 
Figure reproduced from Hamilton et al.118
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options using these commonly prescribed medications for the various disorders experienced 
by older people. PIEA contained 45 explicit criteria (rules that could be directly applied and 
produce a true or false answer) and three implicit criteria (based on clinical judgement). The 
explicit criteria included 25 PIM criteria, 19 criteria relating to prescribing omissions and one 
monitoring criterion. Details of the criteria are shown in Appendix 1.
Only  two studies  were  found which  assessed  the  PIEA in  practice.128,129 The  PIEA were 
applied  to  Spanish  nursing  home  patients  and  were  compared  with  the  STOPP/START 
criteria. The PIEA were found to be more likely to detect DRPs in patients and more likely to 
detect  more  than  two  DRPs  per  patient.  Similarities  between  the  criteria  involved: 
undertreatment  with  osteoporosis,  undertreatment  with  statins,  and  inappropriate  use  of 
psychotropic drugs. The most frequent DRPs identified by the PIEA involved lengthy use of 
benzodiazepines,  and  psychotropic  drug  use  in  patients  with  a  history  of  falling,  and 
anticholinergic drug use in patients with dementia.129
A study by the authors of the PIEA applied the tool to hospital discharge patients who were 
using 5 or more medications.128 Patients with dementia were excluded from the trial. This 
study found an average of 7 DRPs per patient involving both inappropriate prescribing and 
under-prescribing.  The most  frequent  DRPs identified were inadequate treatment  of  pain, 
insufficient antihypertensive therapy, and similar to the Spanish study, undertreatment with 
statins. Lengthy use of benzodiazepines also featured prominently.128
It has been acknowledged that the use of the PIEA has been low, one reason provided was 
lack of awareness of the tool.130 One drawback of the PIEA was it had not been independently 
validated. The original tool was subsequently validated in 2012 by an expert panel using the 
RAND/UCLA method (based on the Delphi method).94 The 2012 validated PIEA resulted in 
41 criteria, 9 original criteria deleted, 2 new criteria added, and some rewording of original 
criteria.94 The revised criteria contained 38 explicit criteria and 3 implicit criteria.
Sets of criteria, as discussed here, are in essence tools to be employed by health professionals, 
such as pharmacists, to address deficiencies in medication use. Tools such as these are an 
important component in the medicines review process.
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 2.3 Home Medicines Reviews
Medicines review services are offered in various countries including the USA, the UK and 
Australia  for  community-based  patients  through  specially  trained  community 
pharmacists.13,15,16 
In Australia,  the Commonwealth Government Department of Health and Ageing,  through 
community pharmacy agreements,  has provided funding since 2001 for Home Medicines 
Reviews (HMRs), a service for community-based patients. The HMR service has steadily 
grown with nearly 80,000 HMRs funded in the 2011/2012 financial year.131 The purpose of 
HMRs is to reduce ADEs, improve QUM, improve health care professional collaboration and 
ultimately improve patient health outcomes.16 Pharmacists are required to be accredited for 
provision  of  these  services  through  the  Australian  Association  of  Consultant  Pharmacy 
(AACP) or the Society of Hospital Pharmacists of Australia.16 A similar process is in place for 
patients  of  aged  care  facilities  and  is  called  residential  medication  management  review 
(RMMR).17
The HMR process is initiated with the identification of patients who are most likely to benefit 
from an HMR. Eligibility criteria include age, number of medications, changed medication 
plans, medications which require monitoring or have a narrow window of therapeutic effect, 
ADRs or  other  difficulties  with  patients  managing their  medications.16 These  criteria  are 
drawn from the evidence pertaining to DRP factors discussed in section 2.1.1.
A GP identifies a patient who is eligible for the HMR service and once patient consent is 
obtained,  an  accredited  pharmacist  is  contacted  to  conduct  the  HMR.  The  accredited 
pharmacist visits the patient, usually in the patient’s home, to conduct a patient interview. The 
interview elicits information about the patient’s medication use, health conditions and any 
other relevant factors. This information is analysed and a report is sent to the GP identifying 
DRPs and making suggestions for changes to the patient’s existing medication management. 
The process culminates in a medication management plan with the aim of improving patient 
medication therapy. Patient follow-up is required to determine the success, failure, or need for 
further adjustment to the plan.
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 2.3.1  The HMR process
The  medicines  review task  requires  the  pharmacist  to  obtain  detailed  medication-related 
information  concerning  the  patient.  The  patient's  GP  can  provide  details  of  prescribed 
medications,  diagnoses,  observations  and  laboratory  test  results.  The  patient's  regular 
community pharmacy can supplement the prescribed medications obtained through the GP 
with  medications  not  prescribed  by  the  GP,  such  as  those  obtained  through  medical 
specialists, pharmacists, optometrists and nurses. Medications dispensed at the community 
pharmacy can be reconciled with prescribed medications to assess adherence.
Much information is provided by the referring GP and patient's regular community pharmacy, 
however  this  is  supplemented  by pertinent  information  obtained  by conducting  a  patient 
interview preferably at  the patient's  home. Alternatively, interviews may be conducted on 
pharmacy premises. HMR accredited pharmacist Grant Kardachi explained “...my experience 
shows me that in the home the patient is more comfortable and relaxed and offers information 
more readily”132
The patient interview, preferably in the patient's home, elicits additional information, such as: 
how  the  patient  actually  uses,  or  does  not  use,  prescribed  medication;  the  use  of  non-
prescribed medications – over the counter medicines, herbal and vitamin supplements;  an 
understanding of the patient's motivation behind the actual rather than directed medication 
use; patient understanding of their health condition(s) and the purpose of their medications 
for  treating  or  preventing  illness.133 Apart  from  determining  medication  awareness  and 
compliance, previously unknown medication toxicity and untreated illness may be identified. 
The  home  interview  gives  the  pharmacist  insight  into  the  patient's  physical,  social  and 
financial situation as well as their compliance with therapy. These factors may directly impact 
on therapy.32,71 Many of these factors are associated with DRPs in older people, see section 
2.1.1. Social factors such as family and peer support can be more readily understood when 
observing patient interactions with other family members or peers in the patient's own home. 
Such support has been acknowledged as an element of improved adherence to therapy.65
Once  sufficient  information  is  gathered,  the  pharmacist  assesses  the  current  therapy, 
comparing prescribed versus actual  patient  use,  including potential  or actual  side effects, 
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costs,  drug  interactions,  conditions  requiring  treatment  and  treatment  complexity.32 If 
treatment  has  been  found  to  be  suboptimal  the  pharmacist  prioritises  treatment 
recommendations in a report of findings. In Australia, the report is submitted to the patient's 
GP for consideration of changes to therapy, some issues within the pharmacist's capacity, 
such as patient education can be resolved without the GP.
A flowchart of the typical medicines review process, from Lowe et al.32, is shown in Figure 7.
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 2.3.2  Benefits and limitations of HMRs
A retrospective analysis by Nishtala et al.134 of 500 Australian medicines reviews of aged care 
residents,  found  pharmacists  identified  medication-related  problems  in  96% of  residents. 
Similarly, an analysis of older, at-home, Australian patients by Castelino  et al.135, showed 
pharmacists identified medication-related problems in 99% of patients. Stafford et al.136 found 
pharmacist HMRs identified nearly 5 DRPs per patient on average. 
Several recent trials have shown evidence for the positive impact of medication reviews on 
patient health for various chronic conditions including HIV137, heart failure20 and diabetes.138 
A study by Ma  et al. Which was through a hospital outpatient service, showed pharmacist 
medicines review involving medication changes and improvements to medication adherence 
in HIV positive patients improved CD4+ cell counts and increased the number of patients 
with undetectable HIV viral load.137 Receiving an HMR was shown to delay a subsequent 
hospitalisation in patients with heart failure (45% reduction in hospitalisation rate).20 Fornos 
et  al.  implemented  a  pharmacist  care  program  for  diabetic  patients  through  which 
pharmacists reviewed medications and provided individualised patient education.138 A range 
of  measures  were  improved  including  reductions  in  HbA1c  (mean  8.5  to  7.9%),  total 
cholesterol (mean 217 to 202 mg/dl) and systolic blood pressure (mean 150 to 135mmHg).138
Medication specific benefits have shown reduced hospitalisations resulting from warfarin use 
(79% reduction in hospitalisation)139 and a positive effect on polypharmacy through reduction 
of over-prescribed medications.18,137
Castelino  et  al.42 investigated  whether  Australian  pharmacists  provided  evidence-based 
recommendations, and found 94% of recommendations made were evidence-based. Castelino 
concluded “a suitable trained pharmacist, with full access to the patient, medical record and 
supporting resources, can help to improve the quality use of medicines…” Supporting this 
finding, a number of Australian and international medication reviews and studies have found 
improvements in patient outcomes, quality of life and reduced hospital admissions.6,8,9,12,140 
Although  trials  may  not  always  show the  ultimate  benefit  in  terms  of  improved  patient 
outcomes, positive findings include reduced polypharmacy,18,137 and resolution of actual or 
potential DRPs.9,139,141 
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Conversely, several studies have not found improved patient outcomes.142,143 The MEDMAN 
trial  conducted  in  England  during  2002  to  2004  found  no  improvement  in  appropriate 
medication use, nor improved quality of life in patients who received community pharmacist 
medicines review compared to a control group.142 Additionally, the intervention arm was also 
found to incur greater cost.142 Another similarly conducted English trial in 2002 found no 
change in the prescribing of appropriate medications, nor improved health outcomes.143 A trial 
examining the impact of HMRs several weeks after hospital discharge actually found patients 
who were recipients of HMRs had a higher rate of hospital readmission.144  Despite the lack 
of  positive change shown from these trials, medicines reviews are broadly supported within 
England.13 
Campbell Research and Consulting conducted qualitative research into HMRs in Australia 
published  in  2008  and  obtained  consumer,  pharmacist  and  GP  perspectives  concerning 
HMRs.21 Consumer opinion was found to be positive with the main benefits seen from a 
consumers point of view being education, provided reassurance and the removal of out of 
date medication. However, despite positive opinion, consumers also reported that they did not 
consider the HMR to be a necessary service.21 Strong consumer satisfaction with medicines 
review services was also documented in a large US study, which showed consumer-identified 
benefits of improved education and better health.9 
The Campbell  report  highlighted several  barriers to  the implementation of the Australian 
HMR  program  by  pharmacists,  primarily  time  and  resource  limitations,  communication 
problems and administrative problems.21 Several problems raised by pharmacists from the 
report are listed:
• Lack of resources 
• Quality of report compromised due to time constraints 
• Poor communication between GPs and pharmacists, in particular lack of face-to-face 
communication and lack of professional relationship 
• Lacking confidence in making clinical recommendations to GPs
• Accreditation process: lost clinical knowledge since university
23
Inappropriate medication use in older people
• Older pharmacists feeling they have lost clinical knowledge
Some of these issues overlapped with concerns  from the GP perspective,  particularly the 
perception of inadequate clinical knowledge. GP perspectives from the report are listed:
• A feeling that community pharmacists were too busy to effectively participate in the 
HMR process 
• A lack of training and qualification of pharmacists in medication management of this 
nature 
• An  inappropriate  supply  of  information  by  pharmacists,  who  were  reported  to 
sometimes supply irrelevant or unhelpful information as part of HMRs 
The report also noted positive GP perspectives including:
• Improving patient awareness of their medications 
• Decreasing polypharmacy and costs to all 
• Gaining a second opinion on prescribing trends 
• Gaining a more complete understanding of the patient and their attitude towards their 
health and medications
Subsequent to the Campbell Report, a survey of HMR recipients and HMR naïve but eligible 
patients  was  conducted  during  2008  and  2009.145 The  majority  of  recipients  expressed 
opinions that they had better understanding of their medications and that they had reduced 
concerns about their medications compared to HMR naïve patients. The HMR recipients also 
preferentially rated saving money on medicines, taking fewer medicines and the ability to live 
independently at home compared to HMR naïve patients.145
The Campbell report showed the perspectives from both pharmacists and GPs of pharmacist 
lack of clinical knowledge, despite Castelino et al. finding Australian pharmacists were quite 
capable of identifying evidence-based problems.21,42 CDSS that are custom-designed to aid 
pharmacist  medication review may provide the  support  needed to address  some of  these 
concerns. CDSS is discussed in the next Chapter.
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 3 Clinical decision support systems
A HMR report must present an evaluation of a patient's medication therapy in light of a wide 
range of patient-specific factors, as discussed in section 2.3. CDSS may well have a part to 
play in the evaluation of patient medical information to assist with the detection of DRPs and 
potentially  provide  recommendations  for  their  resolution.  This  chapter  discusses  the  key 
issues of CDSS and what part these systems may play in assisting pharmacists with the task 
of medicines review.
 3.1 CDSS Definition
CDSS have been simply defined as “access to knowledge stored electronically to aid patients, 
carers and service providers in making decisions on healthcare”146 This definition includes 
passive CDSS and active CDSS. Passive CDSS requires an individual to actively search for 
information within an electronic system whereas active CDSS brings the information to the 
users attention, avoiding the individual's need for them to search.
A  more  detailed  definition  incorporates  the  important  concept  of  rules  –  machine 
interpretable representations of human expert knowledge – that allow software to analyse 
cases in a similar manner to the human expert and actively present its findings: 
“Electronic decision support systems have three main components:  knowledge, rules,  and 
software.  Knowledge  stored  electronically  includes  published clinical  practice  guidelines, 
commercial  databases,  and  custom-designed  knowledge  bases,  based  on  expert  opinion. 
Knowledge is translated into active rules used within the system. The software applies the 
knowledge, rules,  and local patient and clinical data,  and presents the electronic decision 
support functionality on the clinician’s desktop”146
 3.2 CDSS,  electronic health records and data standardisation
The  use  of  information  technology,  such  as  electronic  health  records  (EHRs),  has  been 
promoted and implemented to various degrees by various Governments (Australia, Canada, 
France, USA) as an important driver to improve patient health outcomes.147–151 This aim can 
be  achieved  through  the  use  of  electronic  standards  to  collate  and  communicate  health 
information  to  relevant  parties,  both  patients  and  health  care  professionals.152 Electronic 
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standards  including  EHRs  provide  a  consistent  structure  on  which  to  implement  CDSS 
capabilities.153 Data  standardisation  may  also  assist  health-care  professionals  and 
organisations to screen patients for health problems and to assist health-care professionals 
implement  best  care  practices  through  automated  analysis  of  patient  information  (data 
mining).154 Standardised formats are important to maximise communications between various 
electronic systems, which allows for efficiency gains, as the information must only be entered 
once, yet can be re-used many times by many different health providers.153,155–159
 3.3 CDSS Role
CDSS encompass a range of electronic resources, from passive electronic reference material 
to software that interprets data to actively advise healthcare professionals.160 CDSS can also 
have an impact on patient health management from a distance through the use of the internet 
and mobile technology.161,162 For the purposes of this thesis, CDSS will apply to software that 
actively applies rules to interpret patient data. Active advice includes prepared templates for 
completing information (work-flow support) reminders regarding due clinical tests (process-
based support), health condition screening, alerting (abnormal laboratory test values, allergy- 
drug- disease interactions), and therapeutic decision support.163 A common use of CDSS have 
been in combination with computerised prescriber order entry (CPOE) software which checks 
drug interactions, dosing, or patient contraindications such as allergies.164 Figure 8 shows an 
example of CDSS warning of multiple medications with sedative activity.165
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 3.4 CDSS Technology
CDSS implementations can vary from simple hard-coded static rules to complex artificial 
intelligence (AI). Knowledge based systems, also known as expert systems, are AI which 
have  been  developed  based  on  various  approaches.164 Examples  include  rules-based, 
probability-based and neural network systems.164 Expert systems have been defined as “... a 
computer model of expert human reasoning, reaching the same conclusions that the human 
expert would reach if faced with a comparable problem”.166
Expert  systems are  an  approach  to  replicate  the  problem solving  reasoning of  an  expert 
typically through the incorporation of a database of facts (such as a patient dataset) and rules 
(a knowledge base), with the rules applied to the facts via an inference engine to produce 
solutions.164,167–170 An overview of an expert system is shown in Figure 9.
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Case-based reasoning is a type of expert system in which the presenting problem is compared 
to similar cases stored in the knowledge base and solutions to the problem are presented. 
When a case is misclassified the correct classification is identified (usually by the expert 
user) and the case is stored in the bank as a new exemplar for that classification. As each new 
case is added and the knowledge base grows, incorrect solutions are gradually reduced.167 The 
flow of assessing cases and adding to the knowledge base is shown in Figure 10. This figure, 
provided by Dr Ivan Bindoff, is for a specific kind of case-based reasoning called multiple-
classification ripple-down rules (MCRDR).
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CDSS in general and expert systems in particular need to be validated to ensure they produce 
accurate results. Validation is defined as the “Determination of the correctness of the final 
program or software … with respect to the user needs and requirements”171 Flaws in software 
accuracy do occur, see section 3.6.2.
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 3.5 CDSS Benefits
CDSS has  generally  been found to be beneficial  providing assistance  in  areas  of  patient 
screening, prescribing, diagnosis, and preventative health.22,172–175 A comprehensive and oft 
cited review by Garg et al.22 found CDSS did improve healthcare professional performance in 
the majority of studies in the areas of diagnosis, disease prevention, disease management and 
prescribing. Despite improved healthcare performance, reviews of CDSS articles have found 
few have investigated or shown improved patient outcomes.22,176,177 
 3.5.1  Consistent advice
A  second  potential  advantage  of  CDSS  is  an  expectation  of  improved  consistency  of 
therapeutic decision-making.153,167,178 One of the fundamental problems of medical decision 
making was and is  the  explosion  of  knowledge;  this  quote  captures  the  enormity  of  the 
problem:
'Medical  educators of the middle and latter  19th century were the first  physicians in 
history to feel the real shock of the information explosion in medical science. By the  
1870s, an enormous increase in medical information was radically transforming medical 
thought  and  practice,  and  the  amount  of  medical  literature  began  to  become 
overwhelming.'179
Guidelines exist for the management of many diseases, apart from the prescribing criteria 
discussed previously in section  2.2. Australian guidelines have been developed by several 
organisations including: NPS (www.nps.org.au) and Therapeutic Guidelines (www.tg.org.au) 
covering  many  health  conditions,  as  well  as  disease-centred  guides  from specific  health 
organisations  such  as:  The  Heart  Foundation  (www.heartfoundation.org.au)  and  Diabetes 
Australia (www.diabetesaustralia.com.au). CDSS advice can be tailored from such guidelines 
to be displayed to the healthcare professional.
Many CDSS have been successfully trialled focussing on specific disease states and/or drug 
interaction  and  dosage  checking.170,175,180–186 Reviews  of  CDSS  have  generally  shown 
improved practitioner adherence to guideline-based recommendations.22,24,174,176,187 
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 3.5.2  Capacity to screen many patients
The ability to screen a database of patients to identify patients who require additional care 
such as routine monitoring, or risk of DRPs is a distinct advantage over manually searching 
patient  records.188 CDSS  screening  can  also  raise  health  care  practitioner  awareness  of 
patients who may require additional treatment or monitoring at the time of presentation.181 
 3.6 CDSS Limitations
The use of CDSS involves a broad range of factors beyond simply the decision support itself.  
An attempt to classify the CDSS workflow was undertaken by Sim and Berlin.189 A figure 
from their article highlights some core components of any CDSS, particularly considerations 
of  knowledge source,  the decision support  itself,  information delivery, context  of  use  and 
work-flow, detailed in  Figure 11. This figure raises awareness of the many factors that are 
involved in the development or implementation of CDSS solutions.
Many factors for successful implementation of CDSS are not immediately apparent, yet may 
be essential for user acceptance and ultimately the success or failure of the software. Factors 
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include:  work-flow integration  and  ease  of  use,  CDSS in  context  to  the  setting  or  task, 
organisational support, and user acceptance of CDSS recommendations.172,189 Authors from 
health disciplines have investigated and suggested factors that may impact on the end user's 
acceptance of  such technology,181,190–192 yet  few studies  provide  sufficient  design detail  to 
allow for identification of detrimental or beneficial design features. 23,193,194
The technology acceptance model (TAM) developed by Fred Davis was based on the theory 
of  reasoned  action,  to  help  explain  the  acceptance  and  use  of  technology.195,196 Several 
modifications  have  been  proposed,  however  the  model  comprises  two  core  components: 
perceived usefulness and  perceived ease of use.197 Perceived usefulness was defined as “the 
degree to which a person believes that using a particular system would enhance his or her job 
performance” and  ease of use was defined as “the degree to which a person believes that 
using a particular system would be free of effort”.195
In a review of health information technology perceived usefulness was considered the prime 
factor in intention to use or actual use of technology.197 Ease of use was found to correlate 
with  perceived  usefulness  although both  components  have  been confirmed to  be  distinct 
factors.197,198 The authors investigating health information technology stated the TAM “did a 
fair job predicting … end-user acceptance” in the health care environment although further 
improvements may increase acceptance predictions.197
Perceived usefulness implies confidence, or trust, in the appropriateness of findings presented 
by CDSS.  However, too much or too little trust in the findings of a decision aid can result in 
undesirable  outcomes;  Parasuraman  and  Riley  provide  examples  of  aviation  disasters 
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associated with both too much and too little trust in automation.199 The authors provide the 
following useful terms:
'Misuse refers  to  the  overreliance  on  automation,  which  can  result  in  failures  of 
monitoring or decision biases. Factors affecting the monitoring of automation include 
workload, automation reliability and consistency, and the saliency of automation state 
indicators.
Disuse, or the neglect or underutilization of automation, is commonly caused by alarms 
that  activate  falsely. This  often  occurs  because  the  base  rate  of  the  condition  to  be 
detected is not considered in setting the trade-off between false alarms and omissions.'199
Addressing human/computer factors of  misuse,  disuse,  ease of use and  perceived usability 
may lead to improvements in the uptake of CDSS. Reviews of CDSS studies identified the 
need to incorporate these factors.23,177 Several of these factors are described below.
 3.6.1  Alert fatigue
One of the well-established issues experienced with many CDSS is the excessive display of 
unsuitable alerts or reminders that leads to desensitisation to the proffered warning, known as 
alert  fatigue.200–203 This may be due to overly simple rules triggering an alert,  rather than 
taking  a  wide  range  of  patient  factors  into  context  as  has  been  noted  by  several 
authors.184,200,204 A  number  of  CDSS  studies  have  looked  at  health  care  professionals 
overriding CDSS alerts, finding the majority of alerts were ignored.205–207
Instead of simple static rules, more robust AI approaches such as expert systems may be less 
likely  to  produce  alert  fatigue  if  sufficient  data  were  available  to  apply  intelligence  and 
produce more specific and sensitive responses.
As concluded by Taylor et al. “Non-adherence to alert information appears to be associated 
with  additional  knowledge  of  the  clinical  situation,  beyond  that  inherent  in  the  decision 
support tool, for the specific patient context.”204 And, “We have really great technology for 
simple rules … The problem is getting beyond these simple rules,” Mark Musen, MD, PhD, 
professor of medicine, Stanford University.208
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 3.6.2  Information accuracy
Apart  from alert  sensitivity, alert  content  has  also  been  questioned.  An  Australian  study 
identified  the  lack  of  alert  sensitivity  involving  selected  major  drug  interactions  in 
investigated GP and community pharmacy software, and also a general lack of management 
advice within these alerts.209 Similarly an American study found a commercial database, First 
DataBank, classified investigated drug interactions with greater severity than was considered 
appropriate, also contributing to alert fatigue.210 
 3.6.3  Commercial interest
Commercial interest may not generally be viewed as a limitation of CDSS, in all likelihood 
CDSS may promote commercial  interest  in  a positive way through advertising of such a 
service to healthcare professionals,  see  Table 6 for examples of companies who promote 
decision support capabilities of their products to health professionals. Yet commercial interest 
in CDSS has been shown to be detrimental, and potentially damaging, as was the case to the 
Australian pharmacy profession during 2011.
The  Pharmacy  Guild  of  Australia,  an  organisation  representing  community  pharmacy 
proprietors, formed a partnership with Blackmores Pty Ltd, a company producing vitamin 
and  herbal  supplements.  The  partnership  centred  on  adding  CDSS to  existing  pharmacy 
dispense  software  which  prompted  pharmacists  when  dispensing  medications  for  several 
health  conditions  to  suggest  Blackmores companion products  for  these patients.211–215 The 
products  had no or minimal  scientific  evidence to  support their  use.216 The inflammatory 
“coke and fries” comment which likened the pharmacist's role to a fast food outlet, expressed 
by Blackmores chief executive Christine Holgate, made national television and newspaper 
headlines.211,214,215,217 Subsequently the plan for the CDSS deal was dropped.218
 3.7 Literature review of CDSS
Healthcare professionals, particularly pharmacists, undertake patient medication reviews to 
maximise QUM. It has been shown that pharmacists identify many DRPs and do provide 
evidence-based  recommendations  to  resolve  DRPs.42,134–136 Studies  have  generally  shown 
medication  reviews  result  in  improved  patient  outcomes.8,9,12,18,20,137,138,219 Pharmacists 
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generally rely on passive guidelines, and sometimes drug interaction checking software to 
assist in the identification and resolution of DRPs.42
CDSS  have  been  shown  to  improve  the  performance  of  healthcare  professionals  with 
diagnosis, disease prevention, disease management, drug dosing and drug prescribing.22,172–175 
Medication reviews assisted by CDSS can be anticipated to benefit in terms of improved 
prescribing of medications and/or improved patient outcomes, as both medication reviews 
and CDSS were independently associated with improved performance, as discussed above. A 
literature review was undertaken to determine if the combination had previously occurred, 
and what benefits occurred, if any.
The aim of this review was to identify and summarise literature about CDSS which actively 
assisted  the  healthcare  provider  in  the  context  of  general  or  disease-specific  medication 
review to identify problems and, if possible, provide recommendations for improved patient 
therapy.
 3.7.1  Search terms and criteria
Articles describing the use of CDSS for the purpose of actively assisting decision making 
during the medication review process were selected. Studies were excluded if they focused on 
a  specific  medication,  review  articles,  software  description  articles,  passive  electronic 
reference  materials,  exclusive  patient  disease  screening  software,  exclusive  drug 
interaction/dose  check  computerised  provider  order  entry  (CPOE)  decision  support  and 
manual medication review combined with electronic dissemination of results. 
PubMed and Embase databases were searched from 1990 to 2014. The PubMed search terms 
are shown in  Table 2. No unique articles were found in Embase. A total of 4,649 PubMed 
articles were found via search criteria. Additional studies were identified by screening the 
references in included articles, and through the PubMed related citations index. From these 
sources 23 articles matched the inclusion criteria.
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Table 2: PubMed search terms to July 2014
Search Term
(decision support medication review ambulatory) AND "1990/01/01"[Publication Date] : 
"2014/07/14"[Publication Date]
("1990/01/01"[Publication Date] : "2014/07/14"[Publication Date]) AND home medication reviews
("1990/01/01"[Publication Date] : "2014/07/14"[Publication Date]) AND inpatient medication reviews
("1990/01/01"[Publication Date] : "2014/07/14"[Publication Date]) AND medication therapy management 
software
(Drug Utilization Review/methods*[MeSH Terms]) AND "1990/01/01"[Publication Date] : 
"2014/07/14"[Publication Date]
(("1990/01/01"[Publication Date] : "2014/07/14"[Publication Date]) AND Evidence-Based Medicine[MeSH 
Terms]) AND Decision Making, Computer-Assisted[MeSH Terms]
("1990/01/01"[Publication Date] : "2014/07/14"[Publication Date]) AND Drug Therapy, Computer-
Assisted[MeSH Terms]
(Medical Records Systems, Computerized/utilization[MeSH Terms]) AND "1990/01/01"[Publication 
Date] : "2014/07/14"[Publication Date]
 3.7.2  Literature Results
Twenty-three  articles  were  found  concerning  the  use  of  CDSS  assisting  the  medication 
review process,  summarised  in  Table  3.  These  were  utilised  by  pharmacists,  nurses  and 
medical practitioners. Articles were specific to practice settings: hospital, general practice, 
pharmacy and shared care.  The articles have been divided into general review or related to 
specific  conditions  such  as:  CHF,  CAD,  angina,  diabetes,  asthma,  chronic  obstructive 
pulmonary disease (COPD), hypertension and lipid management.
Five articles220–224 describing one CDSS identified through a Google search in Section  3.8 
were not located through the above search terms and are not included in this section.
  General patient medication review
Medication reviews of hospital patients aged 65 or over were undertaken by nurses briefly 
trained in pharmacology compared with control in a Swedish study by Bergqvist et al.225 The 
Janus  web  application226 assisted  in  calculating  creatinine  clearance  and  drug-drug 
interactions  (DDIs).   Outcomes  investigated  were  re-admission  within  three  months, 
inappropriate  drug  use  (anticholinergics,  long  acting  benzodiazepines,  multiple 
psychotropics) and the number of DRPs detected. No significant differences were found for 
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readmission  or  inappropriate  drug  use.  Utilisation  of  the  CDSS  identified  86  clinically 
significant DRPs in 53 patients, which would have otherwise been missed. The number of 
clinically insignificant alerts was not mentioned.
Bindoff  et al.167 developed a prototype CDSS expert system, using MCRDR technology227, 
specifically for patient medication review. Patient medication review data for 126 real cases 
were  sequentially  entered  into  the  expert  system  by  a  medication  review  accredited 
pharmacist.  This  resulted  in  250  rules  which  included  information  of  patient  symptoms, 
demographics, medical history, medications and pathology results. The expert system was 
able to identify 80% of the potential problems detected by the medication review pharmacist. 
Less than 10% of the problems identified by the expert system were incorrect, reducing to 0% 
during entry of the final 15 cases. Based on the entered rules which covered 80% of potential 
DRPs detected by the pharmacist, the expert system identified at least one more DRP than the 
pharmacist per case entered. This suggested the pharmacist missed problems even though the 
pharmacist knew about the same problems, and had at some point entered a rule into the 
expert system for these problems. Interestingly, the pharmacist routinely identified problems 
with later cases that they had previously missed on earlier cases.
A subsequent article by Bindoff  et al.178 discussed the progression of the prototype CDSS. 
Improvements were enacted in the way medications and medical conditions were portrayed 
enabling the pharmacist expert training the system to develop suitable rules with greater ease. 
The revised system was trained with 244 patient cases resulting in 383 rules which covered 
90% of  the  potential  DRPs  detected  by  the  pharmacist.  The  authors  concluded  that  the 
pharmacist  expert in the study, and likely experts in general,  do appear to routinely miss 
relevant DRPs and this type of software can help to reduce this issue. A limitation of this 
finding was the use of only one pharmacist expert.
Another  Swedish study by Bladh  et  al.228 investigated CDSS-assisted hospital  medication 
reviews vs. control, assessing patient quality of life, DRPs and drug appropriateness. Reviews 
were assisted with use of CDSS which incorporated electronic guidelines for DDIs and drug 
appropriateness in the elderly. The CDSS was not well described but may have been similar 
to  the  Janus  application.  Patient  self-rated  health  was  improved  using  a  post-six  month 
analysis of the medication review intervention. Health-related quality of life was improved in 
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the intervention group mean 3.14 ±  0.87 compared with the control mean 2.77 ± 0.94, p = 
0.02, using a one to five rating to the question “In your opinion, how is your state of health?”  
Other self-rated quality measures were not significant using EuroQol-5 dimensions (EQ-5D) 
or EuroQol Visual Analogue Scale (EQ VAS). A reduction was found in the prescribing of 
three or more psychotropic drugs per patient (percentage of patients: control: 9.4%, intention 
to treat analysis: 7.9%, per protocol analysis: 2.3%, p = 0.034). Whilst CDSS was involved in 
this trial, it may not have been the only factor leading to the positive results. The intervention 
group  included  additional  interventions  of  medication  discussions  with  patients  and 
medication reports sent to patients' GPs. The positive results shown in this study may not be 
entirely due to the use of CDSS.
Software,  titled  Pharmanurse,  was  developed  to  assist  nurses  to  identify  ADRs  as  a 
component of medication review of nursing home residents.229 The software presented nurses 
with  resident-individualised  lists  of  potential  DRPs  for  418 residents  from eight  nursing 
homes. The nurses identified a mean of 3.7 DRPs per resident of which GPs agreed in 54% of 
DRPs  implementing  214  medication  changes  in  88  residents.  Health  professionals  were 
generally satisfied with Pharmanurse which scored 7 out of 10 for the potential to improve 
pharmacotherapy.  As  with  the  study  by  Bladh  et  al. the  DRPs  identified  and  changes 
implemented were not entirely due to the CDSS.
In  a  year-long  trial  by  Monane  et  al.230,  2.3  million  elderly  patients  were  automatically 
screened according to Beers criteria to initiate a short medication review. Pharmacists were 
alerted to 43,007 potential problems. Subsequently, pharmacists were able to contact 19,368 
GPs regarding 24,255 alerts to discuss potential DRPs and recommendations for resolution. 
Change of therapy was determined through GP telephone contact and through analysis of 
subsequent  patient  prescription  claims.  Change  of  therapy  to  more  suitable  medications 
occurred  at  differing  rates  depending on the  class  of  medication.  The largest  medication 
groups  resulted  in  significantly  changed  prescribing:  24%  change  for  most  long-acting 
benzodiazepines  (11,344 alerts,  p<0.001),  40% change  for  flurazepam (1,679 alerts,  p  < 
0.001),  25% change for shorter-acting benzodiazepines exceeding the recommended daily 
dose (4,532 alerts, p < 0.001), 17% change for anticholinergic antidepressants (2,856 alerts, p 
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< 0.001). The strength of this study was the very large number of patients involved, finding a 
small proportions of DRPs which resulted in substantial therapy changes.
Tamblyn et al.231 compared the effect of an active computer-triggered CDSS alert against a 
passive physician activated analysis alert by comparing follow-up prescription information. 
CDSS  was  triggered  during  CPOE  as  well  as  when  a  patient  chart  was  opened.  Alert 
sensitivity settings were available to either group and could be adjusted in display sensitivity 
by physicians in either group. In both groups not all physicians actively used patient EHRs 
reducing the opportunity to detect changes. The active CDSS identified 6,505 problems of 
which 668 alerts were displayed to the physician and 81 prescribing problems were revised. 
The passive physician activated alerts identified 4,445 problems of which 41 were seen by 
physicians and 31 were revised.  At the end of the follow-up period no difference in  the 
number of prescribing problems was identified, yet there was a significant reduction in the 
number of therapeutic duplication problems (odds ratio (OR) = 0.43, 95% confidence interval 
(CI) 0.29 – 0.64, p < 0.001). It is of interest to note the active CDSS alerts were ignored in 
88% of alerts. Physician reasons mostly concerned lack of benefit or clinical irrelevance. The 
high number of false positive alerts, even with adjustable alerting sensitivity was of interest, 
as  it  highlighted  the  issue  of  providing  patient  contextually  relevant  alerts,  which  was 
suggested  by  the  authors  as  a  cause  of  alert  fatigue  and  for  future  improvement  of  the 
software.200,201 
Another  Swedish  study  by  Ulfvarson  et  al.232 utilised  the  Janus  software  for  medication 
reviews in 233 elderly patients.  Medication review included pharmacologist  opinions and 
CDSS advice concerning DDIs and medication appropriateness from patient data entered into 
CDSS software. Measurements were conducted for DRP frequency, dosage changes, number 
of drugs used, and frequency of inappropriate drug use before and after. Evaluation of the 
CDSS itself,  or its impact on the medication review process, was not investigated.  Initial 
review found a mean of 10.4 drugs  and a mean of 1.5 DRPs per patient. Three or more 
psychotropic drugs were used by 34% of elderly patients.  The pharmacologist issued a mean 
of 3.3 physician recommendations per patient. A follow-up at two months found a mean 9.5 
drugs per patient was observed. Reductions were found for: drugs associated with kidney 
impairment  (17%),  anticholinergics  (40%),  long-acting  benzodiazepines  (17%),  drug 
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duplication  (30%),  and  use  of  three  or  more  psychotropics  (19%).  At  two  months  the 
adoption  of  recommendations  did  not  affect  patient  health  in  213 patients  and improved 
health in 51 patients, yet worsened health in 30 patients as assessed by researchers and health 
care staff.
  Specific disease management
An English study by Eccles et al.233 looked at adherence to asthma and angina management 
guidelines with assistance of CDSS. The CDSS was activated to provide guidelines for each 
condition  based  on  the  patient  EHR.  Data  was  collected  from one  year  prior  to  CDSS 
implementation and until one year post implementation. No significant changes were found 
regarding medications prescribed or in other care actions such as smoking education provided 
or inhaler technique assessed. At the end of the study, 2,241 angina patients and 1,760 asthma 
patients completed the one year prior, midpoint and one year post implementation quality of 
life  questionnaires.  There  was  low  use  of  the  software  and  no  changes  were  identified 
between control or intervention groups.
Modest improvements were found in a three year study of lipid management by Gilutz  et  
al.234 The  CDSS  implemented  in  the  study  identified  patients  with  CAD  and  produced 
monitoring and treatment recommendations which were mailed to GP clinics. GP clinics were 
randomised to control (56 clinics, 3753 patients) or intervention (56 clinics, 3695 patients). A 
health maintenance organisation obtained data from GP clinics and laboratory and pharmacy 
data for the CDSS. Study variables were lipid monitoring, statin initiation or optimisation and 
treatment  trends.  Investigators  also  looked  at  mortality  and  cardiovascular  associated 
hospitalisations.  Intervention  patients  had  significantly  greater  history  of  myocardial 
infarction and angioplasty at the trial start. Overall, the intervention group recorded better 
lipid monitoring (54.8% vs. 48.7%, p < 0.001) and a comparison of non-hospitalised patients 
showed a strong improvement (relative risk = 1.423,  CI 1.24 - 1.64, p < 0.001). Slightly 
improved statin prescribing occurred in the intervention group (59.1% vs. 53.7%, p < 0.003). 
Patient compliance determined via drug usage indicated only 28% of patients were therapy 
compliant (defined at taking 75% or more of their medication) with 47% of patients obtaining 
less than a quarter of the expected medication. The low rate of compliance impacted on the 
potential for improvement in LDL outcomes. Low-density lipoprotein (LDL) levels showed a 
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marginally improved reduction in the intervention group  (16.2% vs. 14.8% reduction, p < 
0.02) for patients whose initial LDL levels were over 120mg/dl. Clinical outcome showed a 
slight but significant reduction in all-cause mortality and hospitalisation (57.1% vs. 59.2%, p 
< 0.03). This important finding that points to the ultimate benefit of CDSS, improved patient 
outcomes, achieved through prescriber targeted activities.
A rule-based CDSS which provided advice on lipid management was tested by Hobbs et al.235 
in  21 GP practices against  4 control  practices during 1992. Measured outcomes after six 
months included changes in laboratory testing, changes in referral to a specialist and changed 
prescribing.  Data  from  one  control  and  seven  intervention  practices  were  unable  to  be 
collected due to various issues. No details of drug prescribing were presented although no 
change in drug costs between groups was found. A slight increase in full lipid profile tests  
occurred in the intervention group (χ2  = 49.5,  df  = 3, p < 0.05) but overall no significant 
change occurred. Hobbs noted the CDSS was used infrequently, as noted with other CDSS 
studies, although a particular limitation was the requirement to manually enter information 
into the software and the slow speed of the computers used.
Management of diabetics was investigated using a CDSS diabetic module with EHR in a 
study by Hunt  et al.236 at baseline and two years after implementation (4,265 patients from 
start  to  finish).  The  CDSS  included  alerts  for  diabetic  care  during  patient  visit,  daily 
identification of patients who were overdue for routine tests, benchmarking and feedback 
regarding  physician  and  clinic  performance  regarding  diabetic  measures,  and,  access  to 
electronic resources for physician and patient. LDL goal (<100mg/dl)) attainment improved 
from 32% to 56% patients (p = 0.002), average LDL decreased by 0.003 mmol/l (p = 0.002). 
Blood pressure (BP) goal (<130/80 mmHg) was attained from 30% to 52% patients (p = 
0.002). Mean  HbA1c was not changed overall but the number of patients who attained an 
HbA1c of 7% or less improved from 47% to 50% patients (p = 0.002). Increased proportions 
of patients received laboratory tests  for LDL (16% increase,  p = 0.002) and HbA1c (7% 
increase,  p  = 0.002).  Greatly  increased recorded use of  lipid  therapy (48% to  70%, p = 
0.002),  angiotensin-converting  enzyme  inhibitor(ACEI)  or  angiotensin  receptor  blocker 
(ARB)  (54%  to  69%,  p  =  0.002),  oral  hypoglycaemics  (56%  to  68%,  p  =  0.002)  and 
antiplatelet therapy (54% to 88%, p = 0.002) occurred. Increased retinal (39% to 59%, p = 
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0.002) and foot examinations occurred (26% to 79%, p = 0.002). Patient satisfaction did not 
change, nor was there an association with improved clinical outcomes. It would have been 
interesting to determine the impact of the feedback mechanism on physician use of the CDSS 
module. It would also have been desirable to compare the results against a control group as it 
could be difficult to determine whether GP education regarding diabetes care had generally 
improved over the two years of the study, independent of the CDSS module.
An expert system, Hypercritic237, provided review of hypertension treatment. Independently, 
Hypercritic  and  eight  physicians  reviewed  20  randomly  selected  patient  records  making 
comments  concerning  patient  treatment  to  assess  of  the  capability  of  the  CDSS.  The 
physicians  then  compared  their  findings  with  Hypercritic  findings.  Majority  agreement 
among the physicians determined 260 physician findings were appropriate of which 118 were 
also  identified  by  Hypercritic.  Several  barriers  were  identified  concerning  both  the 
applicability of the software and regarding medical judgement in general: Findings outside 
the scope of knowledge (rules not  incorporated for problems other than hypertension)  of 
Hypercritic and knowledge based on free text (not coded for computer analysis) accounted 
for 99 of the missed findings. The researchers also noted low agreement between physicians 
as to the most appropriate standard of care.
The  identification  of  adherence  to  asthma  and  COPD  guidelines  were  investigated 
retrospectively using EHR data from 28 GP clinics over a one year period by Kuilboer  et  
al.238 AsthmaCritic a knowledge based CDSS was designed to screen EHRs, identify DRPs 
and provide GPs with recommendations for specific patients. AsthmaCritic identified 8,412 
asthma or COPD patients who visited a GP at least once during the trial period (total 74,709 
visits, average 9 per patient). AsthmaCritic found an average of 3.4 DRPs per patient per visit 
(total  255,664).  In  patients  aged 12 years  old  or  over  the  main  DRPs consisted  of  non-
compliance (1,467) and contraindications - use of anti-inflammatory medication (1,381). In 
patients  less  than  12 years  of  age  non-compliant  route  of  administration  (691)  and non-
compliance  (304)  were  the  most  frequent  types  of  DRPs.  Non-compliant  route  of 
administration was the use of an inhaled device that  was considered by guidelines to be 
inappropriate for the age of the patient, an example was provided of the use of a powder 
inhaler in a 3 year old child. Whilst this retrospective, feasibility study is of interest, it would 
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have  been  beneficial  to  have  collected  information  regarding  GP  acceptance  and 
implementation of the recommendations, and perhaps in those patients where follow up was 
possible, outcome measures.
An expert system for hypertension management, ATHENA-HTN, was tested for accuracy by 
Martins  et  al.239 A  series  of  92  patient  cases  were  entered  and  ATHENA  drug 
recommendations were compared with GP review for the same cases. ATHENA produced 
181 recommendations, the GP made 184 recommendations. Difference of opinion occurred in 
19 recommendations. For 15 of these ATHENA was found to be more thorough concerning 
the change of drug therapy. Three cases resulted in the need to update ATHENA rules. This 
CDSS was able to match GP recommendations in the majority of cases and importantly the 
CDSS was considered to be more thorough in a number of recommendations. This highlights 
the usefulness of such a tool as an aid to GP review.
Diabetic care was also examined in a before and after trial involving GP practices by Montori 
et al.240 using a Diabetes Electronic Management System (DEMS) which included action plan 
recommendations,  clinical  alerts  and  medication  warning  advice.241 The  intervention  also 
included  implementation  of  planned  care  headed  by  a  practice  diabetes  nurse  educator. 
Diabetic care measures included frequency of laboratory test performance (lipids, HbA1c), 
physical examinations (foot, retina), counselling (exercise, smoking, diet), health care usage 
and patient metabolic outcomes for HbA1c, lipid profile and BP. DEMS was associated with 
significant improvements in implementation of examinations, advice and test requests (OR 
ranged  from  1.6  to  5.0)  except  total  cholesterol.  DEMS  alone  was  not  associated  with 
improved patient metabolic outcomes.
Perlini  et  al.242 developed a prototype expert system, using IBM ESE243, designed to assist 
GPs with choice of CHF drug treatment. This pre-EHR system required entry of relevant 
patient data such as demographics,  existing diagnoses and medications.  For 20 test  cases 
CDSS  therapy  recommendations  were  compared  against  cardiologist  recommendations. 
CDSS drug recommendations  covered  all  cardiologist  drug recommendations  in  9  cases. 
Recommendations mostly matched in another 5 cases and partially matched in 5 cases, the 
recommendation discrepancies were considered minor. Recommendations were completely 
different in one case involving a patient with arrhythmia. In 6 cases the CDSS recommended 
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an additional drug and in 7 cases the cardiologist recommended an additional drug. Overall 
the CDSS recommendations were comparable to cardiologist advice.
An expert system using the ILOG rules engine244 was developed for general practice use by 
Schnipper et al.245 This software provided a template for disease data entry with free text and 
coded data, to support patient management by providing recommendations for due tests (e.g. 
cholesterol) and medications (e.g. antiplatelets). Schnipper  et  al.246 trialled the CDSS with 
intervention  GPs  (3441  patients)  against  control  GPs  (3578  patients)  among  CAD  and 
diabetic patients. They measured the number of care deficiencies addressed within 30 days of 
the patient consultation. Results showed the system was used by intervention GPs for only 
5.6% of their eligible patients. The intervention group as a whole compared to control had 
more resolution of care deficiencies (OR = 1.14; 95% CI 1.02-1.28, p = 0.02). However, 
those 5.6% patients with whom the expert system was used, had greater resolution of care 
deficiencies  such  as  tests,  documentation  of  results  and  prescription  of  recommended 
medication compared with control plus intervention patients in whom the expert system was 
not used (OR = 1.58, 95% CI 1.31 - 1.90, p < 0.001). In this group antiplatelet prescribing, or 
documented  reason  for  not  prescribing,  was  significantly  increased  (4  prescribed  or 
documented per 101 patients vs. 111 per 7379, p = 0.02). The system showed promise, but its 
use was low due to GP reluctance to change their existing documentation habits, and due to  
the need to spend time to learn how to use the system. Unfortunately, no investigation of the 
appropriateness of the CDSS recommendations was undertaken.
The use of CDSS guideline reminders for diabetic and CAD patients was trialled by Sequist 
et  al.247 The  guidelines  included  recommendations  for  routine  tests,  and  for  diabetics, 
initiation of ACEI or statin therapy, and for CAD patients, initiation of aspirin, beta-blockers 
or  statins.  Medication  recommendations  were  triggered  by  medical  condition  and  lipid 
results. Reminders were displayed on a patient summary screen, yet both GP groups could 
print a paper patient summary which included the CDSS reminders. GPs were also surveyed 
concerning use of the guidelines and attitude to the CDSS. Control had 3,319 patients and 
intervention had 2,924 patients. There were significant differences between the groups with 
higher age, more white patients, more male patients and more Medicare insurance patients in 
the control group. The CDSS improved the use of three of nine guidelines, for cholesterol 
44
Clinical decision support systems
testing of diabetics (Hazard Ratio (HR) = 1.41, 95% CI 1.15 - 1.72, p < 0.001), and in CAD 
patients, use of aspirin (HR = 2.36, 95% CI 1.37 - 4.07, p = 0.002) and statins (HR = 1.51,  
95% CI 1.05 - 2.17, p = 0.03). Only one third of GPs noticed the CDSS reminders, yet of 
these 70% said they had acted on the recommendations. GPs thought the reminders were 
useful for disease management (53% CAD, 68% diabetes).
Cardiac care with GPs and pharmacists exposed to CDSS evidence-based medication and 
lifestyle guidelines via CPOE compared with control was trialled by Tierney et al.248 Patients 
were associated with intervention GPs only (N = 197), intervention GPs plus intervention 
pharmacists (N = 170), intervention pharmacists only (N = 158), or no intervention GPs nor 
pharmacists  (control,  N  =  181).  Patient  medication  adherence  and  quality  of  life  were 
measured  at  baseline  and  at  12  months.  EHR  data  was  collected  to  assess  therapeutic 
modifications  according  to  the  guidelines  (unmeasurable  lifestyle  recommendations  were 
excluded).  No  significant  improvements  in  compliance  with  guidelines  (initiation  or 
improved  therapy  with  ACEIs,  β-blockers,  aspirin,  antihyperlipidaemic  drugs,  diuretics, 
nitrates or calcium channel blockers) occurred (pharmacists and GPs p > 0.8, GPs only p > 
0.7,  pharmacists  only,  p  >  0.4).  There  were  no  differences  in  patient  quality  of  life  or 
medication  compliance,  emergency department  visits  or  hospitalisations.  A survey of  GP 
attitudes found the CDSS was a source of advice but too simplistic to apply to individual 
patients. The CDSS reminders were passive and able to be ignored and pharmacists rarely 
contacted the GPs concerning the recommended guidelines.
The same Indiana University research group (as Tierney) undertook a subsequent study by 
Subramanian et al.249 of CDSS and EHR via CPOE for chronic heart failure and investigated 
similar outcomes, patient quality of life and physician adherence to guidelines, and health 
care utilisation. Control (365 patients) and intervention GPs (355 patients)  were provided 
with ACEI, beta-blocker or diuretic recommendations but intervention GPs had additional 
recommendations triggered by patient symptoms (e.g.  oedema).  No overall  differences in 
adherence to guidelines (initiation or improved therapy with ACEIs,  β-blockers, diuretics, 
digoxin or referral to heart failure clinic) were found at 6 months (p = 0.5) or 12 months (p = 
0.4). Yet, at 12 months intervention patients had increased guideline use of diuretics (p = 
0.05).  Control patients were more satisfied,  scored with the 36 item Short  Form (SF-36) 
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Physical Component Score (p = 0.03). Intervention patients were more satisfied with their 
GPs at 6 and 12 months. The authors noted less than half of enrolled patients were prescribed 
beta-blockers or ACEIs indicating the need for trialling an intervention, although both groups 
were provided with recommendations for beta-blocker or ACEI use. A significant response 
may have occurred if these recommendations were applied to the intervention group only.
Tierney  et al.250 again with the Indiana University research group investigated CDSS and 
EHR via  CPOE with  evidence-based  asthma and  COPD guidelines.  Guidelines  included 
pulmonary tests, vaccinations, prescribing of inhaled steroids and inhaled anticholinergics, 
step  up  beta-agonist  use  and  smoking  cessation.  Patient  groups  were  studied  based  on 
intervention GPs (N = 194), intervention pharmacists (N = 161), both (N = 182) or none (N = 
169), as occurred in the earlier Tierney study.248 No significant changes occurred in any group 
for guideline adherence. No significant changes occurred with patient medication adherence, 
emergency  department  visits  or  hospitalisations.  Patient  quality  of  life  was  significantly 
improved for the SF-36 Physical Component Score only for patients in the combined GP and 
pharmacist intervention group (p < 0.05). As with the two previous studies by this research 
group, GPs were surveyed concerning the CDSS, with similar results suggesting the guideline 
recommendations were a good idea but too simplistic to apply to individual patients. As with 
the prior Tierney study, little communication occurred between pharmacists and physicians.
A small Swedish study of 48 CHF patients by Toth-Pal  et al.251 looked at  GP confidence 
regarding  diagnosis,  investigations  and  prescribed  medications.  The  Evibase®252 CDSS 
provided  recommendations  concerning  diagnosis,  further  investigations  and  prescribed 
medications based on available patient data. The CDSS increased GP diagnosis confidence in 
6 cases, and reduced diagnosis confidence in 6 cases. The GPs considered 31 investigations 
of  which  14  were  recommended  by  the  CDSS.  The  CDSS  recommended  adding  ACEI 
treatment to 11 patients whereas GPs added ACEIs to 5 patients. In 17 of the 48 cases, GPs 
considered CDSS support to be substantial. Some limitations of the CDSS were: inability to 
decide between dose adjustments or recommend additional medications, and having sufficient 
data to analyse. The CDSS affected GP confidence in their diagnosis and treatment plans by 
both agreement with GP decisions and by disagreement with GP decisions allowing further 
GP reflection of the case at hand.
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Table 3 summarises the various studies. The complexity of approach used by each of the 
CDSS  is  shown  in  the  integration  of  assessment  factors  column.  The  various  relevant 
assessment  factors  were  considered  to  be  medications,  diagnoses,  laboratory  results  and 
demographics.  The CDSS findings  were then classified  based on the  integration  of  one 
factor, two factors or multi-factorial, determined from the study methodology.
Table 3: Studies of decision support assisting medication reviews
Author Setting and study 
Type
Integration of 
assessment 
factors
Study Measures Conclusion
Bergqvist 2009225 Hospital.
Historical control
 Two factors Hospital 
readmission. 
Inappropriate 
drug use. DRPs 
detected.
No significant outcomes were found. 
Additional 86 DRPs were identified in 
53 patients
Bindoff 2007167 Pharmacist and 
software.
Case series 
comparison
Multi-factorial Number of DRPs 
identified, 
accuracy of DRP 
identification
80% pharmacist DRPs were identified 
by the CDSS. Less than 10% DRPs 
were incorrectly identified by software
Bindoff 2011178 Pharmacist and 
software.
Case series 
comparison
Multi-factorial Number of DRPs 
identified, 
accuracy of DRP 
identification
90% pharmacist DRPs were identified 
by the CDSS. 4% DRPs were 
incorrectly identified by the software
Bladh 2011228 Hospital. 
Randomised 
controlled trial
One factor Self-rated quality 
of life (global, 
EQ-5D, EQ-5D 
VAS), medication 
appropriateness
Improvement in global health rating 
score (p=0.02). Reduction in 
prescribing three or more 
psychotropic drugs. (p=0.034). EQ-5D 
was insignificant.
Dilles229 Nursing homes
pre /post
Multi-factorial Number of DRPs 
identified, 
Number of DRPs 
agreed by GPs,
Number of 
medication 
changes 
implemented
1527 DRPs identified by nurses in 
339 residents, 821 DRPs in 251 
residents agreed by GPs, 214 
medication changes implemented in 
88 residents
Eccles 2002233 General practice.
Cluster 
randomised 
controlled trial. 
One group 
asthma 
interventions and 
angina control. 
Other group 
angina 
intervention, 
asthma control.
Two factors Adherence to 
guidelines – 
general care or 
drugs prescribed. 
Patient quality of 
life 
questionnaires
No significant results regarding 
physician adherence to guidelines. No 
significant results regarding patient 
quality of life.
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Author Setting and study 
Type
Integration of 
assessment 
factors
Study Measures Conclusion
Gilutz 2009234 General practice.
Cluster 
randomised trial
Multi-factorial Lipid monitoring, 
statin initiation or 
optimisation, LDL 
levels, mortality, 
associated 
hospitalisations
Improved lipid monitoring (54.8% vs. 
48.7%, p<0.001). Improved statin 
prescribing (59.1% vs. 53.7%, 
p<0.003).
Reduced LDL in patients with high 
LDL levels (16.2% vs. 14.8% 
reduction, p<0.02).
Reduced mortality/hospitalisation 
(57.1% vs. 59.2%, p<0.03). 
Hobbs 1996235 General practice,
Randomised 
controlled trial
Multi-factorial Laboratory tests, 
changed lipid 
medication 
prescribing, 
patient referrals
Improved full lipid profile testing 
(χ2=49.5, df=3, p<0.05). No change 
identified in other tests performed, 
referrals or prescribed medication
Hunt 2009236 General practice.
Pre/Post
Two factors LDL, BP, HbA1c, 
anti-platelet 
therapy, foot and 
retinal exams
Improved LDL goal attainment 
(p=0.002), BP goal attainment (p), 
HbA1c below 7% (p=0.008). 
Increased retinal and foot 
examinations (p=0.002). Increased 
use of diabetic (p=0.002), lipid, 
(p=0.002) antiplatelet (p=0.002) 
medications.
Kuilboer 2002238 General practice.
Case series – 
post-test
Multi-factorial Number of 
patients identified 
with asthma and 
COPD, number 
and type of 
recommendation
s produced
Identified 8,412 patients who visited 
GP during study period. Produced 3.4 
therapeutic recommendations per 
patient.
Martins 2006239 GP and software.
Case series 
comparison
Multi-factorial Number of 
hypertension 
DRP 
recommendation
s, accuracy of 
DRP 
identification
In 92 cases, CDSS made 181 
recommendations, GP made 184 
recommendations. Discrepancy in 19 
recommendations of which CDSS 
was considered more thorough
Monane 1998230 Pharmacy / 
General Practice
Cohort study
One factor Number of 
potential Beers 
criteria DRPs 
alerted, number 
of GPs 
contacted, 
number of 
therapy changes 
by drug type 
43,007 alerts for 2.3 million patients, 
19,368 GPs contacted about 24,255 
alerts. Change of therapy varied 
according to drug class: main types: 
24% change long-acting 
benzodiazepines, 40% change 
flurazepam, 25% change excess 
dosing of shorter-acting 
benzodiazepines, 17% change for 
anticholinergic antidepressants. All 
changes p<0.001
Montori 2002240 General practice,
Cluster 
Two factors Frequency of 
laboratory tests, 
Improved provision of advice, 
examinations, test requests (OR 
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Author Setting and study 
Type
Integration of 
assessment 
factors
Study Measures Conclusion
randomised trial examinations, 
advice. Patient 
outcomes for 
HbA1c, BP, lipid 
profile
ranged from 1.6 to 5.0). No improved 
patient outcome measures associated 
with DEMs use.
Perlini 1990242 Cardiologist and 
software.
Case series 
comparison
Two factors Number of 
matching, similar 
or wrong CHF 
drug 
recommendation
s
9 cases: cardiologist recommended 
drugs were matched by CDSS
10 cases: partial but non-harmful 
match
1 case: inappropriate conclusion
Schnipper 
2010246
General practice. 
Randomised 
controlled trial
Multi-factorial Number of care 
deficiencies for 
coronary artery 
disease and 
diabetes 
resolved within 
30 day of patient 
visit
Low use of system by GPs (5.6% of 
eligible patients). Care deficiencies 
significantly resolved in this group 
compared to all other patients, 
OR=1.58; 95% CI, 1.31-1.90, p<0.001
Sequist 2005247 General practice. 
Randomised 
controlled trial
Two factors Adherence to 
care guidelines. 
Physician 
attitude
3 of 9 guidelines showed significant 
improvement.
Improved cholesterol testing of 
diabetics (Hazard Ratio (HR) 1.41 
(1.15-1.72) p<0.001)
CAD patients improved use of aspirin 
(HR 2.36 (1.37-4.07), p=0.002) and 
statins (HR 1.51 (1.05-2.17), p=0.03)
Subramanian 
2004249
General practice. 
Randomised 
controlled trial
Two factors Adherence to 
guidelines, 
patient quality of 
life, healthcare 
utilisation, GP 
attitude
No improvement in guideline 
adherence. No improvement in patient 
quality of life, except SF-36 physical 
component in control group
Tamblyn 2008231 General practice. 
Cluster 
randomised 
controlled trial
Two factors Difference in 
prevalence of 
prescribing 
problems
With CDSS reduced therapeutic 
duplication (p=0.02), no difference in 
overall prescribing problems. 
Tierney 2003248 General practice 
and pharmacy. 
Randomised 
controlled trial.
Multi-factorial Adherence to 
care 
recommendation
s, quality of life, 
exacerbations, 
medication 
compliance. GP 
attitude. 
Healthcare 
utilisation
No improvement in adherence to care 
guidelines or patient outcomes. GPs 
thought guidelines were a good idea 
but too simplistic for individual 
patients
Tierney 2005250 General practice Multi-factorial Adherence to No improvement in guideline 
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Author Setting and study 
Type
Integration of 
assessment 
factors
Study Measures Conclusion
and pharmacy. 
Randomised 
controlled trial.
care 
recommendation
s, quality of life, 
exacerbations, 
medication 
compliance. GP 
attitude. 
Healthcare 
utilisation and 
cost
adherence.  Generally no 
improvement in patient quality of life 
except SF-36 physical component 
(p<0.05) in combined intervention 
group.
Toth-Pal 2008251 General practice 
Case series 
comparison
Two factors Confidence 
change in 
diagnosis, further 
tests, medication 
change
Diagnosis confidence increased and 
decreased 25% cases, 31% cases 
further investigations considered 
(45% agreement with CDSS). 
Medication changed 19% cases (40% 
agreement with CDSS). Perception of 
substantial CDSS support 35% of 
GPs
Ulfvarson 2010232 Pharmacy/Gener
al practice.
Pre/post
Multi-factorial DRPs identified, 
changes in drugs 
used and 
dosages, total 
drugs used, 
number of 
inappropriate 
drugs
Reduction of average drugs used 
from 10.4 to 9.5 per patient. 343 
DRPs identified. Reductions in 
inappropriate drug use: 40% 
anticholinergics, 17% long-acting 
benzodiazepines, drug duplication 
30%, 3 or more psychotropics 19%.
Van der Lei 
1991237
General practice 
case comparison
Multi-factorial Number of 
comments in 
agreement with 
expert 
assessment
118 of 260 comments in agreement 
with experts. 99 comments outside of 
knowledge domain or in free text.
 3.7.3  Discussion
The positive findings in  15 of 20 studies167,178,228–232,234,236,237,239,240,242,246,247 were encouraging. 
Several further studies provided results that did not provide insight into how successful the 
CDSS was.237,238,251 However, proof of positive benefit on actual patient outcomes that can be 
attributed  to  the  CDSS  was  limited.232,234 Most  of  the  studies  investigated  improved 
prescribing or investigative tests, and about half of studies did not examine CDSS versus 
control.167,178,229,230,232,238,239,242,251
Several studies focussed on identifying DDIs, or where additional data was available, drug 
appropriateness and dosage in the patient population (notably: excess use of psychotropics 
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and  anticholinergics  in  the  elderly).225,228–232 Studies  investigating  specific  disease 
management looked at guidelines for test frequency, lifestyle management and appropriate 
drug and dosage use.233–236,238–240,242,246–251 
One study noted an excess of clinically insignificant alerts produced by CDSS231 which was 
also suggested by three others.248–250 The authors of the Tamblyn study231 suggested patient 
context was lacking, with similar findings concerning the application of simple guidelines in 
other  studies.248–250 Two  thirds  of  GPs  in  the  Sequist  study247 reported  not  noticing  the 
reminders, which may have been in some part due to alert fatigue. Whilst details of the types 
of approaches, or rules used, for the various CDSS are unclear, many studies appeared to use 
simple conditional rules.228,230,231,233,234,236,240,247–251 
One study using Janus provided results of CDSS alerts of clinically significant incidences, 
but did not say how often insignificant alerts occurred.225 The Swedish Janus application was 
previously identified with excessive alert production by Mannheimer et al.253, yet no mention 
of  this  effect  was  provided  in  the  two reviewed studies.225,232 Mannheimer  noted  clinical 
monitoring  context  was not  incorporated and would have  been likely  to  reduce  the high 
number  of  clinically  unimportant  DDI alerts  issued,  again  highlighting  the  issue of  alert 
fatigue (Janus employed a severity coded DDI database253).
Although the Janus application classified alerts by severity, and the Tamblyn study231 allowed 
GPs to modify alert sensitivity, the issue of displaying reminders and alerts in the context of 
patient health factors remained.
Eight studies involved the use of CDSS for the general medication review process.167,178,225,228–
232 Most  of  these  studies  targeted  patients  who  would  have  been  likely  to  benefit  from 
medication review, being the elderly or hospitalised patients.225,228–230,232 Of the studies225,228–232 
measuring the effect of the CDSS intervention, five found positive benefit.228–232
Many  studies  utilised  CDSS for  specific  disease  management.233–240,242,246–250 Many  of  the 
diseases  studied  (CHF,  hypertension,  CAD,  angina,  diabetes,  asthma,  COPD,  lipid 
management), were more common conditions which typically involved the use of complex 
management  guidelines.  Many  of  these  conditions  have  been  associated  with  evidence-
practice  gaps,  CHF254,  CAD28,29,  asthma40,255,  lipid  management29,  diabetes.29,256 The 
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complexity of management suggested CDSS could have a positive impact in the management 
of patients with these conditions, yet of the eleven studies233–236,240,242,246–250 which investigated 
guideline  adherence  or  patient  outcome,  only  six  showed  at  least  some  positive 
benefit.234,236,240,242,246,247
Half of the studies228,231,233–235,246–250 used a randomised controlled trial (RCT) design which 
provided a more rigorous basis for comparison of the effect of CDSS intervention, with or 
without  any  associated  interventions,  of  which  six  produced  some  positive 
results.228,231,234,240,246,247 
The three studies associated with the Indiana University research group used the Regenstreif 
Medical  Record  System  (www.regenstreif.org)  resulted  in  virtually  no  improvements  in 
guideline adherence or patient outcomes.248–250 Tierney suggested the reminders were invasive 
and time consuming. Tierney also stated GPs could easily skip past the reminder by pressing 
a  key rather  than read and provide a response.248 The subsequent  studies  by Tierney and 
Subramania may have also had this limitation.249,250
Six167,178,232,239,242,246 of  eight167,178,225,232,235,239,242,246 studies  using  knowledge  based systems 
showed positive results. Two studies of knowledge based systems did not assess change in 
terms of patient or healthcare practitioner outcomes.237,238 Six knowledge based system studies 
were either pre-deployment or prototypes.167,178,237–239,242 The advantage of knowledge based 
CDSS  is  the  capacity  of  the  system  to  integrate  a  wide  range  of  patient  contextual 
information to provide a more considered response. This is shown by the majority of positive 
studies of expert systems found in this review. Unlike simple conditional rules which were 
apparently used in many of the reviewed studies, expert systems may be expected to be able 
to provide more suitable, patient-contextual alerts and reminders, minimising the excessive 
alerting effect mentioned or suggested in several of the studies.231,248–250
An interesting observation was of three studies that utilised knowledge based systems. These 
were found to be more thorough (or perhaps more consistent) in detecting DRPs than their 
human counterparts.167,178,239
Lack  of  uptake  by  health  professionals  of  the  trialled  systems  was  noted  in  several 
studies.235,246–248 This lack of uptake also could have affected other studies, though no clear 
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mention of this was made. Several reasons for lack of uptake were discussed in some of the 
studies: CDSS advice was too simplistic, advice was not tailored for the needs of individual 
patients, CDSS advice was passive and as a result easy to ignore and practitioner reluctance 
to change existing processes.
There have been other articles which have discussed the possible lack of effectiveness of 
CDSS in general.153,257,258 More than half of the studies examined support the effectiveness of 
CDSS, particularly when implemented with rules that incorporate individual patient detail. 
Utilising such detail has provided conclusions of greater complexity when drawn from such 
individualised patient context, particularly as can occur with expert systems. 
 3.7.4  Conclusion
Excluding the studies by Bergqvist, Bindoff, Martins, Perlini, Kuilboer, Toth-Pal and Van Der 
Lei  which  did  not  measure  practitioner  change  of  therapy  or  patient  outcome,  ten228–
232,234,236,240,246,247 of fifteen228–236,240,246–250 CDSS applications, did improve at least some aspects 
of patient medication therapy or care, yet the intensity of effect was generally modest. 
Aspects  of  CDSS  that  appear  to  require  improvement  include:  overcoming  health 
professional inertia to improve user uptake of these tools; and improved specificity of CDSS 
advice utilising patient contextual rules, of which judging from this review, expert systems 
may  have  the  potential  to  achieve.  Of  great  interest  were  three  recent  knowledge  based 
system studies167,178,239 which produced more comprehensive identification of DRPs than their 
human counterparts, perhaps pointing a way forward for the improved use of CDSS.
 3.8 Google search for medication review software
As discussed in section 3.7, there were a variety of published studies involving CDSS with 
medication  review capabilities.  A background  search  of  medication  review software  was 
undertaken to identify commercial products that were able to to be evaluated for this thesis.
A search was undertaken to determine how many software companies provided medication 
review software, and particularly whether the software provided was advertised with decision 
support capability. The first  twenty links for the Google search term “medication therapy 
management software” and the first twenty links for the Google search term “medication 
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review software” were investigated. The initial search was undertaken 3 March 2011. The 
search criteria were applied using only English wording to identify websites of companies 
producing English language software.
Table 4: Google search term "medication therapy management software"
Website (from the first 20 
links)
Website refers to Software Data 
collection
Reporting Decision 
Support
http://en.wikipedia.org/wiki/
Medication_therapy_manag
ement
www.mirixa.com Mirixa √ √
www.medsmanageme
nt.com
Assurance System √ √ √
From 
www.medsmanageme
nt.com
Monitor-Rx √ √ √
http://www.pharmacychoice.
com/marketplace/category.cf
m/listing/MTM_Medication_
Therapy_Management
http://csshealth.com/pr
oducts.php
Medication Pathfinder √ √
http://www.pharmacychoice.
com/marketplace/category.cf
m/listing/MTM_Medication_
Therapy_Management
www.pharmacychoice.
com/marketplace/link.c
fm/mp_link_id/F9DCC
BF0-64A7-4749-
ACDC-20128F460C46
CommunityMTM
No information 
available – failed link
http://www.pharmacychoice.
com/marketplace/category.cf
m/listing/MTM_Medication_
Therapy_Management
See Assurance 
system
http://www.pharmacychoice.
com/marketplace/category.cf
m/listing/MTM_Medication_
Therapy_Management
See Medication 
Pathfinder
http://www.pharmacychoice.
com/marketplace/category.cf
m/listing/MTM_Medication_
Therapy_Management
www.nexdose.com/for
_hcp/MTM.htm
NexDose √ √
http://www.pharmacychoice.
com/marketplace/category.cf
m/listing/MTM_Medication_
Therapy_Management
www.getoutcomes.co
m/
Outcomes 
Pharmaceutical Health 
Care
√ √
http://rxinsider.com/medicati
on_therapy_management.ht
ml
See Assurance 
system
http://rxinsider.com/medicati
on_therapy_management.ht
ml
See Outcomes 
Pharmaceutical Health 
care
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Website (from the first 20 
links)
Website refers to Software Data 
collection
Reporting Decision 
Support
http://rxinsider.com/medicati
on_therapy_management.ht
ml
See Medication 
Pathfinder
http://rxinsider.com/medicati
on_therapy_management.ht
ml
http://www.mediware.c
om/
WORx
Dispense System not 
medication review
√
www.pillhelp.com/ www.pillhelp.com/ PillHelp Works
Consulting service
√ √
http://www.silverscript.com/e
n-US/medication-therapy-
management-
programs.aspx
SilverScript
Patient focussed site
? ?
Table 5: Google search term "medication review software"
Google Link (related 
information from first 20 
links)
Link refers to Software Data 
collection
Reporting Decision 
Support
www.mediflags.com/ MediFlags √ √ √
www.medscope.com.au/ Medscope √ √ √
http://mediview.com.au/ PharmSoft MediView √ √
www.guild.org.au/mmr/conte
nt.asp?id=423
List of Referral 
Templates for various 
medical systems
www.hrdcd.com/HRDMedRe
v.htm
Health Reference Disk √ √
www.pillpedia.com.au/ Pillpedia √ √
https://www.aacp.com.au/Fo
urpointRoot/portal/shared/As
sets/mmr_manual_09/AACP
_Manual_2009_Ch4.pdf
www.guild.org.au/resea
rch/project_display.asp
?id=257
Review of Domicillary 
Medication Management 
Review (DMMR) 
Software
Reviews:
Health Reference disc
MediFlags
Miracle MMR
Pharmcare
Other products 
mentioned:
Cognicare
EyreCare
HomeR
MediTrax
Medreviewer
55
Clinical decision support systems
Google Link (related 
information from first 20 
links)
Link refers to Software Data 
collection
Reporting Decision 
Support
http://www.miraclemmr.
com/
Miracle MMR √ √
http://www.healthcares
oftware.com.au/pharmc
are_index.html
PharmCare √ √
Deregistered company. 
ASIC Gazette 11/08
Cognicare
http://www.pfizer.com.a
u/facts/EffectiveDiseas
eMgt.aspx
EyreCare ? ?
Could not find web site HomeR
www.meditrax.com Meditrax √ √
Could not find web site Medreviewer
http://investing.businesswee
k.com/research/stocks/privat
e/snapshot.asp?
privcapId=113629414
Medication Review Inc.
Telepharmacy services
? ?
The searches identified 20 unique commercial software applications, shown in  Table 4 and 
Table 5, of which several were able to be further examined, shown in Table 6. Four software 
applications were either de-registered or no information was available, Cognicare, HomeR, 
Medreviewer,  CommunityMTM.  One  application  was  for  patient  use  (SilverScript),  one 
application was a dispense system (WORx), and one application was for general practice care 
plan management (EyreCare).
On further investigation, the Health Reference Disk website was out-dated with computer 
requirements stated as “Pentium II/III/IV computer with Windows 98/2000/ME or Windows 
95  with  Internet  Explorer  5  installed.”  On  attempting  to  email  to 
“webenquiry@mediview.com.au” the email was undeliverable. 
Likewise,  the  MiracleMMR  website  was  inoperable,  with  all  website  links  inoperable, 
including links to “contact us” and “order form”. Table 6 shows the medication management 
software applications which were current and available during April  2011 and able to be 
further investigated. These applications indicated medication review assistance was available 
via the software.
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Table 6: Summary of medication management software found through Google search
Software Link Data 
Collection
Reporting 
facility
Decision 
Support
Mirixa www.mirixa.com √ √ √
Medscope www.medscope.com.au/ √ √ √
PharmSoft MediView http://mediview.com.au/ √ √
Pillpedia www.pillpedia.com.au/ √ √
PharmCare http://www.healthcaresoftware.com.au/pharmca
re_index.html
√ √ √
Meditrax www.meditrax.com √ √
Assurance System www.medsmanagement.com √ √ √
Monitor-Rx www.monitor-rx.com √ √ √
Medication Pathfinder http://csshealth.com/products.php √ √
NexDose www.nexdose.com/for_hcp/MTM.htm √ √
Outcomes 
Pharmaceutical Health 
Care
www.getoutcomes.com/ √ √
MediFlags www.mediflags.com/ √ √ √
Each software product shown in Table 6 offered data collection and reporting functionality. 
Six advertised CDSS as  a  software  capability:  Assurance System,  MediFlags,  Medscope, 
Mirixa, Monitor-Rx and PharmCare. 
 3.8.1  Assurance system
The Assurance system (www.medsmanagement.com) is based in the USA. The advertised 
decision support was stated as: 
“Triggers that identify a problem situation suggest appropriate interventions and indicate 
which parameters need monitoring on an ongoing basis.” and “Access to Monitor-Rx 
module to  aid in  identifying medications that  may cause,  aggravate,  or  contribute to 
common geriatric problems and provide medication-monitoring recommendations”
(www.medsmanagement.com/Pharmacists/MTM_Practice/tools.html  accessed  April 
2011).
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Assurance was medication review software which provided patient data collection, decision 
support,  report  generation  and  administrative  services.  The  CDSS  as  suggested  in  the 
advertising appeared to be a rule-based system. A development in January 2011 incorporated 
Monitor-Rx for analysis of geriatric DRPs.259 This software is discussed below.
No studies from the Assurance system were identified though PubMed (searched April 2011).
 3.8.2  Monitor-Rx
Monitor-Rx (MRX)260 was based in the USA and was developed by the American Society of 
Consultant Pharmacists Foundation. It was initially developed and known as the MDS-Med 
Guide in 1999, then redeveloped as the Geriatric Risk Assessment Med Guide (GRAM) in 
2002.260 MRX was software that provided patient data collection,  decision support,  report 
generation and administrative services.
The decision support was advertised as:
“Monitor-Rx  identifies  medications  that  may  …  contribute  to  common  geriatric 
problems,  including  identification  of  potentially  inappropriate  medications  and drugs 
with anticholinergic properties; and provides medication-monitoring recommendations to 
foster  early  recognition  of  medication  problems...”  (https://www.monitor-rx.com/ 
accessed April 2011)
The purpose of the software was to identify DRPs, mainly PIMs, in elderly patients (60 years 
old and older), and to raise awareness of prescribed inappropriate medications and awareness 
of  the  need  to  monitor  for  medication-related  detrimental  effects.  MRX  identified 
medications that caused or worsened common problems in the elderly, grouped by care areas 
from the Resident Assessment Instrument Minimum Data Set 3.0261 (MDS 3.0): daily living 
activities,  behavioural  symptoms,  cognitive  loss  or  memory  impairment,  dehydration, 
delirium, dental care, falls, mood, nutritional status, pressure ulcers, psychotropic drug use, 
urinary incontinence and visual function.260 The software also identified PIMs based on the 
Beers38 criteria such as medications with anticholinergic activity. Coded information could be 
entered for diagnoses using the international classification of diseases, 9th revision (ICD-9)262 
coding system yet this coding was not incorporated into the decision support functionality.
58
Clinical decision support systems
One small  study of 29 elderly patients compared MRX and pharmacist  review of patient 
medication lists to identify those at risk of drug-related geriatric syndromes (MDS 3.0 care 
areas) and the use of PIMs.220 Based on medication lists, both MRX and pharmacists found all 
patients were at risk of falls. MRX identified more patients using medications with risk for 
geriatric syndromes than the pharmacist (175 vs. 124) whereas the pharmacist identified more 
PIMs (41 vs. 36 PIMs).
Papers concerning the MRX predecessor, GRAM, were identified221–224, one study showed 
results from the use of GRAM.222 
Lapane  et al.222 utilised the GRAM software to  assist  pharmacist  medication review in a 
control  versus  intervention  study  in  25  aged-care  homes.  The  GRAM  software  assisted 
pharmacist identification of residents taking medications associated with falls and delirium, 
as well as assisting in providing a guide to monitor these residents. Falls and delirium were 
two care areas within the MDS, and a fraction of the care areas that could be shown in MRX. 
A reduced delirium rate was found in the intervention homes, HR = 0.42, 95% CI 0.35-0.52. 
No reduction in falls was found.
No  other  studies  were  identified  involving  MRX (July  2014).  MRX was  superseded  by 
MedOptz  during  2013,  shortly  after  feedback  was  provided  on  the  MRX  product,  see 
Appendix  3.  The uniform resource  locator  (URL)  www.monitor-rx.com now (July 2014) 
points to a completely different blogging site, shown in Appendix 3. In finalising this thesis it 
was discovered in July 2014 that the MedOptz website www.medoptz,com had closed, see 
Appendix 3.
 3.8.3  MediFlags
Mediflags (www.mediflags.com) is based in Australia. Advertised decision support stated: 
“Flags  identify  clinical  scenarios  encountered  in  medication  reviews  and  are 
accompanied  by  background  information  (statements)  and  suggested 
recommendations…”  (https://www.mediflags.com/MediFlags_features_-
_sample_statements.pdf accessed April 2011)
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MediFlags is medication review software which provides patient data collection,  decision 
support recommendations, report generation and access to clinical resources. The CDSS uses 
a  flag  associated  with  a  medical  condition.  The  pharmacist  can  choose  to  view  the 
information  associated  with  the  flag  and incorporate  the  flag  information  into  the  HMR 
report. Mediflags is essentially a passive reference tool. The flags can be extended by the 
pharmacist  to  cover  various  routine  scenarios.  The  CDSS also  contained  HMR relevant 
reference materials concerning evidence-based medical information.
The  author  briefly  examined  Mediflags.  The  software  was  found  to  be  a  passive 
implementation of CDSS wherein the user of the software identifies the problem and assigns 
a prepared flag containing generic advice to resolve the problem.
One  study  was  found  in  PubMed which  appeared  to  be  a  paper-based  precursor  to  the 
MediFlags software.263 The study was trialled by GPs in over 700 patients. The study showed 
therapeutic  flags  resulted  in  medication  changes  in  14.5%  of  patients'  medications  and 
changes in other recommended activities such as therapeutic monitoring (7%). No further 
studies were found to July 2014, however a Mediflags press release dated 16h December 
2013 (available  from  www.mediflags.com/MediflagsPresselease.pdf)  stated  Medscope had 
acquired Mediflags.
 3.8.4  Medscope
Medscope  (www.medscope.com.au)  is  based  in  Australia.  Medscope  provided  decision 
support through software called Medication Review Mentor (MRM).
Advertised decision support stated: 
“MRM is an ‘expert system’. This means that it draws upon thousands of existing cases  
for knowledge on how to deal with the presented case. However, if an issue is presented  
for  the  first  time,  MRM will  be  unable  to  identify  it.  This  is  where  the  enormous 
advantage of the expert system technology used by MRM comes in. Pharmacists using 
the system can add new issues, and these are included in the knowledge base after being  
assessed by Medscope's clinical team. MRM, by design, grows in knowledge every time 
it is used.” (www.medscope.com.au/index.php?lMenuId=154 accessed April 2011)
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Medscope  is  medication  review software  which  organises  referrals,  collates  patient  data, 
produces reports and uses decision support to detect DRPs and provide recommendations. 
The CDSS is a knowledge based system using MCRDR, discussed in section 3.4, and based 
on the work of Dr. Ivan Bindoff.167
Apart  from studies  published as  a  part  of  this  thesis,  no studies  were found in  PubMed 
(searched to July 2014).
 3.8.5  Mirixa
Mirixa (www.mirixa.com) is based in the USA.
Advertised  decision  support:  “…our  sponsored  MTM  services  include  flagged  clinical 
alerts…” (http://mirixa.com/pdf/PharmacySlipsheet.pdf accessed April 2011)
Mirixa is a software application which assists pharmacists with identifying patient medication 
non-adherence and drug interactions.  It collates patient data and generates reports. It also 
contains packages which train pharmacists to educate patients. The CDSS as suggested in the 
advertising appears to be a rule-based system. However, very little detail of this product was 
available.
On searching for ‘Mirixa’, five studies were found in PubMed (searched to July 2014).264–268 
Of these, one study measured clinical effect in diabetics264 and showed improved low density 
lipoprotein cholesterol (LDL-C), diastolic and systolic blood pressure and body mass index 
(BMI), although the specific effect of the CDSS component was not examined.
 3.8.6  Pharmcare
Pharmcare (www.healthcaresoftware.com.au) is based in Australia.
Advertised decision support: “The HCS Clinical Suite is a comprehensive collection of 
decision support tools, assisting hospital and community care providers in delivering a 
complete  continuum  of  care  for  their  patients.” 
(http://www.healthcaresoftware.com.au/portal_cm.html accessed April 2011) 
Pharmcare  is  medication  review  software  which  collates  patient  data,  provides  decision 
support, produces reports, provides access to clinical resources, patient support and education 
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material  and administrative services.  The type or  capability  of the CDSS is  unclear.  The 
author was briefly shown the system implemented at the Royal Hobart Hospital, Tasmania. It 
appeared to highlight drug interactions rather than provide a more comprehensive medication 
review.
No studies were found in PubMed (searched July 2014).
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 4 Thesis Outline
Medication review is within the scope of practice of pharmacists and is performed in various 
countries world-wide. Previous published studies have shown generally positive results of the 
benefit  of CDSS to improve medication management.  However, alert  fatigue and lack of 
relevance, is a known problem with CDSS and occurred in some of the reviewed studies. 
Several studies of knowledge based expert systems showed the potential of more thorough 
assessment  of  patient  medication  management,  although  these  studies  were  in  prototype 
systems.
This investigation aimed to evaluate CDSS that were in active use by pharmacists to assist 
the medication review process.  The evaluation was aimed at  determining how successful 
different commercially implemented technologies were at the medication review task.
This thesis aims to address several questions concerning the commercial CDSS:
• Did they provide useful, clinically relevant decision support?
• Did they address or succumb to alert fatigue?
• Was the end user satisfied and accepting of the decision support?
• Did  the  knowledge  based  CDSS provide  more  thorough  reviews  as  suggested  in 
prototype articles?167,178
The  core  of  this  research  was  to  examine  the  potential  of  the  decision  support  systems 
developed for the medication review domain to identify clinically relevant DRPs and to make 
recommendations to resolve identified DRPs. Essentially, can CDSS be considered useful 
tools in assisting pharmacists with the medication review process? The fundamental features 
of CDSS in this domain is the identification of clinically relevant DRPs, to identify those 
DRPs without missing important DRPs, and to do so without presenting excessive irrelevant 
material, a known problem of many CDSS. 
The  actual  clinical  relevance  of  identified  DRPs  was  the  central  problem  within  this 
investigation. Clinical relevance depends on the subjective interpretation of the likelihood of 
harm  resulting  from  a  particular  DRP in  a  particular  patient  considering  that  particular 
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patient's  circumstances.  Clinical  relevance  of  DRPs  was  defined  for  the  expert  panel 
assessors as: “If [the DRP was] unresolved [the DRP] would have resulted in suboptimal 
outcome for this patient”. I will define clinical relevance in the context of DRP identification 
more generally as “Any DRP that would have reasonably been expected to have resulted in a 
suboptimal outcome considering the patient's individual circumstances”.
An evaluation of the decision support required measurement of two principal and interacting 
concepts.  The first  was the clinical relevance of identified DRPs and the second was the 
scope  of  DRP  detection.  To give  an  example  of  this  scope,  consider  a  patient  whose 
medication  therapy has  been assessed  by a  pharmacist  and found to  have  five  clinically 
relevant DRPs. This same patient is then assessed using software. If the software found only 
one DRP yet this DRP was clinically relevant, then one could say the software could identify 
clinically relevant DRPs but it's scope of detection was narrow and other clinically relevant 
DRPs were missed. This narrow scope may have a negative impact on the opinion of the end 
user of such software. Similarly, software finding numerous clinically irrelevant problems 
may also have a negative impression on the end user. Negative opinion of the usefulness of 
the software through poor relevance and scope may then lead to lack of use of such software, 
or at least of the decision support component.
The  evaluation  incorporated  several  distinct  yet  complementary  methods  of  assessment. 
Assessment was undertaken using the DOCUMENT classification system, examination of 
descriptive classifications of DRPs - the concepts capturing the core of the DRP allowing 
comparison between DRP sources,  and examination through expert  opinion.  Standards  of 
measure for comparative purposes were the original pharmacists DRP findings and sets of 
prescribing criteria (Beers03, Beers12, PIEA, STOPP/START).
A final approach to determining clinical relevance and usefulness of the MRM product, was a 
survey of pharmacists who used this product.
Medication review has been defined as:
 “the process where a health professional reviews the patient, the illness, and the drug 
treatment during a consultation. It involves evaluating the therapeutic efficacy of each 
drug and the progress of the conditions being treated. Other issues, such as compliance,  
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actual and potential adverse effects, interactions, and the patient’s understanding of the 
condition and its treatment are considered when appropriate. The outcome of the review 
will be a decision about the continuation (or otherwise) of the treatment”269
I have defined medication review software as:
The process where software reviews the patient, the illness, and the drug treatment for the 
therapeutic efficacy of each drug and the progress of the conditions being treated.  Other 
issues, such as compliance, actual and potential adverse effects, interactions, and the patient’s 
understanding  of  the  condition  and  its  treatment  are  considered  when  appropriate.  The 
outcome of the review will be decisions about the continuation (or otherwise) of treatments.
The primary hypothesis was: 
Medication review software with clinical decision support capabilities based on pharmacist 
knowledge should detect DRPs at a similar frequency and of a similar scope to those detected 
by pharmacists.  Secondarily, if recommendations presented to resolve therapeutic problems 
by medication review software are representative of contemporary therapeutic practice, then 
recommendations presented for problem resolution will be appropriate. 
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 5 General methods
This investigation aimed to evaluate CDSS that were in active use by pharmacists to assist 
the medication review process. The search for commercial CDSS medication review products 
in section 3.7 uncovered a range of possibilities,  from these, MRM and MRX were selected 
to be evaluated. The reasons for selection were: the products were available in the English 
language and approval for use of the software was provided.
MRM was chosen because it was developed in Australia and designed for the requirements of 
the medication review process in Australia. It also was advertised as providing “intelligent 
decision support”.270 MRX as a second source of software was found in the United States of 
America. This software was also advertised as a product which “...  assists in identifying, 
resolving and preventing medication-related problems among older adults”260 This source was 
chosen  because  it  was  English  language  software  which  provided  decision  support,  its 
predecessor  had  a  published  article222 showing  benefit  regarding  reduction  of  potential 
delirium and the software was an international comparator.
To assess the capacity of MRM and MRX to detect DRPs, a rich source of patient data was  
obtained. This data also needed to have the original reviewing pharmacist-identified DRPs to 
allow for comparison between software and pharmacist findings. Patient details also needed 
to be entered into each software application to obtain the core DRP data for analysis.
A schema of the various projects to achieve the aims of this thesis is presented in Figure 13.
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 5.1 Methodology
 5.1.1  VALMER data
The VALMER data available for this project was contained in a Microsoft Access database 
(Microsoft  Corporation, Redmond, Washington). This database was developed by Andrew 
Stafford for the VALMER project.8 The database contained the details of 661 HMR cases 
with review dates ranging from 28 March 2008 to 14 November 2008. Two of the cases did 
not contain patient birth dates, an essential requirement for software analysis leaving 659 
usable cases. The 659 HMRs were performed by 149 different AACP accredited medication 
review pharmacists, 108 of these pharmacists each submitted five HMR reports.
The  MRM  software  was  launched  in  February  2009  (personal  communication  Dr  Peter 
Tenni)  and  was  not  available  for  HMR  pharmacist  use  at  the  time  of  VALMER  data 
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collection. The MRX software was developed for the US market and launched during 2008.271 
A survey which recorded 117 responses of pharmacists involved in the VALMER project 
found twenty-two pharmacists utilised the Mediflags passive decision support product, no 
other products were mentioned.272,273
Six-hundred and fifty-nine cases were entered into MRM. MRX only analysed cases where 
the patient age was 60 years old or older. This resulted in 611 cases being suited for MRX. 
However, due to the voluminous and extremely repetitive output from MRX only 108 cases, 
aged 60 years old and older were actually entered into MRX. The selection of these cases was 
performed using Microsoft Access (Microsoft, Redmond, WA). Firstly, a randomly generated 
number was assigned to each case and the cases were ordered by random number from the 
lowest to highest values. A list of all cases aged 60 years old or older ordered by the lowest to 
highest random number was created. Cases aged 60 years old or older were entered one at a 
time into MRX until 100 cases aged 65 years old or older were entered.
The initial  intention was to enter patient  details  regardless of patient  age into MRM and 
patients aged 60 and older into MRX. However, prescribing criteria such as those discussed 
in section 2.2 were utilised in this investigation. The prescribing criteria were developed to be 
applicable to patients aged 65 years old and older, therefore the primary dataset used for 
analyses in this thesis was the cohort of 570 patients aged 65 years old and older. Four sets of 
prescribing criteria were automated as sets of database queries and applied to the VALMER 
patient data, discussed in section 5.1.4. DRPs identified through this process were recorded 
for comparisons with MRM, MRX and pharmacists original findings.
Patient data generally (but not always) included:
 Patient birth date, gender, height, weight
 Patient  diagnoses,  classified  with  the  International  Classification  of  Primary  Care 
Version 2 PLUS (ICPC2-PLUS)274
 Medications including directions
 Laboratory test results including date of result
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 Other symptoms
Drug related problems identified by the pharmacist:
 Description of the DRP
 DRP type by DOCUMENT275 classification
 Identification of the problem drug
 Identification of the relevant related medical condition where appropriate
 Pharmacist recommendations, if any, for resolution of the DRP
The medications for each patient were stored in a  PatientDrugs table which linked to the 
HMR case; each medication had a unique identifier and was assigned an ATC code. Anatomic 
Therapeutic Chemical (ATC) coding was used to group medications hierarchically.
Patient diagnoses and symptoms, stored in  Diagnoses, were linked to ICPC2-PLUS terms, 
stored  in  ICPC2Master.  ICPC2-PLUS was  used  to  group  diagnoses  and  symptoms  in  a 
hierarchical fashion similar to ATC coding. An example is the diagnoses of leg oedema and 
fluid  retention  or  swollen  ankle were  grouped  under  the  same  code  K07  Swollen 
ankles/oedema. These were then grouped under chapter  K Cardiovascular. These grouping 
classifications were generally convenient for the development of database queries. Tables for 
patient blood pressure and most recent creatinine clearance were developed from data stored 
originally in a Pathology table. A schematic of the database tables is portrayed in Figure 14, 
the ReviewDetail table contained patient demographic information.
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 5.1.2  MRM interface and data entry
The MRM software was accessed through a website. The details of each case were entered 
through various screens. Patient demographics,  medical conditions, allergies, medications, 
directions, observations and laboratory test results were able to be entered. For all of these 
data, option lists were available to select the appropriate item. This ensured data was suitably 
coded for analysis by MRM. An option list for medication directions was not provided but a 
list of terms understood by MRM was displayed. This was used to determine the estimated 
daily dose for a medication.
Virtually all information stored in the VALMER cases could be entered into MRM due to the 
similarity of the drug names, laboratory test names, and the use by both VALMER and MRM 
of  ICPC2-PLUS for  diagnoses  and  symptoms.  MRM accepted  extra  detail  that  was  not 
always available in the VALMER cases.
The work flow for entering VALMER cases is shown:
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1.  Enter the details of a VALMER case
2. Submit the case for analysis
3. Confirm details entered accurately
4. Record  the  DRPs  identified,  rules  for  identifying  the  DRP  and  the  associated 
recommendations for each case
  MRM Data fields
The following patient information was able to be entered into MRM:
 Patient identifier, birth date, gender, HMR date.
 Medical  conditions  (using  ICPC2-PLUS)  and  temporal  history  of  the  medical 
condition defined as: recent, ongoing, patient concern or past history.
 Allergies  –  selected  by  entering  part  or  all  of  a  medication  name  but  not  by 
therapeutic group.
 Medications – selected by entering part  or all  of name, directions,  daily dose and 
duration of treatment. Duration was defined as: unknown, more than 12 months, 3 to 
12 months  or less than 3 months  (recent).  Medications  were further  classified as: 
taken as prescribed, not taken as prescribed, or not taken. Pro re nata (PRN) (English: 
as the occasion arises) dosing could be left blank or an estimate of daily use could be 
entered.
 Observations – height, weight, body mass index (BMI), blood pressure, heart rate, 
respiratory  rate,  temperature,  mini-mental  state  exam (MMSE),  blood  sugar  level 
(BSL), Kessler psychological distress scale (K10), blood pressure (BP) and date of 
observation.
 Patient  laboratory  test  results  –  list  of  options  categorised  as  biochemistry, 
haematology, lipids, thyroid, arterial blood gases, and the date of the result.
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All  entries  showed  the  type  of  units  that  the  software  expected,  e.g.  haemoglobin  was 
expected to be entered as g/L. Other information was also able to be entered, such as contact 
details, and reference notes but these were not directly relevant to MRM analysis of DRPs.
  Entry of medications into MRM
Medications were entered into MRM as the original or generic equivalent medication via a 
data entry screen shown in Figure 15. 
Due to the approximately two year separation from the VALMER data collection until MRM 
data entry, several medication brands were not available in the MRM medication list. Close 
equivalents were entered; discontinued brands with frequency greater than one are shown in 
Table 7. A small number of medications, mostly herbal medications and topical preparations, 
had no equivalent and were not entered into MRM.
Table 7: Medication equivalents
VALMER medication brand MRM equivalent brand Active ingredient
Diamicron 30mg [2 daily] Diamicron MR 60mg [1 daily] Glicliazide
Ovestin vaginal cream Ovestin vaginal pessaries Oestriol
Nu-lax Senokot tablet Senna
Ducene 2mg or 5mg Valium 2mg or 5mg Diazepam
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Some  medication  directions  directly  entered  into  MRM  could  be  assessed  by  MRM  to 
determine an estimated daily dose. Where it was possible to do so directions were entered 
into  MRM in  an  MRM-assessable  format.  Many  VALMER medications  had  PRN usage 
instructions so estimated daily doses of these medications could not be entered, except in the 
rare  instances  where  the  pharmacist  comments  indicated  how  frequently  a  patient  was 
utilising a PRN medication.
Additional  comments  assigned  to  particular  VALMER  cases  assisted  with  determining 
whether medications were being taken as directed, partially as directed, or not at all. This 
information was entered into MRM.
Additional comments assigned to VALMER cases indicated how long a medication had been 
used. MRM provided the following options: unknown, less than 3 months, 3 to 12 months or 
over  12  months.  Very  little  information  was  available  concerning the  duration  of  use of 
medications. The duration for the majority of medications was entered as unknown.
  Entry of medical conditions into MRM
Medical conditions were entered through a screen depicted in Figure 16. When entering the 
cases from VALMER, the duration for medical conditions were marked as ongoing unless the 
condition was clearly a unique event (e.g. hysterectomy), mentioned as a patient's concern, or 
annotated as past history in the VALMER case notes.
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Figure 16: MRM medical history data entry screen
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  Entry of laboratory test results and observations into MRM
Observational information (e.g. blood pressure) and laboratory test results were stored in a 
pathology table in the VALMER database. Patient height and weight, where available, were 
stored separately. This information was entered into MRM via data entry screens, shown in 
Figure 17. 
Several VALMER laboratory test values required conversion into values suitable for MRM, 
shown in Table 8.
Table 8: Laboratory test value conversions
Item VALMER units Conversion factor MRM units
Vitamin B12 ng/L 304.056 pmol/L
Folate Serum mcg/L 10.87868 nmol/L
Transferrin umol/L 0.208 g/L
Several VALMER laboratory test results did not have equivalents in MRM and were entered: 
creatinine kinase, urinary albumin and fructosamine. Also, several cases indicated ‘normal’ 
values for various laboratory test items rather than numeric values. These 'normal' laboratory 
test items were entered into MRM.
  Reports created by MRM
On submitting the patient case to MRM for analysis, MRM produced a list of potential DRPs, 
illustrated in Figure 18. Each DRP was titled and an explanation of the potential problem and 
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Figure 17: MRM observations data entry screen
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recommendations  were provided.  A yellow link  provided a  short  list  of  rules  and values 
which triggered the DRP rule.
  MRM Data entry check
Twenty per cent of the 659 cases entered into MRM (N=132) were examined for accuracy. 
Data  contained patient  demographics,  diagnoses,  laboratory  test  results,  observations  and 
medications. The numbers of data point entry errors per case are shown in  Table 31. The 
majority of data point errors were omissions of entry into MRM. Three errors were entry of 
incorrect values. Each of these errors was subsequently amended.
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Figure 18: Example MRM-identified DRPs
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Table 9: Data entry errors showing count of audited cases and count of datum errors
Number of cases Count of data point errors Total data points
122 0 4064
4 1 169
1 2 56
2 3 95
1 4 23
1 9 47
1 23 46
Total 132 Total 42 Total 4500
Percentage of errors per case (42/4500 x 100) 0.93%
 5.1.3  MRX interface and data entry
MRX software was also accessed through a website. The details of each case were entered 
through various  screens.  Patient  demographics,  medical  conditions utilising  ICD-9  codes, 
allergies, medications and directions were able to be entered. MRX only analysed patients 
who were 60 years old and older – user manual Monitor-Rx Overview – NF 101119-1.276 One 
hundred and eight cases randomly sampled from the larger dataset of patients aged 60 years 
old or over were entered into MRX, of which 100 were aged 65 years old or older.
The selection of these cases was performed using Microsoft Access (Microsoft, Redmond, 
WA). Firstly, a randomly generated number was assigned to each case and the cases were 
ordered  by random number  from the  lowest  to  highest  values.  The first  108 cases  were 
selected for data entry into MRX.
MRX only examined the potential problems of medications used for chronic conditions, all 
medications  were  entered  into  the  software,  except  those  listed  in  the  section  Entry  of
medications into MRX.260 
  MRX Data fields
The following patient information was able to be entered into MRX:
 Patient identifier, birth date, gender,  date.
 Diagnoses stored as free text or linked to ICD-9 codes.
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 Allergies as free text entries.
 Medications – selected by entering part or all of name and directions. Medications 
could be marked with start dates and discontinued dates.
  Entry of medications into MRX
MRX was developed for use in the USA by the American Society of Consultant Pharmacists 
(ASCP)  Foundation  so  medication  brand  names  were  USA  brand  names.  Equivalent 
Australian branded medications were entered using brand or generic names where possible. 
Prescription  medications  that  were  not  listed  in  MRX included:  lercanidipine,  gliclazide, 
nitrazepam,  betahistine,  flunitrazepam.  Some  non-prescription  medications  could  not  be 
entered into MRX as the software did not have the products listed. These were: bromhexine 
and several herbal or vitamin supplements. The data entry screen is depicted in Figure 19, a 
drop down list of medications was presented on entering medication names.
  Entry of medical conditions, laboratory test results and observations into MRX
MRX was able to identify PIMs based solely on medication brand names or generic names. 
MRX did not utilise medical conditions nor laboratory test values for its assessments so this 
data was not entered into MRX (per discussion with the Director of business development 
ASCP, Douglas Allen).
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Figure 19: MRX medication data entry screen
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  Reports created by MRX
MRX provided three types of DRP report: 
 Intervention overview
 Geriatric Problem-Med
 Med-Problem
The intervention overview report displayed a table of the patient’s medications and a list of 
potential geriatric problem titles. Medications which were not screened for problems were 
listed as ‘no problems found’.
The geriatric problem-med report displayed a table divided into rows of problem areas, a 
description  of  the  medication-related  problem  and  a  list  of  medications  that  could  be 
associated with the problem area and monitoring indicators.  On the website,  medications 
identified  as  PIMs  were  highlighted  in  red  indicating  the  potential  for  more  significant 
problems. Monitoring indicators were a list of side effects that could result from the use of 
the problem medication. For each care area many monitoring indicators could be linked to an 
assessment test within the MDS for use within nursing homes. The purpose of the monitoring 
indicators  was  to  help  health  care  professionals  identify  geriatric  problems  that  may  be 
associated with a medication.
The geriatric problem-med report contained the greatest information so this was used as the 
basis  of data collection from MRX. This report  included the information available in the 
other  tables as well  as additional  short  comments which indicated the type of problem a 
medication could cause. As described in the user manual “This report is the heart and soul of 
Monitor-Rx.  It  presents  the  information  in  a  helpful  format  for  a  quick  and  clinical 
evaluation.”276
The med-problem report was similar to the geriatric problem-med report, but each row was a 
medication of interest followed by a list of problem titles and descriptions of medication-
related problems. Each description was identical to the description shown in the  geriatric  
problem-med display.
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Examples of the intervention overview report, geriatric problem-med report and med-problem 
report are shown in Appendix 6. Care areas are listed in Appendix 19.
  MRX Data entry check
Twenty  per  cent  of  the  108  cases,  21  cases,  were  examined  for  accuracy  of  entered 
medications. No data entry errors were found.
 5.1.4  Automation of prescribing criteria
The Beers03, Beers12, STOPP/START and PIEA prescribing criteria were automated, where 
possible,  to  provide electronic reports  of  identified  DRPs.  Beers12 criteria  were  released 
during this research but the work involving the Beers03 criteria was retained. Automation 
was considered an appropriate action due to the large number of patient cases (570 patients 
aged 65 and over).
All HMR cases contained patient age, and gender. Some cases did not contain diagnoses or 
laboratory test results, shown in Table 10.
Table 10: HMR case information available
Case information
(patients aged 65 years old and older)
Information present 
(number of cases)
Information absent 
(number of cases)
Medications 570 0
Diagnoses 566 4
Laboratory tests 455 115
Development of structured query language (SQL) queries and the application of these queries 
to the case data resulted in reports of cases which met specific criteria. Each criterion was 
assigned a DOCUMENT classification code, see section 6. Each criterion was also assigned a 
descriptive  classification,  see  section  7,  to  assist  further  analysis.  Lists  of  descriptive 
classifications are tabled in . A schematic of the database tables is portrayed in Figure 20, the 
ReviewDetail table contained patient demographic information.
  Beers03 automation
A  daily  dose  column  was  completed  for  medications  where  criteria  contained  dosage 
requirements  (aspirin,  lorazepam,  oxazepam,  alprazolam,  temazepam,  triazolam,  digoxin, 
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ferrous  sulphate,  piroxicam,  naproxen,  ketoprofen,  ibuprofen,  indomethacin,  diclofenac). 
This was achieved by filtering for the required medication and determining the daily dose 
from  the  medication  strength  and  the  medication  directions.  A limitation  was  lack  of 
directions or ‘when required’ directions; for these medications no daily dose was entered. 
Individual queries were developed for 53 criteria, listed in Appendix 1. 
Several medications in the Beers03 criteria were not available in Australia,  and were not 
specifically  included  for  the  development  of  the  automated  process,  although  they  were 
included if a query required the use of a higher ATC umbrella classification rather than the 
fifth chemical substance level. These excluded medications are listed in Appendix 4.
Fifty-one of the 68 criteria  were implemented as database queries,  listed in  Appendix 1. 
Several limitations existed with the rules developed for the criteria, listed in Appendix 4. 
  Beers12 automation
A daily dose column was completed for medications where the criteria  contained dosage 
requirements (aspirin, digoxin, doxepin, spironolactone). This was achieved by filtering for 
the required medication and determining the daily dose from the medication strength and the 
medication directions. A limitation was lack of directions or ‘when required’ directions, for 
these medications no daily dose was entered. Individual queries were developed for 48 of 52 
criteria from Beers12 tables 2 and 3, listed in Appendix 1. Several limitations existed with the 
rules developed, listed in Appendix 4.
Several medications in the criteria were not available in Australia, and were not specifically 
included for  the  development  of  the  automated  process.  These  excluded medications  are 
listed in Appendix 4.
  PIEA automation
The PIEA tool  of 48 prescribing indicators  contained both PIM and potential  therapeutic 
omissions, discussed under 2.2.4 PIEA. The SQL queries were written with the reverse intent 
to  identify  DRPs  as  potentially  inappropriate  medications  or  as  potential  therapeutic 
omissions. This was purposefully undertaken to allow comparisons with the STOPP/START 
and both Beers  criteria.  Generally  PIEA was more explicit  in  stating specific  conditions, 
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unlike the criteria defined in Beers03, Beers12 and even in STOPP/START. The advantage of 
this approach may be the greater sensitivity in targeting patients who met the prescribing 
indicators, yet the disadvantage was the greater complexity in attempting to reproduce the 
criteria in database queries, particularly when considering the limited data that was able to be 
utilised to develop the queries. This limitation may also apply to pharmacists who conduct 
HMRs, as they may also be hampered by lack of information to fully apply these criteria. 
Thirty-seven of 48 criteria were implemented as SQL queries based on the available data. The 
majority  of  implemented  criteria  were  assigned  the  following  DOCUMENT  codes:  14 
instances  D6 – Contraindications apparent  and 12 instances  U1 – Condition undertreated. 
Appendix  1 details  which  criteria  were  implemented  and  which  were  not  and  the 
DOCUMENT classification of each criterion.
There were limitations in the application of the database queries, listed in Appendix 4.
  STOPP automation
Database  queries  were  developed  for  the  STOPP criteria  utilising  the  patient  data  tables 
shown in Figure 45. Database queries were developed for each of the STOPP criteria, where 
it was possible to do so. The majority of implemented criteria were assigned DOCUMENT 
code D6 – Contraindications apparent (36 of 57 criteria),  seconded by DOCUMENT code 
U1 –  Condition  undertreated (6  of  57  criteria).  Appendix  1 tables  which  criteria  were 
implemented and which were not and the DOCUMENT classification of each criterion. Fifty-
seven of 65 criteria were able to be implemented as database queries.
Several limitations applied in the application of the database queries, listed in Appendix 4. 
  START automation
SQL queries were developed for the START criteria utilising the patient data tables shown in 
Figure  45 where  it  was  possible  to  do  so.  Seventeen  of  22  criteria  were  able  to  be 
implemented as SQL queries. All implemented criteria were assigned DOCUMENT code U2 
– Condition untreated. Appendix 1 lists which criteria were implemented and which were not 
and the DOCUMENT classification of each criterion.
Several limitations applied to the application of the database queries, listed in Appendix 4.
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 5.1.5  Ethical approval
Minimal risk ethics approval was granted for this project through the University of Tasmania 
Human Research Ethics Committee to conduct this research: H0011845. The approval letter 
is  shown in  Appendix 5.  The data on which this  project is  based,  the original VALMER 
project,  was approved by the University of Tasmania Human Research Ethics Committee 
ethical approval (HREC9360). 
 5.2 Results
Patient demographics and demographics of data subsets are shown in this section. Figure 20 
Also shows the summaries of DRPs identified within the main cohort of 570 patients aged 65 
years old or older. The figure also summarises the frequencies of DRPs identified by MRM, 
MRX and four prescribing criteria. The term case represents a patient.
 5.2.1  Cases aged 65 years old and older
There were 570 cases where the patient was aged 65 years old or older, shown in Table 11.
Table 11: Demographics of patients aged 65 years old and older
Cases 65 years old and older (N = 570) Result, count or mean ± standard deviation
Age (years) 80 ± 7
Gender Male 234 (41.1%) : Female 336 (58.9%)
Diagnoses With 566 (99.3%) : Without 4 (0.7%)
Laboratory test results With 455 (79.8%) : Without 115 (20.2%)
Number of medications 12.0 ± 4.4
Number of diagnoses 9.1 ± 5.2
 5.2.2  Cases entered into MRX
One hundred cases,  hereafter  referred  to  as  test  cases,  aged 65 years  old  and over  were 
entered into MRX. Statistical  analyses were performed to determine whether  the random 
sample of cases were representative of the 470 remaining cases, details shown in Table 12. 
Shapiro-Wilk tests for normality and quantile-quantile plots were examined to determine if 
age, number of medications and number of diagnoses violated normality test assumptions. 
Number of medications and number of diagnoses were found to be non-parametric. There 
were no significant differences between the 100 test cases and the remaining 470 cases.
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Table 12: Demographics of patients entered into MRX
Demographic Test cases (N = 100),
count, median and range, 
or mean ± standard 
deviation
Remaining cases (N = 470),
 count, median and range, or 
mean ± standard deviation
Statistical results for 
representativeness
Age (years)  78 ± 6 80 ± 7 T-test, t(149.521) = 1.80, p = 0.074
Gender Male  44 : Female 56 Male 190 : Female 280 Chi-squared test, Χ2 = 0.300, df = 
1, p = 0.584
Diagnoses With 99 : Without 1 With 467 : Without 3 Fisher's Exact Test, p = 0.539
Laboratory test 
results
With 78 : Without 22 With 377 : Without 93 Chi-squared text, Χ2 = 0.132, df = 
1, p = 0.716
Number of 
medications
Median 11.5, range 4 - 28 Median 11.0, range 2 - 27 Wilcoxon rank sum test,  W = 
23923, p = 0.777
Number of 
diagnoses
Median 8.0, range 0 - 29 Median 8.0, range 0 - 33 Wilcoxon rank sum test,  W = 
24520.5, p = 0.494
 5.2.3  DRP frequency
The  frequency  of  DRPs  for  pharmacists,  MRM,  MRX  and  prescribing  criteria  are 
summarised in  Table 13 and illustrated in  Figure 20. Frequencies of DRPs for the expert 
panel cases are shown here and in  Figure 20.  Details  of the expert  panel assessment are 
described in Chapter 8.
Table 13: DRPs identified by each source.
DRP source 570 cases aged 65 plus 100 test cases 20 expert panel cases
Pharmacist 2020 346 73
MRM 3209 547 125
MRX 1265 1265 265
STOPP/START 1032 166 36
Beers03 404 55 12
PIEA 1492 245 52
Beers12 399 68 15
In the 570 cases pharmacists identified a range of 0 to 13 DRPs per patient, median 3 DRPs. 
MRM identified a range of 0 to 16 DRPs per patient, median DRPs. 
The pharmacists, being human, and having visited patients and interviewed in their homes, 
can be expected to utilise more variables which would not be available to computer software. 
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Similarly, MRM was able to utilise more variables than MRX. Additionally, there were 256 
instances  where  MRM repeated  the  presence  of  a  DRP, although  the  DRP was  worded 
slightly differently. Two examples of MRM repetition are shown:
• GORD - Patient has a history of oesophagitis and is taking a calcium channel blocker  
which  may  exacerbate  the  situation.  Alternative  treatment  of  hypertension  or  
ischaemic heart disease may be considered.
• Reflux with Calcium Channel Blocker - Patient is receiving a proton pump inhibitor  
and is taking a calcium channel blocker. CCBs may exacerbate or precipitate GORD.  
It may be possible to use an alternative agent with a view to reducing or ceasing the  
proton pump inhibitor.
• Potassium  levels  -  Patient  has  moderately  elevated  potassium  and  is  taking  an  
angiotensin  inhibitor  which  may  be  contributing  to  this.  Dose  reduction  of  the  
offending agent may be appropriate if risk of cardiac adverse events is high.
• Potassium levels - Patient is taking an agent affecting the angiotensin system and has  
an elevated potassium level. Confirmation of ongoing hyperkalaemia and evaluation  
of  clinical  risk,  followed  by  dose  adjustment  of  the  offending  agent  may  be  
appropriate.
To make a  fair  and balanced comparison possible,  several  DRPs were excluded prior  to 
analysis, depicted in Figure 20.  Exclusions were the duplicate MRM DRPs, and pharmacist 
DRPs classified with DOCUMENT as Compliance or Not-classifiable. 
Duplicated MRM DRPs would skew frequencies and ratios, the real interest is in the number 
of  different  DRPs  found in  each case.  Compliance and  not-classifiable DRPs  were  only 
identified by the pharmacist,  since they were the only ones with the information at  hand 
required  to  determine  if  a  patient  was  being  compliant  with  their  medication  or  not. 
Pharmacists identified 250 compliance DRPs and 44 not-classifiable DRPs. The majority of 
the  compliance DRPs  (N=130)  concerned  patients  taking  too  little  medication  and  the 
majority of not-classifiable DRPs (N=36) concerned cost of therapy. Both MRM and MRX 
did  not  have the capacity  to  identify  compliance or  not-classifiable DRPs so these were 
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excluded.  DOCUMENT classifications excluding C and N categories will be referred to as 
DOUMET classifications. MRX was found to present a limited set of responses centred on 
elderly care areas. These responses are shown in Appendix 19.
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Figure 20: Frequency of DRPs identified by MRM, MRX and prescribing criteria
DOCUMENT classifications
 6 DOCUMENT classifications
The frequencies of DRPs identified by MRM, MRX, pharmacists and prescribing criteria are 
shown in Chapter 5. Frequencies  of DRPs alone provide little information about the types of 
DRPs  which  have  been  identified.  Classification  of  these  DRPs  using  a  validated  DRP 
classification system was desirable to give greater insight into the types of problems that were 
able to be detected by each of these DRP-identification sources.
Each of these DRP-identifying sources may differ widely in the problem types that may be 
identified  as  each  source  may  take  a  unique  approach  in  the  identification  process.  The 
original reviewing pharmacists may be anticipated to detect the broadest range of DRPs as 
they are most able to use a wide variety of information that may either not be available for 
use by software, or even if available for use by software, is not actually utilised within the 
software  algorithms.  Pharmacists  may  also  be  expected  to  draw  upon  a  repository  of 
experience and knowledge acquired from their training and practical experience in the field. 
MRM and MRX have been described in Chapter 5 and each utilised a different range of 
information. MRM incorporated a variety of information to produce lists of DRPs whereas 
MRX produced lists of DRPs solely based on the presence of certain medications. Apart from 
these commercial  products,  prescribing criteria  also utilised various information to  detect 
DRPs, primarily the presence of a medication of interest and often the presence of a disease 
state.38,87,93,119
The  DOCUMENT  classification  system  had  been  developed  in  Australia  and  has  been 
applied in an Australian locale to categorise DRPs identified by pharmacists.275 DOCUMENT 
is a two-tiered classification summarised in Table 14, with a letter denoting the main type of 
DRP e(.g. D - Drug-selection) and a number allocated to a particular problem type, (e.g. D2 
Drug-interaction). Detail of the classifications and sub-classifications are shown in Appendix
9.  Validation  of  the  DOCUMENT  system  was  performed  and  found  to  have  moderate 
agreement between pharmacists (Fleiss' Kappa 0.53) and re-test concordance rate of 69%.275 
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Table 14: DOCUMENT main classifications
DOCUMENT letter 
code
Description Number of sub-classifications
D Drug selection 8
O Over or under dose 4
C Compliance 6
U Undertreated 4
M Monitoring 3
E Education or information 3
N Not-classifiable 1
T Toxicity or adverse reaction 1
The DOCUMENT classifications have been utilised in several Australian studies assessing 
DRPs identified in HMRs and in community pharmacy practice. Williams  et al. presented 
results  of  DRPs  recorded  by  pharmacists  during  a   three  month  trial  in  185  Australian 
community pharmacies.275 Stafford  et al. examined the nature of DRPs identified from 234 
HMRs and aged-care medicines reviews conducted between 1998 and 2005 in Australia.136 
The  details  of  DRPs  were  examined  from HMRs  conducted  after  hospital  discharge  of 
Australian patients taking warfarin.277 The proportions of the DOCUMENT classifications 
from these three studies do vary, however, drug selection (25% to 31%), compliance (3% to 
11%), monitoring (2% to 10%) and not-classifiable (2% to 6%) present in similar proportions 
between the studies. Not surprisingly education issues comprised a substantial proportion of 
DRPs  within  the  warfarin  study.277 Drug  selection issues  comprised  a  consistent  and 
substantial proportion of DRPs in all three studies.
DOCUMENT classifications  provide  an  appreciation  of  the  range  of  DRPs  that  can  be 
identified  with  any  given  approach.  This  may  provide  a  greater  understanding  of  the 
differences between original pharmacists, MRM, MRX as well as the four sets of prescribing 
criteria. Nonetheless, one important limitation is that despite the assignment of DOCUMENT 
classifications to any DRP, no appreciation of the severity or clinical relevance of such DRPs 
is possible using this approach.
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 6.1 Methodology
Pharmacist,  MRM  and  MRX  DRPs  were  classified  using  the  validated  DOCUMENT 
classification  system.275 The  assignment  of  DOCUMENT  classifications  to  DRPs  were 
guided by the notes and examples provided in the Standard and guidelines for pharmacists  
performing  clinical  interventions.278 DOCUMENT  classifications  were  assigned  by  the 
author,  who  has  extensive  experience  and  has  participated  in  training  in  using  the 
DOCUMENT classification system.
All DRPs assigned C - Compliance or N – Not classifiable were excluded from analyses as 
these were only identifiable by the original reviewing pharmacists.  Only pharmacists  had 
access  to  the  information  required  to  determine  these  issues,  see  section  6.2.  DOUMET 
denotes  the  DOCUMENT  codes  excluding  Compliance (C)  and  Not  classifiable (N). 
DOUMET allowed for a less pharmacist biased comparison of the types of DRPs identified 
by commercial software, sets of prescribing criteria and pharmacists. It is important to note 
that the pharmacist's ability to detect these issues as part of their medicines review process is 
important and valued, and the inability of other approaches to do so is an acknowledged 
limitation. However, these issues were excluded from this analysis so as to allow for a fair 
and balanced evaluation of each DRP source's ability to identify DRPs that an automated 
computer software solution could reasonably be expected to identify, considering the patient 
data available to them.
DRPs  assigned  DOCUMENT  classifications  were  compared  by  frequency  and  type. 
Statistical  analyses comparing MRM DRPs with pharmacist  DRPs and MRX DRPs with 
pharmacists DRPs were performed using chi-square or where necessary Fisher's Exact tests. 
Data was split into two subsets for analysis: all 570 cases which excluded MRX and 100 test 
cases  which  included  MRX  DRPs.  Data  analysis  was  performed  using  the  R  statistical 
software, R Foundation for Statistical Computing, Vienna.279
 6.2 Results
The  results  are  divided  into  two  sections:  DRPs  identified  in  all  570  cases,  and  DRPs 
identified in the 100 test cases which were entered into MRX.
89
DOCUMENT classifications
 6.2.1  DRPs in 570 cases (excluding MRX)
Across 570 patients, pharmacists identified a range of 0 to 13 DRPs per patient, median 3. 
MRM identified a range of 0 to 16 DRPs per patient, median 5. The differing medians and 
long tails indicating skewed data can be seen in the box-plots in Figure 21. 
Table  15 summarises  the  DOUMET classifications  of  DRPs  for  pharmacists,  MRM and 
prescribing criteria.
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Figure 21: DRPs identified per patient, 570 cases
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Table 15: DRPs by DOUMET 
Source D O U M E T Total
Pharmacist 467 170 540 213 46 290 1726
MRM 1143 206 881 504 27 192 2953
Beers03 383 21 0 0 0 0 404
Beers12 378 21 0 0 0 0 399
PIEA 868 119 500 5 0 0 1492
STOPP/ 
START
625 19 388 0 0 0 1032
Total 3864 556 2309 722 73 482 8006
A chi-square  test  showed  significant  difference  between  all  six  sources  of  DRPs,  χ2 = 
2126.249, df = 25, p < 0.001. The chi-square approximation may be incorrect due to small 
numbers  in  12  cells,  Fisher's  Exact  Text  was  not  able  to  be  performed.  Chi-square  and 
Fisher's Exact Test comparisons between each source of DRPs were performed, shown in 
Table 16. There were significant differences in DOUMET proportions between most of the 
DRP sources. The exception was the Beers2003 and Beers2012 prescribing criteria in which 
proportions of DOUMET categories were almost identical.
Table 16: Chi-square and Fisher's Exact Test comparisons
Source MRM Beers03 Beers12 PIEA STOPP/ START
Pharmacist Χ2 = 204.3801,
df = 5,
p < 0.001
Χ2 =
639.2937,
df = 5,
p < 0.001
Χ2 =
632.6459,
df = 5,
p < 0.001
Χ2 =
651.8787,
df = 5,
p < 0.001
Χ2 =
579.4555,
df = 5,
p < 0.001
MRM Fishers Exact 
Test not able to 
be performed
Fishers Exact 
Test not able to 
be performed
Χ2 =
441.7172,
df = 5,
p < 0.001
Χ2 =
385.1902,
df = 5,
p < 0.001
Beers03 Fisher,
p= 1
Fisher,
p < 0.001
Fisher,
p < 0.001
Beers12 Fisher,
p < 0.001
Fisher,
p < 0.001
PIEA Fisher,
p < 0.001
The DRPs found by each source are also shown in Figure 22. The identification of DRPs by 
prescribing criteria  were limited to  drug selection,  over or under-dose and for PIEA and 
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START  under-treatment.  The identification of  DRPs by MRM was broader  and included 
monitoring,  education and  toxicity. Similar types and quantities of DRP were identified by 
both Beers03 and Beers12.
It can be seen in Figure 23 that MRM identified similar proportions of DRPs by DOUMET 
classification as those identified by pharmacists. 
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Figure 22: Count of DRPs for each source and DOUMET classification
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The proportions of DRPs assigned DOUMET classifications are shown in  Figure 23. The 
main differences between MRM and pharmacist  DRPs were in the classification of  drug 
selection where MRM found a greater proportion of DRPs than pharmacists, and the toxicity 
classification  where  pharmacists  found  a  greater  proportion  of  DRPs.  Yet  very  similar 
proportions of DRPs were found in the categories of  over or underdose,  undertreated and 
monitoring. 
 6.2.2  DRPs identified in test cases
Results of  DOUMET analysis of DRPs found in the 100 test cases entered into MRX are 
shown in this section.
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Figure 23: Proportion of DRPs from each source with DOUMET classifications
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Pharmacists identified a range of 0 to 8 DRPs per patient, median 3. MRM identified a range 
of 1 to 12 DRPs per patient, median 5. MRX identified a range of 3 to 19 DRPs per patient,  
median 13, shown in Figure 24.
Table 17 shows the DOUMET classifications of DRPs of the 100 cases which had been 
entered into MRX.
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Figure 24: DRPs identified per patient, 100 cases
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Table 17: DRPs by DOUMET, cases entered in MRX
Source D O U M E T Total
Pharmacist 77 32 86 47 7 54 303
MRM 191 42 148 91 4 30 506
MRX 0 0 0 1265 0 0 1265
Beers 2003 51 4 0 0 0 0 55
Beers 2012 61 8 0 0 0 0 69
PIEA 147 26 69 3 0 0 245
STOPP/STAR
T
105 5 56 0 0 0 166
Total 632 117 359 1406 11 84 2609
Fishers Exact Test was not able to be performed. However, an approximation using a chi-
square test showed significant differences between all seven sources of DRPs, χ2 = 2632.524, 
df = 30, p < 0.001. Where Fisher's Exact Test was able to be performed there were significant 
differences in the proportions of DOUMET classifications between most DRP sources, shown 
in Table 18. The exception was the Beers2003 and Beers2012 prescribing criteria.
Table 18: Fisher's Exact Test comparisons
Source MRX MRM Beers03 Beers12 PIEA STOPP/ START
Pharmacist Fishers Exact 
Test not able 
to be 
performed
Fishers Exact 
Test not able 
to be 
performed
Fishers Exact 
Test not able 
to be 
performed
Fishers Exact 
Test not able 
to be 
performed
Fishers Exact 
Test not able 
to be 
performed
Fishers Exact 
Test not able 
to be 
performed
MRX Fishers Exact 
Test not able 
to be 
performed
Fisher,
p < 0.001
Fisher,
p < 0.001
Fisher,
p < 0.001
Fisher,
p < 0.001
MRM Fishers Exact 
Test not able 
to be 
performed
Fishers Exact 
Test not able 
to be 
performed
Fishers Exact 
Test not able 
to be 
performed
Fishers Exact 
Test not able 
to be 
performed
Beers03 Fisher,
p = 0.546
Fisher,
p < 0.001
Fisher,
p < 0.001
Beers12 Fisher,
p < 0.001
Fisher,
p < 0.001
PIEA Fisher,
p = 0.008
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The  frequency  of  DRPs  found  by  each  source  is  illustrated  in  Figure  25.  This  figure 
highlights the great quantity of DRPs found by MRX, more than twice a great as MRM, and 
four times as much as the pharmacists original findings. It also clearly shows the specificity 
of MRX for the monitoring classification.
It can be seen in  Figure 26 that MRM identified a similar type and proportion of DRPs by 
DOUMET classification as those identified by pharmacists. 
One  hundred  percent  of  MRX  DRPs  involved  drug  monitoring,  whereas  MRM  and 
pharmacist DRPs were spread across all of the six DOUMET classifications.  The prescribing 
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Figure 25: Count of DRPs by DOUMET classification
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guidelines PIEA and STOPP/START identified DRPs from drug selection, over or underdose 
and  undertreated classifications.  The  Beers03  and  Beers12  guidelines  identified  drug 
selection and over or underdose classifications.
 6.3 Discussion
The MRM software was able to identify DRPs that could be classified into six DOCUMENT 
categories. MRX was restricted to the identification of DRPs presented as  monitoring for 
problems arising from medication therapy.
There were significant differences between the types and frequency of problems identified, 
with MRX showing the greatest extreme in the number of DRPs identified, quadruple that of 
pharmacist  DRPs,  and  the  narrowest  range  of  DRP  classifications.  In  contrast  MRM 
identified  a  wide  range  of  DRPs  at  double  the  frequency  of  pharmacists.  MRM  was 
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Figure 26: Proportion of DRPs by DOUMET classification
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significantly  different  in  the  composition  of  identified  DRPs,  with  classification  of  drug 
selection where MRM found a greater proportion of DRPs and  toxicity where pharmacists 
found a greater proportion of DRPs.
MRX based its  findings solely on the presence of medications of interest.  This approach 
limited  the  range  of  DRPs  that  could  be  identified  to  only  warning  pharmacists  of  the 
potential for problems to occur. Essentially, the DRP text was telling pharmacists to monitor 
the  patient  for  the  presence  of  medication  side  effects,  hence  the  exclusive  use  of  the 
monitoring category for MRX. There was no incorporation of the medication strength or 
dosage to give identify DRPs involving of over or under-dosing. Similarly, while diagnoses 
were  able  to  be  entered  into  MRX,  there  was  not  capacity  for  the  software  to  identify 
medications which were unsuitable in the presence of certain medical conditions. Similarly, if 
a medical condition existed where treatment ought to have been initialed, MRX was not able 
to identify the treatment omission.
The  MRM  software  also  identified  a  much  larger  number  of   DRPs  than  pharmacists, 
however MRM did identify a variety of DRP types, shown in Figure 26. Unlike MRX, MRM 
did factor in medication strength and dosing to enable it to identify potential over or under-
dosing  problems.  MRM  also  was  able  to  incorporate  medical  conditions  allowing  it  to 
identify untreated conditions where medication was absent and to identify medications which 
were inappropriate in certain medical conditions.  
The  sets  of  four  prescribing  criteria  each  identified  fewer  DRPs  overall  compared  to 
pharmacists, MRM or MRX. The scope of DRP classifications was also generally narrower, 
limited  to  drug  selection and  overdose  and  additionally  undertreatment  for  PIEA  and 
STOPP/START. Surprisingly, both  PIEA and STOPP identified  a  larger  number  of  drug 
selection issues than did pharmacists. The Beers2003 and Beers2012 prescribing criteria were 
very similar in both the frequency of findings as well as the types of DRPs.
Not unexpectedly, pharmacists were able to identify the widest range of problems with DRPs 
in all 8 DOCUMENT categories. Pharmacists uniquely identified  compliance DRPs (N = 
250)  and  not-classifiable  DRPs  (N  =  44).  Not-classifiable DRPs  mainly  consisted  of 
medication cost issues.
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The  classification  of  DRPs  using  DOCUMENT classifications  did  allow for  comparison 
between the sources of DRPs in a broad sense. It gave insight into the frequency of findings 
and the general type of DRPs that were identifiable. However, DOCUMENT classifications 
did not provide for determination of the clinical relevance of identified DRPs. Assessment of 
clinical relevance requires an understanding of each DRP in the context of each patient's 
individual  circumstances.  This  is  one of  the  main  limitations  of  using  the  DOCUMENT 
classifications. A second limitation was that the clinical detail of each DRP – the medication 
and/or  medical  condition  -   were  lost  when  comparing  DOCUMENT  classifications. 
Comparing the clinical detail of DRPs by frequency and type would have provided a stronger 
sense of the similarities and differences between MRM, MRX and pharmacists, as well as 
the prescribing criteria. Thus further assessments using alternative methods were performed.
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 7 Descriptive classifications
The DOCUMENT classifications allowed some insight into the frequency and types of DRPs 
that were identifiable by the various sources. However, the  DOCUMENT analysis did not 
provide sufficient detail regarding the particular problems that were identifiable. Naturally, 
each source of DRPs used their own vocabulary to describe the DRPs they were identifying, 
making direct comparison of the specific DRPs each source identified challenging. To solve 
this problem we developed a set of descriptive classifications for each of the DRPs. This set  
of classifications provided a set of descriptive terms describing each DRP in sufficient detail 
to allow for comparison between DRP sources. Descriptive classifications typically included 
specific drugs, drug classes and/or disease states giving clinical context to aid comparison.
 7.1 Methodology
All  DRPs  identified  by  each  source  were  mapped  to  descriptive  classifications  which 
described the drug and/or the disease or other therapeutic problems in greater detail than 
DOCUMENT  classifications.  Descriptive  classifications  allowed  direct  and  detailed 
comparison of the DRPs that were identified by pharmacists, MRM, MRX and prescribing 
criteria.  
The similarities between sets of prescribing criteria, shown in Appendix 8, formed the basis 
of the list of classifications. The initial list of classifications was developed where at least two 
or  more  sets  of  prescribing  criteria  were  in  agreement  concerning  particular  prescribing 
problems. Classifications described the PIM and often the associated diagnosis. An example 
is the classification: NSAIDs used with (risk of) renal failure.
DRPs identified by prescribing criteria, MRM, MRX and pharmacists were mapped to this 
initial list of classifications. The unmapped DRPs were then examined. Further classifications 
were developed where at least any two of MRM, MRX, pharmacists or prescribing criteria 
described the same DRP concept. Unmapped DRPs were then mapped to these additional 
classifications,  where  possible.  Again,  the  remaining  unmapped  classifications  were 
examined.  Classification  descriptions  were  broadened  and  included  DRP  classifications 
found in the DOCUMENT classification system.275 Examples include:  therapeutic dose too  
high; other drug no indication. Finally, remaining unmapped DRPs which did not have any 
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commonality with other prescribing criteria, software or pharmacists were assigned unique 
classifications. An example pharmacist-only classification is:  compliance – using too little  
medication.
The list of descriptive classifications are tabled in  Appendix 9. Distinct classifications per 
source are shown, that is, where two or more DRPs from the same source mapped to just one 
classification,  that  classification  was  counted  only  once,  so  as  to  eliminate  duplicated 
findings.
Several descriptive classifications were excluded from comparisons as they were exclusively 
associated with pharmacists and were considered clearly out of scope of analysis that was 
achievable  by  software,  given  the  nature  of  the  available  data.  Excluded  classifications 
involved  pharmacist-only  compliance and  not-classifiable DRPs,  specifically: 
Communication  breakdown,  Documentation  insufficient,  Compliance  –  Confusion  about  
therapy, Compliance – using too little medication, Compliance – using too much medication,  
Cost  of  therapy  concern,  Difficulty  using  dosage  form,  Eligible  for  DVA funded  DAA,  
Medication expired, Medication regimen complicated, Other DRP pharmacist. 
Examples of DRPs mapped to the same classifications are presented in Table 19.
Table 19: Examples of DRPs mapped to the same classification
Classification DRP Source DRP Source
Hyperlipidaemia undertreated MRM: Patient has elevated triglycerides 
and is only takng a statin. Additional 
treatment, such as a fibrate, may be 
worth considering.
Pharmacist: Patient's cholesterol and 
triglycerides remain elevated despite 
Lipitor. This may be due to poor 
compliance or an inadequate dose.
Glibenclamide prescribed STOPP: Glibenclamide or 
chlorpropamide with type 2 diabetes 
mellitus (risk of prolonged 
hypoglycaemia)
Beers12: Sulphonylureas long acting: 
glibenclamide, chlorpropamide
Heart failure and concurrent 
verapamil or diltiazem
STOPP: Use of diltiazem or verapamil 
with NYHA class III or IV heart failure 
(may worsen heart failure)
Beers12: Heart failure: NSAIDS, COX2, 
diltiazem, verapamil, pioglitazone, 
rosiglitazone
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Classification DRP Source DRP Source
Heart failure and concurrent 
verapamil or diltiazem
MRM: Heart failure with calcium channel 
blocker: Patient has a history of heart 
failure and is taking either verapamil or 
diltiazem. These agents can worsen 
signs and symptoms of systolic heart 
failure. Alternative agents should be 
considered if possible.
Pharmacist: Diltiazem may adversely 
affect patients with heart failure
Sedative long-acting or sedative 
long-term
MRX: Diazepam: Potentially 
inappropriate medications: Certain 
medications or medication classes 
should generally be avoided in older 
persons because they are either 
ineffective or they pose unnecessarily 
high risk for older persons and a safer 
alternative is available. Is there an 
indication for the medication? 
Pharmacist: Patient has been taking 
diazepam and temazepam for several 
years, which increases the risk of 
adverse CNS effects
The list of classifications was validated by a second pharmacist (and supervisor) – Professor 
Gregory Peterson. The table of 141 classifications and the 28 groups into which they were 
categorised are shown in Appendix 9.
Descriptive  classifications  were  compared  by  frequency  and  type  between  pharmacists, 
MRM,  MRX  and  sets  of  prescribing  criteria.  Analysis  of  classifications  was  mainly 
descriptive, presenting classification frequencies found by one DRP source or another and by 
those  found  in  common.  Classifications  were  considered  to  be  'in  common'  if  the  same 
classifications could be identified by two DRP sources in the same patient.
The basic unit of analysis was the number of distinct classifications found in each case. The 
number of distinct classifications found in each case may differ from the number of actual 
DRPs  found  in  each  case.  An  example  may  be  a  patient  using  both  atorvastatin  and 
simvastatin, both statins. If statins are contraindicated due to risk of myopathy, each of these 
DRPs might be assigned the classification statin myopathy risk. These two DRPs were then 
collated  into  only  one  distinct  classification,  since  the  end  goal  was  to  determine  if 
pharmacist or software was able to detect this central theme in this patient, with no extra 
credit being given for finding essentially the same problem multiple times.
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The Jaccard index, also known as the Jaccard similarity coefficient,280 was calculated on a per 
patient  basis  for  classifications  found  by  pharmacists  and  by  software.  The  index  was 
calculated as the number of classifications in common (set intersection) divided by the total 
number of classifications found by software and by pharmacists in the same patients (set 
union). The equation is shown in Figure 27. Potential values range from zero (no similarity) 
to one (complete similarity). The mean Jaccard index across all patients was calculated to 
determine how similar classifications were between pharmacists and MRM, pharmacists and 
MRX, and pharmacists and prescribing criteria.
 7.2 Results
Descriptive classification results between MRM and pharmacists are shown for the larger 570 
case cohort, and for the smaller 100 test case cohort which included MRX. The following 
subsections also show the classifications found by prescribing indicators. Bar charts highlight 
the  unique  classifications  identified  by  software  sources  in  dark-blue and  unique 
classifications  identified  by  pharmacists  in  light-blue.  Beige highlights  the  classifications 
which were identified in common.
 7.2.1  Descriptive classifications in 570 cases
The classifications from MRX DRPs were excluded from this section as only 100 of the 570 
cases were entered into MRX.
MRM identified 2953 DRPs which were mapped to  2854 classifications representing 100 
different types of problem. Pharmacists identified  1726 DRPs which were mapped to  1680 
classifications representing 113 different types of problem.
Ten classification types were identified by MRM and not pharmacists and 23 classification 
types were identified by pharmacists and not MRM. Ninety of the same classification types 
were identified by both MRM and pharmacists. Of these, 68 were observed to be identified 
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Figure 27: Jaccard Index equation
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concurrently by both sources on at least one patient. A table detailing the classifications and 
their frequencies is in Appendix 14.
Descriptive classifications identified by pharmacists, MRM and by prescribing criteria were 
summed  and  compared,  shown  in  Table  20 and  Table  21.  Comparison  with  published 
prescribing criteria  was performed.  The details  of descriptive classifications identified by 
each of the prescribing criteria are shown in Appendix 14.
As  a  percentage  of  the  pharmacist  classifications,  MRM  found  23%,  PIEA  9%, 
STOPP/START  8%,  Beers12  5%  and  Beers03  4%.  Compared  to  pharmacists,  greater 
proportions of DRPs identifiable by each of the prescribing criteria were identified by MRM.
Table 20: Classifications found by each source and classifications in common with MRM
Beers03 Beers12 Pharmacist PIEA STOPP/START
Total  classifications found 374 387 1680 1460 977
Number of different 
classification types identified by 
each source
23 21 113 33 42
Classifications in common with 
MRM
119 108 389 314 314
Total MRM classifications 2854 2854 2854 2854 2854
Percent of classifications in 
common with MRM 
classifications
4% 4% 14% 11% 11%
Percent of prescribing criteria 
classifications found in common 
by MRM
32% 28% 22% 32%
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Table 21: Classifications found by each source and classifications in common with 
pharmacists
Beers03 Beers12 MRM PIEA STOPP/START
Total classifications found 374 387 2854 1460 977
Number of different 
classification types identified by 
each source
23 21 100 33 42
Classifications in common with 
pharmacists
66 77 389 158 126
Total pharmacist classifications 1680 1680 1680 1680 1680
Percent of classifications in 
common with pharmacist 
classifications
4% 5% 23% 9% 8%
Percent of prescribing criteria 
classifications found in common 
by pharmacists
18% 20% 11% 13%
Jaccard Index, mean ± standard 
deviation
0.03  ± 0.09 0.04 ± 0.12 0.09 ± 0.12 0.05 ± 0.10 0.04 ± 0.10
Jaccard Index Range 0 – 0.67 0 – 1 0 - 1 0 – 0.67 0 – 0.67
Figure 28 also highlights the overlap of classifications identified by software sources with 
pharmacist classification findings. There was low overlap (identification of the same types of 
problems in the same patients) between pharmacists and all software or prescribing criteria 
using  the  Jaccard  Index,  shown in  Table  21.  The  highest  albeit  low overlap  was  shown 
between MRM and pharmacists with a mean  Jaccard index of 0.09  ± 0.12 across the 570 
patients.
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Classification categories found by MRM and pharmacists and those found in common in the 
same patient cases are shown in Table 22 and Figure 29, ordered by most to least common 
findings. 
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Figure 28: Classifications unique to pharmacists or computer source and classifications in 
common
Descriptive classifications
Table 22: Classification groups found by MRM and pharmacists (570 cases)
Classification category Total cases 
MRM found
Total cases 
pharmacist found
Total number of 
cases found in 
common
Total cases Overlap percent 
of total cases
GORD 304 44 15 333 4.5%
Coagulation/platelet 208 96 39 265 14.7%
Renal impairment 211 74 39 246 15.9%
Lipidaemia 191 75 33 233 14.2%
Analgesia 147 103 24 226 10.6%
Osteoporosis 144 118 50 212 23.6%
Other cardiovascular 144 66 23 187 12.3%
Mineral/vitamin 
supplementation
95 74 18 151 11.9%
Respiratory 113 27 10 130 7.7%
Diabetes 104 39 18 125 14.4%
Interaction 62 59 5 116 4.3%
Toxicity 39 81 11 109 10.1%
NSAID 81 52 26 107 24.3%
Neurologic (Epilepsy / 
parkinsons / other)
95 14 7 102 6.9%
Undertreatment 61 34 4 91 4.4%
Anticholinergic 59 40 11 88 12.5%
Gout 76 13 11 78 14.1%
Sedative 55 31 18 68 26.5%
No indication 35 34 1 68 1.5%
Digoxin 55 20 10 65 15.4%
Other 28 19 2 45 4.4%
Constipation 36 11 4 43 9.3%
Monitoring 22 19 5 36 13.9%
Heart failure 23 6 4 25 16.0%
Dose or duration of 
therapy
2 3 1 4 25.0%
The classification categories with the most in common between MRM and pharmacists were 
Osteoporosis (50),  Renal  impairment (39), Coagulation/antiplatelet (39),  Lipidaemia (33) 
and NSAID (26). The majority of classification categories were dominated by findings from 
MRM with the exception of Toxicity. Findings in the classification categories of GORD (304 
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vs. 44), Gout (76 vs. 13), Neurological (95 vs. 14) and Heart failure (23 vs. 6) were heavily 
weighted toward MRM.
Classifications in common between MRM and pharmacists are shown in Appendix 15 and in 
Figure 30 and Figure 31. Of 90 classification types found by both MRM and pharmacists,  68 
of these had at least one patient in common.
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Figure 29: Classification categories in common or unique to MRM or pharmacists
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Figure 30: Overlap of common classifications between MRM and pharmacists (first 34 of 68), 
count of classifications equals the number of patients
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The most frequent 'in common' classifications identified were:  osteoporosis (or risk) may 
require calcium or vitamin D - 49, renal impairment and using or check for renally excreted  
drugs -  24,  hyperlipidaemia under/untreated - 20,  sedatives long-acting or sedative long-
term - 18,  NSAID not recommended (CV/HF/bleed/other) – 17,  cardiovascular disease/risk  
requires antiplatelet – 16, and vitamin B12 and or folate deficiency possible – 16.
MRM found fifty percent or more of pharmacist findings for twenty classifications: Digoxin 
dose over 125mcg or considered too high (53%),  COPD/Asthma and using a beta blocker  
(50%), Antiplatelet not indicated (75%), Sedatives long-acting or sedative long term (58%), 
Anticholinergics  and  constipation (57%),  NSAID  not  recommended  (CV/HF/bleed/other) 
(61%),  Opioid  constipation  may  require  laxative  or  increased  lax  therapy (54%), 
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Figure 31: Overlap of common classifications between MRM and pharmacists (second 34 of 
68), count of classifications equals the number of patients
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Cardiovascular  disease/risk  requires  antiplatelet (62%),  Diabetes  and  CV risks  or  renal  
disease requires ACEI or ARB or CCB  (75%),  Renal impairment and using or check for  
renally excreted drugs (50%), Antigout medication (might) not indicated (85%), ACEI cough 
(58%),  Quinine  prescribed (91%),  Hyperlipidaemia  under/untreated (65%),  Diabetes  
undertreated  (HBA1c  or  BSLs  high) (53%),  Depression  un(der)treated (56%),  Iron  no 
indication (50%), Thyroid function monitoring required (57%), Anticoagulant toxicity (54%), 
Allopurinol with reduced renal function (63%).
MRM  found  all  of  the  pharmacists  findings  for  ten  classifications: Heart  failure  and 
concurrent verapamil or diltiazem, Dextropropoxyphene prescribed, Rosiglitazone prescribed  
and (risk of)  HF, Iron and constipation, Nitrofurantoin prescribed, Osteoporosis (or risk)  
requires  antiosteoporotic,  Calcium  channel  blocker  and  reflux,  Glaucoma  untreated,  
Antilipidaemic drug no indication, Lithium monitoring required.
The scope of DRP detection is shown in Figure 32. It can be seen MRM identified a wide 
range of problems approaching the range of problems detectable by pharmacists, yet MRM 
identified a far greater frequency of problems. The various prescribing criteria identified a 
small variety of problem types and in smaller volume. Interestingly, the two sets of Beers 
criteria identified the least number of problems by both volume and problem type.
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 7.2.2  Descriptive classifications in 100 test cases
MRM  identified  506  DRPs  which  were  mapped  to  492  classifications  representing  80 
different  types  of  classification.  MRX identified  1265 DRPs which were mapped to 880 
classifications representing 17 different  types of classification.  Pharmacists  identified 303 
DRPs  which  were  mapped  to  297  classifications  representing  79  different  types  of 
classification.
All 100 cases which were entered into MRX and aged 65 years old or over were used in this  
section.  Classifications  were  summed  and  compared  with  pharmacist  and  MRM 
classifications, shown in Tables 23, 24 and 25.
Sixty of the same types of classifications were identified by both MRM and pharmacists. Five 
of the same types of classifications were identified by both MRX and pharmacists.
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Figure 32: Frequency and variety of classifications for each DRP 
source
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Table 23: Classifications found by each source and classifications in common with MRM 
findings (test cases)
Beers03 Beers12 MRX Pharmacist PIEA STOPP/START
Total other source 
classifications
53 68 880 297 241 156
Number of different 
classification types 
identified by each source
10 16 17 79 27 32
Classifications in common 
with MRM
19 21 22 69 51 54
Total MRM classifications 492 492 492 492 492 492
Percent in common MRM 
classifications
4% 4% 4% 14% 10% 11%
Percent of prescribing 
criteria classifications 
found in common by MRM
36% 31% 21% 35%
Table 24: Classifications found by each source and classifications in common with 
pharmacists findings (test cases)
Beers03 Beers12 MRM MRX PIEA STOPP/START
Total other source 
classifications
53 68 492 880 241 156
Number of different 
classification types 
identified by each source
10 16 80 17 27 32
Classifications in common 
with pharmacists
9 15 69 11 24 20
Total Pharmacist 
classifications
297 297 297 297 297 297
Percent in common with 
pharmacist classifications
3% 5% 23% 4% 8% 7%
Percent of prescribing 
criteria classifications 
found in common by 
pharmacists
17% 22% 10% 13%
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Table 25: Classifications found by each source and classifications found in common with MRX 
findings (test cases)
Beers03 Beers12 MRM Pharmacist PIEA STOPP/START
Total other source 
classifications
53 68 492 297 241 156
Number of different 
classification types 
identified by each source
10 16 80 79 27 32
Classifications in common 
with MRX
25 28 22 11 18 14
Total MRX classifications 880 880 880 880 880 880
Percent in common with 
MRX classifications
3% 3% 3% 1% 2% 2%
Percent of prescribing 
criteria classifications 
found in common by MRX
47% 41% 7% 9%
As a percentage of the pharmacist classifications, MRM found 23%, PIEA 8%, STOPP 7%, 
Beers12 5%, MRX 4%, Beers03 3%. MRX identified the greatest number of classifications 
overall with minimal overlap of pharmacist classifications. Unlike MRX, MRM identified a 
smaller number of classifications yet a much greater proportion of classifications overlapped 
with  pharmacist  classifications.  MRX  identified  the  largest  proportions  of  classifications 
identified  by  both  sets  of  Beers  criteria  and  the  smallest  proportions  of  PIEA  and 
STOPP/START. MRM identified the largest proportions of the classifications found by PIEA 
and STOPP/START. The proportions of Beers03 and Beers12 classifications identified by 
pharmacists were lower than MRX and similar to MRM. Pharmacists identified more PIEA 
and STOPP/START classifications than MRX but less than MRM.  Figure 33 displays the 
overlap  of  classifications  identified  by  software  and  prescribing  criteria  with  pharmacist 
classification findings. 
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There was a low similarity between MRM and pharmacists with the identification of the same 
types of problems in the same patients calculated using the Jaccard index. The Jaccard index 
ranged from 0 (no similarity) to 0.375 (partial similarity) with a mean of 0.09 ± 0.11 across 
the 100 patients indicating low overlap overall. There was very low similarity between MRX 
and pharmacists with the identification of the same types of problems in the same patients 
calculated using the Jaccard index. The Jaccard index ranged from 0 (no similarity) to 0.125 
(partial similarity) with a mean of 0.008 ± 0.03 across the 100 patients indicating very low 
overlap overall.
Classification categories in common and unique to MRX or pharmacists are shown in Table
26 and  Figure 34, ordered by most to least findings. MRX identified a small scope of 20 
types of potential DRP found in the elderly, these are listed in Appendix 19. However, only a 
small number of DRP types overlapped with pharmacist findings.
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Figure 33: Classifications unique to the pharmacist or computer source and classification in 
common (100 test cases)
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Table 26: Overlap of common classification categories between MRX and pharmacists (100 
test cases)
Classification category Total cases 
MRM found
Total cases 
pharmacists found
Total cases found 
in common
Total cases Overlap 
percent of 
total cases
Other 160 3 3 160 1.9%
Anticholinergic 75 6 6 75 8.0%
Sedative 6 2 2 6 33.3%
Classifications in common between MRX and pharmacists are shown in Table 27 and Figure
35.  The  most  common  classification  identified  was:  Anticholinergic  use  not  elsewhere 
specified (6). This is perhaps not surprising, since anticholinergic and sedative classifications 
were the predominant findings by MRX. These classifications are prominent in the Beers03 
criteria  which  were  incorporated  into  MRX.  MRX  overlapped  with  every  instance  of  a 
descriptive classifications pharmacists found in the four classifications listed in Table 27, as it 
based DRP detection solely on presence of specific medications. However, MRX appeared to 
be unrefined, or excessive, in the frequency of descriptive classifications found.
116
Figure 34: Overlap of theme groups between MRX and pharmacists (100 test cases)
Descriptive classifications
Table 27: Overlap of common classifications between MRX and pharmacists (100 test cases)
Classification Total cases 
MRX found
Total cases 
pharmacists 
found
Total cases 
found in 
common
Total cases Overlap 
percent of 
total cases
Falls risk/history and 
sedatives/antihypertensives/ 
other
100 1 1 100 1.0%
Anticholinergic use not 
elsewhere specified
75 6 6 75 8.0%
Other drug disease 
contraindication
60 2 2 60 3.3%
Sedatives long-acting or 
sedative long term
6 2 2 6 33.3%
The scope of DRP detection is shown in Figure 36. It can be seen that MRM identified a wide 
range of problems approaching the range of problems detectable by pharmacists, yet MRM 
identified a far greater frequency of problems, but surprisingly still failed to identify many of 
the problems that pharmacists identified. MRX identified the greatest number of problems yet 
only identified a narrow range of problem types.
Among this reduced set of cases, the prescribing criteria again identified a smaller variety of 
problems and in smaller volume. Again, the two sets of Beers criteria identified the least 
number of problems by both volume and problem type.
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Figure 35: Overlap of classification between pharmacists and MRX, count of classifications 
equals the number of patients (100 test cases)
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 7.3 Discussion
Two main  classification  approaches  were  used  to  compare  MRM, MRX and the  various 
prescribing criteria alongside the original reviewing pharmacists' findings. The DOCUMENT 
classification system was a fairly straightforward although generic approach to classifying the 
DRPs. The development of a list of descriptive classifications that described the DRPs in 
greater clinical detail was more complex, requiring several iterations to come to the final 
version. Unlike DOCUMENT the themes provided greater insight into the similarities and 
differences of the DRPs associated with drug classes and medical conditions. 
MRX was designed to highlight monitoring recommendations for medications, particularly 
sedatives and anticholinergics that may lead to problems in older people. MRX was limited to 
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Figure 36: Number of classifications identified by type of classification for 
each DRP source
Descriptive classifications
only taking the presence of a medication into consideration, so it was only able to highlight 
the need to monitor for potential  negative medication outcomes. Such negative outcomes 
were  presented  regardless  of  whether  actual  patient  symptoms  occurred  and  without 
consideration  of  other  mitigating  factors  recorded in  the  patient's  details.  MRX was also 
deficient concerning realistic medication side effects. An extreme example was the need to 
monitor for delirium among patients using dermal hydrocortisone therapy, see Figure 37. This 
is an extremely unlikely scenario and is not even mentioned in the product information for 
various  brands  of  hydrocortisone  creams:  e.g.  Cortic-DS  Cream®,  DermAid  Cream®,  in 
MIMs.281
The presentation of every instance of a potential problem no matter how unlikely led to MRX 
having the highest frequency of DRP identification. This is evidenced by looking at those 
themes that overlapped with pharmacist findings. Of the few types of DRPs identifiable by 
MRX, MRX never  failed to identify the problem when the pharmacist  also identified it,  
however, MRX also identified the problem in a vast number of patients where the pharmacist 
did  not  agree.  As  an  example,  the  descriptive  classification  falls  risk/history  and 
sedatives/antihypertensives/other was identified only once by a pharmacist.  Yet,  the same 
issue was identified in every single patient by MRX. This suggests MRX's findings tended to 
lack clinical relevance.
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Figure 37: Problems associated with topical hydrocortisone, from MRX report
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MRM  identified  DRPs  with  a  much  greater  frequency,  about  double,  than  pharmacists 
(Figure 22) although MRM's findings were still quite few when compared to MRX's findings 
(Figure  25).  Unlike  MRX, MRM was  able  to  find  a  broad  variety  of  different  types  of 
problems. While the proportions of DOCUMENT category types were generally similar to 
the  proportions  found  by  pharmacists  (Figures  23 and  26)  there  were  some differences. 
Pharmacists  identified  more  toxicity problems,  likely  due  to  information  obtained  from 
patient discussions. MRM was more likely to detect drug selection problems which may be 
due to more consistency and reliability in identifying DRPs, or perhaps MRM may have 
identified problems that lacked clinical relevance.
The scope of problem types detected by MRM was also demonstrated by the broad range of 
one hundred different themes assigned to MRM DRPs. Ninety of these themes were problem 
types similarly found by pharmacists and ten were only identifiable by MRM. Sixty-eight of 
these problem types were identified in the same patients by both MRM and by pharmacists.  
For a range of these, MRM found the same problems that pharmacists found in half to all of  
the  patients  who were  identified  with  particular  problems by pharmacists,  examples  are: 
cardiovascular disease/risk requires antiplatelet, heart failure and concurrent verapamil or  
diltiazem.  This high overlap for several types of DRP suggests MRM has the capacity to 
identify clinically relevant problems. There were also instances where MRM identified many 
or all pharmacist-identified problems and MRM additionally identified many, more instances 
of the same types of problem. A good example is: calcium channel blocker and reflux. MRM 
identified the one instance where a pharmacist identified this problem, yet MRM also found 
this same problem in 120 more instances.
However,  many  of  the  descriptive  classifications  had  minimal  overlap,  with  MRM 
identifying  many  problems  that  pharmacists  did  not,  and  pharmacists  identifying  many 
problems that MRM did not. There are a range of reasons behind this lack of overlap. Some 
reasons  are  related  to  potential  software  limitations.  An  example  is  the  descriptive 
classification NSAID combined with ACEI or ARB, diuretic - triple whammy. On examination 
of  the instances  where only pharmacists  identified this  problem, the root  cause was that 
pharmacist were able to understand that a combination medication product contained two of 
the three dug classes with the potential for a triple whammy, whereas the MRM software did 
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not  detect  the two ingredients within the combination medication product.  This was also 
likely the reason therapy duplication which was identified far more frequently by pharmacists 
than by MRM, however without any overlap, see Appendix 14. 
Another  reason  pharmacist-identified  DRPs  did  not  overlap  with  MRM was  the  lack  of 
specific  detail  written  in  several  of  the  pharmacists'  DRP  descriptions.  One  pharmacist 
example  was  a  “patient  may  have  low  vitamin  D”,  however  no  reason  supporting  this 
potential  problem  was  provided.  Another  vague  example  in  a  patient  using  both 
antihypertensive medication and sedating medication was “[patient] unsteady on feet and has 
frequent  falls”  which  as  assigned  to  Other  DRP  pharmacist.  However  MRM  provided 
specific potential DRPs for this patient which were assigned  sedatives long-acting or long 
term and  falls risk/history and sedatives/antihypertensives/other. An additional reason was 
pharmacists had knowledge of complementary medicines and vitamins that seemed to be out 
of scope of MRM. An example was a pharmacist suggesting “concurrent use of glucosamine 
and metformin may reduce the efficacy of metformin”.
The  results  so  far  suggest  MRX identified  an  excessive  quantity  of  DRPs  with  perhaps 
insufficient  clinical relevance whereas MRM was less excessive in quantity, had a  broad 
scope  of  problem  detection  and  may  be  more  clinically  relevant.  The  Jaccard index, 
comparing software to pharmacist similarity, although small for each of the software products 
was the greatest for MRM, ten times greater than for MRX, also suggesting greater relevance.
The lack of overlap between MRM or MRX and pharmacists strongly shows that they used 
different  approaches  to  identify DRPs than did  pharmacists.  However, this  main  issue is 
whether the DRPs that there only found by the software were important clinically relevant 
problems that the pharmacists were overlooking in their patient reviews. If this is ascertained 
to be the case then the software has a strong role to complement pharmacists reviews by 
adding consistency and thoroughness to the detection of DRPs in each patient.
Since the sets of prescribing criteria used in this assessment were generally developed by 
expert  consensus  and  generally  had  references  supporting  the  included  criteria,  it  is  not 
entirely unreasonable to treat them as a crude measure of clinical relevance.
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However the various sets  of criteria  were limited in the range of identifiable  DRPs. The 
identifiable  types  of  problems  involved  drug  selection,  over  or  underdose  and 
undertreatment and it was interesting to see these criteria identified drug selection problems 
with  similar  or  greater  frequency  than  did  pharmacists  (Figures  22 and  25).  The  main 
limitation of using prescribing criteria as a guide to clinical relevance was the inability to 
contextualise each criterion to the circumstances of individual patients. This may make using 
prescribing criteria  a less than ideal surrogate for clinical relevance.
MRX identified the largest proportions of Beers03 and Beers12 findings and the smallest 
proportions  of  PIEA  and  STOPP/START  findings.  In  contrast,  MRM  identified  small 
proportions of Beers03 and Beers12 (as did the pharmacists) and the greatest proportions of 
PIEA and STOPP/START.
Several descriptive classifications identified by prescribing criteria such as:  drugs causing 
dyspepsia with PPI (PIEA) - were overly sensitive to triggering conditions, see Appendix 14. 
When compared to other guidelines and pharmacists findings this criterion appeared to lack 
clinical relevance as it was not only too sensitive but too non-specific. Several criteria were 
unique to particular sets of criteria, example themes are: amiodarone or other antiarrhythmic  
prescribed (Beers only) and HF or HTN and using high sodium or salt retaining drugs (PIEA 
only). These criteria likely lack relevance as even pharmacists did not identify these issues. A 
revised and validated PIEA was published September 2012 from which the high sodium 
criterion was removed.94
As such, using prescribing criteria as an indicator for clinical relevance is not ideal and is 
dependent on which set of prescribing criteria are chosen. If either of the sets of Beers criteria 
are considered the ideal standard for clinical relevance then MRX was the best performer 
followed  by  MRM  then  pharmacists.  This  seems  counter-intuitive  if  one  considers 
pharmacists  the  most  capable  of  identifying  clinically  relevant  DRPs.  If  PIEA  or 
STOPP/START are considered the best standards for clinical relevance then MRM is the 
clear  winner  followed  by  pharmacists  and  MRX  last.  Previous  studies  have  suggested 
preference  for  STOPP/START over  Beers03  in  which  case  MRM may  be  the  preferred 
software for identifying clinical relevant DRPs.118,119 Ultimately, this approach to determine 
clinical relevance may be limited when considering pharmacists may be the best marker for 
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clinical relevance and yet pharmacists performed the worst compared to Beers guidelines 
findings and middling compared to PIEA and STOPP/START findings.
  Limitations
There were limitations  in mapping DRPs to common classifications.  The most  important 
potential limitation is the classifications may sometimes be too broad, with classifications 
perhaps describing differing albeit  similar concepts.  DRPs from differing sources may be 
mapped to the same concept, yet the two DRPs may differ in key factors, such as to the actual 
cause of the DRP. To minimise this occurrence, overlapping classifications were checked to 
determine if substantial differences occurred between DRPs from different sources. Iterative 
adjustments were made by increasing both the number and specificity of classifications to 
lessen the potential of conceptually different DRPs being mapped to the same classification.
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 8 Expert panel assessment
 8.1 Introduction
Prescribing criteria were used as a surrogate for clinical relevance, but they were considered 
to be inferior to experts who may assess the patient's medication regimen in the full context 
of  the  available  patient  demographic,  diagnoses  and  laboratory  test  results.  To  more 
accurately  determine  whether  the  DRPs  identified  by the  various  sources  were clinically 
relevant,  an  expert  panel  assessment  of  the  problems  identified  by  MRM,  MRX  and 
STOPP/START was undertaken.
 8.2 Methodology
DRP assessment by a panel of experts for all cases would not have been cost effective, so a 
subset of 20 cases were validated by an expert panel for clinical relevance of any identified 
DRPs and for appropriateness of any recommendations made. Similarly, it was necessary to 
reduce the number of DRPs that the experts were required to assess, so as to reduce the 
amount of time they would be required to spend on the task. It had already been determined 
through earlier analysis that STOPP/START was likely to be the most effective of the various 
prescribing  criteria  evaluated,  so  both  Beers  criteria  and  PIEA  were  removed  from 
consideration for the purposes of this evaluation.
 8.2.1  Recruitment of experts
A panel of ten experts in pharmacology was sought.  The experts were to be drawn from 
accredited pharmacists, general practitioners and clinical pharmacologists. The intention was 
to  have a panel  made up of five accredited pharmacists  and five general  practitioners or 
clinical  pharmacologists  to  give  a  mixture  of  professional  insight.  A list  of  experts  who 
provided assessments for a previous project (PROMISe282) was used as a contact list for this 
project.  In  addition,  expert  recruitment  was undertaken through networking and word of 
mouth. Each of these contacts were emailed an offer of interest to participate in this study, 
along  with  an  information  sheet,  shown in  Appendix  10.  Those  contacts  who expressed 
interest were mailed consent forms to participate in the study.
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 8.2.2  Selection of patients
A random selection of 20 patients who were aged 65 years old or older were selected from 
the VALMER dataset.  The STOPP/START criteria were designed for patients in  this  age 
bracket and the MRX software determined findings based on a minimum patient age of 60 
years.
The selection of these cases was performed using Microsoft Access (Microsoft, Redmond, 
WA). For each of the cases aged 65 years old or older which had been entered into MRX a 
randomly generated number was assigned. The cases were ordered by random number from 
the lowest to highest values. From the lowest random number value every second case was 
selected until 20 cases were obtained. Using every case in order rather than every second case 
resulted in a set of cases which were not representative of the larger cohort.
 8.2.3  Costs and funding
The time involved was estimated to be between 10 and 30 minutes per case, approximately 6 
to  8  hours  for  all  cases.  The  experts  were  reimbursed  $500 for  the  time  involved  for 
completing  an  assessment  of  all  20  cases.  The  total  cost  associated  with  expert 
reimbursement  was  anticipated  to  be  $5,000. Funding  was  obtained  through  Pharmacy, 
School of Medicine, University of Tasmania.
 8.2.4  Expert Panel Survey
The  20 cases  were  presented  via  a  website  to  be  readily  accessible  by  the  experts.  The 
website  was developed by the author. Website  coding was checked for  potential  security 
problems by Dr Ivan Bindoff, and the website was tested in-house for content and usability 
prior  to  being  utilised  by expert  panel  members.  Appendix  11 shows illustrations  of  the 
website.
On logging in to the website, each expert was shown a list of twenty cases, numbered 1 to 20. 
To prevent skewing of results due to human factors such as initial enthusiasm and subsequent 
wane, the cases were presented in a different, randomised order for each expert.
A separate  page  showed each case and its  associated DRP findings.  All  of  the available 
information for each case was displayed for assessment: patient gender, age, date of review, 
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diagnoses  and  symptoms,  laboratory  test  results  with  reference  ranges,  observations  and 
medications by brand name. Where comments were available relating to diagnosis, symptoms 
and drug usage these were included to assist in providing a more complete picture of the case. 
Hovering the mouse pointer over medication brand names displayed ingredient names.
All DRPs identified by each source (HMR pharmacist, MRM, Monitor-Rx, STOPP/START) 
were displayed for  each patient.  The text  was presented as  accurately as possible  for  all 
sources.  Pharmacist  DRPs  texts  were  obtained from transcribed  summaries  stored  in  the 
VALMER  database.  DRPs  identified  by  pharmacists  and  MRM  also  contained 
recommendations to resolve DRPs. The recommendations were also assessed by the expert 
panel. 
Each source was numbered to blind the expert assessor to the true nature of the source:
• 1 – Pharmacist DRPs
• 2 – MRM DRPs
• 3 – MRX DRPs
• 4 – STOPP/START DRPs
The  blinding  of  the  assessor  to  the  source  of  each  set  of  DRPs,  whether  pharmacist  or 
computer-originated, is known as a Turing test.283,284 An important point made by O'Keefe and 
O'Leary is “... there is no assumption that the human expert is correct: the third-party expert 
can compare, rank or criticise as deemed appropriate.”283 In practice experts may have been 
able to determine the identity of each source based on DRP wording, particularly in situations 
where software repetitively presented identically worded DRPs across cases.
The experts had two main assessment sections for each case: assessment of individual DRPs 
from each  source  and an  overall  assessment  of  the  capability  of  each  source  to  present 
relevant DRPs. The assessment items are shown in Appendix 11.
 8.2.5  Assessment items for each DRP from each source in each patient
Each DRP was assessed for clinical relevance, and if recommendations were made, each DRP 
recommendation was assessed for appropriateness. 
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DRP clinical relevance was defined as: “If unresolved would have resulted in suboptimal 
outcome for this patient” 
Appropriate  was  defined  as  “Quality  expected  in  practice  from  a  competent  accredited 
pharmacist” 
These definitions were displayed when the expert hovered the mouse pointer over each term.
The assessment statements were:
• “The DRP is clinically relevant in this case, i.e. if unresolved the DRP would have 
resulted  in  a  suboptimal  outcome  (e.g.  under  treatment,  patient  harm)”  Experts 
indicated agreement with this statement on a 5 point Likert response.
• General comment.
For pharmacist and MRM DRPs assessment of recommendations was required.
• “The  recommendation  for  resolving  this  DRP was  appropriate”  Experts  indicated 
agreement with this statement on a 5 point Likert response.
• If you believe there is a better recommendation to resolve this DRP, please comment.
 8.2.6  Assessment items for overall opinion of each source in each patient
Expert opinion of the overall impression of each source of DRPs was sought. The experts 
were asked to determine the clinical  relevance of each source for identifying DRPs, and 
where recommendations were made, the overall  appropriateness of these.  In addition,  the 
experts were asked to determine whether the source displayed an excessive number of DRPs. 
Finally experts were asked to rate whether each source missed any DRPs that would have 
been relevant to each patient and to provide details of any missed relevant DRPs.
The assessment statements were:
• “Overall, this source identified clinically relevant DRPs” Experts indicated agreement 
to this statement using a 5 point Likert response.
• “The number of DRPs identified was excessive” Experts indicated agreement to this 
statement using a 5 point Likert response.
• “Clinically relevant DRPs were not identified” Experts indicated agreement to this 
statement using a 5 point Likert response.
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• If any clinically relevant DRPs were not identified, please comment.
• General comment.
For both the pharmacist and MRM sources an overall opinion of the recommendations made 
was  required.  This  statement  did  not  apply  to  the  STOPP/START nor  to  MRX as  these 
sources only identified DRPs and did not make recommendations to resolve identified DRPs.
• “Overall,  this  source  offered  appropriate  recommendations”  Experts  indicated 
agreement to this statement using a 5 point Likert response.
 8.2.7  Data analysis
Expert panel responses for each of the four sources of DRPs were obtained mainly using 5 
point Likert items. Normality was assessed using Shapiro-Wilk tests and Bartlett's test for 
homogeneity of variance. Between group Likert item responses were analysed by comparing 
medians and non-parametric statistical techniques, Kruskall-Wallis Tests followed  post hoc 
with  pairwise  Wilcoxon  Rank-Sum  Tests  using  the  Bonferroni  correction.  Inter-rater 
agreement was measured using Kendall's coefficient of concordance (Kendall's W) corrected 
for ties, where 0 is no agreement and 1 is complete agreement. Strength of rater agreement 
was worded according to Landis and Koch.285  Kendall's W values can be interpreted as poor, 
slight, fair, moderate, substantial and almost perfect agreement, shown in Table 28.285
Table 28: Interpretation of Kendall's coefficient of concordance
Kendall's W Strength of Agreement
< 0.00 poor
0.00 – 0.20 slight
0.21 – 0.40 fair
0.41 – 0.60 moderate
0.61 – 0.80 substantial
0.80 – 1.00 Almost perfect
Quantitative data analysis was performed using R, R Foundation for Statistical Computing, 
Vienna.279
Experts were able to provide narrative of their opinions for each source in each of the 20 
cases.  The  data  entry  screen  is  depicted  in  Figure  38.  Qualitative  analysis  of  the  expert 
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narratives  was  performed  to  increase  understanding  of  the  findings  resulting  from  the 
quantitative data.
The intention of qualitative research is to find answers to questions that cannot be easily 
measured.  Rather  than  finding  answers  based  on  counts  or  other  measurements,  the 
qualitative approach attempts to answer questions of why or how through exploring personal 
experiences, feelings and opinions.286 Grounded theory is a term that describes a commonly 
used qualitative methodology.287 The aim of grounded theory is to develop theory 'grounded' 
in the data, systematically gathered and analysed.288
The  systematic  examination  of  the  narratives  followed  the  basic  grounded  theory 
methodology by reading and reviewing the narratives to identify personal perspectives and 
assign or re-assign codes  to text  that  reflected the meaning in  the narrative.286,287  Codes 
describing common concepts were grouped into categories. Revisiting and reviewing the data 
was undertaken to confirm assigned codes and categories were appropriate or if they needed 
to be changed. The intent of the review process was also to ensure the data was exhausted of 
new  ideas  and  concepts,  a  position  known  as  saturation.287 The  coding  process  was 
undertaken  only  by  the  author.  Review  and  reflection  of  the  assigned  codes  and  code 
categories was undertaken to clarify and finalise the accuracy of coding. The RQDA package 
was used to manage and organise the data and codes.289 
Experts were able to provide comments for each individual DRP. True qualitative analysis 
was not undertaken for the assessment of expert comments involving individual DRPs. On 
examination, comments were very specific to each individual DRP so thematic analysis was 
not possible.
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Figure 38: Optional general comment text box for overall opinion
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Minimal  risk  ethics  approval  was  granted  through  the  University  of  Tasmania  Human 
Research Ethics Committee to conduct this research, reference H12269. The approval letter is 
presented in Appendix 5.
 8.3 Results
Emails  were  sent  to  41 GPs,  accredited  pharmacists  and  specialist  physicians.  Fourteen 
experts  consented  to  participate  –  two specialist  physicians,  two GPs  and  10 accredited 
pharmacists. Twelve experts completed the assessment of 20 cases and two did not complete 
any cases, detailed in Table 29.
Table 29: Completion of cases by expert
Expert ID Expert field Cases completed
21 Medicine, Specialist - pharmacologist 20
22 Pharmacy 20
23 Medicine, GP and lecturer in medicine 20
24 Pharmacy 20
25 Medicine, Specialist – pharmacologist and endocrinologist 20
26 Pharmacy 20
27 Pharmacy 0
28 Pharmacy 20
29 Pharmacy 20
30 Medicine, GP 0
31 Pharmacy 20
32 Pharmacy 20
33 Pharmacy 20
35 Pharmacy 20
Table 30 shows the breakdown of the 493 DRPs for each case and DRP source. Unfortunately 
due  to  refinement  of  database  queries  to  automate  the  STOPP/START  criteria,  one 
STOPP/START DRP concerning hypertension remained in one case, this should have been 
removed prior to the website going live. Secondly due to inappropriate labelling of DRPs by 
the  author,  one  MRX  DRP  was  missed  from  6  cases  which  concerned Psychotropic  
Medication Use – Anxiolytics. However, as can be seen in Table 30, the effects of these errors 
were quite minor.
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Table 30: DRPs shown to experts by case and DRP source, * MRX anxiolytic DRP missed, ** 
STOPP hypertension DRP
Case ID Pharmacist MRM MRX STOPP/START Total
51 4 6 11 2 23
138 4 10 16* 0 30
140 6 10 15* 3 34
145 5 11 16 2 34
185 4 1 10 0 15
221 3 3 16* 0 22
297 4 13 14 5 36
312 3 2 5 1 11
313 3 3 14 4 24
323 6 5 16* 2 29
373 4 5 8 3 20
415 2 8 12 1 23
418 3 9 16* 0 28
443 2 9 14 0 25
473 5 4 17 0 26
499 4 5 15* 4 28
522 1 2 6 3 12
573 5 4 9 4** 22
615 2 7 12 0 21
639 3 8 17 2 30
Total 73 125 259 36 493
 8.3.1  Representativeness of randomly selected cases
Twenty cases were used for the expert panel analysis, demographics, detailed in  Table 31. 
Statistical  analysis  was performed to  determine  whether  the  random sample  of  cases  for 
expert assessment were representative of all remaining 550 cases where patients were aged 
65 or older. There were no significant differences between the two groups, shown in Table 31.
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Table 31: Demographics of patients for expert panel
Demographic Panel cases (N = 20), count or 
mean ± standard deviation
VALMER dataset (N = 550), count 
or mean ± standard deviation
Statistical analysis for 
representativeness
Age (years) 79 ± 8 80 ± 7 T-test, t(20.024) = 0.474, p = 
0.641
Gender Male  9 (45%) : Female 11 
(55%)
Male  225 (41%) : Female 325 
(59%)
Chi-squared test, Χ2 = 0.018, df 
= 1, p = 0.893
Diagnoses With 20 (100%) : Without 0 
(0%)
With 546 (99%) : Without 4 (1%) Fisher's Exact test, p = 1
Laboratory 
tests
With 13 (65%) : Without 7 
(35%)
With 442 (80%) : Without 108 
(20%)
Chi-squared text, Χ2 = 1.955, df 
= 1, p = 0.162
Number of 
medications
13.6 ± 6.0 12.0 ± 4.3 T-test,  t(19.727) = -1.241, p = 
0.229
Number of 
diagnoses
10.0 ± 6.2 9.1 ± 5.2 T-test,  t(19.984) = -0.643, p = 
0.527
 8.3.2  Opinion of individual DRPs identified in each case
Each of the 12 experts who completed the assessment provided responses to each of the 493 
DRPs presented to them.
  Clinically relevant DRPs
Likert  responses  to  the  statement  “The  DRP  is  clinically  relevant  in  this  case,  i.e.  if 
unresolved the DRP would have resulted in a  suboptimal  outcome (e.g.  under  treatment, 
patient harm)” were recorded for each of the 493 DRPs across the 20 cases by 12 experts.  A 
summary is shown in Table 32. 
Table 32: Opinions of clinically relevant DRPs identified by each DRP source, total (percent)
Likert response Pharmacists MRM MRX STOPP/START
Strongly agree 116 (13%) 165 (11%) 36 ( 1%) 59 (14%)
Agree 529 (60%) 927 (62%) 600 (19%) 253 (59%)
Neutral 162 (18%) 272 (18%) 471 (15%) 64 (15%)
Disagree 67 ( 8%) 121 ( 8%) 1112 (36%) 52 (12%)
Strongly disagree 2 ( 0%) 15 ( 1%) 889 (29%) 4 ( 1%)
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Shapiro-Wilk tests for normality were significant for each group (each group, p < 0.001) and 
Bartlett's  test  for  homogeneity  of  variance  was  significant  (p  <  0.001)  indicating  non-
parametric data.
A Kruskal-Wallis Test revealed statistically significant difference across the four DRP sources 
(Pharmacists, N = 876, median = 4; MRM, N = 1500, median = 4; MRX, N = 3108, median = 
2; STOPP, N = 432, median = 4) χ2  = 2116.239, df = 3, p < 0.001. 
Inter-rater agreement was assessed using Kendall's coefficient of concordance (Kendall's W) 
corrected for ties, where 0 is no agreement and 1 is complete agreement. Agreement among 
experts was Kendall's W 0.59, p < 0.001, suggesting moderate agreement.
Wilcoxon  rank-sum  tests  between  pharmacists  and  software  sources  were  performed, 
Bonferroni  correction  required  p  <  0.017  for  significance.  There  were  no  significant 
differences between pharmacists and MRM (W = 674591, p = 0.212) and pharmacists and 
STOPP/START (W = 193358.5,  p  =  0.465).  There  was  a  significant  difference  between 
pharmacists and MRX (W = 2284845, p < 0.001).
Although MRX identified the most DRPs (259 DRPs), most of the DRPs it identified were 
not considered clinically relevant. In contrast, experts were of the opinion that pharmacists, 
MRM and STOPP found clinically relevant DRPs in a majority of cases, shown in Figure 39.
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  Appropriateness of recommendations
Each of the 12 experts were presented with 73 pharmacist DRPs and with 125 MRM DRPs. 
For each of these DRPs responses to the statement “The recommendation for resolving this 
DRP was appropriate” were obtained. Responses are shown in Table 33. 
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Figure 39: Expert responses of source identified clinically relevant DRPs, bar width 
proportional to the number of DRPs
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Table 33: Opinions of appropriateness of recommendations for each source, total (percent)
Likert response Pharmacists MRM
Strongly agree 82 ( 9%) 141 ( 9%)
Agree 380 (43%) 853 (57%)
Neutral 244 (28%) 335 (22%)
Disagree 146 (17%) 151 (10%)
Strongly disagree 24 ( 3%) 20 ( 1%)
The Shapiro-Wilk test for normality was significant for each group (each group, p < 0.001) 
and Bartlett's test for homogeneity of variance was significant (p < 0.001) indicating non-
parametric data. A Wilcoxon rank-sum test between pharmacists and MRM was performed. 
There was significant difference between pharmacists and MRM (W = 568346, p < 0.001)
Experts were of the opinion both pharmacist and MRM recommendations were appropriate in 
the  majority  of  DRPs.  Despite  this  positive  finding  a  greater  proportion  of  MRM 
recommendations  were  considered  to  be  appropriate  whereas  a  greater  proportion  of 
pharmacist  findings  were  considered  to  be  neutral  or  not  appropriate.  There  was  fair 
agreement among experts (Kendall's W 0.29, p < 0.001).
The differences in proportions of findings can be seen in Figure 40. It is interesting to note 
not only did MRM identify more DRPs than pharmacists, but experts were of the opinion a 
greater proportion of MRM recommendations were appropriate.
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  Summary of individual DRP comments
There were 969 comments  made for  441 of  493 DRPs.  All  experts  provided comments, 
ranging from 1 comment to 186 comments (average of 81 ± 61 comments per expert).  Many 
DRPs (N = 277) were assigned comments made by more than one expert, ranging from 2 to 8 
comments (average 3 ± 1).
136
Figure 40: Expert responses of source provided appropriate recommendations, bar width 
proportional to the number of DRPs
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There were too many varied opinions concerning a wide range of DRPs to easily summarise. 
One DRP produced by the automation of the STOPP criteria resulted in uniform criticism 
from five experts –  E05 Warfarin and NSAID together (risk of gastrointestinal bleeding) – 
was associated with a patient's concomitant use of warfarin and glucosamine. The comments 
are shown:
“Glucosamine is not an NSAID” (by three experts)
“Patient is not taking an NSAID”
“Hmmm, not  sure  about  describing glucosamine as NSAID but  agree with the  DRP, 
Could also mention fish oil”
Glucosamine is not a NSAID but is classified through the ATC classification system under 
classification M01AX - Other antiinflammatory and antirheumatic agents, non-steroids. The 
classification is correct, but the database query developed for this STOPP criterion did not 
exclude  M01AX from its  result  set.  The  author  was  aware  of  the  potential  interactions 
between glucosamine and warfarin and chose not to exclude M01AX from the result  set. 
Three case reports have identified an interaction between glucosamine and warfarin resulting 
in changed INR.290
  DRPs found by MRM but missed by pharmacists
This  section  evaluates  the  DRPs  that  were  found  by  MRM  but  were  not  found  by 
pharmacists. It attempts to answer the question – did MRM identify clinically relevant DRPs 
that were missed by pharmacists?
A subset of DRPs were identified for this evaluation. Where MRM identified duplicate DRPs, 
only the 'second' DRPs were excluded (N = 9). MRM DRPs in common with pharmacist 
DRPs, based on the descriptive classifications described earlier, were also excluded (N = 17).
This subset resulted in 1188 opinions of 99 MRM DRPs with a range of 1 (strongly disagree)  
to 5 (strongly agree) and a median of 4 (agree), shown in Table 34. This shows the potential 
of this software to add clinical value to medication review reports.
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MRM did miss the identification of 56 DRPs found only by pharmacists. This resulted in 672 
opinions of 56 pharmacist DRPs, range of 1 (strongly disagree) to 5 (strongly agree) and a 
median  of  4  (agree),  details  also  shown  in  Table  34.  These  included  pharmacist  only 
compliance and not-classifiable DRPs.
Table 34: Opinions of clinical relevance of pharmacist DRPs missed by MRM and vice versa, 
total (percent)
Likert response Pharmacists DRPs missed by 
MRM
MRM DRPs missed by pharmacists
Strongly agree 80 (12%) 120 (10%)
Agree 397 (59%) 716 (60%)
Neutral 142 (21%) 230 (19%)
Disagree 51 ( 8%) 108 ( 9%)
Strongly disagree 2 ( 0%) 14 ( 1%)
A Wilcoxon rank-sum test showed no significant difference between the clinical relevance of 
pharmacist DRPs missed by MRM and of MRM DRPs missed by pharmacists, W = 409246, 
p = 0.304.
Subsetting resulted in 672 opinions of 56 recommendations from pharmacist DRPs, range of 
1 to 5 and a median of 4 and 1188 opinions of 99 recommendations from MRM DRPs with a  
range of 1 to 5 and a median of 4. The breakdown of opinion is shown in Table 35.
Table 35: Opinions of appropriateness of recommendations arising from missed DRPs, total 
(percent)
Likert response Recommendations from 
pharmacists DRPs missed by 
MRM
Recommendations from MRM DRPs 
missed by pharmacists
Strongly agree 62 ( 9%) 108 ( 9%)
Agree 294 (44%) 674 (57%)
Neutral 186 (28%) 261 (22%)
Disagree 112 (17%) 128 (11%)
Strongly disagree 18 ( 3%) 17 ( 1%)
A Wilcoxon rank-sum test showed a significant difference between the clinical relevance of 
pharmacist recommendations from DRPs missed by MRM and of MRM recommendations 
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from DRPs missed by pharmacists,  W = 349218, p < 0.001. There was a preference for 
recommendations made by MRM.
 8.3.3  Overall opinion of each source in each case
For  each  of  the  20  cases  presented  the  experts  provided  opinions  to  three  statements 
concerning their overall impression of each of the four DRP sources within each case. An 
additional  statement  concerning  recommendation  appropriateness  was  presented  for 
pharmacists and MRM.
  Identification of clinically relevant DRPs
Responses  to  the  statement  “Overall,  this  source  identified  clinically  relevant  DRPs” are 
shown in Table 36. The Shapiro-Wilk test for normality of each group was significant (each 
group p < 0.001) and the Bartlett test for homogeneity of variance was also significant (p < 
0.001) indicating non-parametric data.
Table 36: Opinions of clinical relevance of each source in each case, total (percent)
Likert response Pharmacists MRM MRX STOPP/START
Strongly agree 13 ( 5%) 17 ( 7%) 0 ( 0%) 13 ( 5%)
Agree 169 (70%) 176 (73%) 30 (13%) 103 (43%)
Neutral 47 (20%) 34 (14%) 34 (14%) 72 (30%)
Disagree 10 ( 4%) 12 ( 5%) 93 (39%) 30 (13%)
Strongly disagree 1 ( 0%) 1 ( 0%) 83 (35%) 22 ( 9%)
A Kruskal-Wallis Test revealed a statistically significant difference between the four DRP 
sources (Pharmacists, N = 240, median = 4; MRM, N = 240, median = 4; MRX, N = 240, 
median = 2; STOPP/START, N = 240, median = 3) χ2 = 368.9353, df = 3, p < 0.001. There 
was substantial agreement among experts (Kendall's W 0.612 p < 0.001).
Wilcoxon  rank-sum  tests  between  pharmacists  and  each  of  the  software  sources  were 
performed,  Bonferroni  correction  required  p  <  0.0167  for  significance.  There  was  no 
significant difference between pharmacists and MRM (W = 27305, p = 0.213). There was 
significant difference between pharmacists and MRX (W = 51552.5, p < 0.001) with a more 
positive  opinion  of  pharmacists.  Similarly  there  was  a  significant  difference  between 
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pharmacists and STOPP/START (W = 37212, p < 0.001) with a more positive opinion of 
pharmacists.
Expert opinion of clinical relevance of DRPs produced by each source is shown in Figure 41. 
It can be seen experts were in agreement that pharmacists and MRM identified clinically 
relevant  DRPs.  The  experts  generally  had  an  agree or  neutral position  regarding 
STOPP/START identifying clinically  relevant  DRPs. The experts  generally disagreed that 
MRX identified clinically relevant DRPs. 
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Figure 41: Expert opinion per case, source identified clinically relevant DRPs
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  Clinically relevant DRPs not identified
Responses to the statement “Clinically relevant DRPs were not identified” are shown in Table
37.  The  Bartlett  test  for  homogeneity  of  variance  was  not  significant  (p  =  0.298).  The 
Shapiro-Wilk  test  for  normality  of  each  group  was  significant  (each  group  p  <  0.001) 
indicating non-parametric data.
Table 37: Opinions of clinical relevant DRPs missed for each source in each case, total 
(percent)
Likert response Pharmacists MRM MRX STOPP/START
Strongly agree 11 ( 5%) 8 ( 3%) 55 (23%) 42 (18%)
Agree 154 (64%) 108 (45%) 127 (53%) 111 (46%)
Neutral 35 (15%) 54 (23%) 37 (15%) 66 (28%)
Disagree 40 (17%) 68 (28%) 19 ( 8%) 21 ( 9%)
Strongly disagree 0 ( 0%) 2 ( 1%) 2 ( 1%) 0 ( 0%)
A Kruskal-Wallis Test revealed statistically significant difference across the four DRP sources 
(Pharmacists, N = 240, median = 4; MRM, N = 240, median = 3; MRX, N = 240, median = 4; 
STOPP/START, N = 240,  median = 4)  χ2 = 70.5388,  df  =  3,  p  < 0.001. There was fair 
agreement among experts (Kendall's W 0.255, p < 0.001).
Wilcoxon  rank-sum  tests  between  pharmacists  and  each  of  the  software  sources  were 
performed, Bonferroni correction required p < 0.0167 for significance. There was significant 
difference between pharmacists and MRM (W = 34843, p < 0.001) with pharmacists missing 
more clinically relevant  DRPs. There was significant  difference between pharmacists  and 
MRX (W = 22891, p < 0.001) with MRX missing more clinically relevant DRPs (despite 
finding  more  DRPs).  No  significant  difference  was  found  between  pharmacists  and 
STOPP/START (W = 26664, p = 0.1204).
Opinion of missed clinically relevant DRPs for each source can be seen in Figure 42. Across 
all four sources experts generally agreed clinically relevant DRPs were missed. The responses 
of  agree and  strongly  agree were larger  for  pharmacists,  MRX and STOPP/START. The 
responses that disagreed with the statement were larger for MRM. The STOPP/START source 
had a significant neutral response.
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  Excessive DRPs identified
Responses to the statement “The number of DRPs identified was excessive” are shown in 
Table 38. The Shapiro-Wilk test for normality of each group was significant (each group p < 
0.001) and the Bartlett  test  for homogeneity of variance was also significant (p < 0.001) 
indicating non-parametric data.
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Figure 42: Expert opinion per case, source missed clinically relevant DRPs
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Table 38: Opinions of excessive findings for each source in each case, total (percent)
Likert response Pharmacists MRM MRX STOPP/START
Strongly agree 0 ( 0%) 8 ( 3%) 108 (45%) 1 ( 0%)
Agree 7 ( 3%) 39 (16%) 116 (48%) 13 ( 5%)
Neutral 22 ( 9%) 38 (16%) 8 ( 3%) 55 (23%)
Disagree 180 (75%) 141 (59%) 6 ( 3%) 118 (49%)
Strongly disagree 31 (13%) 14 ( 6%) 2 ( 1%) 53 (22%)
A Kruskal-Wallis Test revealed statistically significant difference across the four DRP sources 
(Pharmacists, N = 240, median = 2; MRM, N = 240, median = 2; MRX, N = 240, median = 4; 
STOPP/START, N = 240, median = 2)  χ2 = 503.3437, df = 3, p < 0.001. Expert agreement 
was substantial (Kendall's W 0.649, p < 0.001).
Wilcoxon  rank-sum  tests  between  pharmacists  and  each  of  the  software  sources  were 
performed, Bonferroni correction required p < 0.0167 for significance. There was significant 
difference between pharmacists and MRM (W = 20742.5, p < 0.001) with greater agreement 
MRM was excessive. There was significant difference between pharmacists and MRX (W = 
1713,  p  < 0.001)  with  greater  agreement  MRX was excessive.  There  was no significant 
difference between and pharmacists and STOPP/START (W = 26976, p = 0.166).
Opinion about the identification of excessive DRPs produced by each source is displayed in 
Figure  43.  Experts  disagreed  that  pharmacists,  MRM  and  STOPP/START presented  an 
excessive number of DRPs. In stark contrast, opinion concerning MRX showed agreement or 
strong  agreement  that  MRX  presented  an  excessive  number  of  DRPs,  which  may  be 
associated with expert opinion of the lack of clinical relevance of this source (see above).
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  Appropriateness of recommendations
Responses to the statement “Overall, this source offered appropriate recommendations” are 
shown in Table 39.
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Figure 43: Expert opinion per case, source identified excessive number of DRPs
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Table 39: Opinions of clinical relevant DRPs missed for each source in each case, total 
(percent)
Likert response Pharmacists MRM
Strongly agree 9 ( 4%) 16 ( 7%)
Agree 130 (54%) 165 (69%)
Neutral 75 (31%) 48 (20%)
Disagree 26 (11%) 10 ( 4%)
Strongly disagree 0 ( 0%) 1 ( 0%)
This statement was only displayed for the pharmacist and MRM sources. The Shapiro-Wilk 
test for normality was significant for each group (each group, p < 0.001) and the Bartlett test 
for homogeneity of variance was also significant (p < 0.001) indicating non-parametric data. 
A  Wilcoxon  rank-sum  test  between  pharmacists  and  MRM  was  performed.  There  was 
significant  difference  between  pharmacists  and  MRM (W =  23264,  p  <  0.001).   Expert 
agreement was fair (Kendall's W 0.285, p < 0.001).
Expert opinion concerning the appropriateness of recommendations provided by pharmacists 
and MRM are displayed in Figure 44. A majority of responses indicated agreement that each 
source provided appropriate recommendations, yet there was a significant difference between 
groups which may reflect the greater proportion of agreement with MRM recommendations 
compared  to  pharmacist  recommendations.  This  finding  is  corroborated  by  analysis  of 
individual DRP recommendations, see section 8.3.2.
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 8.3.4  Qualitative analysis – Overall opinion of each source
Narrative recorded by panel experts in text boxes allocated to each DRP source in each case 
was analysed  to  draw out  issues  surrounding each source  to  supplement  the  quantitative 
research.
One hundred and fifty-six comments were entered by 10 of 12 experts. Codes were assigned 
to the majority of the text and where possible codes were grouped under one or more code 
categories.  Codes,  code frequencies  and code categories  are  tabled in  Appendix 15.  One 
comment appeared to relate to the wrong DRP source – a source which displayed no DRPs 
for the particular case had a comment relating to display of generic DRPs which appeared to 
follow on from comments of a previous source. Various themes emerged and are discussed 
below.
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Figure 44:  Expert opinions per case, source provided appropriate recommendations
Expert panel assessment
  Clinical relevance of DRPs
Experts commented on lack of relevance of DRPs identified by each software source  and 
possibly also pharmacist DRPs.
“Not excessive number [of DRPs] - but I would probably have swapped some in for 
others!” Pharmacist, ID 31 re pharmacist
“Many of the above identified problems were not specifically patient related but more 
general in nature” Pharmacist, ID 32 re MRM
“This  source  did  not  relate  issues  to  the  specific  patient”  Pharmacist,  ID  32  re  
STOPP/START
“Golly gosh, it raised a lot of things which were likely to be completely irrelevant for this 
patient” Pharmacist, ID 33 re MRX
The number of comments about the lack of relevance of MRX greatly exceeded those of any 
other source and may be indicative of the strength of expert opinion of MRX. In addition, 
only MRX elicited vehement emotional responses.
“More crap” Clinical pharmacologist, ID 25 re MRX
“I really hate this source....” Pharmacist, ID 33 re MRX
The capacity of MRX to identify DRPs was summed up by experts in the following quotes.
“This is not medication review but just textbook information” Pharmacist, ID 32 re MRX
“Source is a mere regurg [sic] of facts, hence useless” General practitioner, ID 23 re 
MRX
One  clinical  pharmacologist  identified  the  patient's  treatment  goals  as  an  important 
characteristic of clinical relevance.
“The context is not considered. This is a patient with months to live. Most of this was 
irrelevant to this case” Clinical pharmacologist, ID 25 re MRM (This patient was an 80 
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year old female with a history of congestive heart failure and multiple cerebrovascular 
accidents)
In contrast experts also considered each source's DRPs to be relevant in various cases. Two 
comments were about pharmacists.
“This source dealt with specific issues identified for the specific patient” Pharmacist, ID 
32 re pharmacist
 Nine comments stated MRM produced a good review of patients' DRPs, these were written 
mostly by a pharmacologist and a general practitioner.
“Most important clinical DRPs identified” Pharmacist, ID 29 re MRM
“Perfect assessment” Clinical pharmacologist, ID 21 re MRM
Only one comment indicated STOPP had identified relevant DRPs.
“Yes, NSAID is a problem...” Pharmacist, ID 33 re STOPP/START
Considering the strongly negative opinions of MRX, three comments disparagingly indicated 
this source was sometimes relevant.
“Some relevant DRP's identified - majority not relevant” Pharmacist, ID 31 re MRX
  Repetition of DRPs
Experts  commented  on the  repetitive  nature  of  DRPs  presented  to  them by each  of  the 
software  sources.  No  commentary  identified  pharmacists  being  repetitious.  In  particular 
MRM elicited fifteen such comments. Experts proffered suggestions of combining repeated 
DRPs  into  single  DRPs  by  collating  similar  issues  into  drug-specific  or  disease-specific 
DRPs.
“There were a number of DRPs that were duplicates or were different facets of a larger 
issue.” Pharmacist, ID 28 re MRM
“Please avoid repetitive recommendation and try to combine recommendations under 
each disease state if possible” General practitioner, ID 23 re MRM
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“Number of DPRs excessive but if the issues about digoxin were grouped into one then 
the number of DPRs is not excessive” Pharmacist, ID 29 re MRM
One  general  practitioner  commented  on  several  occasions  MRX  was  repetitive.  Two 
pharmacists  found STOPP/START repetitive,  referring to NSAID use and benzodiazepine 
use.  Inappropriate  prescribing with these medications  is  listed multiple  times in  different 
contexts within the STOPP/START criteria.
“Yes, NSAID is a problem but it's not necessary to state it in 3 problems” Pharmacist, ID 
33 re STOPP/START
  Preparation for an HMR interview
Two pharmacists identified the potential benefit of MRX as a preparatory list to prompt the 
HMR pharmacist to check for potential DRPs during an HMR interview.
“This would be more helpful prior to conducting the HMR, as a reminder to ask about 
incontinence,  anticholinergic  side effects,  assess  cognition etc”  Pharmacist,  ID 28 re 
MRX
  Lack of thoroughness
Pharmacists and STOPP/START identified the least number of DRPs of the four sources, 73 
and 36 respectively. The STOPP/START criteria consisted of 74 implemented criteria and in 
7 of the 12 cases did not identify any DRPs leading to some confusion. 
“No comments to review ???” Pharmacist, ID 32 re STOPP/START
An  extension  of  this  limited  capacity  to  identify  DRPs  involved  opinion  of  lack  of 
thoroughness.
“Does not identify very much at all” Pharmacist, ID 31 re STOPP/START
Similarly, comments suggested pharmacists were not thorough in identifying DRPs.
“Significant issues with patients management of cardiovascular issues not addressed in 
the review. Anticoagulant issues not addressed.” Pharmacist, ID 32 re pharmacist
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Interestingly, lack of thoroughness was not associated with MRM or MRX.
 8.4 Discussion
Discussion of the expert panel results is broken into several distinct yet overlapping sections: 
clinical  relevance  of  identified  DRPs,  missed  relevant  DRPs  and  excessive  number  of 
identified DRPs.
 8.4.1  Clinical relevance of identified DRPs
The assessment of DRPs was determined through two main methods: by expert opinion of the 
overall DRP findings made in each case and by expert opinion of each individual DRP in the 
context  of  each  case.  This  assessment  was  corroborated  by  general  comments  made  by 
experts concerning each DRP source.
Experts  agreed  on a  'case  by  case'  assessment  that  pharmacists  and  MRM were  able  to 
identify clinically relevant DRPs. Experts also agreed to a lesser extent that STOPP/START 
identified clinically relevant DRPs although a pronounced portion of opinions were neutral. 
This neutrality likely reflected the uncertainty of how to respond in several cases in which 
STOPP/START did not identify any DRPs. MRX however, elicited contrary views from the 
expert panel. Whilst experts wrote comments about both relevance and lack of relevance of 
each source, the majority of comments related to the lack of relevance of MRX. Presence of 
potentially inappropriate medicines without considering any other variables, that is without 
patient, context produced excessive findings with minimal clinical relevance, in other words 
alert fatigue.  
Interestingly, MRM found a larger number of DRPs (125 DRPs) than pharmacists (73 DRPs) 
and MRM's findings were considered to be as relevant as the findings by pharmacists. The 
implication is MRM is finding DRPs that are missed by pharmacists. There were only 17 
DRPs that overlapped between pharmacist and MRM – that is the same issue identified in the 
same patients by both. This left a substantial number of problems detected by pharmacists 
and by MRM which were not able to be detected by the other. However, not only did both 
identify different DRPs from the other, but both MRM and pharmacists did identify clinically 
relevant DRPs. This is strong evidence for MRM to add consistency and thoroughness to the 
pharmacist's  work through supplementing pharmacist  findings.  MRM being an automated 
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tool, is likely to be more consistent at finding DRPs, using the artificial intelligence case-
based  reasoning  approach.  Such  consistency  mirrors  the  results  of  other  studies  using 
knowledge  based  systems167,178,239,  including  two  which  use  similar  case-based 
implementation as the MRM software.167,178
There are good reasons behind why the experts having the opinion that MRX lacked clinical 
relevance. MRX did not identify a wide range of issues, primarily potential problems in the 
elderly, such as use of anticholinergics or PIMs or areas of concern for elderly patients (falls, 
incontinence,  visual function,  etc.).  The main difference of MRX was it  associated many 
medications,  no  matter  how unlikely, to  these  few issues.  MRX was  really  nagging  the 
pharmacist to check in every instance that the patient was actually suffering these side-effects 
from the medications. MRX lacked the ability to state that due to the presence of a medical 
condition  or  observation,  such  as  frequent  falling,  that  relevant  medications  were  to  be 
scrutinised  for  the  potential  to  cause  the  observed  effect.  The  implications  of  clinical 
relevance  are  strong  –  it  is  likely  pharmacists  will  ignore  software  warnings  when  the 
software by and large presents irrelevant findings.
 8.4.2  Missed identification of relevant DRPs
On assessment  of  each  case,  experts  agreed each source failed  to  identify all  potentially 
relevant  DRPs.  Interestingly,  MRM  was  considered  the  source  least  likely  to  miss  the 
identification of relevant DRPs. This supports the concept that MRM may be more consistent 
at identifying DRPs. This consistency was identified in earlier experimental prototypes.167,178
Experts did comment on the lack of DRPs identified by STOPP/START. This is not surprising 
as in 7 of the cases STOPP/START did not identify any DRPs. STOPP/START was limited to 
74 specific criteria unlike the wider array of DRPs that could be identified by pharmacists or 
MRM, or the narrow range but copious quantity of DRPs associated with MRX. Comments 
were not made regarding the missed identification of DRPs for MRM or MRX. 
 8.4.3  Excessive number of identified DRPs
The  excessiveness  of  findings  directly  links  to  the  perception  of  clinical  relevance.  As 
discussed in section 8.4.1 MRM was considered to be clinically relevant however the experts 
perception of excessive findings was low. At the opposite end of the spectrum, MRX was not 
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considered  to  be  clinically  relevant,  and  expectantly, experts  were  of  the  opinion  MRM 
presented an excessive number of findings.
Several experts commented on the repetition of DRPs identified by MRM, STOPP/START 
and particularly MRX. Pharmacists being human are most likely to be able to collate DRPs 
into core issues or simply present core issues and may ignore minor problems. This is not an 
ability that appears to have been programmed into any of the software applications.
MRM as discussed in  section  5.2.3 did present  'duplicate'  DRPs which were identical  in 
concept but worded only marginally differently. MRX was repetitive due to the narrow scope 
of problems identified (20 problem areas were observed, see Appendix 19). Also MRX DRPs 
overlapped, for example, a medication may have been assigned to several of the 20 problems: 
Potentially Inappropriate Medications (PIMs) and  Anticholinergic and  Delirium and  Falls. 
STOPP was implemented as listed in the guidelines and no attempt was made to combine 
similar DRP problems such as those noted by a pharmacist expert (ID 33) – “Yes, NSAID is a 
problem but  it's  not  necessary  to  state  it  in  3  problems”  –  referring  to  NSAID-specific 
STOPP/START criteria E03, E04 and E06.
It should be noted that the MRM and MRX products, and also the prescribing criteria, are not 
designed to be stand-alone systems. The reviewing pharmacist is the arbiter of MRM DRPs 
and free to choose those DRPs considered relevant to include in GP reports, and to add DRPs 
of their own. Similarly, MRX and the various sets of prescribing criteria were to be used 
judiciously  by reviewing pharmacists,  to  identify  those  patients  at  high  risk  of  actual  or 
potential DRPs.
 8.4.4  DRP recommendations for resolution
Experts agreed both pharmacists and MRM provided appropriate recommendations to resolve 
identified  DRPs.  However, the  recommendations  provided by MRM were  rated  as  more 
appropriate than the pharmacists own recommendations. There may be good reasons for the 
preference  for  MRM's  recommendations  to  resolve  DRPs.  A team of  medication  review 
pharmacists develop the wording for each recommendation. This collaboration along with 
any  feedback  from  pharmacist  users  of  the  system  provides  for  a  more  detailed  and 
considered recommendation than perhaps an individual medication review pharmacist may be 
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able to write. The advantage of the input of a team of experts is that the end user can directly  
draw  on  the  expertise  of  the  team  by  using  the  written  recommendations  in  their  own 
medication review reports. Individual pharmacists, particularly those who are new to writing 
medication review reports, may need to develop the writing skills needed for quality reports, 
so a tool such as MRM may be particularly beneficial to these pharmacists.
 8.4.5  Qualitative analysis
Several  points of  interest  appeared from the qualitative analysis.  There appeared to be a 
divide between pharmacists and software sources over DRP repetition and relevance.
Each software source displayed DRPs surrounding similar concepts but did not collate and 
display these DRPs as consolidated problems. The STOPP/START criteria as with the MRX 
software simply presented any findings which were triggered by specific rules. MRM also 
presented repetitious findings which may be unavoidable, perhaps the AI routines may be 
able to be modified to minimise this effect. Pharmacists, being human, may have been able to 
collate aspects of DRPs into one central issue and likely ignored lesser facets, perhaps in the 
knowledge that when the main issue was resolved related facets would also naturally resolve.
Lack  of  clinical  relevance  or  patient  context  was  associated  with  each  software  source, 
although the majority of comments were related to MRX. Lack of relevance was suggested 
but  not directly commented upon concerning pharmacists.  Lack of relevance may not be 
surprising  with  simpler  software  implementations  for  identification  of  DRPs  such  as 
STOPP/START with the implementation of 74 criteria, or MRX triggered only by presence of 
specific drugs. MRM utilised a large number of rules in conjunction with patient-specific 
information, but still lack of relevance was commented upon. Contrarily, clinical relevance 
was  also  associated  with  each  software  source.  In  particular  MRM  was  considered  in 
particularly  favourable  light  with  numerous  comments,  particularly  from  one  clinical 
pharmacologist,  indicating  both  the  identification  of  DRPs  and  recommendations  for 
resolving DRPs were good.
Experts did express the lack of thoroughness of pharmacists in several reviews, suggesting 
pharmacists did not identify all the relevant DRPs in cases and (or) more pertinent DRPs 
153
Expert panel assessment
could have been identified. Lack of thoroughness was also an issue for STOPP/START. This 
is not surprising considering the limited set of criteria which could be applied to the cases.
 8.4.6  Summary
The DRP findings and recommendations by pharmacists  were the baseline against  which 
software  was  measured.  It  is  reassuring  the  experts  agreed  that  pharmacists  did  identify 
relevant  DRPs  in  the  majority  of  cases  and  that  they  did  provide  appropriate 
recommendations.
Pharmacists were not considered to have found an excessive number of DRPs, indeed they 
were thought to have missed some relevant DRPs. This was similar to a finding in a study by 
Martins  et  al. in  which  the  CDSS  was  considered  to  be  more  thorough.239 Between 
pharmacists and MRM there were only a few instances where the same DRPs were identified 
in the same patients. Even so, both MRM and pharmacists were each considered to have 
identified clinically relevant DRPs. This finding sheds light on the lack of overlap uncovered 
in the analysis in Chapter 7  using descriptive classifications. Both pharmacists and MRM are 
finding important but different problems in the patients under examination. This is a key 
finding as it shows that MRM is a tool that can complement the work of pharmacists. It also 
highlights the fact that software such as MRM cannot replace a pharmacist's knowledge as 
there are many factors and nuances outside MRM's ambit.
MRX was not favoured by the experts. MRX was thought to lack clinical relevance and was 
described as “...  not medication reviews but just textbook information”.  The potential  for 
preparing questions for an HMR interview was noted “This would be more helpful prior to 
conducting the HMR, as a reminder to ask about incontinence, anticholinergic side effects, 
assess cognition etc”.
Unlike  MRX,  he  experts  thought  MRM  and  STOPP/START were  also  able  to  identify 
relevant DRPs. The main difference when compared to pharmacists was the number of DRPs 
identified. STOPP/START found a much smaller number of DRPs whereas MRM found a 
much greater number of DRPs than pharmacists.
STOPP/START have  a  small  set  of  criteria,  essentially  a  small  scope  for  problem 
identification, yet it has been shown the criteria can be successfully automated for detection 
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of relevant  DRPs. MRM on the other  hand has  a  wide scope for  problem identification, 
identifying a larger number of DRPs than STOPP/START or pharmacists. The results suggest 
MRM may be more consistent than pharmacists at identifying relevant DRPs. Such results 
concur  with  previous  investigations  involving  the  prototype  artificial  intelligence 
software.167,178 
The  combination  of  the  identification  of  a  wide  range  of  clinically  relevant  DRPs  and 
provision of appropriate recommendations rendered a satisfactory measure of confidence in 
the decision support output of MRM. Additionally, whilst MRM did identify more DRPs than 
pharmacists its did not appear to do so at the expense of causing alert fatigue, in fact the 
identification of a larger number of relevant DRPs per patient highlighted the support such a 
tool can provide to pharmacists conducting HMRs.
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 9 MRM user survey
 9.1 Introduction
Other assessments undertaken within this thesis examined the type, frequency and clinical 
relevance  of  DRPs  identified  by  software.  An  important  complementary  factor  is  the 
acceptance,  or  trust,  placed  in  the  software  by  the  end  user  –  the  medication  review 
pharmacist.  Pharmacist  acceptance  of  such  software  may  be  closely  associated  with  the 
capacity of the software to identify a suitable number of clinically relevant DRPs. Pharmacist 
acceptance of software may likely also affect the inclusion of software identified DRPs in the 
medication review report that is ultimately sent to the GP.
The Technology Acceptance Model (TAM) – a model based on the theory of reasoned action 
to explain actual acceptance and use of technology is made up of two central and measurable 
components – usability and perceived usefulness, see section 3.6.
Several general purpose scales have been developed to assess technology usability including: 
Software  Usability  Measurement  Inventory  (SUMI)291,  System  Usability  Scale  (SUS)292, 
Summated Usability Metric293, Usability Magnitude Estimation.294 Perceived usefulness is the 
second core constituent of the TAM, helping to predict acceptance and use of technology. 
Perceived usefulness has been defined as “...the degree to which a person believes that using 
a particular system would enhance his or her job performance.”195
 9.2 Methodology
Pharmacist opinion of the decision support capabilities of the MRM software was sought. 
This company was locally based and readily approachable. The MRX software company was 
not approached as the company was located in the USA and the company was superseded by 
MedOptz during February 2013, see Appendix 3.
 9.2.1  Recruitment of pharmacists
Staff from Medscope Pty. Ltd. were approached to send emails to subscribers. An email was 
prepared  which  presented  the  details  of  the  study,  an  attached  information  sheet  (see 
Appendix 12) and a link to the online survey.
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 9.2.2  Survey development
A survey was developed to obtain pharmacist opinion of factors associated with the use of 
MRM. Several sections addressed various software use factors, screen-shots of all the survey 
questions are shown in  Appendix 13. The survey was prepared using LimeSurvey version 
2.00+ (www.limesurvey.org). Survey items are discussed under the following subheadings.
  Pharmacist background and intended use of software
This section covered pharmacist medication review experience, use of the software to prepare 
patient  interview  questions  and  use  of  software  to  include  software-identified  DRPs  in 
medication review reports presented to GPs.
  Data entry into MRM
The ability of MRM to identify DRPs is linked to the availability of information to assess. 
One question asked the pharmacists whether patient data was entered manually or through an 
automated process. For manual data entry questions were asked of the completeness of data 
that was available to be entered for patient medications, medical conditions, laboratory test 
results and observations.
  System usability scale
Software must be relatively easy to use if people are likely to make use of it, see section 3.6. 
Several scales have been developed to assess product usability including: Software Usability 
Measurement  Inventory (SUMI)291,  System Usability  Scale  (SUS)292,  Summated Usability 
Metric293, Usability Magnitude Estimation.294
The SUS was chosen because it was freely available and quick to complete with only 10 
statements producing a Likert scale score ranging from 0 to 100.292 Questions are shown in 
Appendix 13. How to score the SUS is quoted: 
'To calculate the SUS score, first sum the score contributions from each item. Each item's 
score contribution will range from 0 to 4. For items 1,3,5,7,and 9 the score contribution 
is the scale position minus 1. For items 2,4,6,8 and 10, the contribution is 5 minus the 
scale position. Multiply the sum of the scores by 2.5 to obtain the overall value...'292
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The SUS has been applied to a variety of technology including software295 and has been 
shown to correlate closely with the SUMI.296 A score of 70 or more indicates good usability, 
illustrated in Figure 45.295
The original SUS used the word “cumbersome” in statement 8. This word was replaced with 
the suggested word “awkward”.295,297 Testing undertaken by Finstad and by Bangor  et al. 
found some participants were unclear of the meaning of “cumbersome”.295,297 The statements 
are shown in Appendix 13.
  Perceived usefulness score
The MRM software organises and stores patient and medication review details as well as 
being CDSS. The objective of this assessment was to examine the perceived usefulness of the 
CDSS component of this product rather than the product overall.  A short Likert scale for 
perceived usefulness, scored using a mean of statement scores, was developed by Davis.195 
Higher mean scores indicate greater perceived usefulness.195 
Brinkman  et  al. applied the perceived usefulness scale  to components within software as 
opposed to the software overall and found the scale was able to be used to assess individual 
components that make up software.298 Mean scores of more than 3.5 imply positive opinion of 
perceived usefulness whereas mean scores below 3.5 indicate negative opinion.
The  original  “CHART-MASTER”  wording  was  replaced  with  “MRM  decision  support” 
shown in Appendix 13.
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  Pharmacist opinion of decision support
Five statements were presented to pharmacists requiring responses of  strongly disagree to 
strongly agree using 5 point Likert items. Four of these statements matched the statements 
presented to the expert panel, see section 8.2.6. The intention was to compare the pharmacist 
MRM user responses with the responses from the expert panel.
The matching statements were:
• “Overall,  this  source  identified  clinically  relevant  DRPs”  Pharmacists  indicated 
agreement to this statement using a 5 point Likert item response.
• “The number of DRPs identified was excessive” Pharmacists indicated agreement to 
this statement using a 5 point Likert item response.
• “Clinically relevant DRPs were not identified” Pharmacists indicated agreement to 
this statement using a 5 point Likert item response.
• “Overall,  this  source  offered  appropriate  recommendations”  Pharmacists  indicated 
agreement to this statement using a 5 point Likert item response.
An additional statement was:
• “MRM  identifies  clinically  relevant  drug-related  problems  which  you  may  have 
overlooked” Pharmacists indicated agreement to this statement using a 5 point Likert 
response.
  User satisfaction with MRM
Pharmacists' satisfaction with the software was assessed based on questions from a frequently 
cited article by McDougall and Levesque.299 The authors examined the relations between core 
service quality, relational service quality and perceived value, and customer satisfaction. Core 
service quality was defined by the authors as “the basic service, 'contracted for' or promised” 
and relational service quality was defined as “the way in which the service was delivered”. 
Core service quality and perceived value were the main factors associated with satisfaction. 
Satisfaction in turn led to loyalty to a service (or product) and non-intention to switch to 
another service (or product), illustrated in Figure 46. 
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Core service quality was assessed as “How would you rate the assistance MRM software 
provides for managing your medication reviews, 1:terrible to 100:best” based on an example 
from McDougall and Levesque “If an ideal rating was 100 percent, how would you rate the 
dentist on: technical ability?”. Perceived value was assessed using a 7 point Likert item as 
“Overall MRM offers good value for money” based on the example “The dentist offered 
good value for money”. Satisfaction was assessed using a 7 point Likert item as “MRM meets 
my expectations” based on the example “The dentist met my expectations”. Questions are 
shown in Appendix 13.
 9.2.3  Data analysis and ethics
Results  from the  SUS,  perceived  usefulness  and  core  service  quality  were  presented  as 
histograms.  Opinions  of  the  decision  support  were  presented  as  tables  and  results  were 
compared with expert panel results using either chi-square or Fisher's Exact Test. Five point 
Likert item responses were presented as median and range. Shapiro-Wilk tests for normality 
were performed for the SUS, perceived usefulness and core service quality.  Various factors 
such as years of pharmacy practice and years accredited for medication review, gender, SUS, 
perceived usefulness, opinions of decision support and software satisfaction were examined 
for correlations using either Kendall's tau-b (for one or two ordinal variables taking tied ranks 
into  account)  or  Spearman's  rho,  (for  interval  and  continuous  variables  which  are  not 
normally distributed).300
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Levesque299
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Correlation  tests  were  performed  using  Spearman's  correlation  test  for  non-parametric 
continuous variables  and Kendall's  tau-b correlation  test  for  ordinal  data  with  many tied 
values.300 Correlation coefficients were interpreted according to Swinscow301 shown in Table
41. Plots of correlation tests are shown in Appendix 20.
Table 40: Interpretation of correlation coefficient
Correlation coefficient range Correlation strength
0.00 – 0.19 Very weak
0.20 – 0.39 Weak
0.40 – 0.59 Moderate
0.60 – 0.79 Strong
0.80 – 1.00 Very strong
Text entry was provided to obtain user comments regarding data entry and a final comments 
text  entry  was  provided  for  any  additional  comments.  True  qualitative  analysis  was  not 
undertaken for the assessment of data entry comments as too few comments were received. 
Qualitative analysis of the  final comments narrative was performed to ascertain additional 
facets of information to add support or refute results acquired though quantitative analyses. 
This was conducted in the same manner as described in section  8.2.7. The RQDA package 
was used to assist with this activity.289
Ethics approval was obtained for the MRM user survey. Minimal risk ethics approval was 
granted through the University of Tasmania Human Research Ethics Committee to conduct 
this research, reference H13161. The approval letter is presented in Appendix 5.
 9.3 Results
Emails were sent on Friday 12th April 2013 to 335 present and past pharmacist subscribers of 
MRM software.  The pharmacists  were asked to  complete  an online  survey of  the MRM 
software by the end of May 2013. Thirteen email addresses were invalid providing a pool of 
322 potential participants. After 10 incomplete responses were excluded, 60 fully completed 
responses were received, a response rate of 19 percent.
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 9.3.1  Pharmacist Background
The majority of respondents were female with a mean of 22 years of pharmacy practice and a 
mean of  8 years medication review practice, shown in  Table 41.  One respondent provided 
percentage responses exceeding 100 percent for two questions involving the proportion of 
HMRs  and  the  proportion  of  residential  medication  management  reviews  (RMMRs)302 
performed using MRM. The same respondent  also provided the highest  response  for  the 
number of HMRs performed over the last 12 months (900). These specific responses were 
excluded  from  analyses.  This  respondent  otherwise  provided  responses  that  were  not 
exceptional.
Table 41: Pharmacist background
Demographic variable Result, count, median and range or mean ± standard deviation
Gender Female: 41     Male: 19
Number of years of pharmacy practice 22 ± 12 years
Number of years accredited for medication 
reviews
8 ± 5 years
HMRs conducted over the last 12 months Median 50, range 0 to 900
Percent of HMRs completed using MRM 86 ± 27
RMMRs conducted over the last 12 months Median 0, range 0 to 1000
Percent of RMMRs completed using MRM 64 ± 44 (excluding 32 pharmacists who did not do any RMMRs)
Include MRM-identifed DRPs in report Median: Often (range Always to Rarely)
Include MRM-identified DRPs to prepare interview Median: Sometimes (range Always to Never)
Pharmacists  performed a median of  50 HMRs with the majority using MRM for HMRs, 
shown in Table 41 and Figure 47. Only one pharmacist indicated no HMRs were performed. 
Pharmacists  performed a median of zero RMMRs over the last 12 months, over half of the 
respondents (N = 32) indicated no RMMRs were performed. These pharmacists exclusively 
performed HMRs. The 28 pharmacists who did perform RMMRs used MRM for the majority 
of their reports, shown in Table 41 and Figure 48.
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Figure 47: Histograms of HMRs performed over the last 12 months and the proportion 
performed using MRM
Figure 48: Histograms of RMMRs performed over the last 12 months and performed using 
MRM
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High numbers of HMRs and RMMRs were entered by several pharmacists, the validity of 
these could not be confirmed. Pharmacists who provided higher numbers of HMRs generally 
focussed  on  HMR  services  and  similarly  pharmacists  who  provided  higher  numbers  of 
RMMRs generally focussed on RMMR services shown in Figure 49.
A larger proportion of pharmacists (45%) always or often used MRM DRPs to prepare for a 
patient  interview.  A smaller  proportion  (24%)  sometimes  used  MRM  DRPs.  A third  of 
pharmacists (32%) used MRM DRPs rarely or never to prepare for patient interviews. Results 
are shown in Figure 50 and Table 41.
The use of MRM DRPs for reports was different to the use of MRM DRPs for preparing 
patient interviews. The majority of pharmacists (65%) included MRM DRPs always or often 
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Figure 49: Medication review services provided over the last 12 months
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in their medication review reports. Another 30% sometimes included MRM DRPs in their 
reports. Results are shown in Figure 50 and Table 41.
A range  of  guidelines  were  used  by  pharmacists  to  aid  detection  of  DRPs  and  provide 
recommendations  to  resolve  DRPs.  The  published  prescribing  guidelines  in  the  elderly 
consisting of Beers, STOPP/START and PIEA were infrequently used, shown in Figure 51. 
Guidelines frequently used were the Therapeutic Guidelines,303 Diabetes Australia,304 Heart 
Foundation305 and NPS306 guidelines, shown in Figure 51. Several other guidelines, references 
and  software  were  also  used:  Australian  Medicines  Handbook  (https://shop.amh.net.au/), 
Australian  Medicines  Handbook  Aged  Care  (https://shop.amh.net.au/),  MIMs 
(www.mims.com.au/),  AusDi  Advanced 
(http://www.phoenixmedical.com.au/ausdi_advanced.php),  Medscape  Drug  Interaction 
Checker  (http://reference.medscape.com/drug-interactionchecker),  Drugs.com  Drug 
Interactions  Checker  (http://www.drugs.com/drug_interactions.html),  NICE 
(www.nice.org.uk/), tripdatabase (www.tripdatabase.com), CKD guidelines (may be the CKD 
Management  Guideline  Booklet  produced  by  Kidney  Health  Australia),  Veterans  Mates 
(www.veteransmates.net.au).
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Figure 50: Use of MRM-identified DRPs for patient interview preparation and for medication 
review reports
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 9.3.2  Data Entry into MRM
The  majority  of  pharmacists  did  manually  enter  all  patient  medications,  diagnoses, 
observations and pathology results, shown in  Table 42. A smaller majority of pharmacists 
also entered all  patient observations and laboratory test  results. These questions were not 
mandatory so totals do not add to 60. One pharmacist who consistently chose never may have 
been a past, but not current, subscriber of MRM.
Table 42: Pharmacist manual data entry
Always Often Sometimes Rarely Never Total
Medications 57 2 59
Diagnoses 55 3 1 59
Observations 40 6 10 1 1 58
Pathology results 37 11 8 2 1 59
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A data entry score was calculated by adding the responses to the four questions. Always was 
assigned the value of 1 and Never was assigned the value of 5. The minimum score attainable 
was 4 indicating  all  patient  data  was entered and the  maximum score  attainable  was 20 
indicating no patient data was entered. Scores for two pharmacists were not calculated as not 
all four questions were completed. The median score was 4 with scores ranging from 4 to 20, 
shown as a histogram in Figure 52.
Correlation  tests  using  the  data  entry  score  and  various  factors  were  performed  using 
Kendall's tau-b correlation test. No correlations were identified.
There  were  25  comments  concerning  data  entry.  Thirteen  of  these  were  grouped  into 
categories  of  time consuming and  cumbersome.  A related  category was  interest  in  direct  
downloading from GP surgeries. Another category mentioned several times was the software 
contained limited diagnoses to select from.
 9.3.3  System Usability Scale
An objective measure of software usability was determined through the SUS with a median 
of 77.5 and range 2.5 to 100. The majority of pharmacists scored 70 or more indicating the 
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MRM software was easy to use, shown in Figure 53. Eleven pharmacists found the software 
had acceptable usability. Four pharmacists indicated the software was not easy to use.
An independent samples t-test was performed to compare SUS score in males and females. 
There was a significant difference in the scores for males (mean 67) and females (mean 79); t  
= 2.11, p = 0.045. The result suggests females found MRM easier to use.
A Shapiro-Wilk test for normality showed the SUS was not normally distributed, W = 0.9069, 
p < 0.001. Correlation tests between SUS and various factors were performed using, where 
appropriate, Spearman's correlation or Kendall's tau-b (for tied ordinal values). Results using 
Spearman's correlation  tests  of  the  SUS score  with  years  accredited,  years  of  pharmacy 
practice, HMRs per year, RMMRs per year, inclusion of MRM DRPs in medication reports 
interview were very weak and not significant. Results using Kendall's tau-b of the SUS score 
with  including MRM DRPs in medication review reports,  and with  using MRM DRPs to  
prepare for a patient interview were also very weak and not significant.
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Correlations were found with clinical relevance of MRM DRPs, MRM providing appropriate 
recommendations (see section 9.3.5); core service quality, value for money and satisfaction 
with the software (see section 9.3.6).
 9.3.4  Perceived usefulness of MRM
Perceived usefulness  was calculated as the mean score for all  six  items in the perceived 
usefulness scale, the lowest attainable score was 1, a neutral score was 4 and the highest 
attainable score was 7. Perceived usefulness of MRM's decision support ranged from 2 (quite 
unlikely  to  be  useful)  to  7 (extremely  likely  to  be  useful)  with  a  median  of  5.8.  Two 
pharmacists indicated the decision support was unlikely to be useful (scores: 2.0, 2.2). Five 
pharmacists indicated a neutral opinion of the decision support (scores: as 4.0, 4.0, 4.0, 4.3, 
4.5). The majority of pharmacists (N=53) indicated MRM's decision support was useful. The 
range of responses is shown in Figure 54.
A Shapiro-Wilk test for normality showed perceived usefulness was not normally distributed, 
W =  0.8786,  p  <  0.001.  Correlation  tests  between  perceived  usefulness  of  the  decision 
support and various factors were performed, using where appropriate, Spearmans correlation 
or  Kendall's  tau-b  (for  tied  ordinal  values).  Correlation  with  years  accredited,  years  of 
pharmacy practice, HMRs per year, RMMRs per year, using MRM DRPs to prepare for a 
patient interview were very weak and not significant.
There was a weak negative correlation between perceived usefulness and inclusion of MRM 
DRPs in medication review reports, Kendall's tau-b = -0.36, p < 0.001, with greater perceived 
usefulness associated with increased inclusion of MRM DRPs in medication review reports. 
The direction was negative because always include MRM DRPs was assigned the value 1 and 
never include MRM DRPs was assigned the value 5. There was a weak positive correlation 
with the SUS, Spearman's rho = 0.27, p = 0.035. Correlations were also found with MRM 
finding clinically relevant DRPs, MRM not missing the identification of DRPs, MRM not 
finding excess DRPs, MRM providing appropriate recommendations, MRM finding DRPs 
pharmacists  overlook  (see  section  9.3.5);  core  service  quality,  value  for  money  and 
satisfaction  (see  section  9.3.6).  Figure  55 illustrates  the  main  factors  correlating  with 
perceived usefulness.
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 9.3.5  Pharmacist opinion of decision support
Four statements in the user survey matched the statements presented to the expert panel to 
allow for comparison. The only difference was the pharmacists were presented with the full 
text drug-related problem, whereas the expert panel statements used the acronym DRP, which 
had been defined elsewhere on the expert panel website. A range of correlation tests were 
performed.
  Clinical relevance of DRPs
Pharmacist responses to the statement “Overall, this source identified clinically relevant drug-
related problems” are shown in  Table 43. The majority of pharmacists, N = 44, indicated 
MRM identified clinically relevant DRPs.
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There was a weak negative correlation between MRM identifying clinically relevant DRPs 
and perceived usefulness, Kendall's tau-b = -0.37, p < 0.001, with greater agreement MRM 
identified  clinically  relevant  DRPs  associated  with  greater  perceived  usefulness.  The 
direction  was  negative  because  Strongly  agree was  assigned  the  value  1  and  Strongly 
disagree was  assigned  the  value  5.  This  finding  was  supported  by  a  moderate  positive 
correlation between MRM identifying clinically relevant DRPs and including MRM DRPs in 
medication review reports, Kendall's tau-b = 0.46, p < 0.001. 
There was a weak positive correlation between MRM identifying clinically relevant DRPs 
and using MRM DRPs to prepare for a patient interview, Kendall's tau-b = 0.22, p = 0.042. 
There was a weak negative correlation between MRM identifying clinically relevant DRPs 
and the SUS, Kendall's tau-b = -0.39, p <0.001. The direction was negative because Strongly 
agree was assigned the value 1 and Strongly disagree was assigned the value 5. Correlations 
were also found with core service quality, value for money, appropriate recommendations and 
missed  DRPs (see  sections  9.3.5 and  9.3.6).  Factors  that  correlated  with finding clinical 
relevance are shown in  Figure 56.
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Pharmacist  responses  were compared with responses obtained from the expert  panel,  see 
Table 43. Fisher's Exact Test showed no difference between the opinions of the expert panel 
and the opinions of the pharmacists, p = 0.267.
Table 43: MRM pharmacist opinion of MRM clinical relevance
Likert response MRM pharmacists
count (percent of total)
Expert panel
count (percent of total)
Strongly agree 6 (10%) 17 ( 7%)
Agree 38 (63%) 176 (73%)
Neutral 9 (15%) 34 (14%)
Disagree 7 (11%) 12 ( 5%)
Strongly disagree 0 (  0%) 1 ( 0%)
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Figure 56: Factors associated with MRM identifying clinically relevant DRPs
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  MRM missed DRPs
Pharmacist responses to the statement “Clinically relevant drug-related problems were not 
identified” are shown in Table 45. Almost half of pharmacists, N = 25, indicated MRM did 
not miss clinically relevant DRPs although an additional third, N = 20, were unsure.
Correlation tests  between core service quality of the decision support and various factors 
were performed. Interestingly, many factors correlated with core service quality, shown in 
Table 44.
Table 44: Factors correlating with MRM missed DRPs
Factor Test results Correlation 
strength
Summary
MRM finding clinically 
relevant DRPs
Kendall's tau-b = -0.44, p < 
0.001
moderate There was greater agreement MRM did not 
miss clinically relevant DRPs associated 
with MRM finding clinically relevant DRPs
MRM identified DRPs 
pharmacists overlooked
Kendall's tau-b = -0.35, p = 
0.002
weak MRM identifying pharmacist overlooked 
DRPs associated with MRM not missing 
clinically relevant DRPs
MRM identified excessive 
number of DRPs
Kendall's tau-b = 0.26, p = 
0.022
weak MRM not missing clinically relevant DRPs 
associated with MRM not finding excessive 
DRPs
Perceived usefulness Kendall's tau-b = 0.25, p = 
0.015
weak Greater agreement MRM did not miss 
clinically relevant DRPs associated with 
greater perceived usefulness
including MRM DRPs in 
medication review reports
Kendall's tau-b = -0.23, p = 
0.047
weak Pharmacists including MRM DRPs in 
reports associated with MRM not missing 
the identification of DRPs
Core service quality Kendall's tau-b = 0.37, p < 
0.001
weak Increased disagreement of MRM missing 
clinically relevant DRPs associated with 
greater core service quality
Value for money Kendall's tau-b = -0.22, p = 
0.047
weak Increased agreement with value for money 
was associated with MRM not missing 
DRPs
MRM pharmacist responses were compared with responses obtained from the expert panel, 
see Table 45. Fisher's Exact Test showed a significant difference between the opinions of the 
expert panel and the opinions of the pharmacists, p = 0.010. A greater proportion of the expert 
panel  were  of  the  opinion  MRM  missed  clinically  relevant  DRPs  whereas  pharmacist 
opinions were fairly evenly divided.
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Table 45: MRM pharmacist opinion of MRM missing the identification of clinically relevant 
DRPs
Likert response MRM Pharmacists
count (percent of total)
Expert panel
count (percent of total)
Strongly agree 1 ( 2) 8 ( 3)
Agree 14 (23) 108 (45)
Neutral 20 (33) 54 (23)
Disagree 23 (38) 68 (28)
Strongly disagree 2 ( 3) 2 ( 1)
  MRM excessive DRPs
Pharmacist responses to the statement “The number of drug-related problems identified was 
excessive”  are  shown in  Table  46.  The majority  of  responses, N =  31,  disagreed MRM 
identified an excessive quantity of DRPs.
There  was  a  weak positive  correlation  between  MRM  identifying  excessive  DRPs  and 
perceived usefulness, Kendall's tau-b = 0.29, p = 0.005, with greater agreement MRM did not 
identify  excessive DRPs associated with  greater  perceived usefulness.  There  was a  weak 
positive  correlation  between  MRM  missed  clinically  relevant  DRPs  and  MRM  finding 
excessive DRPs, Kendall's tau-b = 0.26, p = 0.022, with MRM not missing clinically relevant 
DRPs associated with MRM not finding excessive DRPs.
Pharmacist  responses  were compared with responses obtained from the expert  panel,  see 
Table 46. Fisher's Exact Test showed a difference between the opinions of the expert panel 
and the opinions of the pharmacists, p < 0.001. A much greater proportion of pharmacists had 
a neutral opinion of MRM displaying excessive numbers of DRPs compared to the expert 
panel.  A larger proportion of the expert  panel were of the opinion MRM did not display 
excessive numbers of DRPs.
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Table 46: MRM pharmacist opinion of MRM identified excessive DRPs, total (percent)
Likert response MRM Pharmacists Expert panel
Strongly agree 1 ( 2) 8 ( 3)
Agree 5 ( 8) 39 (16)
Neutral 23 (38) 38 (16)
Disagree 24 (40) 141 (59)
Strongly disagree 7 (12) 14 ( 6)
  MRM recommendations
Pharmacist  responses  to  the  statement  “Overall,  this  source  offered  appropriate 
recommendations” are shown in Table 47. The majority of pharmacists, N = 37, agreed MRM 
provided appropriate recommendations.
There  was  a  moderate negative  correlation  between  MRM  providing  appropriate 
recommendations and perceived usefulness, Kendall's tau-b = -0.44, p < 0.001, with greater 
agreement MRM provided appropriate recommendations associated with greater perceived 
usefulness.  There was a moderate positive correlation between MRM providing appropriate 
recommendations and MRM identifying clinically relevant DRPs, Kendall's tau-b = 0.54, p 
<0.001,  with  identifying  clinically  relevant  DRPs  associated  with  appropriate 
recommendations.
There  was  a  weak  negative  correlation  between  MRM  providing  appropriate 
recommendations and the SUS score, Kendall's tau-b = -0.23, p = 0.026, with better usability 
associated  with  more  agreement  of  MRM  providing  appropriate  recommendations.  The 
directions  were  negative  because  Strongly  agree was  assigned  the  value  1  and  Strongly 
disagree was assigned the value 5. There was a weak positive correlation between MRM 
providing appropriate  recommendations  and including MRM DRPs in medication  review 
reports, Kendall's tau-b = 0.35, p = 0.002, with greater agreement MRM provided appropriate 
recommendations  associated  with  greater  inclusion  of  MRM DRPs in  medication  review 
reports.  Correlations were also found with core service quality and value for money (see 
section 9.3.6).
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Pharmacist  responses  were compared with responses obtained from the expert  panel,  see 
Table 47. Fisher's Exact Test showed no difference between the opinions of the expert panel 
and the opinions of the pharmacists, p = 0.117.
Table 47: MRM pharmacist opinion of MRM provided appropriate recommendations, total 
(percent)
Likert response MRM Pharmacists Expert panel
Strongly agree 4 ( 7) 16 ( 7)
Agree 33 (55) 165 (69)
Neutral 16 (27) 48 (20)
Disagree 6 (10) 10 ( 4)
Strongly disagree 1 ( 2) 1 ( 0)
  MRM identified DRPs pharmacists overlooked
Pharmacist  responses  to  the  statement  “MRM  identifies  clinically  relevant  drug-related 
problems  which  you  may  have  overlooked”  are  shown  in  Table  48.  The  majority  of 
pharmacists, N = 44, indicated MRM did identify clinically relevant DRPs that they may 
have overlooked.
There  was  a  weak negative  correlation  between  MRM identifying  DRPs  overlooked  by 
pharmacists  and  perceived  usefulness,  Kendall's  tau-b  =  -0.31,  p  =  0.003,  with  greater 
agreement that MRM identified DRPs that pharmacists overlooked associated with greater 
perceived usefulness.
There  was  a  weak  positive  correlation  between  MRM  identifying  DRPs  overlooked  by 
pharmacists and the inclusion of MRM DRPs in medication review reports, Kendall's tau-b = 
0.24, p = 0.041, with greater agreement MRM identified DRPs that pharmacists overlooked 
with greater inclusion of MRM DRPs in medication review reports.
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Table 48: MRM pharmacist opinion of MRM identified DRPs overlooked by pharmacists, total 
(percent)
Likert response MRM Pharmacists
Strongly agree 8 (13)
Agree 36 (60)
Neutral 9 (15)
Disagree 7 (12)
Strongly disagree 0 (0)
 9.3.6  Service and value for money
Service and value for money may likely have an impact on the use of software products. 
Likewise the usefulness and ease of use may affect the pharmacist software users perception 
of value for money.
  Core service quality
Responses to the question “How would you rate the assistance MRM software provides for 
managing your medication reviews” were to be entered on a scale of 0 to 100. This question 
encompasses the core service quality of the MRM product. One response of 110 exceeded the 
maximum allowable score of 100 and was set to 100. Most pharmacists were of the opinion 
the core service quality of the Medscope company was good scoring 70 or more, mean 79 ± 
14. A histogram of results shown in Figure 57.
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A Shapiro-Wilk test showed core service quality scores were not normally distributed, W = 
0.9271, p = 0.002. Correlation tests between core service quality of the decision support and 
various  factors  were  performed.  Interestingly,  many  factors  correlated  with  core  service 
quality, shown in Table 49.
Table 49: Factors correlating with core service quality
Factor Test results Correlation 
strength
Summary
Perceived usefulness Spearman's rho = 0.54, p < 
0.001
moderate Higher perceived usefulness associated 
with greater core service quality.
SUS Spearman's rho = 0.45, p < moderate Higher SUS scores associated with greater 
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Factor Test results Correlation 
strength
Summary
0.001 core service quality
MRM identified clinically 
relevant DRPs
Kendall's tau-b = -0.50, p < 
0.001
moderate More agreement of MRM's capacity to 
identify clinically relevant DRPs associated 
with greater core service quality
MRM missed clinically 
relevant DRPs
Kendall's tau-b = 0.37, p < 
0.001
weak  More disagreement of MRM missing 
clinically relevant DRPs associated with 
greater core service quality
MRM provided appropriate 
recommendations
Kendall's tau-b = -0.40, p < 
0.001
moderate More agreement of MRM providing 
appropriate recommendations associated 
with greater core service quality
Included MRM DRPs in 
medication review reports
Kendall's tau-b = -0.29, p = 
0.006
weak Increased inclusion of  MRM DRPs into 
reports associated with greater core service 
quality
Used MRM DRPs to prepare 
patient interviews
 Kendall's tau-b = -0.27, p = 
0.008
weak Increased use of MRM DRPs to prepare for 
patient interviews associated with greater 
core service quality
Value for money Kendall's tau-b = -0.40, p < 
0.001
moderate  Increased agreement with value for money 
was associated with greater core service 
quality
Satisfaction Kendall's tau-b = -0.53, p < 
0.001
moderate Greater satisfaction associated with greater 
core service quality. 
The factors that correlated with core service quality are illustrated in Figure 58.
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  Value for money
Responses to the statement “Overall MRM offers good value for money” are shown in Table
50.  The  majority  of  pharmacists  agreed  that  the  MRM software  offered  good  value  for 
money.
Table 50: Responses to MRM offers good value for money
Strongly Agree Agree Neutral Disagree Strongly Disagree
8 30 14 6 2
Correlation tests between value for money and various factors were performed. Interestingly, 
many factors correlated with value for money, shown in Table 51.
181
Figure 58: Factors associated with core service quality - managing medication reviews
MRM user survey
Table 51: Factors correlating with value for money
Factor Test results Correlation 
strength
Summary
Core service quality Kendall's tau-b = -0.40, p < 
0.001
moderate  Increased agreement with value for money 
was associated with greater core service 
quality
SUS Kendall's tau-b = -0.30, p = 
0.003
weak Increased agreement with value for money 
associated with greater SUS score
Perceived usefulness Kendall's tau-b = -0.23, p = 
0.022
weak Increased agreement with value for money 
associated with greater perceived 
usefulness
MRM identified clinically 
relevant DRPs
Kendall's tau-b = 0.38, p < 
0.001
weak Increased agreement with value for money 
associated with greater agreement that 
MRM identified clinically relevant DRPs
Providing appropriate 
recommendations
Kendall's tau-b = 0.41, p < 
0.001
moderate Increased agreement with value for money 
associated with greater agreement that 
MRM provided appropriate 
recommendations
MRM missed clinically 
relevant DRPs
Kendall's tau-b = -0.22, p = 
0.047
weak Increased agreement with value for money 
was associated with MRM not missing 
DRPs
  Satisfaction with MRM
Responses  to  the  statement  “MRM meets  my expectations”  are  shown in  Table  52.  The 
majority of pharmacists agreed that the MRM software met their expectations.
Table 52: Responses to MRM meets my expectations
Strongly Agree Agree Neutral Disagree Strongly Disagree
8 37 8 5 1
There  was  a  moderate  positive  correlation  between  satisfaction  and  value  for  money, 
Kendall's tau-b = 0.53, p < 0.001, with increased satisfaction associated with greater value for 
money. 
There was a  moderate  negative  correlation between satisfaction and core  service quality, 
Kendall's tau-b = -0.53, p < 0.001, with increased satisfaction associated with greater core 
service quality. 
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There was a moderate negative correlation between satisfaction and SUS scores, Kendall's 
tau-b = -0.44, p < 0.001, with increased satisfaction associated with greater SUS scores.
There was a weak negative correlation between satisfaction and perceived usefulness scores, 
Kendall's  tau-b  =  -0.35,  p  <  0.001,  with  increased  satisfaction  associated  with  greater 
perceived usefulness scores.
 9.3.7  Qualitative analysis of pharmacists who used MRM
Twenty-seven pharmacists provided additional comments via a free text field. Codes were 
assigned to the text and grouped by category where possible. Codes, code frequencies and 
categories are tabled in Appendix 21.
  Satisfaction with Medscope and MRM
There were disparate views on whether pharmacists were satisfied with MRM although a 
greater number of coded comments indicated satisfaction rather than dissatisfaction. Eight 
comments displayed satisfaction with MRM, another 5 stated MRM represented good value 
for  money and 4 stated  that  MRM saved time.  Four  comments  indicated good customer 
service.
“Because I don't do a lot of HMRs I find MRM helps me focus on pertinent points to 
include in  my report  to  GP. It  also  gives  me a  consistent,  easy  to  read  format  as  a 
template  and  then  gives  me  the  option  to  reword,  change  and  add  to  if  I  need.” 
Pharmacist id 16
“It has provided a big increase in efficiency” Pharmacist id 47
“Using MRM and the HMR Alert software is the only reason I pursued setting up a  
business specialising in Home Medicine Reviews.  Without it I would not have gone out 
on my own and would have continued to just do a few reviews each year.” Pharmacist id  
20
“I like using the software as it  is  a safety net  for me to make sure I haven't  missed 
anything crucial” Pharmacist id 72
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Pharmacists  were  sometimes  dissatisfied  with  the  DRPs  that  were  identified  by  MRM, 
discussed later. Other problems were grouped under the category product needs polish. One 
pharmacist  mentioned  occasional  bugs  on  saving  information,  another  mentioned  drug 
products were out-dated and new products were not added. Also, the video tutorial was also 
outdated. Several comments stated that using MRM was time consuming, tying in with the 
data entry aspect.
“Data entry became far too time consuming” Pharmacist id 8
Several  comments  stated  that  layout,  presentation,  punctuation  and  spelling  were  not 
professional.
“The layout and presentation of the final MRM product together with spelling mistakes 
and punctuation are far from professional. A proof reader should have been given the job 
to rectify all these oversights that should have been done in the first instance. I strongly  
believe  these  aspects  should  be  part  and  parcel  and  a  basic  expectation  of  a 
professionally prepared (credible) document.” Pharmacist id 9
  DRPs could be better
Several problems with identified DRPs were stated: DRPs were contradictory, DRPs were not 
current practice, DRPs or recommendations were irrelevant, DRPs were duplicated, and data 
was incorrectly analysed.
“All confidence in the program is lost when it fails to recognise that a pathology test has 
been entered and it  then suggests in  its  recommendations  that  this  pathology test  be 
undertaken, saying that this area has not been investigated.” Pharmacist id 63
“Occasionally it gives the same recommendation with slightly different wording for the 
same patient” Pharmacist id 35
“I find that the issues present often contradict themselves.  Eg.  Patient is on an NSAID 
prophylactic  PPI  therapy  required,  next  issue:  patient  has  been  on  a  PPI  long  term 
consider ceasing” Pharmacist id 52
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Confirmation of the validity of MRM-identified DRPs was requested through provision of 
references.
“I would like to see reasons and references for recommendations.” Pharmacist id 38
  Time and efficiency
There were divided opinions concerning use of time, with five comments stating MRM was 
time consuming and four comments stating MRM saved time.
“data entry became far too time consuming” Pharmacist id 8
 “The  book keeping,  reports  and  claiming are  an  awesome help  to  streamlining  the 
process and allowing me to efficiently use my time” Pharmacist id 14
One pharmacist had a bet each way:
“I am unable to simply download the report & send to the Dr - I usually need to 'polish'  
& personalise quite a lot which is time consuming. Having said that, it certainly saves 
time & eliminates a lot of double entry." Pharmacist id 5
One pharmacist stated MRM was slower to user than a competitor product:
“frequently slower to work with than Mediflags” Pharmacist id 7
  Additional functionality
Pharmacists  expressed  the  need  for  additional  features.  Several  pharmacists  wanted  the 
software to be able to store their own comments to apply to particular DRPs.
“I would like to be able to save my own comments, etc into my system to save copy and 
pasting.” Pharmacist id 10
Other functionality requests were: the ability to directly download patient information from 
GP surgeries, ordering the medication list by medical condition, a report section for RMMR 
staff, add in standard drug interaction capability, electronic form to fill in during an interview.
185
MRM user survey
 9.4 Discussion
Most pharmacists  who used MRM were  experienced with  medication reviews and many 
years  pharmacy  experience.  Most  pharmacists  performed  HMRs  whereas  only  half  of 
respondents  performed RMMRs.  The  majority  of  pharmacists  used  a  range of  published 
prescribing  guidelines  to  assist  with  the  identification  of  DRPs  and  to  make 
recommendations.  However,  the  Beers,  STOPP/START  and  PIEA  prescribing  criteria 
intended  for  use  in  older  people  and  recommended  by  the  Pharmaceutical  Society  of 
Australia were only rarely used by pharmacists.25 The rare use of these materials may be 
because these materials are not actively promoted to pharmacists, and pharmacists have to 
actively search for them through bibliographic databases such as PubMed. Materials such as 
the  Therapeutic  Guidelines  and  NPS  guidelines  are  actively  and  directly  promoted  to 
pharmacists in Australia. 
The amount of patient information manually entered by the pharmacist was anticipated to 
affect the software's findings and consequently pharmacist opinion of the software's findings. 
For many pharmacists data entry was a major bugbear, with pharmacists finding the process 
cumbersome and time consuming. 
“It's slow and boring! And information that is given back is only as good as the data  
entered in the first place!” Pharmacist id 15
According to the TAM, pharmacist attitude towards and actual use of MRM are dependent on 
the perceived usefulness and ease of use of the software.195 Software must be relatively easy 
to use if people are likely to make use of it. Technology usability is one core constituent of 
the Technology Acceptance Model (TAM) – a model based on the theory of reasoned action 
to explain actual acceptance and use of technology, see section 3.6. The perceived ease of use 
of  technology  has  been  defined  as  “the  degree  to  which  a  person  believes  that  using  a 
particular system would be free of effort”195 Both ease of use and usability scored highly, 
suggesting that pharmacists were accepting, or willing to use, the software. 
“All over I have found the MRM program very useful” Pharmacist id 19
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Most  pharmacists  perceived  MRM's  clinical  decision  support  to  be  useful.  Many  of  the 
central medication review decision processes such as identifying clinically relevant DRPs and 
providing appropriate recommendations were associated with the usefulness of the decision 
support shown in Figure 55. Perhaps in part due to the usefulness of MRM, pharmacists were 
satisfied with the software as they thought MRM helped manage their medication reviews 
and  provided  value  for  money. The  use  of  the  software''s  findings  for  patient  interview 
preparations and for GP reports  strongly indicate pharmacists found MRM's decision support 
to be useful in their medication review work.
Pharmacists generally thought MRM did identify clinically relevant DRPs and did provide 
appropriate  recommendations  to  resolve  DRPs.  These  opinions  were  supported  by  the 
opinions of the expert panel, with no statistically significant differences. Pharmacist opinion 
was less strong on whether MRM missed the identification of DRPs, with nearly half  of 
pharmacists  indicating  DRPs were  not  missed  and another  third  unsure.  The majority  of 
pharmacists thought MRM did not identify too many DRPs which may be due to suitable 
patient  context  through  the  use  of  AI.  A  range  of  factors  were  associated  with  the 
identification of clinically relevant DRPs, shown in Figure 56.
Pharmacist  opinions  showed that  the  pharmacists  did not  absolutely  rely on the  decision 
support and that MRM did not always produce good results. However, the rule base for this 
software can continually evolve through the addition of new rules and refinement of existing 
rules. Feedback from the pharmacists who are using the software to those who implement and 
refine rules in Medscope company is an important pathway for improvement. The company 
in turn need to verify rule additions and refinement are valid and to respond promptly to user 
feedback  to  enhance  MRM's  usefulness  from  the  user  perspective.  The  use  of  clinical 
guidelines, such as the Therapeutic Guidelines,303 by many pharmacists confirms pharmacists 
do not rely on MRM alone.
“I find that you can't rely on it entirely” Pharmacist id 72
“I don't use the decision support very much as I find that many of the recommendations 
aren't clinically relevant” Pharmacist id 36
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“On some occasions I have found PPI use is stated no indication for use, because no 
GORD but does not identify that long-term prednisolone is used for RA etc.” Pharmacist 
id 28
MRM's core service quality, the provision of assistance to pharmacists for the management of 
medication reviews, was mostly very positive. Core service quality was also associated with 
identification  of  clinically  relevant  DRPs  and provision  of  appropriate  recommendations. 
Core  service  quality  was  associated  with  many  factors,  shown  in  Figure  58,  which 
unsurprisingly  included  perceived  usefulness  and  system  usability.  Additionally,  most 
pharmacists thought MRM met their expectations and was value for money and these factors 
were not unexpectedly associated with core service quality. Although value for money did 
appear to depend on the frequency and type of reviews performed.
“It is not cost effective if I only average 12 hmmrs [sic] per year” Pharmacist id 29
“Needs to be cheaper so I can use for RMMRs” Pharmacist id 48
A compelling argument for the use of MRM comes from the opinions of the majority of 
pharmacists  that  MRM  identified  clinically  relevant  DRPs  that  were  missed  by  the 
pharmacists themselves.
“I like using the software as it  is  a safety net  for me to make sure I haven't  missed 
anything crucial” Pharmacist id 72
Earlier  examinations  of  expert  systems  have  found  thoroughness  in  the  identification  of 
DRPs.167,178,239 Thoroughness and consistency of findings were benefits suggested by Bindoff 
et al.  through work on  prototype software which formed the basis of MRM.178 Previous 
work, see Chapter 7, showed that pharmacists and MRM generally find different problems in 
different patients. The use of MRM to supplement the work of the pharmacist is expected to 
add  this  consistency  and  thoroughness  to  the  pharmacists  medication  review  reports  as 
indicated by the pharmacists who use the software. This finding was hypothetically proposed 
by Bindoff et al. and appears to be justified.167,178
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 10 Discussion
 10.1 Background
Medication  reviews  are  conducted  for  the  benefit  of  patients  who  may  be  at  risk  of 
medication misadventure.  The process begins with the identification of a suitable patient, 
patient interview, preparation of a report of findings and recommendations for the patient's 
GP. The  GP and  patient  discuss  a  medication  management  plan  culminating  ideally  in 
improved patient health and quality use of medicines.25 Pharmacist expertise of medication 
knowledge is applied to identify clinically relevant DRPs and provide recommendations for 
their  resolution.  A survey of accredited pharmacists  found that assessment  of the clinical 
appropriateness of medication therapy was considered the most important duty in performing 
HMRs.273
Identification  of  clinically  relevant  DRPs  requires  proficient  knowledge  of  medications, 
common  health  conditions  and  evidence-based  guidelines.  Observational  results  and 
laboratory test results add to the conglomeration of patient medical information. Other factors 
such as health literacy, poverty, compliance, and physical limitations increase the complexity 
of determining suitably relevant DRPs and recommendations to resolve those DRPs.
Commercial  decision  support  tools  have  been  developed  to  aid  pharmacists  with  the 
identification of DRPs. Two commercially-available software applications (MRM abd MRX), 
as well as well known sets of prescribing criteria,  were assessed for their capacity to identify 
DRPs. Through the early phase of this investigation, neither of the commercial products had 
published assessments of their capacity to identify clinically relevant DRPs.
During this investigation one article was published regarding MRX applied to community-
based  elderly.220 The  authors  concluded  MRX  “...  was  successful  at  identifying  those 
[patients] with a high risk of drug-related geriatric syndromes.” although the justification for 
this conclusion was not entirely clear. The impression was that the software identified broad 
classes  of  potential  drug-related  problems  whether  such  problems  existed  or  not.  When 
compared, within the article, to an assessment by a geriatric-specialised pharmacist MRX 
appeared to overestimate the incidence of these syndromes. However, MRX identification of 
anticholinergics was in line with PIMs identified by the pharmacist.
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These  applications  were  not  assessed for  their  ability  to  collect  or  organise  patient  data, 
although  this  was  a  central  function  of  both  products.  These  applications  were  assessed 
specifically  on  their  decision  support  capabilities.  Both  companies  –  MedscopeTM and 
Monitor-Rx stated claims purporting the benefit their decision support provided, but these 
claims cannot be truly justified without scientific assessment.
The Monitor-Rx website stated:
“... clinical tool that assists in identifying, resolving and preventing medication-related 
problems ... identifies medications that may cause, aggravate, or contribute to common 
geriatric problems... ”260
The MedscopeTM Medication Review Mentor website stated:
“... takes into account the patient's entire profile and identifies the issues that matter ...  
Missing medications are identified ”307
To be effective as decision support, both applications must justify their stated claims and they 
must be practically useful to the end user – the pharmacist conducting the medication review. 
This practical usefulness is defined as software validation and has been clearly expressed in a 
2002 FDA report General principles of software validation:
“confirmation  by  examination  and  provision  of  objective  evidence  that  software 
specifications  conform  to  user  needs  and  intended  uses,  and  that  the  particular 
requirements implemented through software can be consistently fulfilled.”308
Validation of MRM and MRX was based on the output resultant from the input of patient  
information from the VALMER HMR data. Both MRM and MRX applications were black 
boxes, defined in the Oxford English dictionary as:
“2. A device which performs intricate functions but whose internal mechanism may not  
readily be inspected or understood; (hence) any component of a system specified only in  
terms of the relationship between inputs and outputs.”309
The decision support tools were black boxes, however it  was known each differed in the 
scope  of  information  utilised  for  the  determination  of  actual  or  potential  DRPs.  MRX 
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produced  results  based  solely  on  the  presence  of  selected  medications  used  in  chronic 
medical conditions. MRM produced results based on a wide range of data including patient 
medications,  strength,  directions,  daily  dose,  diagnoses,  observations  and  laboratory  test 
results.  The difference  in  the  breadth  of  information  analysed  is  likely  to  be  one of  the 
primary drivers between the markedly different results reported in this document.
 10.1.1  Evaluation with DOCUMENT classification
Using  the  DOCUMENT  classification  system,  pharmacists  not  unexpectedly,  found  the 
widest range of DRPs covering all  of the eight DOCUMENT categories.  MRM similarly 
identified a wide range of DRPs, six of eight categories, but nothing in the  compliance or 
not-classifiable categories.
In contrast with MRM, MRX exclusively identified medications for chronic conditions in the 
elderly that required monitoring. In other words, a screening tool, producing a check-list of 
potential problems which may be caused by medications. Potential problems were described 
in  detail  as  well  as  descriptions  of  their  signs  and  symptoms.  No  contextualisation  or 
incorporation of drug dosages of these monitoring problems was performed by the software. 
The findings of the automated prescribing criteria were also examined. Unlike pharmacists, 
MRM, or MRX, each set of prescribing criteria identified fewer instances of DRPs and the 
main classification of DRPs identified were associated with the drug selection category.
On application of the DOCUMENT classification system, the assessment of MRM and MRX 
showed strong differentiation: the seemingly excessive number of DRPs identified by MRX 
and MRX's narrow scope of DRP types contrasted with MRM. MRM seemed excessive in the 
number of DRPs identified compared with pharmacists but not when compared with MRX. 
MRM also showed the ability to identify a range of problem types. The information obtained 
using DOCUMENT classification is of interest however there were two drawbacks: the types 
of DRP identified were classified in a general manner without any detail of drug class or any 
associated  disease,  and  there  was  no  information  relating  to  the  clinical  relevance  of 
identified DRPs.
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 10.1.2  Descriptive classifications
The assessment using DOCUMENT classifications offered a broad overview of the frequency 
and  type  of  DRPs  identified  by  the  software.  This  method  of  assessment  was  extended 
through  the  development  of  descriptive  classifications  -  detailed  classifications  which 
captured the central  issue of each DRP and, through comparison with sets  of prescribing 
criteria, some measure of clinical relevance. 
Looking at the cohort of 570 patients, there were nearly seventy different types of descriptive 
classifications where MRM and pharmacists found the same problem in one or more of the 
same  patients.  The  most  commonly  occurring  example  was  osteoporosis  (or  risk)  may 
require calcium and or vitamin D. This particular issue was identified by both MRM and by 
pharmacists in the same patients on nearly fifty occasions. However, this same problem was 
identified in an additional nearly ninety patients by MRM. Pharmacists also identified nearly 
another seventy patients which who were had this under-treatment problem. This situation 
repeated  itself  throughout  the  majority  of  the  descriptive  classifications  where  there  was 
overlap of findings between pharmacists and MRM.
This situation did not occur across all classifications. For nine classifications MRM identified 
every instance where the pharmacist found a problem, and MRM found more, for example: 
calcium channel blocker and reflux. MRM also identified the majority of issues found by 
pharmacists in other areas such as:  hyperlipidaemia undertreated. Conversely, pharmacists 
identified every instance where MRM found the problem vitamin no indication. 
On  looking  at  the  varying  levels  of  overlap,  two  questions  arose:  Why  did  MRM  find 
problems that pharmacists did not? And why did pharmacists find problems that MRM did 
not?
 10.1.3  Why did pharmacists find problems and MRM did not?
The classifications vitamin no indication provided a strong clue as to the reason pharmacists 
found issues where MRM did not. Herbal medications and various multivitamin preparations 
were not listed in MRM and so were not able to be assessed. This line of reasoning may 
explain why pharmacists could find problems that MRM could not – namely that pharmacists 
had  information  that  was  not  available  to  MRM.  That  is,  they  had  a  greater  range  of 
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accessible data. There are two likely explanations behind this – information was available to 
the pharmacists but not recorded for entry into MRM, and the knowledge domain model used 
by MRM may not have been adequately designed to capture and utilise some of this expert 
knowledge.  The  higher  proportion  of  DOCUMENT  toxicity  findings  also  suggests 
pharmacists had additional information, likely gleaned from the patient interviews. Another 
possible  explanation  may  be  that  pharmacists  identified  irrelevant  or  incorrect  problems. 
Research  conducted  on  community  pharmacists  in  Ireland  discovered  those  pharmacists 
lacked knowledge of EBM,310 however Australian studies have shown pharmacists do follow 
evidence-based guidelines.42,311 However, results from the expert panel assessment indicated 
that both MRM and pharmacists identified clinically relevant problems for the most part.
 10.1.4  Why did MRM find problems that pharmacists did not?
Realising pharmacists had a greater range of available data makes this question particularly 
pertinent  –  several  suggestions  are  postulated.  Overall,  MRM  did  identify  many  more 
problems than pharmacists, even when excluding MRM's duplicate DRPs.
The first possibility is , again that MRM identified issues which were irrelevant or incorrect. 
There  has  been much discussion  and research  surrounding the  issue of  alert  fatigue  and 
accuracy (see section  3.6) impacting on relevance. For many of the various themes MRM 
identified more instances of problems than pharmacists. This may indicate lack of relevance 
which may have been the case involving calcium channel blockers. Calcium channel blockers 
may aggravate reflux disease,  as was consistently identified by MRM, yet this issue was 
identified on only one occasion by a pharmacist, suggesting MRM was either thorough, or 
was  over-exaggerating  a  minor  issue. However,  the  lack  of  relevance  theory  was  not 
supported by the expert panel, nor was it supported by the majority of surveyed pharmacists 
who used MRM. Although some comments from pharmacists who used MRM did indicate 
that lack of relevance was, at least sometimes, a concern. The smaller quantity of pharmacist 
DRPs may indicate that pharmacists prioritised problems of greater importance and did not 
report  on  lesser  problems.  A  survey  of  pharmacists  who  provided  the  data  for  this 
investigation found that pharmacists did prioritise their findings.273
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The second possibility is that MRM may be more consistent at identifying DRPs, perhaps 
through not prioritising DRPs. Consistency was a finding from three expert system studies 
including two precursor systems to MRM.167,178,239 Certainly, consistency was clearly shown 
for  several  classifications:  dextropropoxyphene  prescribed,  quinine  prescribed.  These 
medications  no  longer  have  a  place  in  current  practice,  with  the  exception  of  quinine 
treatment  for  chloroquine  resistant  strains  of  Plasmodium  falciparum malaria.312 Unlike 
MRM,  why  did  pharmacists  not  identify  these  problem  medications  in  more  patients? 
Quinine was extremely commonly prescribed for nocturnal cramp and the risk of quinine-
induced  thrombocytopenia  has  been  known  for  many  years.312,313 Dextropropoxyphene 
products  were  initially  removed  from  the  register  of  therapeutic  goods  in  Australia  in 
2012.314,315  However, recent appeals have allowed dextropropoxyphene products to continue 
to be marketed in Australia albeit with increased prescribing restrictions.316,317
The likelihood of greater consistency in the identification of DRPs by MRM is an important 
point. The combination of MRM's ability to find, with machine regularity, a wide range of 
potential problems in medication review patients is likely to make this software a useful tool 
to complement the pharmacist's assessments. The only proviso in this discussion so far is the 
possibility that MRM has identified issues which were irrelevant or plain wrong.
 10.1.5  Why did MRX find problems that pharmacists did not?
Similar to MRM, MRX also highlighted many potential DRPs which pharmacists did not. 
The same suggestions are postulated as for MRM – that is, MRX's findings may be irrelevant 
or incorrect and/or MRX may be more consistent at identifying DRPs. However, the nature of 
DRP detection  was very different  with MRX. The DOCUMENT classifications  of  DRPs 
showed that MRX identified both a much greater volume of DRPs than MRM, or any other 
method of DRP detection, yet a much narrower scope of problem types. 
When looking at descriptive classifications, MRX identified only four classifications which 
overlapped with pharmacists findings. This is in stark contrast to the many classifications that 
overlapped  between  MRM and  pharmacists.  This  again  emphasises  the  narrow scope of 
issues  that  could  be  identified  by  MRX  (see  Appendix  19).  One  of  those  issues,  falls  
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risk/history and sedatives/ antihypertensives/ other, was associated with every single one of 
the 100 patients entered into MRX (see Figure 35).
The  second  difference  was  where  MRX  overlapped  with  pharmacists.  In  this  rare 
circumstance, MRX always found every instance of the pharmacist identified problems. This 
indicates MRX was very sensitive in finding problems within its scope of knowledge, that is, 
purely the presence of a medication of interest. This leads to the two possibilities, was MRX 
simply extremely consistent and clinically relevant in the rare overlapping circumstances, or 
was MRX simply excessively sensitive and clinically irrelevant?
 10.2 Resolving the issue of relevance
Both MRM and MRX found descriptive classifications which overlapped with pharmacist 
findings and they both found more of the same kinds of problems in additional patients where 
the  pharmacist  did  not  identify that  problem. Also  both software sources  did find issues 
which pharmacists did not find, or prioritise, at all such as for MRM: aspirin or thiazide  
contraindicated in gout, NSAID without acid suppressant, opioid sedation; and examples for 
MRX:  medication  monitoring  for  cognitive  or  communication  problems,  medication  
monitoring for nutritional status  and medication monitoring for urinary incontinence. The 
issue of software identifying more problems than pharmacists needed to be investigated with 
consideration of clinical relevance. It would be reasonable to expect pharmacists prioritised 
their DRP findings and chose not to include minor problems. This expectation was confirmed 
through  a  survey  of  accredited  medicines  review  pharmacists  conducted  by  Dr  Andrew 
Stafford.273 However, if  the  software  was  finding more  clinically  relevant  problems than 
pharmacists,  then  such  software  may  be  considered  to  be  a  beneficial  tool  to  assist 
pharmacists conducting HMRs. Conversely, if the software was finding a lot of irrelevant 
problems then the decision support functionality is likely to frustrate the user, and result in 
alert fatigue.
 10.2.1  Original pharmacist findings as a measure of clinical relevance
The original pharmacists  findings may be the best measure of clinical relevance as these 
pharmacists were likely to have the best knowledge of the clinical situation of each patient 
through the additional  information obtained from patient  interviews. Secondly, they were 
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likely to have prioritised the most important DRPs in their GP reports. MRM identified more 
of the same descriptive classifications in the same patients as those identified by pharmacists 
than did MRX. In contrast MRX identified very few of the same descriptive classifications in 
the same patients as did pharmacists. This comparison clearly suggests that MRM had greater 
clinical relevance than MRX, at least in the view of the reviewing pharmacist.
 10.2.2  Prescribing criteria as a measure of clinical relevance
The findings of MRM, MRX and pharmacists were compared with the explicit criteria from 
the Beers03, Beers12, PIEA and STOPP/START prescribing criteria. The assumption was 
that  such  criteria  were  clinically  relevant,  being  mostly  based  on  expert  consensus  and 
developed mainly in agreement with supporting evidence.
MRX was found to have more in common with both sets of Beers criteria than pharmacists, 
but less in common with STOPP/START or PIEA than pharmacists, see Tables  25 and  36. 
Such a finding is expected as MRX was designed in part around the Beers03 criteria and 
HEDIS 2006 criteria.38,318,319 One of the main themes identified by MRX was anticholinergic  
use  not  elsewhere specified,  anticholinergic  medications  feature  prominently  within  these 
criteria.38,320
MRM was found to have more in common with  all four criteria than pharmacists, yet was 
less aligned with either of the Beers criteria than MRX. This finding reinforces the wider 
scope of problems that were able to be identified by MRM, illustrated in Figure 23.
Comparisons with prescribing criteria showed mixed results. Certainly alignment with Beers 
criteria may be a positive finding. However, it should be noted that the Beers03 criteria has 
come under some criticism as several listed medications were either rarely prescribed or had 
insufficient evidence to be included in the criteria.63,103,117 As is shown in  Figure 25, other 
criteria identified a wider scope of issues including problems relating to undertreatment. Do 
these associations with differing prescribing criteria truly reflect MRM and MRX's ability to 
detect  clinically  relevant  DRPs?  Perhaps.  An  assessment  of  clinical  relevance  based  on 
comparison with prescribing criteria was somewhat limited as it was dependent on which 
prescribing criteria were preferred. An investigation into a preferred prescribing criteria was 
subsequently performed.
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Several  studies  have  given  greater  preference  to  STOPP/START  over  the  Beers03 
criteria.45,103,118 The findings from STOPP/START were also assessed by the expert panel and 
the panel found the STOPP/START findings, although fewer in number than other sources, 
were  clinically  relevant.  The  STOPP/START  criteria  were  more  in  alignment  with 
pharmacists  findings by both frequency and scope of problems identified,  than either the 
Beers12  or  the  PIEA  criteria.  The  findings  discussed  in  this  paragraph  suggest  the 
STOPP/START criteria have the most suitable clinical relevance of those investigated.
Considering  STOPP/START as  the  best  prescribing  criteria  for  the  measure  of  clinical 
relevance, MRX sat at the bottom, pharmacists came a strong second and MRM was marked 
as the most relevant. Still do these rankings truly reflect MRM and MRX's ability to detect 
clinically relevant DRPs? The two main limitations are that STOPP/START cannot address 
DRPs  outside  of  it's  scope  and  that  DRPs  within  scope  are  not  sufficiently  tailored  for 
individual  patient  context.  Other  approaches  were  attempted  to  help  answer  the  clinical 
relevance conundrum.
 10.2.3  Expert and user opinion as a measure of clinical relevance
Expert opinion indicated that pharmacists, MRM and the STOPP/START criteria could all 
identify clinically relevant DRPs in the sample of cases examined. It is worth noting that 
MRM identified more DRPs than pharmacists yet was still considered just as relevant. The 
opposite view was held of MRX. These opinions add clarity to the lack of overlap in the 
descriptive classifications analysis between pharmacists and MRX.
The question of why MRX found problems that pharmacists did not can now be answered. 
The issues identified by MRX lacked clinical relevance.  In addition,  experts  thought that 
MRX identified an excessive quantity of DRPs. Despite these findings MRX had much in 
common with the Beers criteria and several expert panel assessors thought MRX may be 
useful as a screening tool to assist in targeting interview questions.
Why did MRM find problems and pharmacists did not? Part of the reason is the additional 
10% of repetitious findings,  but even after excluding repetitious DRP findings MRM did 
identify  a  greater  volume of  DRPs.  Experts  generally  did  not  think  MRM identified  an 
excessive number of DRPs (see  Figure 43). Additionally, experts and the pharmacists who 
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used MRM mostly thought  MRM was clinically relevant.  The mechanical consistency of 
MRM when detecting a wide scope of relevant DRPs appeared to be the primary reason why 
more DRPs were identified. Despite finding a greater frequency of DRPs than pharmacists, 
MRM was still  thought by experts to sometimes miss the detection of clinically relevant 
DRPs, but less so than the original pharmacists. The survey of pharmacists who used MRM 
showed that MRM identified clinically relevant DRPs that the pharmacists themselves had 
missed. This was a distinct advantage of the software as a decision support tool and a good 
reason why MRM was finding more DRPs.  Earlier  work by Bindoff  et  al.  on prototype 
systems upon which MRM's decision support capabilities were based, showed that experts 
did routinely miss DRPs that were identified by the software.167,178 This situation occurred 
despite the fact that the experts knew of the specific problems, as was evidenced by their 
identification  of  such problems in  earlier  and  later  cases.178 MRM's  recommendations  to 
resolve  DRPs  were  also  considered  to  be  appropriate,  by  both  the  expert  panel  and  by 
pharmacists who use MRM, likely adding to the impression of clinical relevance.
 10.3 Summary of clinical relevance
When trying to determine how clinically relevant a particular DRP is in a particular patient, it 
was difficult  to  get  a  definitive answer. MRX found many DRPs and these were mostly 
irrelevant DRPs. MRX identified few types of descriptive classifications with few in common 
with pharmacists.
However, MRM found many more DRPs when compared to pharmacists, yet was considered 
by both the expert panel members and by pharmacists who used the product to find clinically 
relevant DRPs and surprisingly to find a not excessive number of DRPs. The wide variety of 
descriptive  classifications  identifiable  by MRM including some overlap  with  pharmacists 
findings for many different classification types and in many patients adds to the opinion of 
relevance.
The implementation of software like MRX which assesses minimal information, presence of 
a  medication,  is  not  recommended  when  attempting  to  deliver  quality  decision  support 
services.  Many expert  panel  assessors were exasperated examining the MRX tool,  which 
appeared to replicate the alert fatigue problems discussed under section  3.6.1. Additionally, 
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some DRPs were presented which appeared to have so little clinical relevance as to be almost 
laughable,  an  example  of  potential  problems from a patient  using  topical  hydrocortisone 
cream is shown in Figure 59.
MRM on the other hand, was able to incorporate a wide range of patient data available in the 
VALMER records and assess this data using an advanced AI-based approach. This capability 
gave MRM the ability to identify a reasonable quantity and reasonable scope of clinically 
relevant  DRPs. While  the  scope  of  DRPs  was  less  than  that  of  pharmacists  it  was  still 
sufficiently broad so as to cover 100 different descriptive classifications of which 90 were 
classifications also found by pharmacists. Another advantage of the AI approach used for 
MRM, was the functionality that  enables an expert  in the medication review domain,  an 
accredited pharmacist, to readily add rules and refine existing rules stored in the knowledge 
base. Through the implementation of MCRDR, incremental improvements in the precision of 
rules in context of the uniquely varied patient situations developed more precise assessments 
of problems encountered. Direct improvements to the knowledge base also allows for change 
which is a constant in the medical field, as the development of new treatment options and 
methods need to be included into such software on an ongoing basis in order to maintain 
clinical relevance.
One salient point was that MRM identified many more DRPs than pharmacists, however, the 
majority  of  those DRPs were considered to  be clinically  relevant.  Essentially  MRM was 
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identifying DRPs that were missed by pharmacists. This is an important feature and has been 
mentioned  in  association  with  other  AI  software.167,178,239 This  was  clearly  stated  by  one 
pharmacist who used MRM:
“I like using the software as it  is  a safety net  for me to make sure I haven't  missed 
anything crucial” Pharmacist id 72
The  majority  of  pharmacists  who  used  MRM were  of  the  opinion  that  MRM identified 
clinically relevant DRPs that they had overlooked and unsurprisingly this was associated with 
pharmacists opinions that MRM was useful. Not only did MRM identify clinically relevant 
DRPs and find DRPs pharmacists missed, but MRM was considered, by both the expert panel 
assessors and by pharmacists  who use MRM, to provide appropriate recommendations to 
resolve the identified DRPs. 
Having established MRM, unlike MRX, is a clinically relevant tool is not the end of the 
evaluation. There are several further considerations still to be made; particularly, is the CDSS 
used appropriately by pharmacists?
 10.3.1  Use of MRM by pharmacists
The majority of pharmacists  who used MRM thought MRM identified clinically  relevant 
DRPs, in fact there was no statistical difference in the range of opinions when compared to 
the  expert  panel.  Similar  to  the  expert  panel,  the  pharmacists  generally  thought  MRM's 
recommendations  to  resolve  DRPs  were  appropriate,  likely  adding  to  the  impression  of 
clinical relevance.
However, it may not matter how clinically relevant the CDSS is, if the CDSS is not used 
appropriately. No comments made by pharmacists suggested they solely relied on the CDSS 
and no comments stated that the CDSS was completely ignored. MRM's decision support was 
received with healthy scepticism:
“I find that you can't rely on it entirely, and I often add extra points that are more relevant  
to that particular report” Pharmacist id 72
MRM  was  found  to  identify  clinically  relevant  DRPs  and  provide  appropriate 
recommendations within its scope of knowledge. Pharmacists who used MRM found MRM 
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helped  them manage  medication  reviews.  Management  of  patient  details  and  organising 
reports and interviews involves software functionality other than clinical decision support, 
however, many clinical decision support factors were associated with the management of 
medication  reviews  assisted  by  MRM.  Many  factors  were  associated  with  the  ability  to 
manage medication reviews, including factors which appear separate from decision support 
functionality. Decision support factors  included identification of clinically  relevant DRPs, 
providing appropriate recommendations, not missing relevant DRPs, using MRM DRPs in 
medication  review reports  and  using  MRM DRPs to  prepare  for  patient  interviews.  Not 
surprisingly many pharmacists found MRM to be useful and were satisfied with the software. 
The MRM product was certainly not without problems, with repetitive identification of the 
same DRPs in the same patients accounting for 10% if  its  output,  some identification of 
irrelevant DRPs and some lack of finesse of spelling and punctuation in DRP wording. Yet 
the overall opinions of clinical relevance, usefulness and satisfaction with the product were 
good.
 10.4 CDSS Technology
Information technology is an integral component of current work practice.  This has been 
spurred  in  part  by  increased  electronic  data  storage  and  interoperability  through  the 
development of the personally controlled EHR and Australian data standards promoted by 
NEHTA.321 Electronic data  storage and data  standards  provide the substrate  for  proactive 
CDSS implementations. That is software that actively alerts, reminds or otherwise assists as a 
decision aid. 
The technology underpinning MRM was MCRDR. This AI approach allows the software to 
incrementally  learn how the expert  applies their  knowledge,  while  they routinely use the 
system. This approach allows the expert to gradually build up and refine the knowledge base, 
utilising  all  the  factors  of  the  patient  case  as  inputs.  This  means  that  the  rules  are  not 
simplistic,  they  may  combine  many  variables.  They  are  also  not  static,  they  can  be 
incrementally improved or adjusted as new evidence or expert knowledge comes to light, 
without requiring any intervention from a software developer or knowledge engineer.
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MRX implemented simplistic rules focusing only on the presence or absence of medications 
of interest. This simplicity resulted in generic and repetitive advice provided by the software. 
There was no patient contextualisation, not even by drug dosage nor any drug-interaction 
checking. It was summed up by an expert panel assessor:
“This source has little patient relevance and is more of a generic list of ADEs which  
offers no clinical decision support.” general practitioner, id 23
The MCRDR approach appeared to be successfully implemented in the medication review 
domain, although through discussions with Medscope and analysis of the user feedback it 
was clear that there was still room for improvement in the way it has been implemented. For 
instance,  MRM  is  known  to  not  correctly  model  combination  therapeutic  products. 
Additionally,  it  is  thought  to  have  only  partially  implemented  the  validation  stage  of 
MCRDR, which may result  in  slower than  expected  rule  refinement  processes,  requiring 
more refinements to achieve equivalent accuracy. In spite of these minor shortcomings in the 
MRM implementation, this AI technology has shown remarkably good performance, and is 
considered likely to be able to offer similarly good results if it were included in other related 
medical  domains,  such  as  community  and  hospital  pharmacy  and  general  and  specialist 
practice. This approach may be expected to reduce the alert fatigue that has previously been 
observed, and increase the likelihood of consistent and relevant decision-making. There were 
a range of pharmacist identified DRPs that were out of scope of MRM, such as compliance-
related DRPs. Future implementations of the MCRDR technology might integrate a greater 
range of patient variables to enable a wider scope of DRP detection.
 10.5 Automated prescribing criteria
Automated prescribing criteria were used as a measure of clinical relevance, yet they were 
also CDSS. In complexity they sit between the complex MCRDR approach of MRM and the 
simple presence of a drug approach used by MRX.
Sufficient information was obtained for many HMR patients to allow detailed application of 
the four sets of prescribing criteria. Whilst only explicit criteria were able to be automated, 
this encompassed the majority of criteria from each of the four sets of prescribing criteria. 
The main limitation with the implementation of explicit  criteria  was lack of information, 
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specifically lack of information regarding the purpose for which certain medications were 
prescribed or for the duration of use of certain medications.
This research has shown the various prescribing criteria have a limited scope for detection of 
DRPs, concentrating on problems concerning drug selection, overdosage and under-treatment 
(see  Figure 25). The STOPP/START criteria were favourably assessed by the expert panel, 
with the STOPP/START DRPs generally considered to be clinically relevant although the 
actual  number of  problems found was low compared with MRM, MRX and the original 
pharmacists' findings. This reflects the limited set of criteria present in such a guideline. Not 
only were the STOPP/START criteria considered relevant by expert panel assessors but the 
comparison with Beers12 and PIEA also suggested STOPP/START were the preferred option. 
As Levy et al.103 suggested:
“No one set  of  criteria may ever be commonly applicable across the globe, although 
STOPP/START criteria appear to be the most universal and may have an advantage over 
others.”
 10.6 Future research
The simplistic one factor rules used by MRX should not be utilised in future research as the 
results of this thesis have shown this approach produces an excess of irrelevant findings.
The AI approach used by MRM was successful in supplementing clinically relevant DRPs to 
the DRPs identified by pharmacists, so enhancing the consistency and thoroughness of the 
pharmacists reports. However, several implementation problems were identified which may 
be improved in future designs:
• There were a number of instances where MRM identified and presented the same 
findings twice. This situation may have been improved through improved software 
construction.
• The treatment context of the patient needed to be considered, particularly ongoing 
therapy versus end-of-life therapy. If an additional variable was present to determine 
if the patient was nearing end of life then many DRPs associated with under-treatment 
for chronic medical conditions may have been avoided.
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• The  ATC coding  used  to  classify  medications  limited  analysis  when  combination 
medications were assessed by MRM, e.g. paracetamol codeine combination products. 
The  Australian  Medicines  Terminology  available  through  NEHTA  provide  the 
capacity  to  identify  individual  components  within  a  combination  medication 
product.321
• A history of unsuccessful past treatments may have allowed the software to refine the 
DRPs  that  were  displayed,  so  avoiding  presenting  DRPs  findings  which  lacked 
applicability due to previous treatment failure.
• Incorporating the history of medications dispensed to the patient may identify both 
adherence and non-adherence to  treatment  for  routinely used chronic medications. 
However, it is acknowledged that access to this information may be difficult to obtain, 
as patients may frequent multiple pharmacies and such pharmacies nay be reluctant to 
divulge this information.
• Incorporating  treatment  costs,  both  cost  to  patient  and  cost  to  the  public  health 
systems may allow the software to make recommendations that may reduce costs to 
either the patient or the public health system or both. Costs to patients are a factor 
implicated in therapy adherence.71
Future versions of this software should aim to include some or all of these recommendations 
for improvement to further refine the software's ability to identify various types of DRP and 
enhance their clinical relevance. Future implementations may be able to incorporate a wealth 
of data present within EHRs. The advantage of this source of data would be to reduce the 
time taken to manually enter data and also to reduce the opportunity for data transposition 
errors.
This  thesis  examined  a  real-world  implementation  of  AI  approach  that  was  specifically 
designed to assist pharmacists with medication reviews. This AI approach may be able to 
utilise similar, if not identical data, in other contexts. Examples include incorporating such 
software within general practice surgeries, hospital pharmacy, hospital prescriber order entry 
systems and community pharmacy.
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Evaluation of future software that utilise the MCRDR approach may draw from both this 
thesis and from previous research conducted by Dr Ivan Bindoff. Bindoff  et al. compared 
DRPs identified by an pharmacist expert against those identified by software as the expert 
was entering rules into the software through a case-by-case to develop the knowledge-base. 
This approach could determine the frequency DRPs missed by the expert and the frequency 
of incorrect DRPs identified by the software. However, this evaluation was comparable to an 
in  vitro study  without  real-world  involvement.  This  thesis  added  real-world  evaluation 
methodologies including the comparative assessment of DRPs identified by pharmacists in 
the  real-world  against  DRPs  identified  by  the  software.  The  application  of  descriptive 
classifications provided the opportunity to identify the amount of DRP overlap that occurred 
between  pharmacists  and  software.  The  second  useful  evaluation  method  was  the 
employment of an expert  panel to independently judge the quality of DRPs identified by 
pharmacists  and  by  software.  The  final  approach  was  to  obtain  information  from  the 
pharmacists who used the software in their day-to-day work, to get their hands-on opinions of 
the software. The combination of these methodologies is anticipated to be beneficial in future 
analyses of this technology.
 10.7 Limitations
This research evaluated the capacity of two commercial CDSS designed to assist pharmacists 
performing medication reviews. The core features of assessment were the identification of 
clinically relevant problems and provision of appropriate recommendations. Interpretation of 
the results must include consideration of the limitations of this evaluation.
 10.7.1  Data entry errors
A large amount of data had to be entered for assessment by MRM and a lesser amount of data 
had to be entered for assessment by MRX. Checks of 20% of cases entered into each product 
were performed to confirm data was entered correctly. Errors were identified and corrected in 
these cases. Subsequent errors were identified and corrected when they became known. It is 
possible that additional data entry errors were present in the data and not corrected. However, 
based on the results of the validation check, errors are likely to be present in less than 1% of 
cases, making this a relatively minor limitation.
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 10.7.2  Descriptive classifications
The development of the descriptive classifications was an iterative process based initially on 
common DRP concepts found within prescribing criteria and both expanded and refined to 
include  all  DRPs  identified  by  all  sources.  The  initial  'final'  set  of  classifications  was 
validated by a second pharmacist and supervisor, Gregory Peterson. This resulted in several 
minor adjustments. It is considered that the validation process may have provided reliability 
to the final set of classifications. However, alternative approaches may have resulted in a 
different set of classifications, which in turn may have lead to differing results.
The  second  limitation  was  the  mapping  of  DRPs  to  classifications.  This  mapping  was 
undertaken solely by the author, Colin Curtain. The mapping process was not validated by a 
second person.  This  lack  of  confirmation  of  the mapping process  may have affected  the 
results obtained from examining the descriptive classifications, although this process was in 
most cases considered to be fairly straightforward, so the effect of this should not be great.
 10.7.3  DOCUMENT classifications
DOCUMENT  classifications  were  assigned  to  DRPs  by  the  author,  Colin  Curtain. 
Assignment of DOCUMENT classifications to DRPs were guided by the notes and examples 
provided in the Standard and guidelines for pharmacists performing clinical interventions.278 
The assignment process was not undertaken by a second person to confirm the accuracy of 
the assignment process, so it is possible that some errors of classification occurred. However, 
the  standards  are  quite  easy  to  apply,  and  the  author  is  very  experienced  with  the 
DOCUMENT classification system, so errors are considered unlikely to be common.
 10.7.4  Prescribing criteria
Prescribing  criteria  from Beers03,  Beers12,  PIEA and STOPP/START were  implemented 
electronically. Several assumptions were made in the application of these criteria, possibly 
limiting their effectiveness or accuracy when identifying specific DRPs. The main limitations 
were not knowing the prescribed purpose of medications, not knowing the duration of use of 
medications and not having sufficient information recorded to accurately implement criteria 
or even to implement criteria at  all.  Additionally, a number of patients did not  have any 
information  recorded  for  diagnoses,  laboratory  tests  or  observational  measurements. 
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Therefore, for a small number of criteria, the number of patients identified as having DRPs 
using the automated database query method may be understated.
 10.7.5  Expert panel DRP errors
One set of six DRPs associated with MRX were to be included in the expert panel assessment 
but  were missed.  One STOPP DRP was included which on revision of the STOPP SQL 
queries should have been excluded. However, these errors were very minor, and unrelated to 
the major conclusions of this study, so are considered unlikely to have any significant effect 
on the results. 
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 11 Conclusion
The systematic literature review uncovered a variety of CDSS which had the capability to 
align with the medicines  review process  to  aid health  professional  activities.  The use of 
knowledge based software which incorporates many patient variables did lead to improved 
expert practitioner performance167,178,232,246 and prototype systems of this nature also reported 
improved  consistency  for  the  detection  of  DRPs.167,178,239 However,  many  studies  of 
knowledge based software were prototypes and low uptake and acceptance of CDSS was 
identified in many of the studies that evaluated real world implementations.235,246–250 From this 
review it became apparent that one of the key drivers for poor acceptance and uptake was 
software presenting an excessive number of alerts that were too often irrelevant, and failed to 
consider enough of the patient context. The ramifications of this are serious, since there is no 
value in identifying a problem if it is then ignored.
The implementation of overly simple CDSS rules, such as the mere presence of a medication 
as was used by MRX, was insufficient to provide good decision support. The problem with 
such simple rules was the excessive abundance of a narrow range of generally clinically 
irrelevant DRPs. No contextual recommendations were possible, due to the simplicity of the 
rules.  The  excessive  abundance  of  mostly  irrelevant  DRPs  is  considered  likely  to  have 
severely hampered any potential benefit from the decision support provided by MRX, and 
this  view  was  reinforced  by  the  comments  of  the  expert  reviewers.  Additionally,  many 
clinically relevant DRPs including drug-drug or drug-disease interactions were not able to be 
identified by MRX. At best, MRX could be used as a tool to pre-screen patients who may 
require the need for medication review services as a result of a higher burden of sedative or 
anticholinergic medications, or perhaps as a tool to prepare lines of questioning prior to a 
medication review interview.
Automated versions of the prescribing criteria STOPP/START, PIEA, and Beers proved to be 
a slightly better tool for identifying DRPs. These tools took into account a broader spectrum 
of information about the patient’s condition (typically diagnoses), allowing them to identify 
more targeted and relevant problems. The patient data present in the VALMER dataset was 
sufficient  to  be able  to  implement  and evaluate  most  of  these rules.  Of the  four  sets  of 
prescribing  criteria  evaluated,  the  STOPP/START  criteria  were  found  to  be  the  most 
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representative of the original pharmacists findings in terms of both scope and the frequency 
with which problems fell into certain categories. Incorporation of the STOPP/START criteria 
to medical and pharmacy software may be readily achievable and may be able to provide 
basic, but clinically relevant decision support. Definitely more than simple solutions such as 
MRX, but not as broad, contextualised or detailed as more advanced systems such as MRM.
The most noteworthy result of this thesis was the good performance of MRM. The relatively 
detailed and well-formed underlying patient record, combined with the AI technology used 
by MRM, allowed for extensive contextualisation of findings, resulting in a wide variety of 
clinically  relevant  DRPs.  The  associated  recommendations  were  also  appropriately 
contextualised, and were considered by both the pharmacist users of the software, as well as 
the expert panel, to be of high quality and value. The identification of DRPs incorporating 
patient context is vital, as this appears to be the key to maximising clinical relevance and 
minimising irrelevant findings. The opinions from the expert panel strongly supported the 
clinical relevance of these contextualised DRPs, rating them as highly as those identified by 
the original pharmacist reviewers, despite the fact that MRM identified substantially more 
DRPs  than  the  pharmacists.  These  opinions  were  further  supported  by  the  pharmacist 
subscribers  of  MRM,  who  generally  indicated  a  high  regard  for  the  findings  and 
recommendations made by MRM and they were satisfied with the product. They found the 
CDSS to be useful, and importantly, quite capable of identifying clinically relevant DRPs that 
they might otherwise have overlooked themselves.
The overlap of the same DRPs found in the same patients by both pharmacists and MRM was 
low. However, both MRM and pharmacists identified differing although clinically relevant 
DRPs in both the same and different patients. This finding highlights the advantage of using 
this software to complement the pharmacists findings. The software supplements pharmacists 
findings with clinically relevant DRPs so that pharmacists have a wider range of DRPs to 
present in their medication review reports. The additional software-found DRPs promote the 
consistency and thoroughness of the pharmacists work.  The prepared wording in MRM for 
DRP resolutions presented more suitable wording than the pharmacists own wording.
However, MRM was not  without  problems.  The first  and most  evident  problem was the 
presentation of essentially duplicated DRPs, which made up ten percent of the DRP volume. 
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The second problem was the presentation of DRPs based on one rule that did not appear to be 
clinically  relevant.  MRM found over  one hundred instances  of  calcium channel  blockers 
associated  with  reflux,  however, this  problem was  identified  only  once  by  a  pharmacist. 
However, this  problem is  considered to  be relatively minor, since  the  rule  can  easily  be 
refined until it no longer appears erroneously. This is a strength of the MCRDR approach that 
underpins the CDSS within MRM, where rules can easily and naturally be continually refined 
and improved upon while the system is in routine use, without the need for intervention by a 
software developer or knowledge engineer.167
In light of the performance of MRM seen in this research, it  is reasonable to expect that  
future CDSS applications using the MCRDR approach could provide significant benefits over 
the  much  simpler  technologies  that  are  typically  utilised,  with  very  limited  success, 
worldwide.  These  benefits  include  the  identification  of  clinically  relevant  problems  both 
more  frequently, and  more  consistently, yet  with  very  few clinically  irrelevant  problems 
identified. Furthermore, this consistently high performance level leads to better uptake and 
acceptance rates by users, ensuring that the problems are not only identified, but are actually 
acted upon when appropriate to do so. Such CDSS implementations might be successfully 
incorporated into a wide variety of healthcare settings, such as hospital, general and specialist 
practice, and community pharmacy. Given the results of this thesis, that the technology now 
exists, and that quality patient EHR data is gradually becoming more available, it seems that 
the time has come for this technology to be applied more widely.
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Appendix 1 Prescribing criteria and automation
Table 53: Beers03 prescribing criteria
Criteri
on
Imple
mente
d
DOC
UME
NT
Description Descriptiv
e 
classificati
on ID
Beers table 1: PIMs independent of diagnoses or conditions
1 Y D6 (dextro)propoxyphene and combination products 118
2 Y D6 Muscle relaxants and antispasmodics, oxybutinin 11,
3 Y D6 Amitriptyline 11
4 Y D6 Doxepin 11
5 Y O1 Lorazepam >3mg oxazepam >60mg alprazolam >2mg temazepam >15mg 
triazolam >0.25mg
12
6 Y D6 Long acting benzodiazepines 12
7 Y D6 Disopyramide 118
8 Y O1 Digoxin > 0.125mg/day 1
9 N Dipyridamole, short-acting
10 Y D6 Methyldopa 100
11 N Chlorpropamide
12 Y D6 Gastrointestinal antispasmodics 11
13 Y D6 Anticholinergics and antihistamines 11
14 Y O1 Ferrous sulphate > 325mg/day 91
15 Y D6 Pethidine (meperidine) 118
16 Y D6 Ticlopidine 118
17 Y D6 Ketorolac 19
18 Y D6 Amphetamines and anorexic agents 118
19 Y D6 Long term use of full-dosage non-COX selective NSAIDS – piroxicam 20mg, 
naproxen 1000mg
19
20 Y D6 Daily fluoxetine 114
21 Y D6 Long term stimulant laxatives 55
22 Y D6 Amiodarone 113
23 Y D6 Nitrofurantoin 63
24 Y D6 Thioridazine 118
25 Y D6 Short-acting nifedipine 118
26 Y D6 Clonidine 100
27 Y D6 Mineral oil 56
28 Y D6 Cimetidine 118
29 Y D6 Estrogens only (oral) 105
49 Y D6 Indomethacin 19
50 Y D6 Diphenhydramine 11
51 Y D6 Ergot mesyloids 118
52 Y D6 Orphenadrine 118
53 Y D6 Methyltestosterone 118
54 Y D6 Amphetamines excluding methylphenidate and anorexics 118
55 Y D6 Ethacrynic acid 118
N Pentazocine
N Trimethobenzamide
N Flurazepam
N Doxazosin
N Meprobamate
N Reserpine
N Methyltestosterone
N Mesoridazine
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DOC
UME
NT
Description Descriptiv
e 
classificati
on ID
N Desiccate thyroid
N Guanethidine
N Guanadrel
N Cyclandelate
N Isoxsurpine
Beers table 2: PIMs considering diagnoses or conditions
30 Y D6 Heart failure and disopyramide or high sodium drugs 36, 118
31 Y D6 Hypertension and pseudoephedrine or amphetamines 104
32 Y D6 Gastric or duodenal ulcers and NSAIDs or higher dose aspirin 19
33 Y D6 Seizures or epilepsy and clozapine or thioridazine 15
34 Y D6 Blood clotting disorders or receiving anticoagulant therapy and aspirin, NSAIDs, 
dipyridamole, ticlopidine or clopidogrel
10, 19
35 Y D6 Bladder outflow obstruction and anticholinergics, antihistamines, oxybutinin, TCAs 11
36 Y D6 Stress incontinence and alpha-blockers, anticholinergics, TCAs, long-acting 
benzodiazepines
11,
37 Y D6 Arrhythmias and TCAs 11
38 Y D6 Insomnia and theophylline, methylphenidate, mono-amine oxidase inhibitors or 
amphetamine
104
39 Y D6 Parkinson disease and metoclopramide, conventional antipsychotics or tacrine 14
40 Y D6 Cognitive impairment and barbiturates, anticholinergics, antispasmodics, CNS 
stimulants
42
41 Y D6 Depression and long-term benzodiazepines or methyldopa 104
42 Y D6 Anorexia and malnutrition and amphetamine, methylphenidate or fluoxetine 104
43 Y D6 Syncope or falls and benzodiazepines, TCAs, 25
44 Y D6 Syndrome of inappropriate antidiuretic hormone secretion/hyponatraemia and 
SSRIs
104
45 Y D6 Seizure disorder and bupropion 15
46 Y D6 Obesity and olanzapine 104
47 Y D6 COPD and long-acting benzodiazepines, beta-blockers 2
48 Y D6 Chronic constipation and calcium channel blockers, anticholinergics, TCAs 17, 62
68 Beers03 criteria, 53 implemented, 15 not implemented. The criterion number matches the 
order of implementation, not the order of appearance in the Beers03 criteria.
Table 54: STOPP prescribing criteria
Crite
rion
Impleme
nted
DOCUM
ENT
Description Descripti
ve 
classifica
tion ID
A1 Y O1 Digoxin at a long-term dose > 125 μg/day with impaired renal function 1
A2 Y D7 Loop diuretic for dependent ankle edema only 69
A3 Y D6 Loop diuretic as first-line monotherapy for hypertension 82
A4 Y D6 Thiazide diuretic with a history of gout 97
A5 Y D6 Non-cardioselective beta-blocker with Chronic Obstructive Pulmonary 
Disease
2
A6 Y D2 β-blocker in combination with verapamil 86
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DOCUM
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Description Descripti
ve 
classifica
tion ID
A7 Y D6 Use of diltiazem or verapamil with NYHA class III or IV heart failure 3
A8 Y D6 Calcium channel blockers with chronic constipation 62
A9 Y D2 Use of aspirin and warfarin in combination without histamine H2-receptor 
antagonist or proton pump inhibitor
150
A10 Y D7 Dipyridamole as monotherapy for cardiovascular secondary prevention 118
A11 Y D6 Aspirin with a past history of peptic ulcer disease without histamine H2-
receptor antagonist or proton pump inhibitor
10
A12 Y O1 Aspirin at a dose > 150mg/day 8
A13 Y D7 Aspirin with no history of coronary, cerebral or peripheral vascular 
symptoms or occlusive event
9
A14 N Aspirin to treat dizziness not clearly attributable to cerebrovascular 
disease
A15 N Warfarin for first uncomplicated deep venous thrombosis for longer than 6 
months duration
A16 N Warfarin for first uncomplicated pulmonary embolus for longer than 12 
months duration
A17 Y D6 Aspirin, clopidogrel, dipyridamole or warfarin with concurrent bleeding 
disorder
10
B1 Y D6 TCAs with dementia 42
B2 Y D6 TCAs with glaucoma 11
B3 Y D6 TCAs with cardiac conductive abnormalities 11
B4 Y D6 TCAs with constipation 17
B5 Y D2 TCAs with an opiate or calcium channel blocker 17
B6 Y D6 TCAs with prostatism or prior history of urinary retention 11
B7 Y D7 Long-term, long-acting benzodiazepines 12
B8 N Long-term neuroleptics as long-term hypnotics
B9 Y D6 Long-term neuroleptics in those with parkinsonism 14
B10 Y D6 Phenothiazines in patients with epilepsy 15
B11 Y D2 Anticholinergics to treat extrapyramidal side effects of neuroleptic 
medications
11
B12 Y D6 Selective serotonin re-uptake inhibitors with a history of clinically 
significant hyponatremia
104
B13 Y D7 Prolong use of first-generation antihistamines 42
C1 N Diphenoxylate, loperamide or codeine phosphate for treatment of 
diarrhoea of unknown cause
C2 Y D6 Diphernoxylate, loperamide or codeine phosphate for treatment of severe 
infective gastroenteritis
104
C3 Y D6 Prochlorperazine or metoclopramide with parkinsonism 14
C4 Y O1 PPI for peptic ulcer disease at full therapeutic dosage for > 8 weeks 7
C5 Y D6 Anticholinergic anstispasmodic drugs with chronic constipation 17
D1 Y D7 Theophylline as monotherapy for COPD 118
D2 Y D5 Systemic corticosteroids instead of inhaled corticosteroids for 
maintenance therapy in moderate-to-severe COPD
126
D3 Y D6 Nebulized ipratropium with glaucoma 11
E1 Y D6 NSAID with history of peptic ulcer disease or gastrointestinal bleeding, 
unless with concurrent histamine H2-receptor antagonist or PPI or 
misoprostol
19
E2 Y D6 NSAID with moderate-to-severe hypertension 19
E3 Y D6 NSAID with heart failure 19
E4 Y D0 Long-tern use of NSAID for symptom relief of mild osteoarthritis 19
E5 Y D2 Warfarin and NSAID together 4
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rion
Impleme
nted
DOCUM
ENT
Description Descripti
ve 
classifica
tion ID
E6 Y D6 NDAIS with chronic renal failure 20
E7 Y D6 Long-term corticosteroids as monotherapy for rheumatoid arthritis or 
osteoarthritis
127
E8 Y D6 Long-term NSAID for colchicine for chronic treatment of gout where there 
is no contradiction to allopurinol
19
F1 Y D6 Bladder antimuscarinic drugs with dementia 42
F2 Y D6 Antimuscarinic drugs with chronic glaucoma 11
F3 Y D6 Antimuscarinic drugs with chronic constipation 17
F4 Y D6 Antimuscarinic drugs with chronic prostatism 11
F5 Y D6 α-blockers with frequent incontinence 82
F6 N α-blockers with long-term urinary catheter in situ
G1 Y D6 Glibenclamide or chlorpropamide with type 2 diabetes mellitus 24
G2 N β-blockers in those with diabetes mellitus and frequent hypoglycemic 
episodes
G3 Y D6 Estrogens with a history of breast cancer or venous thromboembolism 105
G4 Y U1 Estrogens without progestogen in patients with intact uterus 105
H1 Y D6 Benzodiazepines and fallers 25
H2 Y D6 Neuroleptic drugs and fallers 25
H3 Y D6 First-generation antihistamines and fallers 25
H4 Y D6 Vasodilator drugs with persistent postural hypotension 25
H5 Y D6 Long-term opiates in those with recurrent falls 25
I1 N Use of long-term powerful opiates as first-line therapy for mild-to-moderate 
pain
I2 Y U3 Regular opiates for more than 2weeks in those with chronic constipation 
without concurrent use of laxatives
26
I3 Y D6 Long-term opiates in those with dementia unless indicated for palliative 
care or management of moderate/severe chronic pain syndrome
104
J Y D1 Any duplicate drug class prescription 49
65 STOPP criteria, 57 implemented, 8 not implemented
Table 55: START prescribing criteria
Criter
ion
Impleme
nted
DOCUME
NT
Description Descriptive 
classificatio
n ID
A1 Y U2 Warfarin in the presence of chronic atrial fibrillation 27
A2 Y U2 Aspirin in the presence of chronic atrial fibrillation, where warfarin is 
contraindicated, but not aspirin
27
A3 Y U2 Aspirin or clopidogrel with a documented history of atherosclerotic 
coronary, cerebral or peripheral vascular disease in patients with 
sinus rhythm
28
A4 Y U2 Antihypertensive therapy where systolic blood pressure consistently 
> 160mmHg
52
A5 Y U2 Statin therapy with a documented history of coronary, cerebral or 
peripheral vascular disease, where the patient's functional status 
remains independent for activities of daily living and life expectancy 
is greater than 5 years
29
A6 Y U2 ACEI with chronic heart failure 30
A7 Y U2 ACEI following acute myocardial infarction 125
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ion
Impleme
nted
DOCUME
NT
Description Descriptive 
classificatio
n ID
A8 Y U2 β-blocker with chronic stable angina 31
B1 Y U2 Regular inhaled β2-agonist or anticholinergic agent for 
mild-to-moderate asthma or COPD
B2 N Regular inhaled corticosteroid for moderate/severe asthma or 
COPD, where predicted FEV1 < 50%
B3 N Home continuous oxygen with documented chronic type 1 or type 2 
respiratory failure
C1 N L-DOPA in idiopathic Parkinson's disease with definite functional 
impairment and resultant disability
C2 Y U2 Antidepressant drug in the presence of moderate/severe 
depressive symptoms lasting at least three months
121
D1 N PPI with severe gastroesophageal acid reflux disease or peptic 
stricture requiring dilation
D2 Y U2 Fibre supplement for chronic, symptomatic diverticular disease with 
constipation
62
E1 N Disease-modifying antirheumatic drug with active moderate/severe 
rheumatoid disease lasting > 12 weeks
E2 Y U2 Bisphosphonates in patients taking maintenance corticosteroid 
therapy
67
E3 Y U2 Calcium and vitamin D supplement in patients with known 
osteoporosis
33
F1 Y U2 Metformin with type 2 diabetes ± metabolic syndrome 58
F2 Y U2 ACEI or ARB in diabetes with nephropathy 34
F3 Y U2 Antiplatelet therapy in diabetes mellitus with coexisting major 
cardiovascular risk factors
28
F4 Y U2 Statin therapy in diabetes mellitus of coexisting major 
cardiovascular risk factors present
29
22 START criteria, 17 implemented, 5 not implemented
Table 56: PIEA prescribing criteria
Crite
rion
Implem
ented
DOCU
MENT
Description Descriptive 
classificatio
n  ID
1 Y U1 Patient taking an antihypertensive is NOT at their target blood pressure 52
2 Y U1 Patient at high risk of cardiovascular event is NOT taking an HMG-CoA 
reductase inhibitor
29
3 Y U1 Patient with IHD or history of MI is NOT taking a beta-blocker 31
4 Y U1 Patient with IHD or a history of MI is NOT taking an antiplatelet agent 
unless taking an oral anticoagulant
28
5 Y U1 Patient with heart failure is NOT taking a beta-blocker 31
6 Y U1 Patient with heart failure is NOT taking an ACEI or ARB 30
7 Y D6 Patient with heart failure IS taking medications that may exacerbate 
heart failure
3, 19, 36, 104
8 Y D6 Patient with heart failure or hypertension IS taking high sodium-
containing medications
36
9 Y U1 Patient with AF is NOT taking an oral anticoagulant 27
10 Y O0 Patient with AF taking an anticoagulant DOES NOT have an INR 
between 2 and 3
70
11 Y U1 Patient with a history of non-haemorrhagic stroke or TIA is NOT taking 28
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an antiplatelet agent unless taking an anticoagulant
12 Y O1 Patient with risk factors for myopathy IS taking >= 40mg/day 
simvastatin or atorvastatin
64
13 Y D6 Patient with cardiovascular disease IS taking an NSAID 19
14 N Patient with cardiovascular, respiratory disease or diabetes mellitus 
who smokes has NOT been offered smoking cessation
15 Y U1 Patient with type 2 diabetes and hypertension and albuminuria is NOT 
taking an ACE inhibitor or ARB
34
16 Y U1 Patient with diabetes at high risk of cardiovascular event is NOT taking 
an antiplatelet agent unless taking an anticoagulant
28
17 Y D6 Patient with diabetes IS taking a medication that may increase or 
decrease blood glucose concentrations
44
18 Y M1 Patient with diabetes has NOT had an HBA1c measurement within the 
previous 6 months
137
19 Y O1 Patient taking metformin for diabetes has NOT had the dose adjusted 
for creatinine clearance
71
20 Y D6 Patient taking metformin for diabetes IS concurrently taking 
glibenclamide
24
21 N Patient with OA pain interfering with daily activities has NOT been 
trialled on paracetamol 2-4g daily
22 N Patient taking analgesics DOES have pain that interferes with daily 
activities
23 Y U2 Patient taking an opioid is NOT taking prophylactic treatment for 
constipation
26
24 Y D6 Patient with risk factors for impaired renal function IS taking an NSAID 20
25 Y D2 Patient IS concurrently taking an ACEI or ARB, diuretic and NSAID 
(excluding low-dose aspirin)
21
26 Y D6 Patient with sleep disturbance or anxiety HAS been taking 
benzodiazepines for >4 weeks
12
27 Y D6 Patient with depression IS taking anticholingeric-type antidepressants 11
28 Y D6 Patient with a history of falls IS taking psychotropic medications 25
29 Y D2 Patient taking an SSRI IS concurrently taking medications known to 
increase the risk of gastrointestinal bleeding
4
30 Y D2 Patient taking an SSRI IS concurrently taking other medications that 
may contribute to serotonin syndrome
66
31 Y D6 Patient with dementia IS receiving anticholinergic medication 42
32 Y D2 Patient IS taking more than one medication with anticholinergic activity 11
33 Y D2 Patient taking a PPI IS taking a medication that may cause dyspepsia 101
34 Y D6 Patient with COPD IS taking benzodiazepines 37
35 Y U1 Patient with asthma using an inhaled LABA is NOT also using an 
inhaled corticosteroid
32
36 N Patient using salbutamol or terbutaline inhaler more than three times a 
week for reversible airways disease has NOT been prescribed an 
inhaled corticosteroid
37 Y D6 Patient with asthma IS taking a medication that may worsen asthma 2
38 Y U1 Female patient with recurrent UTI has NOT been prescribed 
intravaginal oestrogen
82
39 Y D6 Patient with a creatinine clearance <60ml/min IS receiving 
nitrofurantoin for UTI
63
40 Y D6 Patient with a creatinine clearance <50ml/min IS receiving 
methenamine for UTI prophylaxis
95
41 N Patient with an URTI IS receiving antibacterials
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42 N Patient with osteoporosis who is not receiving at least 600IU vitamin D 
daily from diet is NOT receiving supplementation with vitamin D
43 N Patient with osteoporosis who is not receiving at least 1200mg calcium 
daily from diet is NOT receiving calcium supplementation
44 Y U2 Patient with osteoporosis is NOT receiving anti-osteoporotic medication 67
45 N Patient using topical corticosteroids DOES have itch or discomfort that 
interferes with daily activities
46 N Patient has NOT received influenza and pneumococcal vaccination
47 N Patient HAS significant medication interactions
48 N Patient HAS HAD significant change in medications in the previous 90 
days
48 PIEA criteria, 37 implemented, 11 not implemented
Table 57: Beers12 prescribing criteria
Criterion Impleme
nted
DOCUMENT Description Descriptive 
classification 
ID
Beers table 2: PIMs
1 Y D6 First generation antihistamines 11
2 Y D6 Antiparkinson agents 11
3 Y D6 Antispasmodics 11
4 N Dipyridamole, short-acting
5 Y D6 Ticlopidine 118
6 Y D6 Nitrofurantoin 63
7 Y D6 Alpha blockers 118
8 Y D6 Alpha blockers central 100
9 Y D6 Antiarrhythmic drugs 113
10 Y D6 Disopyramide 118
11 Y D6 Dronedarone 118
12 Y O1 Digoxin > 0.125mg/d 1
13 Y D6 Nifedipine, immediate release 118
14 Y O1 Spironolactone > 25mg/d 91
15 Y D6 Tertiary TCAs 11
16 Y D6 Antipsychotics 104
17 Y D6 Thioridazine 104
18 Y D6 Barbituates 12
19 Y D6 Benzodiazepines 12
20 Y D6 Chloral hydrate 12
21 Y D6 Meprobamate 12
22 Y D6 Nonbenzodiazepine hypnotics 12
23 Y D6 Ergot mesyloids 118
24 Y D6 Androgens 118
25 N Dessicated thyroid
26 Y D6 Estrogens with or without progestins 105
27 Y D6 Growth hormone 118
28 Y D6 Insulin, sliding scale 118
29 Y D6 Megestrol 118
243
 Prescribing criteria and automation
Criterion Impleme
nted
DOCUMENT Description Descriptive 
classification 
ID
30 Y D6 Sulphonylureas, long duration 24
31 Y D6 Metoclopramide 14
32 Y D6 Mineral oil, oral 56
33 N Trimethobenzamide
34 Y D6 Pethidine (meperidine) 118
35 Y D6 Non-COX-selective NSAIDS, oral 19
36 Y D6 Indomethacin, Ketorolac 19
37 N Pentazocine
38 Y D6 Skeletal muscle relaxants 25, 42
Beers table 3: PIMs considering drug-disease or drug-syndrome interactions
1 (39) Y D6 Heart failure 19, 60, 149, 3
2 (40) Y D6 Syncope 25
3 (41) Y D6 Chronic seizures or epilepsy 15
4 (42) Y D6 Delirium 42, 25
5 (43) Y D6 Dementia and cognitive impairment 42,104
6 (44) Y D6 History of falls or fractures 25
7 (45) Y D6 Insomnia 118
8 (46) Y D6 Parkinson's disease 14
9 (47) Y D6 Chronic constipation 17,62
10 (48) Y D6 History of gastric or duodenal ulcers 19
11 (49) Y D6 Chronic kidney disease Stages 20,
12 (50) Y D6 Urinary incontinence (all types) in women 104
13 (51) Y D6 Lower urinary tract symptoms, benign prostatic hyperplasia 104
14 (52) Y D6 Stress or mixed incontinence 104
52 Beers12 criteria, 48 implemented, 4 not implemented. The criterion number matches the 
order  as  listed  in  Beers12 Table  2  2012 American  Geriatrics  Society  Beers  Criteria  for  
Potentially Inappropriate Medication Use in Older Adults and following on in Table 3 2012 
American Geriatrics Society Beers Criteria for Potentially Inappropriate Medication Use in  
Older Adults Due to Drug-Disease or Drug-Syndrome Interactions That May Exacerbate the  
Disease or Syndrome.
Each  criterion  in  these  sets  of  prescribing  criteria  can  be  matched  using  the  descriptive 
classification ID to the to the descriptive classifications listed in tables in Appendix 9.
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Appendix 2 Changes from Beers03 to Beers12
Table based on  Marcum and Hanlon's article on the new Beers criteria.322
Inappropriate medications in Beers03 excluded from Beers12
 Amphetamines and anorexic agents 
 Chloral hydrate 
 Fluoxetine 
 Ethacrynic acid 
 Cimetidine 
 Long-term use of stimulant laxatives (except in the presence of opioid use) 
 Ferrous sulfate > 325 mg/d 
 Propoxyphene and combination products
Inappropriate medications new additions to Beers12
 Anticholinergics to treat extrapyramidal side effects of neuroleptic medications 
 Antipsychotics (for behavioral problems of dementia) 
 Nonbenzodiazepine (“Z”) hypnotics
Aspirin for primary prevention (to be used with caution in adults ≥80 years old for primary prevention of cardiac events 
 Spironolactone > 25 mg/day 
 Glibenclamide 
 Growth hormone 
 Megesterol 
 Sliding scale insulin 
 Metoclopramide 
Medication - disease interactions in Beers03 excluded from Beers12
CNS stimulants (e.g., dextroamphetamine, methylphenidate, methamphetamine, pemolin) and anorexia or malnutrition 
Tricyclic antidepressants and cardiac conduction abnormalities 
propranolol and COPD 
barbiturates, CNS stimulants and dementia or cognitive impairment 
long-term benzodiazepines, methyldopa, reserpine, guanethidine and depression 
disopyramide, high-sodium content drugs and systolic heart failure 
amphetamines, diet pills, NSAIDs, phenylpropanolamine, pseudoephedrine and hypertension 
mono-amine-oxidase inhibitors, oral decongestants and insomnia 
olanzapine and obesity 
tacrine and parkinsons disease 
long-acting benzodiazepines and stress incontinence
Medication - disease interactions new additions to Beers12
Antipsychotics and chronic constipation 
Bladder antimuscarinic drugs (e.g., oxybutynin) and chronic constipation 
NSAIDS, Triamterene and chronic kidney disease 
Anticholinergics, Benzodiazepines, Chlorpromazine, Corticosteroids, H 2 -receptor antagonists, Meperidine, Sedative 
hypnotics, Thioridazine, Tricyclic antidepressants and delirium 
antipsychotics, benzodiazepines, H 2 -receptor antagonists, tricyclic antidepressants, zolpidem and dementia or cognitive 
impairment 
thiazolidinediones and hear failure 
estrogen with history of breast cancer or venous thromboembolism 
anticonvulsants, antipsychotics, SSRIs, nonbenzodiazepine hypnotics and history of falls or fractures 
promethazine and parkinson's disease 
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maprotiline, tramadol and seizures 
acetylcholinesterase inhibitors, alpha-blockers, chlorpromazine, olanzapine, thioridazine and syncope 
estrogen and urinary incontinence in women
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Appendix 3 MedOptz replaces Monitor-Rx
247
Figure 60: An email providing feedback of expert panel responses was sent to Douglas Allen 
on 22nd January 2013
 MedOptz replaces Monitor-Rx
248
Figure 61: Email from MedOptz co-founder David Dring sent on 31 January 2013
 MedOptz replaces Monitor-Rx
249
Figure 62: Monitor-Rx home page screenshot taken 8th May 2012 (www.monitor-rx.com)
 MedOptz replaces Monitor-Rx
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Figure 63: MedOptz home page screenshot taken 21st Feb 2013 (www.medoptz.com)
 MedOptz replaces Monitor-Rx
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Figure 64: Monitor-RX home page screenshot taken 27 March 2014 (www.monitor-rx.com)
 MedOptz replaces Monitor-Rx
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Figure 65: Medoptz website screenshot taken 14th July 2014 (www.medoptz.com)
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Appendix 4 Prescribing criteria automation limitations
Beers03 limitations
Interpretation of criteria
Accurate  information  regarding  several  patient  conditions  was  not  available  so  umbrella 
grouping terms were used.
 Criterion 19 – “Long-term use of full-dosage,  longer  half-life,  non-COX selective 
NSAIDs … naproxen … piroxicam ...” Full daily dosage was obtained from eMIMs281 
as being 20mg for piroxicam and 1000mg for naproxen.
 Criterion  35  –  Bladder  outflow  obstruction  was  grouped  under  U08  Urinary 
Retention. All cases assigned U08 were identified.
 Criterion 36 – Stress incontinence was grouped under  U04 incontinence urine). All 
cases assigned U04 were identified.
 Criterion 44 – Syndrome of inappropriate antidiuretic hormone did not have a specific 
category in the ICPC-2 plus classifications so the hyponatraemia term (TermID 6087) 
was used. 
Assumption of long term medication use
No information was available to determine whether patients were using certain medications 
over the long term. The assumption was made that patients were using medications long term.
 Criterion 19 – The use of non-COX selective NSAIDs over a long term.
 Criterion 21 – The use of stimulant laxatives over a long term except when using 
opiates.
Medications not available in Australia
Several medications were not incorporated into automated queries as they were not available 
in Australia:  pentazocine, trimethobenzamide, methocarbamol, carisoprodol, chlorzoxazone, 
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metaxalone,  cyclobenzaprine,  flurazepam,  chlordiazepoxide-amitriptyline,  perphenazine-
amitriptyline,  meprobamate,  chlordiazepoxide,  clidinium-chlordiazepoxide,  quazepam, 
halazepam,  clorazepate,  methyldopa-hydrochlorothiazide,  reserpine,  chlorpropamide, 
dicyclomine, hydroxyzine, tripelennamine, hydergine, cyclandelate, barbiturates (excluding 
phenobarbitone), oxaprozin, guanethidine, guanadrel, isoxsuprine, doxazosin, mesoridazine, 
desiccated thyroid, phenylpropanolamine, thiothixene, flavoxate, tacrine, pemolin.
Beers12 limitations
Interpretation of criteria
The following criteria were triggered by the presence of the medication and/or disease state 
but may be erroneous because insufficient information was available to accurately match the 
requirements of the criteria.
 Criterion 7 – Insufficient information available to determine if alpha-blockers were 
primarily prescribed as antihypertensives.
 Criterion 8 – Insufficient information available to determine if clonidine was used as a 
first-line antihypertensive.
 Criterion 9 – Insufficient information available to determine if antiarrhythmic drugs 
were prescribed as first line treatment for atrial fibrillation.
 Criterion 16 – This criterion was triggered if the patient had a diagnosis of dementia 
and had been prescribed an antipsychotic. Insufficient information was available to 
determine the success or failure of non-pharmacological options.
 Criterion  49  –  Any  diagnosis  of  chronic  kidney  disease  was  used  to  trigger  this 
criterion.
Assumptions of long term medication use
No information was available to determine whether patients were using certain medications 
over the long term. The assumption was made that patients were using medications long term 
for the following criteria:
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 Criterion 6 – Insufficient information was available to determine long term use of 
nitrofurantoin.
 Criterion 22 – Insufficient information was available to determine long term use of 
non-benzodiazepine hypnotics.
Medications not available in Australia
Several medications were not incorporated into automated queries as they were not available 
in  Australia:  carbinoxamine,  clemastine,  dexbrompheniramine,  hydroxyzine,  dofetilide, 
ibutilide,  propafenone,  dronedarone,  guanabenz,  guanfacine, pentazocine, 
trimethobenzamide,  methocarbamol,  carisoprodol,  chlorzoxazone,  metaxalone, 
cyclobenzaprine,  flurazepam,  estazolam,  chlorazepate,  chlordiazepoxide-amitriptyline, 
perphenazine-amitriptyline,  meprobamate,  chlordiazepoxide,  quazepam,  clidinium-
chlordiazepoxide,  reserpine,  eszopiclone,  zaleplon,  etodolac,  fenprofen,  meclofanamate, 
nambumetone,  tolmetin,  carisoprodol,  chlorzoxazone,  cyclobenzprine,  metaxalone, 
chlorpropamide,  maprotiline,  dicyclomine,  hydroxyzine,  barbiturates  (excluding 
phenobarbitone), oxaprozin,  isoxsurpine,  doxazosin,  darifenacin,  fesoterodine,  trospium, 
dessicated thyroid, thiothixene(tiotixine), flavoxate. 
PIEA limitations
Interpretation of criteria
Several rules required knowledge of laboratory test results or observational results, such as 
blood pressure measurements. Whilst results were available for some cases, other cases had 
no laboratory test results or observational data at all.
 Indicator 1 – The most recent blood pressure reading was used. The rule was not 
implemented for patients with proteinurea > 1g per day as this information was not 
available.
 Indicator 10 – The query found patients with AF and warfarin and showed all patients 
who had an INR outside the reference range of 2.0 to 3.0. Some patients had multiple 
INRs and this query did not limit results to the most recent and most relevant INR.
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 Indicator  11 –  The  query  found  patients  who  had  a  history  of  transient  cerebral 
ischaemia and attempted to find patients with a history of non-haemorrhagic stroke. 
Insufficient  information  was  available  to  clearly  determine  whether  strokes  were 
haemorrhagic or not, so a range of ICPC-2 terms were used that may have included a 
diagnosis  of  haemorrhagic  stroke.  The  diagnosis  terms  used  for  this  query  were: 
cerebral  artery  thrombosis,  cerebral  embolism,  cerebral  occlusion,  cerebrovascular 
accident, cerebral infarction, carotid disease, stroke, precerebral occlusion, cerebral 
ischaemia, precerebral embolism. 
 Indicator  12  –  No  provision  was  made  to  investigate  medication  directions  in 
sufficient detail to identify and exclude patients taking half of a 40mg atorvastatin or 
simvastatin tablet each day.
 Indicator  18  –  This  query  did  not  identify  diabetic  patients  who  had  no HbA1c 
measurement  recorded.  It  only  identified  those  patients  where  the  most  recent 
recorded HbA1c was over 6 months old.
 Indicator 31 and 32 – Inhaled ipratriopium was not listed in the AMH anticholinergics 
table323,  however,  all  instances  of  inhaled  ipratropium were  included in  the  query 
results.
Assumptions of long term medication use
No information was available to determine whether patients were using certain medications 
over the long term. The assumption was made that patients were using the medications long 
term if the medication was listed.
 Indicator  26  –  “Patient  with  sleep  disturbance  or  anxiety  has  not been  taking 
benzodiazepines for >4 weeks”. The assumption was made the patient had been using 
the medication for 4 weeks or more.
Criteria which were not implemented
 Indicator 14 – Insufficient information available to determine whether patients who 
smoked had been (or had not been) offered smoking cessation therapy.
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 Indicator 21 – Insufficient information to determine if the patient has been trialled 
with  paracetamol,  and  also  insufficient  information  concerning  the  impact  of 
osteoarthritis on daily activities.
 Indicator 22 – An implicit criterion where insufficient information was available to 
determine whether patient pain is interfering with daily activities.
 Indicator 36 – Insufficient information was available to be certain of the actual weekly 
use of salbutamol or terbutaline inhalers.
 Indicator 41 – There was insufficient information to determine whether an antibiotic 
was prescribed specifically for URTI or for another purpose.
 Indicator 42 – Insufficient information available to determine patient’s daily intake of 
vitamin D.
 Indicator 43 – Insufficient information available to determine patient’s daily calcium 
intake.
 Indicator 45 – An implicit criterion where insufficient information was available to 
determine whether patient itch or discomfort was interfering with daily activities.
 Indicator 46 – In the majority of cases vaccination data was not collected.
 Indicator 47 – Patient has no significant medication interactions (agreement between 
two  medication  interaction  databases).  Too  difficult  to  implement  this  implicit 
criterion.
 Indicator 48 – Patient has had no significant change in medications in the previous 90 
days. An implicit criterion, too difficult to implement this criterion.
STOPP limitations
Long term medication usage assumptions
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No information was available to determine whether patients were using certain medications 
over the long term. The assumption was made that patients were using the medications long 
term if the medication was listed.
 A1 – “Digoxin at long term dose > 125mcg/day”
 B7 – “Long-term (i.e. > 1 month), long-acting benzodiazepines…”
 B9 – “Long-term neuroleptics (>1 month) in those with parkinsonism”
 C4 – “PPI for peptic ulcer disease at full therapeutic dosage for > 8 weeks”
 E4 – “Long term use of NSAID (> 3 months)…”
 E7 – “Long-term corticosteroids (> 3 months)…”
 E8 – “Long-term NSAID or colchicine for chronic treatment of gout…”
 I2 – “Regular opiate for more than 2 weeks...”
 I3 – “Long-term opiates in those with dementia…”
Interpretation of criteria
Some interpretation of the STOPP criteria was required to match as closely as possible the 
data available in the patient cases. In some cases insufficient information was available.
 A2 – “Loop diuretic for ankle oedema only, i.e. no clinical signs of heart failure”, was 
triggered by a diagnosis of foot or ankle oedema and no diagnosis of heart failure.
 A3  –  “Loop  diuretic  as  first-line  monotherapy  for  hypertension”.  There  was 
insufficient information to confirm this was first-line monotherapy so the rule was 
triggered  by  existence  of  a  loop  diuretic  and  hypertension  and  no  other 
antihypertensives. 
 A7 – “Use of diltiazem or verapamil in NYHA class III or IV heart failure”. There 
was insufficient information to determine the state of heart failure, so any recorded 
diagnosis of heart failure was used for this rule.
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 B12 – Any diagnosis of hyponatremia was used to assist triggering this rule. 
 C4 – Full therapeutic daily dosage of PPIs for peptic ulcer disease were based on the 
British  National  Formulary,  No.62  (September  2011)  -  esomeprazole  20mg, 
lansoprazole 30mg, omeprazole 20mg, pantoprazole 80mg, rabeprazole 20mg.
 D2 – It was assumed oral corticosteroids were prescribed for COPD if the patient had 
COPD listed as a diagnosis.
 E2 – No code was available to indicate the severity of hypertension. This rule was 
triggered by the existence of an NSAID, a diagnosis of hypertension and either an 
average  systolic  blood  pressure  over  159  mmHg or  an  average  diastolic  blood 
pressure over 99 mmHg.
 E4 – This query selected all patients who were prescribed NSAIDs whether or not 
other analgesics were prescribed.
 E8 – An assumption was made an NSAID was prescribed for gout
 F5  –  Presence  of  a  diagnosis  of  urinary  incontinence  was  used  for  this  query. 
Insufficient information was available to determine “frequent incontinence”.
 H4 – Patients with a diagnosis of hypotension triggered this rule.
 I3 – The presence of a diagnosis of dementia and opiates were used for this query. 
Insufficient information was available to exclude patients who were being treated for 
palliative care or moderate/severe chronic pain.
 J – Duplicate drug classes,  this  query detected all  duplicate  instances of the ATC 
fourth level chemical subgroup, whilst excluding all duplicate instances of ATC fifth 
level  medications,  an  example  would  be  to  trigger  where  a  patient  was  taking 
pravastatin  and  simvastatin,  but  not  two  different  strengths  of  pravastatin. 
Glyceryltrinitrate (GTN) was excluded from triggering this rule as a combination of 
quick acting GTN with oral  or transdermal  nitrate  is  considered standard therapy. 
Based on this implementation several duplications would be overlooked. An example: 
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Fentanyl transdermal and morphine are ATC level 3 matching (N02A opioids), and 
were not matching at ATC level 4 (N02AA morphine,  N02AB fentanyl). Substantial 
work would have been required to implement a database query with this degree of 
accuracy and was not undertaken. Likewise, a query based on detecting all duplicate 
instances  of  ATC  level  3  medications  was  not  implemented,  as  too  many  false 
positives would have occurred. An example: a patient who used allopurinol (ATC: 
M04AA01) as preventative therapy for gout and also had prescribed colchicine (ATC: 
M04AC01) for flare-ups of gout.
Criteria which were not implemented
It  was  impossible  to  develop  rules  to  match  some STOPP criteria.  These  rules  required 
knowledge  of  the  specific  intention  for  the  prescribing  of  a  medication  which  was  not 
captured in the dataset.
 A14 – “Aspirin to treat dizziness” – insufficient information available.
 A15 – “Warfarin for first, uncomplicated deep venous thrombosis for longer than six 
months duration” – insufficient information available.
 A16  –  “Warfarin  for  first  uncomplicated  pulmonary  embolus  for  longer  than  12 
months duration” – insufficient information available.
 B8 – “Long-term … neuroleptics as long-term hypnotics” – insufficient information 
available to determine the purpose of treatment.
 C1 – “…treatment of diarrhoea of unknown cause” – Insufficient information was 
available  to  determine  if  the  cause  of  diarrhoea  was  known  or  unknown so  this 
criterion was not implemented.
 F06 – “α-blockers with long-term urinary catheter…” – Patients were living at home 
and no patients were known to be catheterised so this criterion was not utilised.
 G2  –  “β-blockers  in  those  with  diabetes  mellitus  and  frequent  hypoglycaemic 
episodes” – Insufficient information was available to identify patients with frequent 
hypoglycaemic episodes.
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 I1  –  “Use of  long-term opiates…as  first-line  therapy…” –  There  was insufficient 
information available to determine if opiates were used as first-line therapy.
START limitations
Interpretation of criteria
• A2 – This rule was triggered in patients who did not have a diagnosis of heart failure 
and  did  have  a  loop  diuretic  and  swollen  ankles.  The  assumption  made  was  the 
diuretic was being used to treat the patient's swollen ankles, although it may have 
been prescribed for another purpose. 
• A3 - “Aspirin or clopidogrel with a documented history of atherosclerotic, coronary, 
cerebral or peripheral vascular disease in patients with sinus rhythm” Triggered if 
patient  did  not  have  aspirin,  clopidogrel  or  warfarin  in  medication  list,  and  no 
diagnosis  of  atrial  fibrillation  or  arrhythmia,  yet  did  have  a  diagnosis  of 
atherosclerosis or peripheral vascular disease.
• A4 – This rule was triggered if patients were treated with antihypertensives and all 
recorded systolic blood pressure readings were over 160mmHg.
• B1 – It was assumed the patient had mild to moderate asthma or COPD.
Criteria which were not implemented
• B2 – “Regular inhaled corticosteroid for moderate/severe asthma or COPD, where 
predicted FEV1 < 50%” – Insufficient information was available to implement this 
criterion.
• B3  –  “Home  continuous  oxygen…”  –  Either  no  patients  used  home  continuous 
oxygen or no information was supplied which indicated its use. 
• C1 – “L-DOPA in idiopathic Parkinson’s disease with definite functional impairment 
and resultant  disability”  – Insufficient  information  was available  to  determine  the 
patient’s functional impairment and resultant disability.
261
 Prescribing criteria automation limitations
• D1 – “Proton pump inhibitor  with  severe  gastroesophageal  acid  reflux  disease  or 
peptic  stricture  requiring  dilation”  –  Insufficient  information  was  available  to 
determine severity of reflex or if patient with peptic stricture required dilation.
• E1 – “Disease-modifying antirheumatic drug (DMARD) (with active moderate/severe 
rheumatoid disease lasting > 12 weeks” – Insufficient information was available to 
determine severity or length of the disease, or even if it was active or in remission.
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Appendix 6 Monitor-Rx reports
269
Figure 66: Overview report showing a summary of potential problem medications and notes 
relating to interventions and outcomes
 Monitor-Rx reports
270
Figure 67: Problem-Med report extract showing the first page of the report
 Monitor-Rx reports
271
Figure 68: Med-problem report extract showing the first page of the report
 DOCUMENT classifications
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Code Description Code Description
D Drug selection D1 Duplication
D2 Drug interaction
D3 Wrong drug
D4 Incorrect strength
D5 Inappropriate dosage form
D6 Contraindications apparent
D7 No indication apparent
D0 Other drug selection problems
O Over or underdose O1 Prescribed dose too high
O2 Prescribed dose too low
O3 Incorrect or unclear dosing instructions
O0 Other dose problems
C Compliance C1 Taking too little
C2 Taking too much
C3 Erratic use of medication
C4 Intentional drug misuse
C5 Difficulty using dosage form
C0 Other compliance problem
U Undertreated U1 Condition undertreated
U2 Condition untreated
U3 Preventative therapy required
U0 Other untreated indication problem
M Monitoring M1 Laboratory monitoring
M2 Non-laboratory monitoring
M0 Other monitoring problem
E Education or information E1 Patient requests drug information
E2 Patient requests disease management advice
E0 Other education or information problem
N Not classifiable N0 Problems that cannot be classified under another 
category
T Toxicity or adverse reaction T1 Toxicity, allergic reaction or adverse effect 
present
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Appendix 8 Similarities  between  sets  of  prescribing 
criteria
These tables were initially based on an article by Chang and Chan.104 
Table 58: Similarity between prescribing criteria – PIMs
Medication Beers03 Beers12 STOPP PIEA
Long-acting 
benzodiazepines
√ √ √
Tricyclic antidepressants √ √ √ √
First generation 
antihistamines
√ √ √
Dipyridamole √ √ √
Digoxin √ √ √
Glibenclamide √ √ √
Theophylline √ √ √
NSAIDs √ √ √ √
Warfarin √ √
Aspirin √ √ √ √
Anticholinergics √ √ √ √
Sedatives/hypnotics √ √ √ √
Beta-blockers √ √ √ √
Oestrogens √ √ √ √
Proton pump inhibitors √ √
SSRIs √ √ √ √
Alpha-blockers √ √ √
Amiodarone √ √
Disopyramide √ √
Nifedipine non-SR √ √
Barbiturates √ √
Ergot mesylates √ √
Androgens √ √
Oral mineral oil √ √
Pethidine √ √
273
 Similarities between sets of prescribing criteria
Table 59: Similarity between prescribing criteria – PIM and interaction with drug or diagnosis
Medication and diagnosis Beers03 Beers12 STOPP PIEA
Alpha–blockers and urinary incontinence √ √ √
Anticholinergic use not elsewhere specified √ √ √ √
Anticholinergics and bladder outflow/urinary retention √ √ √
Anticholinergics and cognitive impairment/dementia √ √ √
Anticholinergics and constipation √ √ √
Bleeding disorder and antiplatelet or anticoagulant √ √
COPD and benzodiazepines √ √
COPD and beta–blocker √ √
Epilepsy and antipsychotics √ √ √
HF and high sodium content medications √ √
HF and NSAIDs (non-steroidal antiinflammatory drugs) √ √ √
HF and thiazolidinediones √ √
HF and verapamil or diltiazem √ √ √
NSAIDs and blood clotting disorders √ √
NSAIDs and renal failure, including triple whammy √ √ √ √
NSAIDs SSRIs (selective serotonin re-uptake inhibitors) 
and/or anticoagulants and gastric bleeding risk or peptic 
ulcer disease
√ √(excl SSRIs) √ √
Parkinson's and antipsychotics or metoclopramide √ √ √
Sedatives or antipsychotics and falls √ √ √ √
Sedatives, long acting or for more than 4 weeks √ √ √ √
Table 60: Similarity between prescribing criteria - treatment omission
Medication STOPP PIEA
AF requiring aspirin or warfarin √ √
Asthma - moderate/severe requires inhaled corticosteroid √ √
Cardiovascular disease requiring antiplatelet √ √
Cardiovascular disease/risk requires statin √ √
CHF requires ACEI or ARB √ √
Diabetes and cardiovascular risk requires antiplatelet √ √
Diabetes and renal disease requires ACEI or ARB √ √
HF or angina requires beta-blocker √ √
Opioid requiring preventative laxatives √ √
Osteoporosis requires calcium and/or vitamin D supplementation √ √
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Table 61: Descriptive classifications
Category Descriptive classification Descriptive 
classificatio
n ID
Analgesia Analgesia optimisation with regular paracetamol needed 39
Analgesia Dextropropoxyphene prescribed 53
Analgesia Opioid constipation may require laxative or increased lax therapy 26
Analgesia Opioid sedation 144
Analgesia Pain un(der)treated 127
Analgesia Quinine prescribed 51
Anticholinergic Anticholinergic use not elsewhere specified 11
Anticholinergic Anticholinergics and cognitive impairment 42
Anticholinergic Anticholinergics and constipation 17
Coagulation/platelet AF requires aspirin or warfarin 27
Coagulation/platelet Anticoagulant toxicity 146
Coagulation/platelet Antiplatelet not indicated 9
Coagulation/platelet Bleeding disorder and antiplatelet or anticoagulant 10
Coagulation/platelet Bleeding risk interacting drugs 4
Coagulation/platelet Cardiovascular disease/risk requires antiplatelet 28
Coagulation/platelet Clopidogrel and aspirin interaction 151
Coagulation/platelet INR outside therapeutic range 70
Coagulation/platelet PPI and clopidogrel interaction 153
Coagulation/platelet Warfarin and aspirin interaction 150
Compliance Can reduce daily drug frequency 99
Compliance Compliance - Confusion about therapy 84
Compliance Compliance - using too little medication 75
Compliance Compliance - using too much medication 103
Compliance Difficulty using dosage form 74
Compliance Medication regimen complicated 94
Compliance Timing of dose inappropriate 115
Constipation Calcium channel blocker and constipation 62
Constipation Constipation un(der)treated 122
Constipation Iron and constipation 61
Constipation Mineral oil laxative prescribed 56
Constipation Stimulant laxative long term use 55
Cost Cost of therapy concern 102
Cost Eligible for DVA funded DAA 73
Diabetes Antidiabetic drug no indication 134
Diabetes Diabetes and taking medication that affects glucose levels 44
Diabetes Diabetes monitoring required 137
Diabetes Diabetes undertreated (HBA1c or BSLs high) 58
Diabetes Glibenclamide prescribed 24
Diabetes Pioglitazone and HF 149
Diabetes Rosiglitazone and (risk of) HF 60
Digoxin Digoxin dose over 125mcg or considered too high 1
Digoxin Digoxin monitoring required 138
Digoxin Digoxin toxicity 145
Dose or duration of therapy Duration of therapy may be excessive 89
Dose or duration of therapy Nitrate free period required 98
Dose or duration of therapy Therapeutic dose too high 91
Dose or duration of therapy Therapeutic dose too low 90
Education Patient disease management education provided/required 79
Education Patient drug education provided/required 78
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Category Descriptive classification Descriptive 
classificatio
n ID
Education Smoking cessation education required/provided 80
GORD Calcium channel blocker and reflux 96
GORD Drug causing dyspepsia with PPI 101
GORD GORD drug no indication 130
GORD PPI high dose 7
Gout Antigout medication (might) not be indicated 46
Gout Aspirin or thiazide contraindicated in gout 97
Heart failure Heart failure and concurrent verapamil or diltiazem 3
Heart failure Heart failure or hypertension and using high sodium or salt retaining drugs 36
Heart failure Heart failure or IHD requires beta-blocker 31
Heart failure Heart failure requires ACEI or ARB 30
Interaction Other drug interaction 86
Lipidaemia Antilipidaemic drug no indication 135
Lipidaemia Cardiovascular disease/risk requires statin 29
Lipidaemia Hyperlipidaemia under/untreated 57
Lipidaemia Lipid monitoring required 139
Lipidaemia Statin myopathy risk 64
Lipidaemia Statin toxicity 147
Mineral/vitamin 
supplementation
Iron no indication 131
Mineral/vitamin 
supplementation
Vitamin  no indication 136
Mineral/vitamin 
supplementation
Vitamin B12 and or folate deficiency possible 47
Monitoring Haematology monitoring required 141
Monitoring Medication monitoring - cognitive 111
Monitoring Medication monitoring - communication/social problems 107
Monitoring Medication monitoring - dehydration 112
Monitoring Medication monitoring - nutritional status or dental care 109
Monitoring Medication monitoring - pressure ulcers 110
Monitoring Medication monitoring - urinary incontinence 108
Monitoring Medication monitoring - visual disturbance 106
Monitoring Other monitoring (lab) required 81
Monitoring Other monitoring (non-lab) required 93
Monitoring Thyroid function monitoring required 140
Neurologic 
(Epilepsy/parkinsons/other)
Depression un(der)treated 121
Neurologic 
(Epilepsy/parkinsons/other)
Epilepsy and medication affecting seizure threshold 15
Neurologic 
(Epilepsy/parkinsons/other)
Fluoxetine prescribed 114
Neurologic 
(Epilepsy/parkinsons/other)
Lithium monitoring required 143
Neurologic 
(Epilepsy/parkinsons/other)
Parkinsonism and antipsychotics or metoclopramide 14
Neurologic 
(Epilepsy/parkinsons/other)
Serotonergic drugs interaction 66
No indication Antibiotic no indication 129
No indication Other drug no indication 69
NSAID Aspirin high dose not indicated 8
NSAID NSAID combined with ACEI or ARB, diuretic - triple whammy 21
NSAID NSAID not recommended (CV/HF/bleed/other) 19
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Category Descriptive classification Descriptive 
classificatio
n ID
NSAID NSAID used with (risk of) renal failure 20
NSAID NSAID without acid suppressant 5
Osteoporosis Medication monitoring - calcium intake 116
Osteoporosis Osteoporosis (or risk) may require calcium and or vitamin D 33
Osteoporosis Osteoporosis (or risk) requires antiosteoporotic 67
Other Combine medications into combination product 54
Other Communication breakdown, documentation insufficient 83
Other Falls risk/history and sedatives/antihypertensives/other 25
Other Lifestyle issues - overweight 85
Other Medication expired 72
Other Medication monitoring - Potassium 77
Other Oestrogens and thromboembolism or cancer risk 105
Other Other DRP MRM 120
Other Other DRP pharmacist 119
Other Other drug disease contraindication 104
Other Other PIM 118
Other Therapy duplication 49
Other cardiovascular Amiodarone or other antiarrythmic prescribed 113
Other cardiovascular Beta-blocker for hypertension 117
Other cardiovascular Calcium channel blocker and peripheral oedema 59
Other cardiovascular Cardiovascular drug no indication 132
Other cardiovascular Heart disease un(der)treated 125
Other cardiovascular Hydralazine monitoring required 142
Other cardiovascular Hyperkalaemia (or risk of) and medication 50
Other cardiovascular Hypertension under/untreated 52
Other cardiovascular Methyldopa or clonidine prescribed 100
Other cardiovascular Other cardiovascular drug toxicity 148
Other cardiovascular Short acting nitrate required 88
Renal impairment Allopurinol and reduced renal function 154
Renal impairment Diabetes and CV risks or renal disease requires ACEI or ARB or CCB 34
Renal impairment Hexamine prescribed (poor renal clearance) 95
Renal impairment Metformin dose high with renal impairment 71
Renal impairment Nitrofurantoin prescribed 63
Renal impairment Renal impairment and using or check for renally excreted drugs 45
Respiratory Airway disease un(der)treated 126
Respiratory Asthma moderate/severe requires inhaled corticosteroid 32
Respiratory COPD and using benzodiazepines 37
Respiratory COPD/Asthma and using a beta blocker 2
Sedative Sedatives long-acting or long-term 12
Toxicity ACEI cough 48
Toxicity Hyponatremia drug toxicity 65
Toxicity Other toxicity - drug suspected 92
Undertreatment Current therapy insufficient 82
Undertreatment Family history disease risk, preventative therapy indicated 87
Undertreatment Glaucoma untreated 128
Undertreatment Other disease/symptoms untreated 68
Undertreatment Skin disease un(der)treated 123
Undertreatment Vaccination required (influenza, pneumonia) 76
Undertreatment Weight loss un(der)treated 124
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Appendix 11 Expert panel website
Example screen shots showing various aspects of the expert panel website.
281
Figure 69: Home page and log in
 Expert panel website
282
Figure 70: HMR cases for assessment
 Expert panel website
283
Figure 71: An HMR case showing patient demographics, medications, diagnoses. No 
pathology was available for this case
 Expert panel website
284
Figure 72: The DRPs from each source could be opened allowing expert assessment. The blue 
section provided for an overall assessment of the source in the specific case
 Expert panel website
285
Figure 73: Summary of an expert's responses of assessment of each individual DRP
Figure 74: Summary of an expert's responses to overall opinion of each source 
 Expert panel website
286
Figure 75: A portion of the help page
 MRM user survey information sheet
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Appendix 13 MRM user survey
Screenshots showing the complete web-based MRM user survey. Questions marked with a 
red asterisk were mandatory.
289
Figure 76: MRM survey - introduction screen
 MRM user survey
290
Figure 77: MRM survey - pharmacist background 1
 MRM user survey
291
Figure 78: MRM survey - pharmacist background 2
 MRM user survey
292
Figure 79: MRM survey - pharmacist background 3
 MRM user survey
293
Figure 80: MRM survey - data entry
 MRM user survey
294
Figure 81: MRM survey - SUS
 MRM user survey
295
Figure 82: MRM survey - perceived usefulness
 MRM user survey
296
Figure 83: MRM survey - opinion of decision support
 MRM user survey
 
 
297
Figure 84: MRM survey - opinion of software value
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Table 62: Frequency of descriptive classifications by DRP source
Classification Beers03 Beers12 MRM Pharmacist PIEA STOPP/
START
ACEI cough 11 12
AF requires aspirin or warfarin 4 5 40 28
Airway disease un(der)treated 64 17 5
Allopurinol and reduced renal function 15 8
Amiodarone or other antiarrythmic 
prescribed
11 39
Analgesia optimisation with regular 
paracetamol needed
59 77
Antibiotic no indication 2
Anticholinergic use not elsewhere 
specified
78 65 37 33 33 14
Anticholinergics and cognitive impairment 12 12 4 6 17
Anticholinergics and constipation 47 14 22 7 48
Anticoagulant toxicity 22 13
Antidiabetic drug no indication 15 5
Antigout medication (might) not indicated 76 13
Antilipidaemic drug no indication 56 1
Antiplatelet not indicated 60 4 150
Aspirin high dose not indicated 3 2 2
Aspirin or thiazide contraindicated in gout 21 13
Asthma moderate/severe requires 
inhaled corticosteroid
15 4 1 31
Beta-blocker for hypertension 4 2
Bleeding disorder and antiplatelet or 
anticoagulant
1 4
Bleeding risk interacting drugs 26 31 55 23
Calcium channel blocker and 
constipation
13 4 39
Calcium channel blocker and peripheral 
oedema
20 17
Calcium channel blocker and reflux 120 1
Can reduce daily drug frequency 6 8
Cardiovascular disease/risk requires 
antiplatelet
70 26 39 30
Cardiovascular disease/risk requires 
statin
44 14 177 42
Cardiovascular drug no indication 89 8
Clopidogrel and aspirin interaction 16 13
Combine medications into combination 
product
3 10
Compliance - Confusion about therapy 29
Compliance - using too little medication 113
Compliance - using too much medication 9
Constipation un(der)treated 33 9
COPD and using benzodiazepines 15 38
COPD/Asthma and using a beta blocker 34 6 45 4
Cost of therapy concern 4
Current therapy insufficient 48 32 12 5
Depression un(der)treated 92 9 17
Dextropropoxyphene prescribed 7 8 2
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Classification Beers03 Beers12 MRM Pharmacist PIEA STOPP/
START
Diabetes and CV risks or renal disease 
requires ACEI or ARB (CCB)
36 4 1 1
Diabetes and taking medication that 
affects glucose levels
12 42
Diabetes monitoring required 41 8 5
Diabetes undertreated (HBA1c or BSLs 
high)
36 17
Difficulty using dosage form 35
Digoxin dose over 125mcg or considered 
too high
7 19 17 17 2
Digoxin monitoring required 38 3
Digoxin toxicity 8
Documentation insufficient 5
Drug causing dyspepsia with PPI 25 1 270
Duration of therapy may be excessive 10 16
Eligible for DVA funded DAA 34
Epilepsy and medication affecting seizure 
threshold
2 1 1
Falls risk/history and 
sedatives/antihypertensives/other
13 51 6 15 21 25
Family history disease risk, preventative 
therapy indicated
2
Fluoxetine prescribed 7
Glaucoma untreated 13 2
Glibenclamide prescribed 2 1 1 2 2
GORD drug no indication 115 19
Haematology monitoiring required 11 12
Heart disease un(der)treated 47 13 10
Heart failure and concurrent verapamil or 
diltiazem
13 11 3 11 11
Heart failure or hypertension and using 
high sodium or salt retaining drugs
2 13 37
Heart failure or IHD requires beta-blocker 5 114 24
Heart failure requires ACEI or ARB 12 3 20 20
Hexamine prescribed (poor renal 
clearance)
1 1
Hydralazine monitoring required 3 2
Hyperkalaemia (or risk of) and 
medication
46 29
Hyperlipidaemia under/untreated 83 31
Hypertension under/untreated 38 18 20
Hyponatremia drug toxicity 17 5
INR outside therapeutic range 10 2 15
Iron and constipation 7 3 2
Iron no indication 11 2
Lifestyle issues - overweight 5
Lipid monitoring required 1 14
Lithium monitoring required 1 1
Medication expired 15
Medication monitoring - calcium intake 22
Medication monitoring - Potassium 25 9
Medication regimen complicated 2
Metformin dose high with renal 35 12 8
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Classification Beers03 Beers12 MRM Pharmacist PIEA STOPP/
START
impairment
Methyldopa prescribed 2 5 2
Mineral oil laxative prescribed 3 3 2
Nitrate free period required 2 3
Nitrofurantoin prescribed 3 3 2
NSAID combined with ACEI or ARB, 
diuretic - triple whammy
22 24 54
NSAID not recommended 
(CV/HF/bleed/other)
4 39 59 28 77 84
NSAID used with (risk of) renal failure 9 1 6 87 9
NSAID without acid suppressant 35
Oestrogens and thromboembolism or 
cancer risk
3 5 5 6
Opioid constipation may require laxative 
or increased lax therapy
61 13 5 2
Opioid sedation 25
Osteoporosis (or risk) may require 
calcium and or vitamin D
137 117 50
Osteoporosis (or risk) requires 
antiosteoporotic
7 1 53 32
Other cardiovascular drug toxicity 44
Other disease/symptoms untreated 2 30 67
Other DRP MRM 8
Other DRP pharmacist 48
Other drug disease contraindication 3 5 54 13 4 4
Other drug interaction 62 59 2
Other drug no indication 35 34 14
Other monitoring (lab) required 3 27
Other monitoring (non-lab) required 13 2
Other PIM 8 18
Other toxicity - drug suspected 11 64
Pain un(der)treated 5 28 13
Parkinsonism and antipsychotics or 
metoclopramide
3 16 14 4 3
Patient disease management education 
provided/required
19
Patient drug education provided/required 27 17
Pioglitazone in HF 1 1 3
PPI and clopidogrel interaction 1
PPI high dose 69 24 15
Quinine prescribed 19 11
Renal impairment and using or check for 
renally excreted drugs
122 48
Rosiglitazone prescribed 3 11 6
Sedatives long-acting or sedative long 
term
75 51 55 31 68 56
Serotonergic drugs interaction 2 4 5
Short acting nitrate required 28 5
Skin disease un(der)treated 16
Smoking cessation education 
required/provided
5
Statin myopathy risk 8 29 96
Statin toxicity 15 4
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Classification Beers03 Beers12 MRM Pharmacist PIEA STOPP/
START
Stimulant laxative long term use 60 7
Therapeutic dose too high 2 28 13
Therapeutic dose too low 13 27
Therapy duplication 2 27 29
Thyroid function monitoring required 11 7
Timing of dose inappropriate 14
Vaccination required (Flu, pneumonia) 18
Vitamin  no indication 1 6
Vitamin B12 and or folate deficiency 
possible
83 66
Warfarin and aspirin interaction 4 7 4
Weight loss un(der)treated 3
Totals 374 387 2854 1680 1460 977
Table 63: Frequency of distinct classifications by source, limited to 100 test cases
Description Beers03 Beers12 MRM MRX Pharmacist PIEA STOPP /
START
ACEI cough 3 2
AF requires aspirin or warfarin 3 2
Airway disease un(der)treated 8 2
Allopurinol and reduced renal 
function
4 4
Amiodarone or other 
antiarrhythmic prescribed
2 8 2
Analgesia optimisation with 
regular paracetamol needed
10 17
Anticholinergic use not elsewhere 
specified
10 7 7 75 6 6 3
Anticholinergics and cognitive 
impairment
3 2 76
Anticholinergics and constipation 6 3 3 8
Anticoagulant toxicity 2 3
Antidiabetic drug no indication 1 1
Antigout medication (might) not 
indicated
16 5
Antilipidaemic drug no indication 9
Antiplatelet not indicated 10 1 22
Aspirin high dose not indicated 1
Aspirin or thiazide contraindicated 
in gout
7 4
Asthma moderate/severe requires 
inhaled corticosteroid
2 4
Beta-blocker for hypertension 1
Bleeding risk interacting drugs 3 2 9 4
Calcium channel blocker and 
constipation
2 1 4
Calcium channel blocker and 
peripheral oedema
2 2
Calcium channel blocker and 
reflux
19
Can reduce daily drug frequency 1 3
301
 Descriptive classifications by source
Description Beers03 Beers12 MRM MRX Pharmacist PIEA STOPP /
START
Cardiovascular disease/risk 
requires antiplatelet
10 3 4 5
Cardiovascular disease/risk 
requires statin
8 1 23 4
Cardiovascular drug no indication 15 1
Clopidogrel and aspirin interaction 4 3
Combine medications into 
combination product
2 2
Compliance - Confusion about 
therapy
3
Compliance - using too little 
medication
18
Compliance - using too much 
medication
3
Constipation un(der)treated 2 3
COPD and using 
benzodiazepines
3 6
COPD/Asthma and using a beta 
blocker
7 6 2
Current therapy insufficient 10 4 1 1
Depression un(der)treated 12 1
Diabetes and CV risks or renal 
disease requires ACEI or ARB 
(CCB)
6 1
Diabetes and taking medication 
that affects glucose levels
1 10
Diabetes monitoring required 6 4 3
Diabetes undertreated (HBA1c or 
BSLs high)
6 1
Difficulty using dosage form 5
Digoxin dose over 125mcg or 
considered too high
4 8 9 7 2
Digoxin monitoring required 6 2
Digoxin toxicity 3
Drug causing dyspepsia with PPI 7 48
Duration of therapy may be 
excessive
2 3
Eligible for DVA funded DAA 6
Falls risk/history and 
sedatives/antihypertensives/other
3 12 1 100 1 5 5
Fluoxetine prescribed 2 2
Glaucoma untreated 4 2
Glibenclamide prescribed 1 1 1 1
GORD drug no indication 17 2
Haematology monitoiring required 2 5
Heart disease un(der)treated 7 3 2
Heart failure and concurrent 
verapamil or diltiazem
1
Heart failure or hypertension and 
using high sodium or salt 
retaining drugs
2 5
Heart failure or IHD requires beta-
blocker
2 17 6
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Description Beers03 Beers12 MRM MRX Pharmacist PIEA STOPP /
START
Heart failure requires ACEI or 
ARB
3 1 4 4
Hyperkalaemia (or risk of) and 
medication
7 4
Hyperlipidaemia under/untreated 19 8
Hypertension under/untreated 7 1 5
Hyponatremia drug toxicity 2 1
Medication monitoring – calcium 
intake
5
Medication monitoring - cognitive 91
Medication monitoring - 
communication/social problems
100
Medication monitoring - 
dehydration
55
Medication monitoring - nutritional 
status or dental care
91
Medication monitoring - 
Potassium
4
Medication monitoring - pressure 
ulcers
60
Medication monitoring - urinary 
incontinence
90
Medication monitoring - visual 
disturbance
68
Metformin dose high with renal 
impairment
7 3
Nitrate free period required 1 3
NSAID combined with ACEI or 
ARB, diuretic - triple whammy
2 3 8
NSAID not recommended 
(CV/HF/bleed/other)
4 6 1 6 14 18
NSAID used with renal failure (or 
risks of)
2 1 1 15 2
NSAID without acid suppressant 4
Oestrogens and 
thromboembolism or cancer risk
1 1
Opioid constipation may require 
laxative or increased lax therapy
10 2 1
Opioid sedation 3
Osteoporosis (or risk) may require 
calcium and or vitamin D
28 16 11
Osteoporosis (or risk) requires 
antiosteoporotic
2 1 12 3
Other cardiovascular drug toxicity 11
Other disease/symptoms 
untreated
4 8
Other DRP pharmacist 7
Other drug disease 
contraindication
1 12 60 2 1
Other drug interaction 15 12
Other drug no indication 6 5 3
Other monitoring (lab) required 2 9
Other monitoring (non-lab) 2 1
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Description Beers03 Beers12 MRM MRX Pharmacist PIEA STOPP /
START
required
Other PIM 3 2
Other toxicity - drug suspected 1 12
Pain un(der)treated 2 1
Parkinsonism and antipsychotics 
or metoclopramide
2 2 2
Patient disease management 
education provided/required
2
Patient drug education 
provided/required
4 3
PPI high dose 16 5 3
Quinine prescribed 5 5
Renal impairment and using or 
check for renally excreted drugs
18 9
Rosiglitazone prescribed 1 2 1
Sedatives long-acting or sedative 
long term
11 11 9 6 2 11 11
Serotonergic drugs interaction 1 1
Short acting nitrate required 8 2
Skin disease un(der)treated 2
Smoking cessation education 
required/provided
1
Statin myopathy risk 2 6 23
Statin toxicity 1
Stimulant laxative long term use 9 2
Therapeutic dose too high 5 1
Therapeutic dose too low 2 5
Therapy duplication 4 5
Thyroid function monitoring 
required
2 4
Timing of dose inappropriate 3
Vaccination required (Flu, 
pneumonia)
3
Vitamin  no indication 2
Vitamin B12 and or folate 
deficiency possible
15 12 1
Warfarin and aspirin interaction 1 1
Weight loss un(der)treated 1
In both tables italicised classifications were pharmacist-only identified  compliance or  non-
classifiable. These were excluded from the analysis. In both tables the bold classifications 
other DRP – MRM and other DRP – pharmacist were also not included in analysis, they were 
too difficult to classify in any meaningful way.
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Appendix 15 Descriptive classifications common to MRM 
and pharmacists in 570 cases
Table 64: Classifications found by MRM and pharmacists (570 cases aged 65 and older)
Classification Total cases 
MRM found
Total cases 
pharmacist 
found
Total number of 
cases found in 
common
Total 
Cases
Overlap 
percent of 
total cases
Osteoporosis (or risk) may 
require calcium and or vitamin D
137 117 49 205 23.9%
Renal impairment and using or 
check for renally excreted drugs
122 48 24 146 16.4%
Vitamin B12 and or folate 
deficiency possible
83 66 16 133 12.0%
Analgesia optimisation with 
regular paracetamol needed
59 77 5 131 3.8%
GORD drug no indication 115 19 7 127 5.5%
Calcium channel blocker and 
reflux
120 1 1 120 0.8%
Other drug interaction 62 59 5 116 4.3%
Depression un(der)treated 92 9 5 96 5.2%
Hyperlipidaemia under/untreated 83 31 20 94 21.3%
PPI high dose 69 24 7 86 8.1%
Cardiovascular disease/risk 
requires antiplatelet
70 26 16 80 20.0%
Antigout medication (might) not 
be indicated
76 13 11 78 14.1%
Current therapy insufficient 48 32 2 78 2.6%
Airway disease un(der)treated 64 17 6 75 8.0%
Other toxicity - drug suspected 11 64 3 72 4.2%
NSAID not recommended 
(CV/HF/bleed/other)
59 28 17 70 24.3%
Sedatives long-acting or 
sedative long term
55 31 18 68 26.5%
Other drug no indication 35 34 1 68 1.5%
Opioid constipation may require 
laxative or increased lax therapy
61 13 7 67 10.4%
Hyperkalaemia (or risk of) and 
medication
46 29 10 65 15.4%
Anticholinergic use not 
elsewhere specified
37 33 7 63 11.1%
Antiplatelet not indicated 60 4 3 61 4.9%
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Classification Total cases 
MRM found
Total cases 
pharmacist 
found
Total number of 
cases found in 
common
Total 
Cases
Overlap 
percent of 
total cases
Heart disease un(der)treated 47 13 2 58 3.4%
Antilipidaemic drug no indication 56 1 1 56 1.8%
Cardiovascular disease/risk 
requires statin
44 14 5 53 9.4%
Bleeding risk interacting drugs 26 31 5 52 9.6%
Diabetes monitoring required 41 8 1 48 2.1%
Diabetes undertreated (HBA1c 
or BSLs high)
36 17 9 44 20.5%
Metformin dose high with renal 
impairment
35 12 5 42 11.9%
Constipation un(der)treated 33 9 2 40 5.0%
Digoxin monitoring required 38 3 1 40 2.5%
COPD/Asthma and using a beta 
blocker
34 6 3 37 8.1%
NSAID combined with ACEI or 
ARB, diuretic - triple whammy
22 24 9 37 24.3%
Diabetes and CV risks or renal 
disease requires ACEI or ARB or 
CCB
36 4 3 37 8.1%
Medication monitoring - 
Potassium
25 9 1 33 3.0%
Short acting nitrate required 28 5 2 31 6.5%
Statin myopathy risk 8 29 7 30 23.3%
Calcium channel blocker and 
peripheral oedema
20 17 8 29 27.6%
Anticoagulant toxicity 22 13 7 28 25.0%
Digoxin dose over 125mcg or 
considered too high
17 17 9 25 36.0%
Anticholinergics and 
constipation
22 7 4 25 16.0%
Clopidogrel and aspirin 
interaction
16 13 5 24 20.8%
Haematology monitoring 
required
11 12 1 22 4.5%
Hyponatremia drug toxicity 17 5 1 21 4.8%
Quinine prescribed 19 11 10 20 50.0%
Antidiabetic drug no indication 15 5 1 19 5.3%
Asthma moderate/severe 
requires inhaled corticosteroid
15 4 1 18 5.6%
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Classification Total cases 
MRM found
Total cases 
pharmacist 
found
Total number of 
cases found in 
common
Total 
Cases
Overlap 
percent of 
total cases
Allopurinol and reduced renal 
function
15 8 5 18 27.8%
ACEI cough 11 12 7 16 43.8%
Heart failure requires ACEI or 
ARB
12 3 1 14 7.1%
Thyroid function monitoring 
required
11 7 4 14 28.6%
Glaucoma untreated 13 2 2 13 15.4%
Combine medications into 
combination product
3 10 1 12 8.3%
Iron no indication 11 2 1 12 8.3%
Heart failure and concurrent 
verapamil or diltiazem
11 3 3 11 27.3%
Rosiglitazone prescribed and 
(risk of) HF
11 6 6 11 54.5%
INR outside therapeutic range 10 2 1 11 9.1%
Warfarin and aspirin interaction 4 7 2 9 22.2%
Dextropropoxyphene prescribed 8 2 2 8 25.0%
Osteoporosis (or risk) requires 
antiosteoporotic
7 1 1 7 14.3%
Vitamin no indication 1 6 1 6 16.7%
Serotonergic drugs interaction 2 4 1 5 20.0%
Nitrate free period required 2 3 1 4 25.0%
Hydralazine monitoring required 3 2 1 4 25.0%
Iron and constipation 3 2 2 3 66.7%
Nitrofurantoin prescribed 3 2 2 3 66.7%
Pioglitazone in HF 1 3 1 3 33.3%
Lithium monitoring required 1 1 1 1 100.0%
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and pharmacists in 100 test cases
Table 65: Overlap of common classifications between MRM and pharmacists (100 test cases)
Descriptive classification Total cases 
MRM found
Total cases 
pharmacists 
found
Total cases 
found in 
common
Total 
Cases
Overlap 
percent 
of total 
cases
Osteoporosis (or risk) may require calcium 
and or vitamin D
28 16 8 36 22.2%
Analgesia optimisation with regular 
paracetamol needed
10 17 1 26 3.8%
Vitamin B12 and or folate deficiency 
possible
15 12 1 26 3.8%
Hyperlipidaemia under/untreated 19 8 6 21 28.6%
PPI high dose 16 5 1 20 5.0%
Renal impairment and using or check for 
renally excreted drugs
18 9 7 20 35.0%
Antigout medication (might) not indicated 16 5 4 17 23.5%
Digoxin dose over 125mcg or considered 
too high
9 7 4 12 33.3%
Opioid constipation may require laxative or 
increased lax therapy
10 2 1 11 9.1%
Antiplatelet not indicated 10 1 1 10 10.0%
NSAID not recommended 
(CV/HF/bleed/other)
6 6 2 10 20.0%
Sedatives long-acting or sedative long term 9 2 2 9 22.2%
Hyperkalaemia (or risk of) and medication 7 4 2 9 22.2%
Short acting nitrate required 8 2 1 9 11.1%
Heart disease un(der)treated 7 3 1 9 11.1%
Diabetes monitoring required 6 4 1 9 11.1%
Statin myopathy risk 2 6 1 7 14.3%
Digoxin monitoring required 6 2 1 7 14.3%
Quinine prescribed 5 5 4 6 66.7%
Haematology monitoring required 2 5 1 6 16.7%
Clopidogrel and aspirin interaction 4 3 1 6 16.7%
Allopurinol and reduced renal function 4 4 3 5 60.0%
Bleeding risk interacting drugs 3 2 1 4 25.0%
NSAID combined with ACEI or ARB, 
diuretic - triple whammy
2 3 1 4 25.0%
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Descriptive classification Total cases 
MRM found
Total cases 
pharmacists 
found
Total cases 
found in 
common
Total 
Cases
Overlap 
percent 
of total 
cases
ACEI cough 3 2 1 4 25.0%
Glaucoma untreated 4 2 2 4 50.0%
Thyroid function monitoring required 2 4 2 4 50.0%
Anticoagulant toxicity 2 3 1 4 25.0%
Combine medications into combination 
product
2 2 1 3 33.3%
Nitrate free period required 1 3 1 3 33.3%
Calcium channel blocker and peripheral 
oedema
2 2 2 2 100.0%
Rosiglitazone prescribed and (risk of) HF 2 1 1 2 50.0%
Hyponatremia drug toxicity 2 1 1 2 50.0%
Osteoporosis (or risk) requires 
antiosteoporotic
2 1 1 2 50.0%
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classifications
Table 66: Prescribing guidelines mapped to descriptive classifications
Classification Prescribing
Criteria
Rule Criterion
AF requires aspirin or warfarin START A01 Warfarin in the presence of chronic atrial fibrillation
START A02 Aspirin in the presence of chronic atrial fibrillation where warfarin is 
contraindicated but not aspirin
PIEA 9 Patient with AF is taking an oral anticoagulant
Airway disease un(der)treated STOPP D02 Systemic corticosteroids instead of inhaled corticosteroids for 
maintenance therapy in moderate to severe chronic obstructive pulmonary 
disease (unnecessary exposure to long-term side effects of systemic 
steroids)
Amiodarone or other antiarrythmic 
prescribed
Beers Antiarrhythmic drugs: amiodarone, flecainide, procainamide, quinidine, 
sotalol
Anticholinergic use not elsewhere 
specified
STOPP B02 Tricyclic antidepressant with glaucoma (likely to exacerbate glaucoma)
STOPP B03 Tricyclic antidepressant with cardiac conductive abnormalities (pro-
arrhythmic effects)
STOPP B06 Tricyclic antidepressant with prostatism or history of urinary retention (risk 
of urinary retention)
STOPP D03 Nebulised ipratropium with glaucoma (may exacerbate glaucoma)
STOPP F02 Antimuscarinic drugs with chronic glaucoma (risk of acute exacerbation of 
glaucoma)
STOPP F04 Antimuscarinic drugs with chronic prostatism (risk of urinary retention)
PIEA 32 Patient is not taking more than one medication with anticholinergic activity 
(q)
Beers Anticholinergics and first-generation antihistamines: diphenhydramine, 
cyproheptadine, promethazine, dexchlorpheniramine, doxylamine, 
triprolidine
Beers Antiparkinson agents: belladonna, trihexylphenidyl
Beers Belladonna alkaloids, dicyclomine, hyoscyamine, propantheline, hyoscine
Beers TCAs: amitriptyline, clomipramine, doxepine > 6mg/d, imipramine, 
trimipramine
Anticholinergics and cognitive 
impairment
STOPP B01 Tricyclic antidepressant with dementia (risk of worsening cognitive 
impairment)
STOPP B13 Prolonged use, more than 1 week, of first-generation antihistamines (risk 
of sedation and anticholinergic effects)
PIEA 31 Patient with dementia is not receiving anticholinergic medication (q)
Beers Dementia or cognitive impairment: anticholinergics, benzodiazepines, H2-
receptor antagonists,
Anticholinergics and constipation STOPP B04 Tricyclic antidepressant with constipation (likely to worsen constipation)
STOPP B05 Tricyclic antidepressant with opiate or calcium channel blocker (risk of 
severe constipation)
STOPP C05 Anticholinergic antispasmodic drugs with chronic constipation (risk of 
exacerbation of constipation)
STOPP F03 Antimuscarinic drugs with chronic constipation (risk of exacerbation of 
constipation)
Beers Chronic constipation: oxybutinin, solifenacin, tolterodine, diltiazem, 
verapamil, dexchlorpheniramine, clemastine, cyproheptadine, 
diphenhydramine, doxylamine, promethazine, triprolidine, antipsychotics, 
belladonna alkaloids, hyoscyamine, propantheline, hyoscine, TCAs, 
orphenadrine
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Classification Prescribing
Criteria
Rule Criterion
Antiplatelet not indicated STOPP A13 Aspirin with no history of coronary, cerebral or peripheral vascular 
symptoms or occlusive event (not indicated)
Aspirin high dose not indicated STOPP A12 Aspirin at dose > 150mg/day (increased bleeding risk, no evidence for 
increased efficacy)
Aspirin or thiazide contraindicated 
in gout
STOPP A04 Thiazide diuretic with a history of gout (may exacerbate gout)
Asthma moderate/severe requires 
inhaled corticosteroid
START B01 Regular inhaled corticosteroid or anticholinergic agent for mild-to-
moderate asthma or COPD
PIEA 35 Patient with asthma using an inhaled LABA is also using an inhaled 
corticosteroid
Bleeding disorder and antiplatelet 
or anticoagulant
STOPP A11 Aspirin with a past history of peptic ulcer disease without histamine H2-
receptor antagonist or proton pump inhibitor (risk of bleeding)
STOPP A17 Aspirin, clopidogrel, dipyridamole or warfarin with concurrent bleeding 
disorder (high risk of bleeding)
Bleeding risk interacting drugs STOPP E05 Warfarin and NSAID together (risk of gastrointestinal bleeding)
PIEA 29 Patient taking an SSRI is not concurrently taking medications known to 
increase the risk of gastrointestinal bleeding (o)
Calcium channel blocker and 
constipation
STOPP A08 Calcium channel blockers with chronic constipation (may exacerbate 
constipation)
Beers Chronic constipation: oxybutinin, solifenacin, tolterodine, diltiazem, 
verapamil, dexchlorpheniramine, clemastine, cyproheptadine, 
diphenhydramine, doxylamine, promethazine, triprolidine, antipsychotics, 
belladonna alkaloids, hyoscyamine, propantheline, hyoscine, TCAs, 
orphenadrine
Cardiovascular disease (or risk) 
requires statin
START A05 Statin therapy with a documented history of coronary, cerebral or 
peripheral vascular disease, where the patients functional status remains 
independent for activities of daily living and life expectancy is greater than 
5 years
START F04 Statin therapy in diabetes mellitus if coexisting major cardiovascular risk 
factors present
START F03 Antiplatelet therapy in diabetes mellitus with coexisting major 
cardiovascular risk factors (hypertension, hypercholesterolaemia, smoking 
history)
PIEA 2 Patient at high risk of a cardiovascular event (b) is taking an HMG-CoA 
reductase inhibitor (statin)
Cardiovascular disease(or risk) 
requires antiplatelet
START A03 Aspirin or clopidogrel with a documented history of atherosclerotic 
coronary, cerebral or peripheral vascular disease in patients with sinus 
rhythm
PIEA 4 Patient with IHD or a history of MI is taking an antiplatelet agent unless 
taking an oral anticoagulant (c )
PIEA 11 Patient with a history of non-haemorrhagic stroke or TIA is taking an 
antiplatelet agent unless taking an anticoagulant (c )
PIEA 16 Patient with diabetes at high risk of a cardiovascular event (b) is taking an 
antiplatelet agent unless taking an anticoagulant (c )
COPD and using 
benzodiazepines
PIEA 34 Patient with COPD is not taking benzodiazepines
COPD/Asthma and using a beta 
blocker
STOPP A05 Non-cardioselective beta-blocker with chronic obstructive pulmonary 
disease (risk of increased bronchospasm)
PIEA 37 Patient with asthma is not taking a medication that may worsen asthma (s)
Current therapy insufficient STOPP A03 Loop diuretic as first-line monotherapy for hypertension (safer, more 
effective alternatives available)
STOPP F05 Alpha-blockers in males with frequent incontinence (one or more 
incontinence episodes daily) (risk of urinary frequency and worsening of 
incontinence)
PIEA 38 Female patient with recurrent UTIs has been prescribed intravaginal 
estrogen
Depression un(der)treated START C02 Antidepressant drug in the presence of moderate/severe depressive 
symptoms lasting at least three months
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Classification Prescribing
Criteria
Rule Criterion
Diabetes and CV risks or renal 
disease requires ACEI or ARB or 
CCB
START F02 ACE inhibitor or angiotensin receptor blocker in diabetes with nephropathy 
(overt urinalysis proteinuria or microalbuminuria more than 30mg/24 
hours)
PIEA 15 Patient with type 2 diabetes and hypertension and albuminuria is taking an 
ACE inhibitor or ARB
Diabetes and taking medication 
that affects glucose levels
PIEA 17 Patient with diabetes is not taking a medication that may increase or 
decrease blood glucose concentrations (h)
Diabetes monitoring required PIEA 18 Patient with diabetes has had an HbA1c measurement within the previous 
6 months
Digoxin dose over 125mcg or 
considered too high
STOPP A01 Digoxin at long term dose >125ug/day with impaired renal function. Serum 
creatinine > 150umol/L (increased risk of toxicity) 
Beers Digoxin > 125mcg/day
Drug causing dyspepsia with PPI PIEA 33 Patient taking a PPI is not taking a medication that may cause dyspepsia
Epilepsy and medication affecting 
seizure threshold
Beers Seizures or epilepsy: bupropion, chlorpromazine, clozapine, olanzapine, 
thioridazine, thiothixene, tramadol
Falls risk/history and 
sedatives/antihypertensives/other
STOPP H01 In this patient with a history of falls, benzodiazepines (sedative, may cause 
reduced sensorium, impair balance)
STOPP H02 In this patient with a history of falls, neuroleptic drugs (may cause gait 
dyspraxia, parkinsonism)
STOPP H03 In this patient with a history of falls, first-generation antihistamines 
(sedative, may impair sensorium)
STOPP H04 In this patient with a history of falls, vasodilator drugs with persistent 
postural hypotension ( > 20mmHg drop in systolic blood pressure) (risk of 
syncope, falls)
STOPP H05 Long term opiates in those with recurrent falls (risk of drowsiness, postural 
hypotension, vertigo)
PIEA 28 Patient with a history of falls is not taking psychotropic medications (n)
Beers Falls history or fractures: Anticonvulsants, antipsychotics, 
benzodiazepines, zalepion, zolpidem, TCAs, SSRIs
Glibenclamide prescribed STOPP G01 Glibenclamide or chlorpropamide with type 2 diabetes mellitus (risk of 
prolonged hypoglycaemia)
PIEA 20 Patient taking metformin for diabetes is not concurrently taking 
glibenclamide
Beers Sulphonylureas long acting: glibenclamide, chlorpropamide
Heart disease un(der)treated START A07 Angiotensin converting enzyme inhibitor following acute myocardial 
infarction
Heart failure and concurrent 
verapamil or diltiazem
STOPP A07 Use of diltiazem or verapamil with NYHA class III or IV heart failure (may 
worsen heart failure)
Beers Heart failure: NSAIDS, COX2, diltiazem, verapamil, pioglitazone, 
rosiglitazone
Heart failure or hypertension and 
using high sodium or salt 
retaining drugs
PIEA 7 Patient with heart failure is not taking medications that may exacerbate 
heart failure (d)
PIEA 8 Patient with heart failure or hypertension is not taking high sodium-
containing medications (e)
Heart failure or IHD requires beta-
blocker
START A08 Beta-blocker with chronic stable angina
PIEA 3 Patient with IHD or a history of MI is taking a beta-blocker
PIEA 5 Patient with heart failure is taking a beta-blocker
Heart failure requires ACEI or 
ARB
START A06 Angiotensin converting enzyme inhibitor with chronic heart failure
PIEA 6 Patient with heart failure is taking an ACE inhibitor or ARB
Hexamine prescribed (poor renal 
clearance)
PIEA 40 Patient with a creatinine clearance <50ml/min is not receiving 
methenamine (hexamine) for UTI prophylaxis
Hypertension un(der)treated START A04 Antihypertensive therapy where systolic blood pressure consistently 
>160mmHg
PIEA 1 Patient taking an antihypertensive is at their target blood pressure (a)
INR outside therapeutic range PIEA 10 Patient with AF taking an anticoagulant has an INR between 2 and 3
Metformin dose high with renal 
impairment
PIEA 19 Patient taking metformin for diabetes has had the dose adjusted for 
creatinine clearance
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Classification Prescribing
Criteria
Rule Criterion
Methyldopa or clonidine 
prescribed
Beers Alpha blockers central: clonidine, methyldopa
Mineral oil laxative prescribed Beers Mineral oil, oral
NSAID combined with ACEI or 
ARB, diuretic - triple whammy
PIEA 25 Patient is not concurrently taking an ACE inhibitor or ARB, diuretic and 
NSAID (excluding low-dose aspirin)
NSAID not recommended 
(CV/HF/bleed/other)
STOPP E02 NSAID with moderate to severe hypertension (risk of exacerbation of 
hypertension)
STOPP E03 NSAID with heart failure (risk of exacerbation of heart failure)
STOPP E04 Long term use of NSAID ( > 3 months) for symptom relief of mild 
osteoarthritis (simple analgesics preferable and usually as effective for 
pain relief)
STOPP E08 Long term NSAID or colchicine for chronic treatment of gout where there 
was no contraindication to allopurinol (allopurinol first-choice prophylactic 
drug in gout)
PIEA 7 Patient with heart failure is not taking medications that may exacerbate 
heart failure (d)
PIEA 13 Patient with cardiovascular disease is not taking and NSAID
Beers NSAIDs non-COX selective: Aspirin>325mg, diclofenac, diflunisal, 
ibuprofen, ketoprofen, mefenamic acid, meloxicam, naproxen, piroxicam, 
sulindac
Beers Indomethacin, ketorolac
Beers Heart failure: NSAIDS, COX2, diltiazem, verapamil, pioglitazone, 
rosiglitazone
NSAID used with renal failure (or 
risks of)
STOPP E06 NSAID with chronic renal failure (risk of deterioration of renal function)
PIEA 24 Patient with risk factors for impaired renal function (L) is not taking an 
NSAID
Beers Chronic kidney disease: NSAIDs, triamterene
Oestrogens and 
thromboembolism or cancer risk
STOPP G03 Estrogens with a history of breast cancer or venous thromboembolism 
(increased risk of recurrence)
STOPP G04 Estrogens without progestogen in patients with intact uterus (risk of 
endometrial cancer)
Beers Estrogens with or without progestins, except topical
Opioid constipation may require 
laxative or increased lax therapy
STOPP I02 Regular opiates for > 2 weeks in those with chronic constipation without 
concurrent laxative use (risk of severe constipation)
PIEA 23 Patient taking an opioid (k) is taking prophylactic treatment for constipation
Osteoporosis (or risk) may require 
calcium and or vitamin D
START E03 Calcium and vitamin D supplement in patients with known osteoporosis 
(previous fragility fracture, acquired dorsal kyphosis)
Osteoporosis (or risk) requires 
antiosteoporotic
START E02 Biphosphonates in patients taking maintenance corticosteroid therapy
PIEA 44 Patient with osteoporosis is receiving anti-osteoporotic medication (w)
Other disease/symptoms 
untreated
START F01 Metformin with type 2 diabetes with or without metabolic syndrome (in 
absence of renal impairment)
START D02 Fiber supplement for chronic, symptomatic diverticular disease with 
constipation
Other drug disease 
contraindication
STOPP I03 Long term opiates in those with dementia unless for palliative care or 
management of moderate/severe chronic pain syndrome (risk of 
exacerbation of cognitive impairment)
PIEA 7 Patient with heart failure is not taking medications that may exacerbate 
heart failure (d)
Beers Antipsychotics first and second for behavioural dementia problems: 
chlorpromazine, fluphenazine, haloperidol, thioridazine, thiothixene, 
trifluoperazine, triflupromazine, aripiprazole, asenapine, clozapine, 
olanzapine, paliperidone, quetiapine, risperdone
Beers Dementia or cognitive impairment: anticholinergics, benzodiazepines, H2-
receptor antagonists,
Other drug interaction STOPP A06 Beta-blocker in combination with verapamil (risk of symptomatic heart 
failure)
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Classification Prescribing
Criteria
Rule Criterion
Other drug no indication STOPP A02 Loop diuretic for dependent ankle edema only i.e. no clinical signs of heart 
failure (no evidence of efficacy, compression hosiery usually more 
appropriate)
Other PIM Beers Alpha-blockers: doxazosin, prazosin, terazosin
Beers Nifedipine immediate release
Pain un(der)treated STOPP E07 Long term corticosteroids ( > 3 months) as monotherapy for rheumatoid or 
osteoarthritis (risk of major systemic corticosteroid side-effects)
STOPP E08 Long term NSAID or colchicine for chronic treatment of gout where there 
was no contraindication to allopurinol (allopurinol first-choice prophylactic 
drug in gout)
Parkinsonism and antipsychotics 
or metoclopramide
STOPP C03 Prochlorperazine (Stemetil) or metoclopramide with parkinsonism (risk of 
exacerbating parkinsonism)
Beers Metoclopramide avoid except for gastroparesis
Beers Parkinson's disease: antipsychotics except quetiapine and clozapine, 
metoclopramide, prochlorperazine, promethazine
Pioglitazone and HF Beers Heart failure: NSAIDS, COX2, diltiazem, verapamil, pioglitazone, 
rosiglitazone
PPI high dose STOPP C04 Proton pump inhibitor for peptic ulcer disease at full therapeutic dosage for 
more than 8 weeks (dose reduction or earlier discontinuation indicated)
Rosiglitazone and HF Beers Heart failure: NSAIDS, COX2, diltiazem, verapamil, pioglitazone, 
rosiglitazone
Sedatives long-acting or sedative 
long term
STOPP B07 Long term, more than 1 month, long-acting benzodiazepines (risk of 
prolonged sedation, confusion, impaired balance, falls)
PIEA 26 Patient with sleep disturbance or anxiety has not been taking 
benzodiazepines for >4 weeks
Beers Benzodiazepines: all. Avoid except for: seizures, generalized anxiety 
disorders
Beers Non-benzodiazepine hypnotics: eszopiclone, zolpidem, zalepion
Serotonergic drugs interaction PIEA 30 Patient taking an SSRI is not concurrently taking other medications that 
may contribute to serotonin toxicity (p)
Statin myopathy risk PIEA 12 Patient with risk factors for myopathy (f) is not taking >= 40mg/day of 
simvastatin or atorvastatin
Therapeutic dose too high Beers Spironolactone > 25mg/d
Therapy duplication STOPP J Any duplicate drug classes (optimisation of monotherapy within a single 
drug class should be observed prior to considering a new class of drug)
Warfarin and aspirin interaction STOPP A09 Use of aspirin and warfarin in combination without histamine H2-receptor 
antagonist (except cimetidine because of interaction with warfarin) or 
proton pump inhibitor (high risk of gastrointestinal bleeding)
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Appendix 18 Expert panel qualitative codes
Codes contain the following abbreviations: gen generic, mrm = MRM, mrx = MRX, ph = 
pharmacist, stopp = STOPP, drps = DRPs.
Table 67: Qualitative codes and frequency
Qualitative code Code categories Code frequency
gen_treatment_goal_symptomatic_only Generic issues 4
gen_wrongly_assigned Generic issues 1
mrm_good_recommendations mrm_positive 3
mrm_good_review mrm_positive 6
mrm_lose_impact mrm_negative 1
mrm_need_to_collate_drps mrm_negative 7
mrm_no_patient_context mrm_negative, patient_context_no 4
mrm_no_recommendations_made mrm_neutral 2
mrm_not_relevant mrm_negative, patient_context_no 3
mrm_poor_recommendations mrm_negative 1
mrm_relevant mrm_positive, patient_context_yes 3
mrm_repetitive mrm_negative, repetition 8
mrm_uncertain 1
mrx_alert_fatigue mrx_negative 1
mrx_correct_but_unsatisfactory mrx_negative 2
mrx_excessive_drps mrx_negative 4
mrx_generic_advice_litle_use mrx_negative 19
mrx_good_as_pre-screen mrx_positive 2
mrx_hate_or_similar mrx_negative, negative_emotion 14
mrx_just_a_list mrx_negative 9
mrx_no_patient_context mrx_negative, patient_context_no 31
mrx_not_relevant mrx_negative, patient_context_no 25
mrx_relevant mrx_positive, patient_context_yes 3
mrx_repetitive mrx_negative, repetition 3
mrx_tedious mrx_negative 1
mrx_time_cost mrx_negative 1
mrx_unhelpful mrx_negative 20
ph_benzod_weaning_not_suggested pharm_negative 1
ph_dont_like_dogmatic_approach pharm_negative 1
ph_not_all_good_drps pharm_negative 4
ph_not_thorough pharm_negative 7
ph_relevant pharm_positive, patient_context_yes 2
ph_too_many_drps pharm_negative 1
ph_uncertain 1
stopp_drps_too_generic stopp_negative 1
stopp_identified_no_drps 14
stopp_no_patient_context stopp_negative, patient_context_no 5
stopp_not_relevant stopp_negative, patient_context_no 2
stopp_not_thorough stopp_negative 6
stopp_relevant stopp_positive, patient_context_yes 1
stopp_repetitive stopp_negative, repetition 3
stopp_uncertain 5
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Table 68: Details of DRPs identified by MRX 
Problem Problem description Monitoring indicators
Activities The use of psychoactive medications may result 
in reduced activity participation.
Of special interest are problematic changes that 
may be related to the use of psychoactive 
medications, such as a recent decline in: 
• Cognition 
• Communication 
• Function 
• Mood 
• Behavior
Activities of 
Daily Living – 
Functional 
Status
Adverse medication effects, such as confusion, 
muscle weakness (asthenia) and inability to 
coordinate voluntary muscle movements or 
unsteady gait (ataxia), may interfere with ADL 
performance and contribute to functional decline.
Medication effects that may affect function: 
• Asthenia (muscle weakness) 
• Ataxia 
• Unsteady gait 
• Confusion
Anticholinergic The use of multiple medications with 
anticholinergic properties in older individuals 
may be particularly problematic because of the 
cumulative effects. 
• Are any medications with anticholinergic 
effects potentially inappropriate medications? If 
so, are there safer alternatives? 
• Is the patient experiencing any of the 
following anticholinergic side effects: 
• Dry mouth, skin or eyes 
• Urinary retention or difficulty urinating 
(especially in men) 
• Constipation 
• Rapid heart beat 
• Blurred vision 
• Clumsiness, unsteadiness 
• Dizziness 
• Drowsiness during the day 
• Lethargy, fatigue 
• Distress, nervousness 
• Memory problems 
• Confusion/disorientation 
• Restlessness, irritability 
• Hallucinations
Behavioural 
Symptoms
Medication side effects may cause or contribute 
to behavioral symptoms.
Medication side effects that can cause or 
contribute to behavioural symptoms:
• Delirium/delusions 
• Agitation, difficulty sleeping 
• Hypersexuality, socially inappropriate 
behavior 
• Impaired impulse control
Cognitive 
Loss/Dementia
Older adults are more likely than younger 
persons to develop cognitive impairment as a 
result of taking medications. Medications can 
impair cognitive function by interfering with 
learning, memory, and attention; wakefulness 
and alertness; and orientation and reality 
awareness. Drug-induced cognitive impairment 
Indicators of cognitive impairment: 
• Short-term memory problem (C0700) 
• Long-term memory problem (C0800) 
• Memory/recall ability (C0900) 
• Difficulty in making decisions; exercising 
poor judgment in decision-making (C1000) 
• Difficulty making self understood (B0700) 
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can manifest as delirium and dementia.
Drugs with anticholinergic properties have a 
major impact on learning, memory, and attention. 
• CNS depressant drugs have a major impact 
on wakefulness and alertness. 
• Drugs with a high potential to cause 
confusion have a major impact on orientation 
and reality awareness.
• Difficulty understanding others (B0800) 
Neuro-cognitive effects of medications: 
• Memory loss/impairment 
• Forgetfulness 
• Sleep disruption 
• Impaired alertness 
• Disorientation 
• Inattentiveness, impaired concentration 
(C1300A) 
• Daytime drowsiness, sleepiness (C1300C) 
• Confusion 
• Hallucination (E0100A) 
• Behavioral disturbances (E0200)
Communication Some medications may cause or contribute to 
communication deficits. Ototoxicity (ear damage) 
can occur during aminoglycoside antibiotic 
therapy, which can be manifest as high- 
frequency hearing loss, tinnitus (ringing in the 
ears), vertigo, dizziness, or nausea. Hearing loss 
may occur in patients receiving high-dose and/or 
long-term aspirin therapy; these effects are early 
manifestations of salicylate toxicity. Psychoactive 
medications and some Parkinson's medications 
may cause expressive communication problems, 
such as changes/difficulties in speech and voice 
production, finding appropriate words, 
transmitting coherent statements, describing 
objects and events. 
Signs/symptoms of ototoxicity: 
• New onset hearing problem (B0200) 
• High-frequency hearing loss 
• Tinnitus (ringing in the ears) 
• Vertigo 
• Dizziness 
• Nausea 
Indicators of expressive communication problem: 
• Problem with voice production, low volume 
(B0600) 
• Unclear speech - slurred or mumbled words 
(B0600-1) 
• Impaired ability to make self understood 
(B0700) 
• Difficulty putting sentence together (C1300B)
Dehydration/Flu
id Maintenance
Medications that increase urine output or cause 
fluid loss may contribute to dehydration.
Symptoms of dehydration:
• Dizziness on sitting or standing 
• Confusion or change in mental status 
(delirium) (C1600) 
• Lethargy 
• Recent decrease in urine volume or more 
concentrated urine than usual 
• Decreased skin turgor 
• Dry mouth, dry mucous membranes 
• Constipation 
• Fever
Delirium Delirium is a serious condition that can be 
caused by medical issues/conditions, such as 
adverse medication effects, infection or 
dehydration. Delirium typically develops rapidly, 
over a few days or even hours. Drugs are the 
most common reversible cause of delirium in 
older adults, particularly anticholinergic drugs. 
Recent studies suggest that the total burden of 
anticholinergic drugs may determine 
development of delirium rather than any single 
agen t.
Signs/symptoms of delirium include
• Inattention (C1300A)-easily distracted, out 
of touch or difficulty following what was said. 
• Disorganized thinking (C1300B)-rambling or 
irrelevant conversation, unclear or illogical flow 
of ideas, unpredictable switching from subject to 
subject. 
• Altered level of consciousness (C1300C)- 
e.g., vigilant (startled easily to any sound or 
touch); lethargic (repeatedly dozed off when 
being asked questions but responded to voice or 
touch); stuporous (very difficult to arouse and 
keep aroused); comatose (could not be 
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aroused). 
• Psychomotor retardation (C1300D)- 
Unusually decreased level of activity, such as 
sluggishness, staring into space, staying in one 
position, moving very slowly.
• Acute change in mental status (C1600) 
• Mental function varies over the course of the 
day 
• Sleep disturbances (D0500C) - up and 
awake at night/asleep during day. 
• Agitation and inappropriate movements, 
e.g., unsafe climbing out of bed or chair, pulling 
out tubes (E0500). 
• Hypoactivity (C0500D) - e.g., low or lack of 
motor activity, lethargy or sluggish response. 
• Perceptual disturbances such as 
hallucinations (seeing or feeling things that are 
not there E0100A) and delusions (a fixed false 
belief E0100B).
Dental Care Having teeth/dentures that function properly is 
an important requisite for nutritional adequacy. 
Some medications can cause dry mouth, 
inflamed gums, mouth pain, or chewing 
problems, which may interfere with dental 
hygiene. 
Has the patient experienced any of the following 
symptoms? 
• Dry mouth 
• Inflamed gums 
• Mouth pain 
• Chewing problems 
If so, are the symptoms interfering with 
nutritional intake?
Falls Certain medications can contribute to the risk for 
falls by causing problems such as dizziness, 
drowsiness, low blood pressure, muscle rigidity, 
impaired balance, tremors, and decreased 
alertness.
Medication effects that may contribute to the risk 
for falls:
• Decreased alertness 
• Dizziness (especially when standing or 
sitting up) 
• Drowsiness/lethargy 
• Confusion 
• Impaired balance 
• Muscle rigidity 
• Unsteady gait 
• Tremors
Mood State Certain medications may cause depression or 
contribute to a mood problem. 
Indicators of mood problem: 
• Little interest or pleasure in doing things 
(D0200A, D0500A) 
• Feeling or appearing down, depressed or 
hopeless (D0200B, D0500B) Trouble falling or 
staying asleep, or sleeping too much (D0200C, 
D0500C) 
• Feeling tired or having little energy 
(D0200D, D0500D) 
• Poor appetite or overeating (D0200E, 
D0500E) 
• Feeling bad about oneself (D0200F, 
D0500F) 
• Trouble concentrating on things (D0200G, 
318
 MRX care areas
Problem Problem description Monitoring indicators
D0500G) 
• Moving or speaking so slowly that other 
people have noticed, or the opposite, being more 
fidgety or restless than usual (D0200H, D0500H) 
• States that life isn’t worth living, wishes for 
death, or attempts to harm self (D0200I, D0500I) 
• Being short-tempered, easily annoyed 
(D0500J
Nutritional 
Status
Adverse medication effects may affect appetite 
or the ability to eat.
Medication effects that may affect nutritional 
status:
• Anorexia (loss of appetite) 
• Swallowing problem (K0100)
• Decreased ability to smell or taste food 
• Abnormal or distortion of sense of taste 
(dysgeusia) 
• Mouth pain (odynophagia), stomatitis, oral 
ulcers, chewing problems 
• Dry mouth 
• Gingival hyperplasia (overgrowth of gum 
tissue) 
• Weight loss
Potentially 
Inappropriate 
Medications 
(PIMs)
Certain medications or medication classes 
should generally be avoided in older persons 
because they are either ineffective or they pose 
unnecessarily high risk for older persons and a 
safer alternative is available. 
• Is there an indication for the medication? 
• Is the medication being used to treat an 
avoidable adverse medication effect? 
• Is the patient having any side effects from 
the medication? 
• Does the medication cause, aggravate or 
contribute to any geriatric problem? 
• Is non-drug therapy indicated? 
• Is there a safer alternative?
Pressure Ulcers Pressure ulcers have serious consequences for 
the older person; however, they are one of the 
most common preventable and treatable 
conditions among the elderly who have restricted 
mobility. Some medications can produce or 
contribute to lessened mobility, worsen 
incontinence, and lead to or increase confusion, 
which may increase the risk for pressure ulcers.
Assess for medication effects that can produce 
or contribute to lessened mobility, worsen 
incontinence, and lead to or increase confusion.
Psychosocial 
Well-Being
Medications with side effects, such as 
incontinence, diarrhea, delirium, sleepiness, etc., 
may interfere with or inhibit social interactions.
Assess for medication effects that interfere with 
social interactions. 
Psychotropic 
Medication Use 
– 
Antidepressant
s
Psychotropic medications (prescribed primarily 
to affect cognition, mood or behavior) are among 
the most frequently prescribed agents for elderly 
nursing facility residents. All psychotropic 
medications have the potential for producing 
undesirable and potentially serious side effects, 
including reduced mental functioning, sleep 
disturbances, and falls; or aggravating 
problematic signs and symptoms of existing 
conditions. 
Adverse consequences of antidepressants: 
• Worsening of depression and/or suicidal 
behavior or thinking (D0350) 
• Delirium unrelated to medical illness or 
severe depression (C1600) 
• Hallucinations (E0100A) 
• Dizziness 
• Nausea 
• Diarrhea 
• Anxiety (I5700) 
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• Nervousness, fidgety or restless 
• Insomnia 
• Somnolence 
• Weight gain 
• Anorexia or increased appetite
• Seizures (I5400) 
• MAO inhibitors: hypertensive crisis if 
combined with certain foods, cheese, wine 
• Tricyclics: Postural hypotension; 
anticholinergic effects (constipation, dry mouth, 
blurred vision, urinary retention, etc)
Psychotropic 
Medication Use 
– 
Antipsychotics
Psychotropic medications (prescribed primarily 
to affect cognition, mood or behavior) are among 
the most frequently prescribed agents for elderly 
nursing facility residents. All psychotropic 
medications have the potential for producing 
undesirable and potentially serious side effects, 
including reduced mental functioning, sleep 
disturbances, and falls; or aggravating 
problematic signs and symptoms of existing 
conditions. 
Adverse consequences of antipsychotics:
• Anticholinergic effects, such as constipation, 
dry mouth, blurred vision, urinary retention, etc. 
• Increase in total cholesterol and triglycerides 
• Akathesia (inability to sit still) 
• Parkinsonism: any combination of tremors, 
postural unsteadiness, muscle rigidity, pill-rolling 
of hands, shuffling gait, etc. 
• Neuroleptic malignant syndrome: high fever 
with severe muscular rigidity 
• Blood sugar elevation 
• Cardiac arrhythmias (I0300) 
• Orthostatic hypotension 
• Cerbrovascular accident or transient 
ischemic attach (I4500) 
• Falls (J1700-J1900) 
• Tardive dyskinesia: persistent involuntary 
movements such as tongue thrusting, lip 
movements, chewing or puckering movements, 
abnormal limb movements, rocking or writhing 
trunk movements, etc 
• Lethargy (D0200D) 
• Excessive sedation 
• Depression (D0300, D0600, I5800) 
• Hallucinations (E01
Psychotropic 
Medication Use 
– Anxiolytics
Psychotropic medications (prescribed primarily 
to affect cognition, mood or behavior) are among 
the most frequently prescribed agents for elderly 
nursing facility residents. All psychotropic 
medications have the potential for producing 
undesirable and potentially serious side effects, 
including reduced mental functioning, sleep 
disturbances, and falls; or aggravating 
problematic signs and symptoms of existing 
conditions. 
Adverse consequences of anxiolytics Sedation 
manifested by short-term memory loss (C0500, 
C0700), decline in cognitive abilities, slurred 
speech (B0600), drowsiness, little/no activity 
involvement Delirium unrelated to medical illness 
or severe depression (C1600) Hallucinations 
(E0100A) Depression (D0300, D0600, I5800) 
Disturbances of balance, gait, positioning ability 
(G0100A, G0100C, G0100D, G0300). 
Urinary 
Incontinence
Many medications can affect the bladder and 
urethra and result in urinary incontinence (UI). 
For example, diuretics (N0400G) can cause 
urge incontinence, anticholinergics can lead to 
overflow incontinence, sedative/hypnotics 
(N0400B, N0400D) may cause confusion and 
Symptoms of urinary incontinence:
• Loss of urine when coughing, sneezing, 
laughing, exercising or lifting something heavy 
(stress incontinence). 
• Sudden, intense urge to urinate, followed by 
an involuntary loss of urine (urge incontinence). 
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alter the ability to recognize the urge to void and 
lead to UI.
• Frequently or constantly dribble urine, 
feeling that bladder never completely empty, 
weak stream of urine (overflow incontinence).
Visual Function Vision problems can be an unwanted side effect 
of many different medications. Most of these 
drugs will cause only temporary visual 
disturbances that disappear with time or once 
the medication is discontinued. 
Vision side effects of medications:
• Blurred or double vision 
• Excessive tearing 
• Puffy eyelids 
• Sensitivity to light 
• Changes in color vision or seeing a yellow 
or blue tinge 
• Abnormal eye movements
This table show the elderly care areas, descriptions of the problems associated with each care 
area and monitoring indicators for healthcare professional awareness as displayed in MRX. 
The alphanumeric codes in brackets are assessment items from the MDS 3.0.261
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Appendix 20 Correlation plots
Correlation plots from the pharmacist MRM user survey are shown. Most correlations were 
performed using Kendall's tau-b. Several correlations were performed using Spearmans's  rho 
correlations.  These correlation methods are  based on rankings so regression lines are not 
relevant and not displayed. 
Plots are displayed as sunflower plots, where increased density of values at a single point are 
represented by additional bars at each point.324
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Appendix 21 MRM survey qualitative codes
Qualitative code Code category Frequency
Satisfied with MRM Good impressions 8
DRPs or recommendations irrelevant Bad impressions 6
Time consuming Time 5
Value for money Good impressions 5
Incorrectly analysing data DRPs could be better, Bad impressions 4
Need to edit final report 4
Positive customer service Good impressions 4
Time saving Time 4
General could be better Product needs polish 3
Makes HMRs easier Good impressions 3
Store my own comments functionality Needs functionality 3
DRPs missed by MRM DRPs could be better, Bad impressions 2
Duplicates DRPs and recommendations DRPs could be better, Bad impressions 2
Finds relevant DRPs Good impressions 2
Like report template Good impressions 2
Not value for money for few MRs 2
presentation lacks professionalism Product needs polish 2
Repeated MRs convenient due to data stored Good impressions 2
Suggestions for improvement 2
Add DRPs MRM cannot find DRPs could be better 1
Becomes predictable 1
Better than competitors Good impressions 1
Cannot rely only on MRM DRPs 1
Direct download functionality needed Needs functionality 1
DRPs contradictory DRPs could be better, Bad impressions 1
DRPs need better interactions DRPs could be better, Bad impressions 1
DRPs not current best practice DRPs could be better, Bad impressions 1
DRP wording too strong DRPs could be better, Bad impressions 1
Loss of confidence DRPs could be better, Bad impressions 1
Med list order by condition functionality Needs functionality 1
MRM not useful Bad impressions 1
Navigating software difficult Bad impressions 1
Need references for recommendations 1
Needs report section for RMMR staff Needs functionality 1
need standard drug interaction functionality Needs functionality 1
Negative customer service Bad impressions 1
No longer use MRM Bad impressions 1
Not kept up to date Bad impressions 1
Occasional bugs Product needs polish 1
Outdated data Product needs polish 1
Safety net for pharmacist Good impressions 1
Slower than competitor Time 1
Spelling and punctuation problems Product needs polish 1
Update the tutorial Product needs polish 1
Want electronic form functionality Needs functionality 1
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